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“Each year, more people 
are being reached with 
core malaria interventions, 
and as a result, more lives 
are being saved.”
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Foreword
Dr Margaret Chan
Director-General
World Health Organization
The ﬁ ndings in this year’s World 
Malaria Report demonstrate that 
the world is continuing to make 
impressive progress in reducing 
malaria cases and deaths. Each year, more people are being 
reached with core malaria interventions, and as a result, more 
lives are being saved. The malaria target under Millennium 
Development Goal 6 has been met, and 55 countries are on 
track to reduce their malaria burden by 75%, in line with the 
World Health Assembly’s target for 2015.
In 2013, we saw a major expansion in the use of diagnostic 
testing and the deployment of artemisinin-based combination 
therapies (ACTs). For the ﬁ rst time, more diagnostic tests were 
provided at public health facilities in Africa than ACTs distributed, 
indicating a prominent shift away from presumptive treatment. 
Major progress has been documented in vector control as well: 
in 2014, a record number of long-lasting insecticidal nets were 
delivered to endemic countries in Africa. 
The report shows that malaria mortality rates decreased by an 
impressive 47% between 2000 and 2013 globally, and by 54% 
in the WHO African Region. It also reveals that these trends are 
accompanied by a gradual and substantial reduction in parasite 
prevalence rates across Africa. This means that every year, fewer 
people get infected or carry asymptomatic infections – a sign 
that malaria interventions have an even larger impact than 
previously thought. 
These tremendous achievements are the result of improved 
tools, increased political commitment, the burgeoning of 
regional initiatives, and a major increase in international and 
domestic ﬁ nancing. WHO is grateful for the engagement and 
long-standing commitment of the global health community, 
and inspired by the growing desire to accelerate eﬀ orts towards 
malaria elimination. 
But we must not be complacent. Most malaria-endemic 
countries are still far from achieving universal coverage with 
life-saving malaria interventions; many biological and systemic 
challenges threaten to slow us down.
Available funding is far less than what is required to protect 
everyone at risk. An estimated 278 million people in Africa still 
live in households without a single insecticide-treated bed net, 
and about 15 million pregnant women remain without access 
to preventive treatment for malaria. Malaria is still responsible 
for over 430 000 child deaths in Africa every year. Emerging 
drug- and insecticide-resistance continues to pose a major 
threat, and if left unaddressed, could trigger an upsurge in 
deaths. 
The Ebola outbreak has had a devastating impact on basic 
health service delivery in the most severely aﬀ ected countries, 
including the ability to control malaria. In Guinea, Liberia, and 
Sierra Leone, the collapse of health systems has aﬀ ected all core 
malaria interventions and is threatening to reverse recent gains. 
WHO is working closely with countries and partners to prevent 
a worsening of the malaria situation and reduce the pool of 
fever cases.
This Ebola outbreak is a global tragedy that is rewriting the 
history of public health. It has served as a wake-up call for 
governments and the global development community, urging 
a major global rethink about the importance of strengthening 
health systems and building resilience.
All global health eﬀ orts will beneﬁ t from a strengthening of 
health systems, including eﬀ orts to control and eliminate 
malaria. Such investments will help us close the coverage gap, 
strengthen disease surveillance and research, and support the 
development and roll-out of new tools and approaches. They 
will make malaria and other public health responses more 
eﬀ ective and more sustainable.
Recent progress in reducing the human suﬀ ering caused by 
malaria has shown us that, with adequate investments and the 
right mix of strategies, we can indeed make remarkable strides 
against this complicated enemy. We should act with urgency 
and resolve, and remain focused on our shared goal: to create 
a world in which no one dies of malaria, a world entirely clear 
of this scourge.
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The World malaria report 2014 summarizes information received 
from 97 malaria-endemic countries and other sources, and 
updates the analyses presented in 2013. It assesses global and 
regional malaria trends, highlights progress made towards 
global targets, and describes opportunities and challenges 
in controlling and eliminating the disease. Most of the data 
presented in this report are for 2013.
The public health challenge posed by 
malaria
Malaria transmission occurs in all six WHO regions. Globally, an 
estimated 3.2 billion people are at risk of being infected with 
malaria and developing disease, and 1.2 billion are at high risk 
(>1 in 1000 chance of getting malaria in a year). According to the 
latest estimates, 198 million cases of malaria occurred globally 
in 2013 (uncertainty range 124–283 million) and the disease 
led to 584 000 deaths (uncertainty range 367 000–755 000). 
The burden is heaviest in the WHO African Region, where an 
estimated 90% of all malaria deaths occur, and in children aged 
under 5 years, who account for 78% of all deaths.
Expansion of malaria funding
International and domestic funding for malaria control and 
elimination totalled US$ 2.7 billion in 2013. Although this 
represented a threefold increase since 2005, it is still signiﬁ cantly 
below the estimated US$ 5.1 billion that is required to achieve 
global targets for malaria control and elimination. Total malaria 
funding will only match resource needs if international and 
domestic funders prioritize further investments for malaria 
control.
Overall, funding for countries in the WHO African Region 
accounted for 72% of the global total. Between 2005 and 2013, 
international disbursements for malaria for this region increased 
at an annual rate of 22%. During the same period, the average 
annual rate of increase for domestic funding in the region was 
4%.
Globally, domestic funding for malaria was estimated to be 
US$ 527 million in 2013. This represents 18% of the total malaria 
funding in 2013. In regions outside Africa, the annual rate of 
domestic funding has not increased in recent years.
Progress in vector control
During the past 10 years, coverage with vector control 
interventions increased substantially in sub-Saharan Africa. In 
2013, almost half of the population at risk (49%, range 44–54%) 
had access to an insecticide-treated mosquito net (ITN) in their 
household, compared to 3% in 2004. An estimated 44% (range 
39–48%) of the population at risk were sleeping under an ITN in 
2013, compared to 2% in 2004. Pregnant women and children 
were more likely than the general population to sleep under an 
ITN.
In terms of long-lasting insecticidal net (LLIN) delivery, 2014 has 
been the strongest year so far. A total of 214 million nets are 
projected to be delivered to countries in sub-Saharan Africa by 
the end of 2014, bringing the total number of LLINs delivered to 
that region since 2012 to 427 million.
Globally, 123 million people were protected from malaria 
through the use of indoor residual spraying. This represents 
3.5% of the global population at risk. In the WHO African 
Region, 55 million people, or 7% of the population at risk, were 
protected. This has decreased from 11% in 2010; the decline is 
due to a withdrawal or downsizing of spraying programmes in 
some countries.
In sub-Saharan Africa, the proportion of the population 
protected by at least one vector control method has increased 
in recent years, and it reached 48% in 2013 (range 44–51%). 
Globally, 38 countries reported the use of larval control to 
complement core vector control methods.
Insecticide resistance in malaria vectors has been reported in 49 
of 63 reporting countries around the world since 2010. Of these, 
39 have reported resistance to two or more insecticide classes. 
The most commonly reported resistance is to pyrethroids, the 
most frequently used insecticide in malaria vector control.
WHO has established a system to track insecticide resistance 
globally, and recommends annual monitoring. In 2013, 
some 82 countries report undertaking insecticide resistance 
monitoring. However, only 42 of these countries provided WHO 
with resistance data for 2013, suggesting that many countries 
do not monitor insecticide resistance annually.
Trends in the administration 
of preventive therapies
The proportion of women who receive intermittent preventive 
treatment in pregnancy (IPTp) for malaria has been increasing 
over time, although the levels remain below programme targets. 
IPTp has been adopted in 37 countries and 57% of pregnant 
women in those countries received at least one dose of IPTp in 
2013. However, only nine of those countries have reported to 
WHO on the recommended number of three or more doses of 
IPTp, and within those countries, only 17% of pregnant women 
received three or more doses.
In most countries, attendance rates at antenatal care services 
are much higher than current levels of IPTp administration. This 
suggests that there are missed opportunities to expand access 
to this life-saving intervention.
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The adoption and implementation of preventive therapies for 
children aged under 5 years and for infants has been slower than 
expected. As of 2013, six of the 16 countries recommended by 
WHO to adopt seasonal malaria chemoprevention for children 
aged under 5 years have done so. Only one country has adopted 
intermittent preventive treatment for infants, but has not yet 
implemented the treatment.
Scaling up diagnostic testing
The proportion of patients suspected of having malaria who 
receive a malaria diagnostic test has increased substantially 
since 2010, when WHO recommended testing of all suspected 
malaria cases. In 2013, 62% of patients with suspected malaria 
in public health facilities in the WHO African Region received a 
diagnostic test, compared to 40% in 2010.
The total number of rapid diagnostic tests (RDTs) distributed 
by national malaria control programmes increased from fewer 
than 200 000 in 2005 to more than 160 million in 2013. Of these, 
83% were delivered to countries in the WHO African Region. The 
quality of RDTs has improved substantially since the start of the 
RDT product testing programme in 2008. In the latest round of 
product testing, nearly all tested products met WHO standard of 
detection at parasite levels commonly seen in endemic areas.
In 2013, the number of patients tested by microscopic 
examination remained unchanged from the previous year, at 
197 million. The global total of microscopic examinations is 
dominated by India, which accounted for over 120 million slide 
examinations in 2013.
In 2013, for the ﬁ rst time, the total number of diagnostic tests 
provided in the WHO African Region in the public health sector 
exceeded the number of artemisinin-based combination 
therapies (ACTs) distributed. This is an encouraging sign 
and, given that fewer than half of patients tested will require 
treatment, the ratio of diagnostic tests to ACTs should eventually 
reach two to one.
Expanding access to treatment
By the end of 2013, ACTs had been adopted as national policy for 
ﬁ rst-line treatment in 79 of 88 countries where Plasmodium (P.) 
falciparum is endemic. Chloroquine was being used in 9 Central 
American and Caribbean countries where it remains eﬃ  cacious.
The number of ACT courses procured from manufacturers – for 
both the public and private sectors – rose from 11 million in 
2005 to 392 million in 2013. This increase has been largely driven 
by procurements for the public sector.
Public health facilities had enough ACT in 2013 to treat more 
than 70% of patients with malaria who presented for care. 
However, the estimated proportion of all children with malaria 
who received ACTs was estimated at between 9–26% This 
is because a substantial proportion of these patients do not 
seek care, and not all those who seek care receive antimalarial 
treatment.
Antimalarial drug resistance
P. falciparum resistance to artemisinin has been detected in 
ﬁ ve countries of the Greater Mekong subregion: Cambodia, 
the Lao People’s Democratic Republic, Myanmar, Thailand and 
Viet Nam. In many areas along the Cambodia–Thailand border, 
P. falciparum has become resistant to most available antimalarial 
medicines.
The number of countries that allow marketing of oral 
artemisinin-based monotherapies has declined rapidly. As of 
November 2014, only eight countries allow the marketing of 
oral monotherapies. However, 24 pharmaceutical companies, 
mostly in India, continue to market oral monotherapies. 
Therapeutic eﬃ  cacy studies remain the gold standard for 
guiding drug policy, and should be undertaken every 2 years. 
Studies of ﬁ rst- or second-line antimalarial treatments were 
completed in 72% of countries where P. falciparum eﬃ  cacy 
studies were feasible.
Gaps in intervention coverage
Despite impressive increases in malaria intervention coverage, it 
is estimated that, in 2013, 278 million of the 840 million people 
at risk of malaria in sub-Saharan Africa lived in households 
without even a single ITN, 15 million of the 35 million pregnant 
women did not receive even a single dose of IPTp, and between 
56 and 69 million children with malaria did not receive an ACT. 
Poverty and low levels of education are signiﬁ cant determinants 
of lack of access to these essential services. More can be done to 
ensure all those at risk receive appropriate preventive measures, 
diagnostic testing and treatment.
Changes in malaria incidence and 
mortality
Reported malaria cases
Of the 106 countries that had ongoing malaria transmission in 
2000, reported data in 66 were found to be suﬃ  ciently complete 
and consistent to reliably assess trends between 2000 and 2013.
Based on an assessment of trends in reported malaria cases, 
a total of 64 countries are on track to meet the Millennium 
Development Goal target of reversing the incidence of malaria. 
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Of these, 55 are on track to meet Roll Back Malaria and World 
Health Assembly targets of reducing malaria case incidence 
rates by 75% by 2015.
In 2013, two countries reported zero indigenous cases for 
the ﬁ rst time (Azerbaijan and Sri Lanka), and eleven countries 
succeeded in maintaining zero cases (Argentina, Armenia, 
Egypt, Georgia, Iraq, Kyrgyzstan, Morocco, Oman, Paraguay, 
Turkmenistan and Uzbekistan). Another four countries reported 
fewer than 10 local cases annually (Algeria, Cabo Verde, Costa 
Rica and El Salvador).
The 55 countries that recorded decreases of >75% in case 
incidence accounted for only 13 million (6%) of the total 
estimated cases of 227 million in 2000. Only ﬁ ve countries 
with more than 1 million estimated cases in 2000 (Afghanistan, 
Bangladesh, Brazil, Cambodia, and Papua New Guinea) are 
projected to achieve a reduction of 75% or more in malaria 
case incidence. This is partly because progress has been faster 
in countries with lower numbers of cases, but also because of 
poorer quality surveillance data being submitted by countries 
with larger estimated numbers of cases, particularly in 
sub-Saharan Africa.
Malaria infections
A new analysis of data reveals that the prevalence of 
malaria parasite infection, including both symptomatic and 
asymptomatic infections, has decreased signiﬁ cantly across 
sub-Saharan Africa since 2000. In sub-Saharan Africa, average 
infection prevalence in children aged 2–10 years fell from 26% 
in 2000 to 14% in 2013 – a relative decline of 48%.
Although declines in malaria parasite infection were seen across 
the African continent, they were particularly pronounced in 
Central Africa. Even with a large growth of populations in stable 
transmission areas, the number of infections at any one time 
across Africa fell from 173 million in 2000 to 128 million in 2013 
– a reduction of 26% in the number of people infected.
Estimated malaria cases and deaths
Between 2000 and 2013, estimated malaria mortality rates 
decreased by 47% worldwide and by 54% in the WHO African 
Region. They are estimated to have decreased by 53% in children 
aged under 5 years globally, and by 58% in the WHO African 
Region. If the annual rate of decrease that has occurred over 
the past 13 years is maintained, then by 2015 malaria mortality 
rates are projected to decrease by 55% globally, and by 62% 
in the WHO African Region. In children aged under 5 years, by 
2015 they are projected to decrease by 61% globally and by 
67% in the WHO African Region.
Estimated malaria cases and deaths averted
It is estimated that, globally, 670 million fewer cases and 
4.3 million fewer malaria deaths occurred between 2001 and 
2013 than would have occurred had incidence and mortality 
rates remained unchanged since 2000. Of the estimated 
4.3 million deaths averted between 2001 and 2013, 3.9 million 
(92%) were in children aged under 5 years in sub-Saharan 
Africa. These 3.9 million averted deaths accounted for 20% of 
the 20 million fewer under 5 deaths that would have occurred 
between 2001 and 2013 had under-5 mortality rates for 2000 
applied for each year between 2001 and 2013. Thus, reductions 
in malaria deaths have contributed substantially to progress 
towards achieving the target for MDG 4, which is to reduce, by 
two thirds, the under-5 mortality rate between 1990 and 2015.
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By 2015
Average malaria infection prevalence 
declined 48% in children aged 2–10, 
from 26% to 14% in 2013.
The number of malaria infections at 
any one time dropped 26%, from 
173 million to 128 million in 2013.
Malaria mortality rates have 
decreased by 47% worldwide and 
by 54% in the WHO Africa Region.
Only US$ 2.7 billion
of the US$ 5.1 billion required to achieve global malaria control and elimination targets 
were available through international and domestic funds.
44%
of the population at risk in sub-Saharan Africa 
were sleeping under an ITN, indicating 
that 90% of people used the nets 
available to them.
278 million
of the 840 million people at risk of 
malaria in sub-Saharan Africa lived in 
households without even a single ITN.
49%
of the at-risk population 
in sub-Saharan Africa 
had access to an ITN 
in their household.
15 million
of the 35 million pregnant women did 
not receive a single dose of IPTp.
57%
of pregnant women received at least one dose of IPTp, and 17% 
received three or more doses in the nine reporting countries.
197 million
patients worldwide were tested 
for malaria by microscopic examination.
If the annual rate of decrease over the past 13 years is 
maintained, malaria mortality rates are projected to decrease 
by 55% globally and by 62% in the WHO Africa Region.
Malaria mortality rates in children aged under 
5 years are projected to decrease by 61% globally 
and 67% in the WHO Africa Region.
In 2013
56–69 million
children with malaria did not 
receive an ACT.
70%  of malaria patients could be treated with ACTs distributed 
to public facilities in Africa; however, because not all children with fever are 
brought for care, less than 26% of all children with malaria received an ACT.
62%
of patients with suspected malaria cases in the WHO African 
Region received a diagnostic test in public health facilities.
584 000
malaria deaths (range 367 000–755 000) occurred 
worldwide; 78% of malaria deaths occurred in children 
aged under 5 years.
528 000
malaria deaths (range 315 000–689 000), 90% of 
the global total, occurred in the WHO African Region.
Since the year 2000
KEY STATISTICS
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The World malaria report 2014 summarizes the status of global eff orts 
to control and eliminate malaria. The report is produced every year by the 
WHO Global Malaria Programme, with the help of WHO regional and country 
oﬃ  ces, ministries of health in endemic countries, and a broad range of other 
partners. Data for this year’s report were assembled from 97 countries and 
territories with ongoing malaria transmission, and an additional six countries 
that are working to prevent reintroduction. 
This section outlines the public health burden posed by malaria, the 
strategies that can be used to reduce that burden, and the goals, targets 
and indicators that have been set for 2015. The report then reviews global 
progress towards the goals and targets in relation to funding (Section 2), 
intervention coverage (Sections 3–7), and malaria cases and deaths 
(Section 8). The review is followed by Regional profi les that summarize 
trends in each WHO region. Country profi les are provided both for countries 
with ongoing malaria transmission and for those recently achieving zero local 
cases. Finally, annexes provide sources of data, details of the methodology 
used in the analysis, and tables containing country and regional data.
1.1 The public health challenge posed by 
malaria
Malaria transmission occurs in all six WHO regions. Globally, an 
estimated 3.2 billion people in 97 countries and territories are at risk of being 
infected with malaria and developing disease (Figure 1.1), and 1.2 billion are 
at high risk (>1 in 1000 chance of getting malaria in a year). According to 
the latest estimates, 198 million cases of malaria occurred globally in 2013 
(uncertainty range 124–283 million) and the disease led to 584 000 deaths 
(uncertainty range 367 000–755 000), representing a decrease in malaria 
case incidence and mortality rates of 30% and 47% since 2000, respectively. 
The burden is heaviest in the WHO African Region, where an estimated 90% 
of all malaria deaths occur, and in children aged under 5 years, who account 
for 78% of all deaths.
DATA WERE ASSEMBLED FROM 
97 COUNTRIES AND TERRITORIES 
WITH ONGOING MALARIA 
TRANSMISSION, AND AN 
ADDITIONAL SIX COUNTRIES 
WORKING TO PREVENT 
REINTRODUCTION.
1. INTRODUCTION
Figure 1.1 Countries with ongoing transmission of malaria, 2013
Source: National malaria control programme reports
Conﬁrmed malaria cases per 1000 population
No ongoing malaria transmission
Not applicable
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0–0.1
10–50
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Malaria exacts a heavy burden on the poorest and most vulnerable 
communities. It primarily aﬀ ects low- and lower-middle income countries 
(Figure 1.2). Within endemic countries, the poorest and most marginalized 
communities are the most severely aﬀ ected, having the highest risks 
associated with malaria, and the least access to eﬀ ective services for 
prevention, diagnosis and treatment. Thus, malaria control and ultimately 
its elimination is inextricably linked with health system strengthening, 
infrastructure development and poverty reduction.
Malaria is caused by fi ve species of the parasite belonging to the 
genus Plasmodium. Four of these – P. falciparum, P. vivax, P. malariae and 
P. ovale – are human malaria species, which are spread from one person 
to another by female mosquitoes of the genus Anopheles. There are about 
400 diﬀ erent species of Anopheles mosquitoes, but only 30 of these are 
vectors of major importance. In recent years human cases of malaria have 
also been recorded due to P. knowlesi – a species that causes malaria among 
monkeys, and occurs in certain forested areas of South-East Asia.
P. falciparum and P. vivax malaria pose the greatest public health 
challenge. P. falciparum is most prevalent on the African continent, and is 
responsible for most deaths from malaria. P. vivax has a wider geographic 
distribution than P. falciparum because it can develop in the Anopheles 
mosquito vector at lower temperatures, and can survive at higher altitudes 
and in cooler climates. It also has a dormant liver stage (known as a 
hypnozoite) that enables it to survive for long periods as a potential reservoir 
of infection. The hypnozoites can activate months later to cause a relapse. 
Although P. vivax can occur throughout Africa, the risk of infection with this 
species is quite low, because of the absence in many African populations of 
the Duﬀ y gene, which produces a protein necessary for P. vivax to invade red 
blood cells. In many areas outside Africa, infections due to P. vivax are more 
common than those due to P. falciparum.
Figure 1.2 Percentage of population living under US$ 2 per day, 1995–2013
Percentage of population living 
under US$ 2 per day
>75%
35–75%
15–35%
<15%
No data
Not applicable
Source: World Bank 2014 World Development Indicators: Poverty rates at international poverty lines. 
Available at: http://wdi.worldbank.org/table/2.8, accessed 24 November 2014. Survey years range 
from 1995 to 2013, with about 60% of countries with data from 2010 or earlier.
AN ESTIMATED 3.3 BILLION 
PEOPLE ARE AT RISK OF BEING 
INFECTED WITH MALARIA AND 
DEVELOPING DISEASE, AND 
1.2 BILLION ARE AT HIGH RISK.
4 | WORLD MALARIA REPORT 2014
1.2 Strategies to control and eliminate 
malaria
Malaria interventions are highly eff ective and aff ordable. The main 
interventions – summarized here and discussed in detail in Sections 3–7 – 
comprise vector control (which reduces transmission by the mosquito 
vector from humans to mosquitoes and then back to humans), achieved 
using insecticide-treated mosquito nets (ITNs) or indoor residual spraying 
(IRS); chemoprevention (which prevents the blood stage infections in 
humans); and case management (which includes diagnosis and treatment 
of infections).
ITNs are estimated to reduce malaria mortality rates by 55% in children 
under 5 years of age in sub-Saharan Africa (1). Their public health impact 
is due to a reduction in malaria deaths and to reductions in child deaths 
from other causes that are associated with, or exacerbated by, malaria (e.g. 
acute respiratory infection, low birth weight and malnutrition). ITNs have 
have been shown to reduce the incidence of malaria cases by 50% in a 
variety of settings (2). When the nets are used by pregnant women, they are 
also eﬃ  cacious in reducing maternal anaemia, placental infection and low 
birth weight. Historical and programme documentation has established a 
similar impact for IRS, although randomized trial data are limited (3). 
Chemoprevention is particularly eff ective in pregnant women and 
young children. Intermittent preventive treatment in pregnancy (IPTp) (i.e. 
administration of sulfadoxine-pyrimethamine [SP] during the second and 
third trimester of pregnancy) has been shown to reduce severe maternal 
anaemia (4), low birth weight (5) and perinatal mortality (6). Seasonal 
malaria chemoprevention (SMC) with amodiaquine plus SP (AQ+SP) for 
children aged 3–59 months could avert millions of cases and thousands of 
deaths in children living in areas of highly seasonal malaria transmission in 
Africa’s Sahel subregion; SMC works by maintaining therapeutic antimalarial 
drug concentrations in the blood during periods of greatest malaria risk (7). 
Intermittent preventive treatment for infants (IPTi) with SP, delivered at 
routine childhood immunization clinics, provides protection in the ﬁ rst year 
of life against clinical malaria and anaemia; it reduces hospital admissions for 
infants with malaria and admissions for all causes (8). 
Confi rmation of malaria infection directs care to those most in need, 
and for those in need, current medicines against malaria are highly 
eff ective. In most malaria-endemic areas, less than half of patients with 
suspected malaria infection are actually infected with a malaria parasite. 
Parasitological diagnostic tests for malaria – examination of a blood smear by 
microscopy or rapid diagnostic test (RDT) – conﬁ rm infection in suspected 
cases of malaria, indicating which patients should be treated for malaria 
and for which patients another cause of fever should be sought. In relation 
to treatment, artemisinin-based combination therapy (ACT) treatment of 
uncomplicated P. falciparum malaria has been estimated to reduce malaria 
mortality in children aged 1–23 months by 99% (range: 94–100%), and in 
children aged 24–59 months by 97% (range: 86–99%) (9).
MALARIA CAN BE 
PREVENTED AND CURED 
BY HIGHLY COSTEFFECTIVE 
INTERVENTIONS.
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WHO recommendations on the deployment of these interventions 
are continually reviewed and updated. Current recommendations are 
summarized on the WHO website (10). WHO’s evidence-based policy-
setting work is supported by the Malaria Policy Advisory Committee 
(MPAC), established in 2011. The MPAC brings together some of the world’s 
foremost experts on malaria, and is supported by technical expert groups 
and evidence review groups that focus on speciﬁ c thematic areas. During 
2014, WHO issued several new recommendations and guidance documents 
on malaria control and elimination (see Box 1.1).
Box 1.1 Recommendations and guidance documents 
issued by WHO in 2014
New guidance issued by WHO in line with MPAC recommendations 
In 2014, WHO produced revised guidance on vector control, including 
management of long-lasting insecticidal nets, alone and in combination 
with indoor residual spraying, tackling residual transmission and malaria 
diagnostics:
 ■ Guidance for countries on combining indoor residual spraying and 
long-lasting insecticidal nets (11)
 ■ Recommendations on the sound management of old long-lasting 
insecticidal nets (12)
 ■ Guidance note on the control of residual malaria parasite 
transmission (13)
 ■ Policy recommendation on malaria diagnostics in low transmission 
settings (14,15).
Additional technical documents, evaluations and assessments
WHO also produced or collaborated on other materials, including a new 
manual, modelling software, and updates on rapid diagnostic tests and 
artemisinin resistance:
 ■ From malaria control to malaria elimination: a manual for 
elimination scenario planning (16)
 ■ Malaria Tools (malaria transmission modelling software) (17)
 ■ Malaria rapid diagnostic test performance. Results of WHO product 
testing of malaria RDTs, Round 5 (18)
 ■ Information note on recommended selection criteria for procurement 
of malaria rapid diagnostic tests (19)
 ■ WHO updates on artemisinin resistance (20).
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1.3 Global goals and targets for malaria
Malaria control is critical to achieving the Millennium Development 
Goals (MDGs). MDG 6 (to halt by 2015 and begin to reverse the incidence 
of malaria and other major diseases) speciﬁ cally addresses malaria; malaria 
control also contributes to the achievement of other MDGs. Given that 
malaria accounted for an estimated 13% of post-neonatal child deaths 
globally in 2010, and 21% in sub-Saharan Africa (21), malaria control is 
also central to MDG 4 (to achieve a two thirds reduction in the mortality 
rate among children aged under 5 years between 1990 and 2015). Malaria 
eﬀ orts are additionally expected to contribute to achieving MDG 1 (eradicate 
extreme poverty and hunger), MDG 2 (achieve universal primary education), 
MDG 3 (promote gender equality and empower women), MDG 5 (improve 
maternal health) and MDG 8 (develop a global partnership for development).
Malaria is the focus of World Health Assembly and Roll Back Malaria 
(RBM) targets. In 2005, the World Health Assembly set as a target the 
reduction of malaria cases and deaths by 75% by 2015. In 2011, the RBM 
Partnership updated the objectives and targets that had been set out in the 
Global Malaria Action Plan in 2008 (22). The update shares the Assembly’s 
objective of reducing malaria cases by 75% by 2015, but has a new and 
more ambitious objective to reduce malaria deaths to near zero by 2015 
(see Table 1.1). A further objective is to eliminate malaria by the end of 2015 
in 8–10 new countries (since 2008) and in the WHO European Region. The 
objectives of mortality and morbidity reduction are linked to targets for 
malaria intervention coverage.
Indicators of progress provide a means to monitor the success of 
international control eff orts in achieving these updated goals and 
targets. A list of recommended indicators against each objective and target 
is shown in Table 1.1. Indicators that can be generated from household 
surveys are shown in bold. In some cases, the indicators generated by 
household surveys do not measure a target directly (e.g. all-cause under-5 
mortality rate is not a direct measure of malaria mortality), but the indicator 
is in widespread use and has therefore been placed alongside the most 
appropriate RBM target.
In 2015, WHO aims to launch a new technical strategy for 2016–2030. 
Following a proposal by the MPAC in 2012, WHO began coordinating the 
development of a Global Technical Strategy for Malaria for the post-2015 
period. This strategy will set milestones and goals for burden reduction 
and elimination beyond 2015. It has been developed in close collaboration 
with the RBM Partnership’s Global Malaria Action Plan 2 (GMAP 2), which 
will focus on global advocacy, resource mobilization, partner harmonization 
and the engagement of non-health sectors for the implementation of the 
technical strategy.
The WHO vision is for “A world free of malaria”. This can be achieved 
through country-by-country (and later regional) elimination of malaria 
infection, followed by global malaria eradication. Malaria elimination refers to 
the reduction of the incidence of infection to zero in a deﬁ ned geographical 
area as a result of deliberate eﬀ orts. The oﬃ  cial recognition of malaria-free 
status is granted by WHO once it has been proven beyond reasonable doubt 
that the chain of local human malaria transmission by Anopheles mosquitoes 
has been interrupted in an entire country for 3 consecutive years. Malaria 
eradication is the permanent reduction to zero of the worldwide incidence 
of infection caused by a particular malaria parasite species. Intervention 
measures will no longer be needed once eradication has been achieved.
MALARIA CONTROL IS ONE OF 
THE HIGHEST PRIORITIES ON 
THE INTERNATIONAL HEALTH 
AGENDA.
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Table 1.1 Roll Back Malaria objectives, targets for 2015 and indicators for measuring progress (23)
GMAP Objective or Target Key Indicator Further Analysis Supporting Indicator
Objective 1
Reduce global malaria deaths 
to near zero* by end 2015
Æ Inpatient malaria deaths per 1000 
persons per year
Æ Has health facility reporting 
completeness changed over time?
Æ Completeness of monthly health facility 
reports
Æ All-cause under 5 mortality rate Æ What factors are responsible? Æ Programme coverage indicators in this table  (detailed below)
Target 1.1 
Achieve universal access to 
case management in the 
public sector
Target 1.2 
Achieve universal access 
to case management, or 
appropriate referral, in the 
private sector
Target 1.3 
Achieve universal access 
to community case 
management (CCM) of 
malaria
Æ Proportion of suspected malaria cases 
that receive a parasitological test
Æ
Proportion of children under 5 years 
old with fever in the last two weeks 
who had a ﬁ nger or heel stick
Æ
Are people seeking advice or 
treatment for fever and from 
where?
Æ
Proportion of children under 5 years 
old with fever in the last two weeks 
for whom advice or treatment was 
sought
Æ
Proportion of conﬁ rmed malaria cases 
that receive ﬁ rst-line antimalarial 
treatment according to national policy
Æ Are adequate quantities of 
antimalarial medicines available?
Æ Proportion of health facilities without 
stock-outs of key commodities by month
Æ
Proportion receiving ﬁ rst-line treat-
ment among children under 5 years 
old with fever in the last two weeks 
who received any antimalarial drugs
Objective 2
Reduce global malaria cases 
by 75% by end 2015 
(from 2000 levels)
Æ Conﬁ rmed malaria cases (microscopy 
or RDT) per 1000 persons per year
Æ Has diagnostic eﬀ ort changed 
over time?
Æ Annual blood examination rate
Æ Has health facility reporting 
completeness changed over time?
Æ Completeness of monthly health facility 
reports
Æ Have test positivity rates changed 
over time?
Æ Malaria test positivity rate
Æ
Parasite prevalence: proportion of 
children aged 6–59 months with 
malaria infection
Æ Is there other evidence of 
morbidity change?
Æ
Proportion of children aged 
6–59 months with a hemoglobin 
measurement of <8 g/dL
Target 2.1
Achieve universal access to 
and utilization of prevention 
measures**
Target 2.2
Sustain universal access to 
and utilization of prevention 
measures**
Æ
Proportion of population 
with access to an ITN within 
their household
Æ How many households have at 
least one ITN?
Æ Proportion of households with at 
least one ITN
Æ How many households have 
enough ITNs for each occupant?
Æ Proportion of households with at 
least one ITN for every two people
Æ
Were enough ITNs delivered to 
ensure at least one ITN per two 
people at risk?
Æ Proportion of population at risk 
potentially covered by ITNs distributed
Æ Are speciﬁ c risk groups receiving 
ITNs?
Æ Proportion of targeted risk group 
receiving ITNs
Æ
Proportion of population 
that slept under an ITN 
the previous night
Æ Are speciﬁ c population groups 
using ITNs?
Æ
Proportion of children under 5 years 
old who slept under an ITN the 
previous night
Æ Proportion of pregnant women who 
slept under an ITN the previous night
Æ Are available ITNs being used? Æ Proportion of existing ITNs used the previous night
Æ Proportion of population protected by 
IRS within the last 12 months
Æ
Proportion of households with at 
least one ITN for every two people 
and/or sprayed by IRS within the last 
12 months
Æ
How many households have been 
reached with at least one vector 
control method?
Æ
Proportion of households with at 
least one ITN and/or sprayed by IRS 
within the last 12 months
Æ
Proportion of women who received 
at least three or more doses of IPTp 
during ANC visits during their last 
pregnancy
Æ
Is IPTp received by all pregnant 
women at each scheduled ANC 
visit?
Æ
Proportion of women who received 
at least one, two or four doses of 
IPTp during ANC visits during their 
last pregnancy
Æ
Proportion of women attending 
antenatal care (ANC) who received at 
least one, two, three or four doses of IPTp
Target 2.3
Accelerate development of 
surveillance systems
Æ
Percent of districts reporting monthly 
numbers of suspected malaria cases, 
number of cases receiving a diagnostic test 
and number of conﬁ rmed malaria cases
Objective 3
Eliminate malaria by end 
2015 in 10 new countries 
(since 2008) and in the WHO 
European Region
Æ Number of new countries in which 
malaria has been eliminated
Æ What are the trends in malaria 
cases?
Æ Number of active foci reported per year
Æ Number of cases by classiﬁ cation (indi-
genous, introduced, imported, induced)
Æ How strong are surveillance 
systems?
Æ Proportion of private facilities reporting 
to national malaria surveillance system
Indicators derived from household surveys are in bold.
*  In areas where public health facilities are able to provide a parasitological test for all suspected malaria cases, near zero malaria deaths is deﬁ ned as no more 
than 1 conﬁ rmed malaria death per 100 000 population at risk.
** Universal access to and utilization is deﬁ ned as every person at risk sleeping under a quality insecticide-treated net or in a space protected by indoor residual 
spraying and every pregnant woman at risk receiving a dose of IPTp at each ANC visit after the ﬁ rst trimester (in settings where IPTp is appropriate).
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2.1 Growth in annual funding for malaria
Annual funding for malaria control and elimination totalled 
US$ 2.7 billion in 2013, almost three times the amount spent in 2005. 
International investments represented 82% of total malaria funding in 2013 
(Figure 2.1), totalling US$ 2.18 billion. Domestic funding for malaria reached 
US$ 527 million. However, domestic funding tallied here excludes expenditures 
for health-worker salaries and other shared costs of diagnosing and treating 
patients; therefore, it does not reﬂ ect the full contribution of endemic country 
governments to malaria control. Compared to 2012, total malaria funding in 
2013 increased by 3%. Although the 2013 total exceeds that of any previous year, 
it represents just 52% of the annual estimated requirement of US$ 5.1 billion 1 
to attain international targets for malaria control and elimination (24). 
Growth of funding has been greatest in the WHO African Region, 
where the disease burden is greatest. International investments grew at 
an annual average rate of 22% per year between 2005 and 2013 in the WHO 
African Region, compared to 15% across all other WHO regions (Figure 2.2). 
During the same period, domestic investments grew at an annual average 
rate of 4% in the WHO African Region, compared to 2% in other WHO regions. 
In 2013, the WHO African Region accounted for 72% of total malaria funding, 
compared to 50% in 2005; also, international investments accounted for 
91% of the total investments in the WHO African Region, compared to 41% 
in other WHO regions. Funding for malaria has not grown in the other WHO 
regions since 2010.
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International Development; Global Fund, Global Fund to Fight AIDS, Tuberculosis and Malaria; 
GMAP, Global Malaria Action Plan; PMI, United States President’s Malaria Initiative; USAID, United 
States Agency for International Development
Source: National malaria control programmes; Global Fund, USAID and Centers for Disease Control 
and Prevention (CDC) websites; Organisation for Economic Co-operation and Development (OECD) 
creditor reporting system; and Roll Back Malaria 2008 GMAP
5000
4000
3000
2000
1000
0
Government Global Fund World Bank USAID/PMI
DFID OtherAMFm
GMAP investment target of US$ 5100 million
                 
                 
20122011201020092008200720062005 2013
2013 funding gap:
US$ 2430 million
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Figure 2.2 Trends in domestic and international funding in the 
WHO African Region and other WHO regions, 2005–2013
2. FINANCING 
FOR MALARIA 
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2.2 Future funding directions
Total malaria funding can increase signifi cantly if investments 
increase in line with forecasted total government expenditures, and if 
domestic and international funders prioritize further investments for 
malaria control. Two scenarios for future funding were explored to assess 
the prospects of achieving the targeted annual estimated requirement of 
US$ 5.1 billion between 2014 and 2020. 
 ■ Scenario 1 assumes that domestic and international investments towards 
malaria control increase at the International Monetary Fund (IMF) forecast 
of total government expenditures for both endemic and donor countries. 
This scenario shows that total funding could reach US$ 3.8 billion by 2020, 
but still results in an estimated annual resource gap of US$ 1.3 billion in 
2020 – equivalent to a cumulative funding gap of US$ 13.3 billion for 2014–
2020. The contribution of domestic funding to total global malaria funding 
would nevertheless increase from 20% in 2013 to 29% in 2020 (Figure 2.3a). 
 ■ Scenario 2 assumes that for international sources (i) malaria funding 
between 2013 and 2015 increases in line with a targeted expansion of 
total development budgets to an internationally agreed target of 0.7% of 
gross national income (GNI) by 2015 (25,26) and (ii) malaria funding from 
2016 to 2020 continues to grow in line with the average IMF forecast of 
total government expenditures for donor countries over the same period. 
Scenario 2 also assumes that governments of endemic countries increase 
the priority they give to malaria funding, and assumes that governments 
that show a below average value of a domestic investment priority index 
(DIPI) for malaria (see Annex 1) increase their DIPI to the median level of 
endemic countries. Under this scenario, total funding for malaria control 
would increase to US$ 4.3 billion by 2020, leaving an annual funding gap 
of US$ 774 million in 2020, equivalent to a cumulative total funding gap of 
US$ 10 billion for 2014–2020. Domestic funding would account for 26% of 
total malaria funding by 2020 (Figure 2.3b). 
Under both scenarios, substantial additional funds would be mobilized for 
malaria control and elimination. However, the total amount available in 2020 
would still fall short of the annual estimated US$ 5.1 billion required to achieve 
international targets.
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GMAP, Global Malaria Action Plan; IMF, International Monetary Fund
Source: National malaria control programmes; Global Fund; PMI; OECD Development Assistance Committee database; International Monetary Fund forecast growth rates of government expenditures and 
revenue; and Roll Back Malaria 2008 GMAP
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Figure 2.3 Anticipated funding if a) domestic and international investments increase in line with total government expenditure growth 
estimated by the IMF for 2014–2020, and b) funders prioritize further investments in malaria control
1. Excludes research and development (R&D) 
annual required investments estimated at 
US$ 750–900 million. 
FUNDING GAPS CAN BE 
NARROWED IF GOVERNMENTS 
OF BOTH MALARIAENDEMIC 
AND DONOR COUNTRIES 
GIVE HIGHER PRIORITY TO 
INVESTMENTS IN MALARIA 
CONTROL.
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3.1 Insecticide-treated mosquito nets
Most malaria-endemic countries have adopted policies to promote 
universal access to ITNs. WHO recommends that, in areas targeted for ITNs, 
all those at risk should be protected. Most of the 97 countries with ongoing 
malaria transmission distribute ITNs free of charge, and 83 distribute ITNs or 
LLINs to all age groups (Table 3.1). In 67 countries, ITNs are distributed to all 
age groups through mass campaigns. In the WHO African Region – which 
has the highest proportion of the population at high risk of malaria, and in 
which the characteristics of the malaria vectors in most areas make them 
amenable to intervention with ITNs – mass campaigns are supplemented by 
distribution of ITNs to pregnant women at antenatal care (ANC) clinics in 34 
countries, and to infants through expanded programme on immunization 
(EPI) clinics in 26 countries. 
The proportion of the population with access to an ITN and sleeping 
under one has increased markedly in sub-Saharan Africa over the 
past 10 years. Based on data from household surveys, and reports on ITNs 
delivered by manufacturers and distributed by national malaria control 
programmes (NMCPs), an estimated 49% (range 44–54%) of the population 
at risk had access to an ITN in their household in 2013, compared to 3% in 
2004 (Figure 3.1a). An estimated 44% (39–48%) were sleeping under an ITN 
in 2013 compared to 2% in 2004. ITNs are used by a high proportion of those 
who have access to them (90%); therefore, the population sleeping under 
an ITN closely tracks the proportion with access to an ITN.
Not all households have enough nets to protect all household 
members and achieve universal ITN access. The proportion of 
households owning at least one ITN has increased markedly over the past 
decade, from 5% in 2004 to 67% (61–74%) in 2013 (Figure 3.1b). However, in 
2013, only 29% (27–32%) of households had enough ITNs for all household 
members, limiting attainment of universal ITN access. Moreover, one 
third of households did not own even a single ITN. It is critical to reach all 
households with ITNs, and supply enough ITNs for all household members, 
to ensure that all those at risk are protected from malaria. 
3. VECTOR 
CONTROL FOR 
MALARIA
AN INCREASING PROPORTION 
OF THE POPULATION IN 
SUBSAHARAN AFRICA IS 
PROTECTED BY ITNs.
Table 3.1 Adoption of policies for ITN programmes, by WHO region, 2013
Policy AFR AMR EMR EUR SEAR WPR Total
ITNs/ LLINs are distributed free of charge 41 19 8 2 10 10 90
ITNs/ LLINs are sold at subsidized prices 14 1 2 16
ITNs/ LLINs are distributed to all age groups 38 18 7 1 10 9 83
ITNs/ LLINs are distributed through mass campaigns to all age groups 36 15 6 7 6 67
ITNs/ LLINs are distributed through antenatal clinics 34 3 3  4 5 49
ITNs/ LLINs are distributed through EPI clinics 26 1 1 1 29
Countries/areas with ongoing malaria transmission 45 21 8 3 10 10 97
AFR, African Region; AMR, Region of the Americas; EMR, Eastern Mediterranean Region; EPI, Expanded Programme on Immunization; EUR, European Region; ITN, 
insecticide-treated mosquito net; LLIN, long-lasting insecticidal net; SEAR, South-East Asia Region; WPR, Western Paciﬁ c Region
Source: National malaria control programme reports
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Improvements in access to ITNs and their use vary considerably 
between diff erent geographical areas. In 2005, the proportion of the 
population sleeping under an ITN was generally low, with only six countries 
achieving coverage levels greater than 20% (Figure 3.2). Coverage remained 
low during the next several years, in particular in large countries with a high 
burden of malaria. By 2010, substantial progress had been made, although 
few areas had more than half of the population protected by ITNs. Progress 
in ITN coverage continued and, by 2013, in several high-transmission 
countries in West and Central Africa, over half the at-risk population was 
protected with ITNs. High ITN coverage is linked to mass campaigns, and in 
countries where campaigns have not occurred recently a lower proportion 
of the population is protected with ITNs. 
Figure 3.1 a) Proportion of population with access to an ITN and proportion sleeping under an ITN, b) Proportion of households with 
at least one ITN and proportion of households with enough ITNs for all persons, sub-Saharan Africa, 2000–2013
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IN 15 AFRICAN COUNTRIES OVER 
HALF THE POPULATION AT RISK 
WAS PROTECTED BY ITNs.
Figure 3.2 Proportion of population sleeping under an ITN, sub-Saharan Africa
2005 20132010
ITN, insecticide-treated mosquito net
Source: Insecticide-treated mosquito net coverage model from Malaria Atlas Project
P. falciparum API < 0.1‰P. falciparum free Not applicable100% 0%
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3.2 Delivery and distribution of nets
The number of LLINs delivered to sub-Saharan African countries and 
distributed by national programmes increased in 2013 and 2014. This 
increased procurement and distributions of nets has led to an increase in 
the proportion of the population sleeping under an ITN. In recent years, all 
distributed nets, and therefore most of the available nets, have been LLINs. 
Over 142 million LLINs were delivered to countries in sub-Saharan Africa by 
manufacturers in 2013; a total of 214 million are projected to be delivered 
in 2014, the largest number of LLINs ever delivered in one year (Figure 3.3). 
Adding these nets to the 70 million delivered in 2012, a cumulative total 
of 427 million will have been delivered to countries in sub-Saharan Africa 
between 2012 and 2014. However, a comparison of the estimated number 
of LLINs available in households with the reported number of net deliveries 
suggests that allocation of LLINs during distribution is not 100% eﬃ  cient 
(because some households receive additional nets before their existing 
nets have expired); it also suggests that over half of distributed ITNs are lost 
from households within 24 months. Consequently, not all of the 427 million 
delivered nets were available in households in 2014.
Improvements in net distribution and LLIN durability could reduce 
the number of LLINs needed per year to achieve universal access. 
If allocations of nets to households were 100% eﬃ  cient, and a higher 
proportion of distributed nets were retained in households after 3 years 
(e.g. if nets had a 3-year half-life), then deliveries of 200 million ITNs per year 
would be suﬃ  cient to give 90% of the population at risk access to an ITN in 
their household. However, with current distribution patterns and loss rates 
for nets, nearly 300 million ITNs would be needed per year for 90% of the 
population at risk to have access to an ITN in their household (Figure 3.4).
THE NUMBER OF LLINs 
DELIVERED TO COUNTRIES HAS 
INCREASED DRAMATICALLY 
OVER THE PAST 2 YEARS.
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ITN, insecticide-treated mosquito net; LLIN, long-lasting insecticidal net; NMCP, national 
malaria control programme
*LLIN deliveries in 2014 projected from the report for the third quarter of the year
Source: NMCP reports, Malaria Atlas Project and John Milliner (Milliner Global Associates)
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Figure 3.3 Number of LLINs delivered, distributed and 
estimated in households, sub-Saharan Africa, 2004–2014
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Figure 3.4 Estimated proportion of population with access to an 
ITN compared to the number of ITNs distributed per year, by net 
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ITN, insecticide-treated mosquito net
Source: Insecticide-treated mosquito net coverage model from Malaria Atlas Project; 
household surveys
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Figure 3.5 Proportion of population sleeping under an ITN, by 
selected subpopulations, sub-Saharan Africa, 2000–2013
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Figure 3.6 Proportion of population with access to an ITN and 
proportion sleeping under an ITN, by household use of available 
ITNs, 13 countries, sub-Saharan Africa, 2012–2013
Use of ITNs among vulnerable groups such as young children and 
pregnant women is higher than in the population as a whole. Use of 
available nets by the population with access to them has been consistently 
high during the time that access to ITNs has been steadily increasing. 
Consequently, the proportion of children aged under 5 years and the 
proportion of pregnant women sleeping under an ITN has increased 
steadily over the past decade, and is even greater than the proportion of the 
population as a whole sleeping under a net (Figure 3.5). However, children 
aged 5–19 years are sleeping under ITNs at a lower rate than the population 
as a whole. 
Some households may need more than one net per two persons to 
ensure all household members are able to sleep under an ITN. The 
high level of ITN use among the population with access to nets includes 
households using their available nets at or beyond the assumed capacity of 
two persons per net, and households using nets below their full capacity. 
Analysis of household surveys from 11 countries during 2013–2014 shows 
that, in a median of 79% (range 3–30%) households, the proportion of 
the population sleeping under an ITN was equal to or greater than the 
proportion with access to a net (Figure 3.6). In approximately 21% (range 
70–97%) of households, nets were used below their capacity, with only 
65% of the population with access to an ITN sleeping under one. Due to 
household sleeping arrangements, more than one net per two persons 
may be needed in these households to ensure all household members are 
protected by an ITN.
COMMUNICATION ON ITN USE 
MAY NEED TO BE FURTHER 
TARGETED TO ENSURE FULL USE 
OF AVAILABLE NETS.
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3.3 Spraying and larval control for malaria
IRS for vector control has been widely adopted. It is applicable in 
many epidemiological settings, provided that policy and programming 
decisions take into account the operational and resource feasibility of IRS. 
For programmes conducting IRS, WHO recommends the spraying of at least 
80% (ideally 100%) of houses, structures and units in the target area in any 
round of spraying. In areas where IRS is the main form of vector control, 
the insecticide used for IRS should be rotated annually to preserve the 
eﬀ ectiveness of current compounds. IRS for vector control has been adopted 
as policy for the control of malaria in 88 countries worldwide, including 42 of 
45 malaria-endemic countries in the WHO African Region (Table 3.2).
The WHO African Region has the highest coverage rates for IRS, but the 
proportion of the at-risk population protected has decreased in recent 
years. While national programmes may target diﬀ erent proportions of the 
at-risk populations for IRS, comparison of the number of persons protected by 
IRS among the total population at risk allows for comparison of the extent to 
which IRS is used across countries and regions. National programmes reported 
that 123 million people, representing 3.5% of the global population at risk, were 
protected by IRS in 2013, decreasing from more than 5% in 2010 (Figure 3.7). 
Aside from the WHO European Region, in which populations at risk are small, 
the WHO African Region had the highest proportion of the population 
at risk protected by IRS. That proportion increased substantially during 
2006–2008, and reached 11% in 2010, but it decreased during 2010–2012; in 
2013, 55 million people were protected, representing 7% of the population 
at risk. The recent regional decrease is accounted for by changes in a few 
countries, in particular Ethiopia, which accounted for 42% of the population 
protected by IRS in the region in 2013. The proportion of the population at risk 
protected by IRS did not change substantially in other regions.
Pyrethroids were the primary class of insecticide used by countries 
implementing IRS. Among 63 countries providing information 
on insecticides used for IRS, 53 reported using pyrethroids in 2013. 
Carbamates were used by 12 countries, and 13 countries reported using an 
organophosphate. Of the 48 countries that reported on insecticides used for 
the past 3 years, seven changed from use of a pyrethroid to a non-pyrethroid 
insecticide; changing to an insecticide class with a diﬀ erent mode of action 
is one component of a comprehensive insecticide resistance management 
programme (see Section 3.4).
Larval control is used by 38 countries. Larval control involves vector 
habitat modiﬁ cation and manipulation, larviciding and biological control. 
IRS IS USED BY MOST MALARIA
ENDEMIC COUNTRIES, BUT 
GENERALLY PROTECTS ONLY A 
SMALL PROPORTION OF THE 
POPULATION AT RISK.
Table 3.2 Adoption of policies for IRS programmes, by WHO region, 2013
Policy AFR AMR EMR EUR SEAR WPR Total
IRS is recommended by malaria control programme 42 18 8 3 10 7 88
IRS is used for the prevention and control of epidemics 15 9 4 4 6 38
IRS and ITNs are used together for malaria control in at least some areas 31 11 4 5 6 57
DDT is used for IRS 9 1 11
Insecticide resistance monitoring is undertaken 37 5 6 3 3 2 56
Number of countries/areas with ongoing malaria transmission 45 21 8 3 10 10 97
Number of countries/areas with ongoing P. falciparum transmission 44 18 8 9 9 88
AFR, African Region; AMR, Region of the Americas; EMR, Eastern Mediterranean Region; DDT, dichloro-diphenyl-trichloroethane; EPI, Expanded Programme on Immu-
nization; EUR, European Region; IRS, indoor residual spraying; ITN, insecticide-treated mosquito net; LLIN, long-lasting insecticidal net; SEAR, South-East Asia Region; 
WPR, Western Paciﬁ c Region
Source: National malaria control programme reports
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WHO recommends larviciding only in settings where mosquito breeding 
sites are few, ﬁ xed and ﬁ ndable, and where these sites are easy to identify, 
map and treat. In 2013, 38 countries provided information on the use of 
larval control. Use of vector habitat manipulation (temporary changes) was 
reported by 11 countries, habitat modiﬁ cation (long-lasting transformation) 
by 10; larval control through chemical larviciding by 27, and biological 
control by 28. These reports give an indication of the range of larval control 
methods employed, although the scale of the eﬀ orts was not quantiﬁ ed 
and their impact cannot easily be measured. 
The proportion of the population in sub-Saharan Africa protected by 
at least one of the core vector control interventions (ITNs and IRS) has 
increased substantially since 2000. This increase is evident from combining 
information on the proportion of the population protected by IRS reported 
by NMCPs with the modelled estimates of the proportion of the population 
sleeping under an ITN (Figure 3.8). In 2013, nearly 50% of the population in 
sub-Saharan Africa was protected by at least one vector control intervention. 
More than 75% of the population at risk was protected by either ITNs or IRS in 
Cabo Verde, the Gambia, Sao Tome and Principe and Zimbabwe.
IN AFRICA, THE PROPORTION OF 
THE POPULATION PROTECTED 
BY AT LEAST ONE VECTOR 
CONTROL METHOD HAS 
INCREASED IN RECENT YEARS, 
AND WAS 48% 4451% IN 2013.
Figure 3.7 Proportion of population at risk protected by IRS, by WHO region, 2002–2013
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Figure 3.8 Proportion of the population at risk protected by ITNs or IRS, in sub-Saharan Africa, 2005 and 2013
IRS, indoor residual spraying; ITN, insecticide-treated mosquito net
Source: NMCP reports, insecticide-treated mosquito net coverage model 
from Malaria Atlas Project
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3.4 Insecticide resistance management
The eff ectiveness of vector control is threatened as malaria 
mosquitoes develop resistance to the insecticides used in ITNs and 
IRS. Current global malaria control eﬀ orts rely heavily on a single insecticide 
class: pyrethroids. This is the only class used in LLINs, and it is also applied 
in many IRS programmes (although three other insecticide classes are also 
used in IRS). Resistance of malaria vectors to insecticides has the potential 
to compromise the gains achieved through malaria vector control, and limit 
any further success. 
Recognizing the threat posed by insecticide resistance, WHO released 
the Global plan for insecticide resistance management in malaria vectors 
(GPIRM) (27). The GPIRM emphasises ﬁ ve strategies: undertake resistance 
monitoring; implement insecticide resistance management strategies; ﬁ ll 
knowledge gaps on mechanisms of insecticide resistance and the impact of 
resistance management; develop new vector control tools; and ensure that 
key enabling mechanisms are in place.
A system has been established to track insecticide resistance globally 
in line with the GPIRM. WHO is coordinating international reporting 
of resistance data using a standardized tool. Bioassay data have been 
reported by 81 countries. Challenges include a lack of consolidated data 
at the national level, incomplete reporting of available data, and limited 
information on resistance mechanisms.
Many countries using insecticides for vector control were not 
monitoring insecticide resistance in 2013. Among the 96 countries that 
reported adopting policies for vector control with ITNs or IRS in 2013, only 82 
reported that monitoring of insecticide resistance is undertaken, and only 
42 countries provided resistance data for 2013, suggesting that monitoring 
is not conducted annually, as recommended in the GPIRM (Figure 3.9). 
Monitoring activities have increased since 2000, particularly in the WHO 
African Region. Few countries consistently test all insecticides against all 
local species of malaria vectors at each monitoring site. Pyrethroids are the 
most commonly tested, because of their extensive use in LLINs and IRS. 
INSECTICIDE RESISTANCE 
MONITORING AND REPORTING 
ARE KEY COMPONENTS OF 
INSECTICIDE RESISTANCE 
MANAGEMENT STRATEGIES.
Figure 3.9 Number of countries reporting insecticide resistance monitoring results, by insecticide class and years of monitoring 
activity
2010–20132005–20092000–2004
Source: National malaria control programme reports, African Network for Vector Resistance, Malaria Atlas Project, President’s Malaria Initiative, published literature
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Insecticide resistance, especially to pyrethroids, is widespread in 
malaria vectors. Of the 63 countries reporting any monitoring data for 
2010–2013, 49 reported resistance to at least one insecticide in one malaria 
vector from one collection site (Figure 3.10), and 39 countries reported 
resistance to two or more insecticide classes. Pyrethroid resistance was the 
most commonly reported (Figure 3.9); in 2013, two thirds of the countries 
monitoring this class reported resistance.
Recommendations of the GPIRM are slowly being implemented at 
the country level. In 2013, 14 of 63 countries reported the use of multiple 
insecticides of diﬀ erent classes for IRS. Seven countries that used pyrethroids 
for IRS in 2011 or 2012 used an alternative class with a diﬀ erent mode 
of action in 2013. In six cases this change was associated with a decline 
in IRS coverage, possibly due to the higher cost of the alternative. The 
GPIRM recommends that country programmes develop long-term plans 
for insecticide resistance monitoring and management that include full 
costing of activities. Development of these plans has only just begun: seven 
countries in the WHO African Region have such plans in place while there 
has been limited progress in development of plans in other WHO regions. 
International initiatives in support of GPIRM have commenced. In 
2013, WHO established a Vector Control Advisory Group to facilitate the 
development of new tools, approaches and technologies, and to shorten 
the process of bringing these to market. To improve aﬀ ordability of existing 
and new tools, initiatives such as pooled procurements, improved global 
forecasting, long-term contracts and tax incentives are being explored. WHO 
is also supporting the development of comprehensive regional and national 
databases on insecticide resistance. Information will be used to inform 
locally appropriate vector control, guide policy for managing insecticide 
resistance and facilitate resource mobilization for implementation.
SINCE 2010, INSECTICIDE 
RESISTANCE HAS BEEN 
REPORTED IN 49 COUNTRIES.
Figure 3.10 Countries reporting resistance since 2010, by number of insecticide classes
Source: National malaria control programme reports, African Network for Vector Resistance, Malaria Atlas Project, President’s Malaria Initiative, published literature
Reported resistance status from standard tests
No resistance detected to any classes tested
Conﬁrmed resistance (<90% mortality) to one class
Conﬁrmed resistance to two classes
Conﬁrmed resistance to three classes
Conﬁrmed resistance to four classes
No data reported
No ongoing malaria transmission
Not applicable
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Malaria can have devastating consequences in pregnant women and 
in children. In areas of high transmission, WHO recommends targeting 
these high-risk groups with chemoprevention strategies. Three safe 
and cost-eﬀ ective strategies are available: IPTp with SP, delivered at each 
scheduled ANC visit after the ﬁ rst trimester; SMC with AQ+SP for children 
aged 3–59 months in areas of highly seasonal malaria transmission across 
the Sahel subregion; and IPTi with SP, delivered at the time of the second 
and third diphtheria–tetanus–pertussis (DTP) and measles vaccination. 
IPTi is only recommended in areas with moderate to high transmission 
(entomological inoculation rate ≥10), where resistance to SP is low, and 
where SMC is not concurrently implemented (28). WHO is also evaluating 
the results of clinical trials of vaccines to reduce malaria incidence in young 
children.
4.1 Chemoprevention in pregnant women
Impressive increases in the proportion of pregnant women receiving 
IPTp have been limited by missed opportunities to deliver IPTp during 
ANC visits. IPTp has been adopted in 37 countries in sub-Saharan Africa and 
in Papua New Guinea, in the WHO Western Paciﬁ c Region (Table 4.1). The 
proportion of pregnant women attending ANC clinics and the proportion 
receiving IPTp can be estimated from data reported by NMCPs and from 
household surveys. In data reported by NMCPs for 2013, a median 89% of 
pregnant women in 31 reporting countries attended ANC at least once, 
while 57% received at least one dose of IPTp among 30 reporting countries 
(Figure 4.1). A median of 43% of pregnant women received two doses 
of IPTp among 31 reporting countries, and 17% of all pregnant women 
received three or more doses of IPTp among nine reporting countries. The 
large diﬀ erence between the proportion of women attending ANC clinics 
at least once and the proportion receiving the ﬁ rst dose of IPTp suggests 
a number of missed opportunities for delivery of IPTp at ANC clinics. The 
proportion of pregnant women receiving at least one dose of IPTp increased 
markedly from 2000–2007, and at a slower pace thereafter (Figure 4.2).
4. PREVENTIVE 
THERAPIES FOR 
MALARIA
THE PROPORTION OF 
PREGNANT WOMEN RECEIVING 
AT LEAST ONE DOSE OF IPTp 
INCREASED MARKEDLY FROM 
20002007 AND AT A SLOWER 
PACE THEREAFTER.
Table 4.1 Adoption of policies for national chemoprevention, by WHO region, 2013
Policy AFR AMR EMR EUR SEAR WPR Total
Intermittent preventive treatment in pregnancy 34 – 2 – – 1 37
Intermittent preventive treatment for infants 1 – – – – – 1
Seasonal malaria chemoprevention 6 – – – – – 6
Number of countries with ongoing malaria transmission 45 21 8 3 10 10 97
AFR, African Region; AMR, Region of the Americas; EMR, Eastern Mediterranean Region; EPI, Expanded Programme on Immunization; EUR, European Region; ITN, 
insecticide-treated mosquito net; LLIN, long-lasting insecticidal net; SEAR, South-East Asia Region; WPR, Western Paciﬁ c Region
–, not applicable
Source: National malaria control programme reports
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4.2 Chemoprevention in children and infants
Eff ective implementation of SMC requires adequate resources. As of 
2013, six of the 16 countries in which SMC may be appropriate – Chad, 
Congo, Mali, the Niger, Senegal and Togo – had adopted national SMC 
policies. An adequate drug supply and proper training is needed to 
distribute SP to the target population during the rainy season year after year. 
Recently, the ﬁ nancial resources needed to support SMC implementation 
have been mobilized, exempliﬁ ed by an initiative to approve Global Fund 
grant proposals to support SMC implementation for the 2015–2017 rainy 
seasons across the Sahel subregion (29). Consequently, more countries may 
be able to implement SMC in the future.
Adoption and implementation of IPTi has been slow. Despite the 
WHO IPTi policy recommendation in 2010 (30) and the IPTi Implementation 
ﬁ eld guide, published in 2011 (31), only Burkina Faso has adopted IPTi as 
national policy, and the country has not begun implementation. Reasons 
for the slow progress are unclear, but may be related to the diﬃ  cultly in 
coordinating an intervention across health programmes, the complexity of 
recommendations, and concerns about parasite resistance to SP.
Four malaria vaccines are undergoing fi eld trials. As of July 2014, three 
candidate vaccines are in Phase 2B clinical trials and one has completed 
Phase 3, with a total 25 projects in the pipeline (32). The results from the 
18-month follow-up Phase 3 clinical trial for RTS,S/AS01 were released in 
July 2014. The reduction in severe malaria incidence in vaccine recipients 
was 46% among children and 27% among infants who received all planned 
doses of RTS,S/AS01, compared to their control group counterparts (33). 
A WHO decision regarding a policy recommendation for use is expected in 
2015, after review of the booster dose data, additional research, and expert 
consultations.
INCREASES IN THE DELIVERY 
OF IPTp HAVE BEEN 
IMPRESSIVE, DESPITE MISSED 
OPPORTUNITIES FOR DELIVERY 
DURING ANC CLINIC VISITS.
IPTp, intermittent preventive treatment in pregnancy; NMCP, national malaria control programme
* Median proportions using household data are based on six-year trend analyses
Source: Demographic health surveys, malaria indicator surveys, multiple indicator cluster surveys 
and other household survey data, NMCP reports, UN population estimates
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Figure 4.2 Proportion of pregnant women receiving IPTp, by 
dose, by year of pregnancy in survey and by reporting year for 
NMCP, Africa, 2000–2013
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countries reporting, 2013
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5.1 Adoption of 2010 recommendations 
from WHO
Most malaria-endemic countries have adopted WHO’s policy to test all 
patients with suspected malaria. WHO recommends that all persons in 
all epidemiological settings with suspected malaria should be examined for 
evidence of infection with malaria parasites by either microscopy or RDT 
(34). This policy has been adopted by 89 of the 99 countries with ongoing 
malaria transmission, and diagnostic testing is free of charge in the public 
sector in 86 countries (Table 5.1). Combination RDTs, which can detect 
more than one species of Plasmodium, are available in the public sector in 
40 of 47 countries endemic for both P. falciparum and P. vivax. 
The proportion of suspected malaria cases receiving a malaria 
diagnostic test has increased markedly since 2010, especially in Africa. 
The proportion of suspected cases receiving a parasitological test in the 
public sector can be calculated from information on testing and malaria cases 
reported by NMCPs. The proportion of suspected cases tested is highest in 
the WHO Region of the Americas and the WHO European Region, followed 
by the WHO South-East Asia Region, the WHO Western Paciﬁ c Region and 
the WHO Eastern Mediterranean Region. The WHO African Region has 
seen the largest increase in the proportion of suspected cases tested, from 
47% in 2010 – when WHO’s recommendation to test all suspected malaria 
cases was introduced – to 62% in 2013 (Figure 5.1). The recent increase in 
testing in the WHO African Region is mainly due to an increase in the use 
of RDTs, which has doubled since 2010 and accounted for 52% of all cases 
tested in 2013. The reported testing rate may overestimate the true extent 
of diagnostic testing in the public sector, because it depends on factors 
that may be lacking, such as accurate reporting of presumed malaria cases. 
However, reporting bias, whereby countries with higher testing rates have 
a greater propensity to report, appears to be limited. In the WHO African 
Region, for example, the proportion of suspected cases tested among seven 
countries reporting consistently since 2001 was only slightly higher (67%) 
than the proportion among 31 countries reporting inconsistently since 
2001 (60%). 
5. DIAGNOSTIC 
TESTING FOR 
MALARIA
THE PROPORTION OF 
SUSPECTED MALARIA CASES 
RECEIVING A DIAGNOSTIC TEST 
HAS INCREASED MARKEDLY 
SINCE THE 2010 INTRODUCTION 
OF WHO’S RECOMMENDATION 
TO TEST ALL SUSPECTED 
MALARIA CASES.
Table 5.1 Adoption of policies for malaria diagnosis, by WHO region, 2013
Policy AFR AMR EMR EUR SEAR WPR Total
Patients of all ages should undergo diagnostic test 41 21 8 3 8 8 89
Malaria diagnosis is free of charge in the public sector 37 21 7 3 10 8 86
Combination RDTs are available in public sector 17 9 1 6 7 40
RDTs used at community level 26 8 2 7 5 48
Number of countries/areas with ongoing malaria transmission 45 21 8 3 10 10 97
AFR, African Region; AMR, Region of the Americas; EMR, Eastern Mediterranean Region; EPI, Expanded Programme on Immunization; EUR, European Region; 
ITN, insecticide-treated mosquito net; LLIN, long-lasting insecticidal net; RDT, rapid diagnostic test; SEAR, South-East Asia Region; WPR, Western Paciﬁ c Region
Source: National malaria control programme reports
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5.2 Testing in the private and public sector
The proportion of suspected cases receiving a diagnostic test is lower 
among patients seeking care in the private sector compared to the 
public sector. Data reported by NMCPs on the number of patients examined 
by microscopy or RDTs generally cover the public sector only. However, 
worldwide, about 40% of patients with suspected malaria seek treatment 
in the private sector (which includes private health facilities, pharmacies 
and other retail outlets). Information on the extent of parasitological testing 
in the private sector can be derived from household surveys. Among 
41 household surveys conducted during 2009–2013, the proportion of 
children aged under 5 years who received a blood test for fever (a proxy for 
suspected malaria) was lower in the private sector (median across surveys 
9%, interquartile range [IQR] 6–18%) than in the public sector (median 
across surveys 31%, IQR 17–43%) (Figure 5.2). Overall, a large proportion 
of children with fever in surveyed countries did not seek care (median 34%, 
IQR 29–38%), and therefore were not tested. Consequently, only a minority 
(median 17%, IQR 9–27%) of all febrile children received a parasitological 
test for malaria among countries surveyed during 2009–2013. 
The extent of diagnostic testing for malaria in the public sector measured 
through a household survey is not directly comparable to that reported 
by NMCPs, in part because surveys are usually conﬁ ned to children aged 
under 5 years, whereas NMCPs report on suspected cases in patients of all 
ages. However, in most surveys, the proportion of febrile children seeking 
care in the public sector who received a blood test fell within the range of 
suspected cases receiving a malaria diagnostic test as reported by NMCPs 
(Figure 5.2). Although only a few household surveys are conducted each 
year, the median proportion of febrile children receiving a diagnostic test 
was higher in the 16 surveys conducted during 2012–2013 (31%) than in the 
17 surveys conducted during 2009–2010 (17%).
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EUR, European Region; RDT, rapid diagnostic test; SEAR, South-East Asia Region; WPR, 
Western Paciﬁc Region
Source: National malaria control programme reports
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Figure 5.1 Proportion of suspected malaria cases attending 
public health facilities that receive a diagnostic test, by WHO 
region, 2000–2013
Pr
op
or
tio
n 
IQR, interquartile range; NMCP, national malaria control programme
Source: NMCP reports and household surveys
100%
80%
60%
40%
20%
0%
2012201120102009200820072006200520042003200220012000 2013
Suspected malaria cases receiving a malaria diagnostic test, NMCP (IQR)
Febrile children receiving blood test, public sector (proportion by survey)
Febrile children receiving blood test, private sector (proportion by survey)
Figure 5.2 Proportion of febrile children receiving a blood test, by 
health sector, in household surveys, and proportion of suspected 
malaria cases receiving a parasitological test in NMCP reports, 
sub-Saharan African countries with available data, 2000–2013
DESPITE IMPRESSIVE INCREASES 
IN DIAGNOSTIC TESTING, THE 
PRIVATE HEALTH SECTOR LAGS 
BEHIND THE PUBLIC SECTOR.
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5.3 Availability and quality of malaria 
diagnostic tests
Increased testing of suspected malaria cases is supported by a greater 
number of RDTs supplied by manufacturers and distributed by NMCPs. 
Sales of RDTs reported by manufacturers reached 319 million in 2013 (up 
from 46 million in 2008), of which 59% were for P. falciparum-speciﬁ c tests 
and 39% for combination tests (i.e. those that can detect more than one 
species). RDT sales reported by manufacturers represent global totals for 
both the public and private sector. The reported number of RDTs distributed 
by NMCPs provides information on the numbers of RDTs distributed in the 
public sector only; however, it also provides information on where the tests 
are used. The total number of RDTs distributed by NMCPs increased rapidly, 
from fewer than 200 000 in 2005 to more than 160 million in 2013 (Figure 
5.3). Most of the RDTs delivered in 2013 (83%) were used in the WHO African 
Region, followed by the WHO South-East Asia Region (11%) and the WHO 
Eastern Mediterranean Region (3%). These totals underestimate the total 
quantity of RDTs distributed, because data were missing from seven of the 
44 countries in the WHO African Region with ongoing malaria transmission 
in 2013. There is also likely to be a time lag between sale, delivery and 
distribution. However, the upward trend in RDT distributions by NMCPs 
mirrors that of RDT sales reported by manufacturers.
Increased testing of suspected malaria cases is due in part to a 
higher number of patients tested by microscopy, both in the WHO 
African Region and globally. The global total of 197 million microscopic 
examinations performed was dominated by India, which accounted for over 
120 million slide examinations in 2013. The reported number of microscopic 
examinations in the WHO African Region increased from 33 million in 2010 
to 50 million in 2013. Among 28 countries in Africa supplying information on 
microscopy consistently since 2010, 22 reported an increase in microscopic 
examinations performed in 2013 compared to 2010 (Figure 5.4).
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AFR, African Region; AMR, Region of the Americas; EMR, Eastern Mediterranean Region; 
EUR, European Region; NMCP, national malaria control programme; RDT, rapid diagnostic 
test; SEAR, South-East Asia Region; WPR, Western Paciﬁc Region
Source: Data provided by manufacturers eligible for the WHO Foundation for Innovative New 
Diagnostics/ US Centers for Disease Control and Prevention Malaria Rapid Diagnostic Test 
Product Testing Programme
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Figure 5.3 Number of RDT sales to public and private sectors 
and number of RDTs distributed by NMCPs, by WHO region, 
2005–2013
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Figure 5.4 Number of microscopic examinations performed for 
malaria, by WHO region, 2000–2013
SALES AND DISTRIBUTIONS OF 
MALARIA RDTs HAVE INCREASED 
DRAMATICALLY IN THE PAST 
5 YEARS.
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In 2013, for the fi rst time, the total number of diagnostic tests provided 
exceeded the number of ACTs distributed in the public sector in the WHO 
African Region (Figure 5.5). This result is encouraging since most patients 
tested for malaria will not require treatment; hence, the number of diagnostic 
tests required should always exceed the number of treatments. Given that test 
positivity rates in most areas of Africa are below 50%, the ratio of diagnostic 
tests to ACTs should be at least two if all suspected cases of malaria receive a 
diagnostic test. Thus, while substantial progress has been made, there remains 
further scope to increase diagnostic testing through RDTs and microscopy, 
both in the public and private sector. Increased malaria diagnostic testing 
requires appropriate planning, budgeting and procurement. NMCPs and their 
supporting donors should aim to procure an appropriate number of RDTs and 
ACTs, in accordance with WHO procurement guidance (35). 
The quality of available RDTs continues to be high. RDT product quality 
testing has been conducted since 2008 by WHO, the Foundation for 
Innovative New Diagnostics (FIND), the Special Programme for Research 
and Training in Tropical Diseases (TDR) and the Centers for Disease Control 
and Prevention (CDC). RDT products are assessed against samples of known 
malaria parasite species and density, with each product assigned a panel 
detection score that is based on the sensitivity and reliability of the results. 
Product quality testing undertaken in 2013 showed that most products 
had a high rate of detection of P. falciparum at parasite densities of 2000 
parasites/μL; the same was true of most products for P. vivax (Figure 5.6). At 
low parasite densities (200 parasites/μL), 76% of P. falciparum products but 
only 42% of P. vivax products had acceptable panel detection scores. Work is 
ongoing to improve RDT quality control, including development of positive 
control wells that will help ensure test results are appropriately interpreted 
at the point of care.
THE NUMBER OF DIAGNOSTIC 
TESTS FOR MALARIA IN THE 
PUBLIC SECTOR IS OVERTAKING 
THE NUMBER OF ACTs 
DISTRIBUTED.
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Figure 5.5 Ratio of malaria diagnostic tests (RDTs and 
microscopy) provided to ACTs distributed by NMCPs, WHO 
African Region, 2006–2013
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Figure 5.6 Panel detection score of RDT products evaluated in 
Round 5 RDT product testing programme
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6.1 Use of artemisinin-based combination 
therapy
Most countries with P. falciparum malaria have adopted ACTs as a 
fi rst-line treatment. WHO recommends that uncomplicated P. falciparum 
malaria should be treated with an ACT (34). In areas where chloroquine 
is still eﬀ ective, P. vivax malaria should be treated with this drug. Where 
resistance to chloroquine has been documented, P. vivax malaria should be 
treated with an appropriate ACT. To prevent relapses, both chloroquine and 
ACT should be combined with a 14-day course of primaquine, subject to 
consideration of the risk of haemolysis in patients with glucose-6-phosphate 
dehydrogenase (G6PD) deﬁ ciency. In areas where there is a threat of 
artemisinin resistance and in areas targeted for malaria for P. falciparum 
elimination, a single primaquine dose (0.25 mg/kg) should be given to all 
patients with conﬁ rmed P. falciparum on the ﬁ rst day of their ACT treatment. 
In 2013, ACTs had been adopted as national policy for ﬁ rst-line treatment in 
79 of 88 countries where P. falciparum is endemic (Table 6.1); chloroquine 
is used in 10 Central American and Caribbean countries where it remains 
eﬃ  cacious. A single dose of primaquine was being used for gametocidal 
treatment of P. falciparum cases in 37 low-transmission countries to further 
reduce malaria transmission. In 55 of 56 countries with transmission of 
P. vivax malaria, primaquine was being used for treatment of the hypnozoite 
stage of P. vivax malaria.
The proportion of children in sub-Saharan Africa with P. falciparum 
malaria receiving an ACT has increased markedly since 2005, but 
remained below 20% in 2013. Although household surveys only record 
whether a child has a fever, the results of RDTs performed at the time of the 
survey (to estimate parasite prevalence in children) can be used as a proxy 
for malaria parasite infection in the preceding 2 weeks. Data obtained from 
the same household survey can indicate whether the patient received an 
ACT. In sub-Saharan Africa, the estimated proportion of children aged under 
5 years with conﬁ rmed P. falciparum malaria that received an ACT increased 
steadily from less than 5% in 2005, though it remains low, reaching a range 
of 9–26% in 2013 (Figure 6.1). Among children who were brought for care at 
public health facilities, the proportion with conﬁ rmed P. falciparum malaria 
who received ACT was higher than the overall total for sub-Saharan Africa, 
and ranged from 16 to 41% in 2013.
6. MALARIA 
TREATMENT
ACTs ARE WIDELY USED FOR 
TREATMENT OF MALARIA, AND 
AN INCREASING PROPORTION 
OF MALARIA CASES ARE BEING 
TREATED WITH ACTs IN BOTH 
THE PUBLIC AND PRIVATE 
SECTORS.
Table 6.1 Adoption of policies for malaria treatment, by WHO region, 2013
Policy AFR AMR EMR EUR SEAR WPR Total
ACT is used for treatment of P. falciparum 43 9 8 1 9 9 79
Pre-referral treatment with quinine/artemether IM/artesunate suppositories 40 4 5 5 3 57
Single dose primaquine used as gametocidal for P. falciparum 3 19 4 1 7 3 37
Primaquine is used for radical treatment of P. vivax cases 7 20 6 3 10 9 55
Directly observed treatment with primaquine is undertaken 3 11 2 3 3 4 27
G6PD test is recommended before treatment with primaquine 5 4 2 6 17
Number of countries/areas with ongoing malaria transmission 45 21 8 3 10 10 97
Number of P. falciparum endemic countries/areas 44 18 8 0 9 9 88
Number of P. vivax endemic countries/areas 7 20 6 3 10 10 56
Number of countries/areas endemic for both P. falciparum and P. vivax 6 17 6 0 9 9 47
ACT, artemisinin-based combination therapy; AFR, African Region; AMR, Region of the Americas; EMR, Eastern Mediterranean Region; EUR, European Region; 
G6PD, glucose-6-phosphate dehydrogenase; IM, intramuscular; SEAR, South-East Asia Region; WPR, Western Paciﬁ c Region 
Source: National malaria control programme reports
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Figure 6.1 Estimated proportion of children aged under 5 years 
with conﬁ rmed P. falciparum malaria who received ACTs, sub-
Saharan Africa, 2002–2013
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Figure 6.2 Proportion of febrile children presenting for 
treatment, by health sector, WHO African Region, 29 countries, 
2000–2013
The low proportion of children in sub-Saharan Africa with malaria 
receiving an ACT is due in large part to febrile children not being 
brought for care. Information from household surveys conducted during 
the last decade in sub-Saharan Africa indicates that approximately 40% of 
children with fever do not present for treatment; also, of those who are 
brought for care, approximately 20% seek attention in the informal private 
sector (pharmacies and shops) where rates of malaria diagnostic testing 
are low and where ACT treatments are less likely to be available (Figure 
6.2). Most children who are brought for care attend public health facilities, 
and a small proportion seek care in the formal private sector (clinics and 
other regulated facilities), where rates of malaria diagnostic testing and 
appropriate treatment are higher than in the informal private sector. Eﬀ orts 
to increase access to treatment in the community are ongoing, but only a 
small proportion of febrile children in sub-Saharan Africa seek care there. 
Access to malaria treatment and eﬀ orts to encourage caregivers to bring 
children to health-care facilities need to increase, to ensure all patients with 
malaria are appropriately treated.
The increasing proportion of malaria cases treated with ACTs is 
supported by increased numbers of ACT treatment courses delivered 
by manufacturers. The number of ACT treatment courses procured 
from manufacturers by both public and private sectors has increased 
greatly, rising from 11 million in 2005 to 392 million in 2013 (Figure 6.3). 
Artemether-lumefantrine (AL) accounts for the largest volume of ACTs 
procured (73% in 2013), followed by artesunate plus amodiaquine (26%). 
Fixed-dose combination ACTs, with the two medicines combined in the 
same tablet, are preferred because of improved patient adherence to the 
recommended regimen; such ACTs accounted for nearly 100% of all ACT 
sales. The increase in the number of ACTs procured in 2013 was largely due 
to increased procurements from the public sector.
THE PROPORTION OF CHILDREN 
WITH MALARIA RECEIVING AN 
ACT IN SUBSAHARAN AFRICA IS 
LOW, PARTLY BECAUSE ONLY A 
SMALL PROPORTION SEEK CARE 
AT FORMAL HEALTH FACILITIES.
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ACT, artemisinin-based combination therapy; AL, artemether-lumefantrine; AMFm, 
Aﬀordable Medicine Facility–malaria; AQ, amodiaquine; AS, artesunate; Co-B, co-blister; 
FDC, ﬁxed-dose combination; MQ, meﬂoquine; SP, sulfadoxine-pyrimethamine
Source: ACT deliveries (2005–2013*), data provided by eight companies eligible for procurement 
by WHO/UNICEF. 
*2005–2009 data reﬂects public sector only; 2010– 2013 data includes public sector plus AMFm 
(public and private sectors).
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Figure 6.3 ACT deliveries from manufacturers to the public and 
private sectors, by drug and presentation, 2005–2013
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Figure 6.4 Number of ACT treatment courses distributed by 
NMCPs, by WHO region, and ACT treatment courses delivered to 
the public sector, 2005–2013
THE PROPORTION OF 
MALARIA CASES TREATED 
WITH ACTs IS INCREASING AS 
MANUFACTURERS DELIVER 
GREATER NUMBERS OF 
TREATMENT COURSES.
Increasing quantities of ACTs are being distributed by ministries of 
health worldwide, and particularly in Africa. Manufacturer procurement 
data describes the total number and type of ACTs delivered, whereas the 
number of ACTs distributed reported by NMCPs provides information on 
where ACTs procured are deployed by the public sector. The number of 
ACTs distributed increased from 98 million in 2009 to 181 million in 2013 
(Figure 6.4). The WHO African Region accounted for 172 million of 181 million 
treatments distributed worldwide in 2013. The totals reported by NMCPs do 
not match the number of ACTs delivered by manufacturers to the public 
sector, which totalled 259 million treatments in 2013. This discrepancy is 
reduced if ACT procurements from international donor reports for countries 
with missing NMCP data are taken into account, but more work is needed 
to understand diﬀ erences between the sources of data.
The number of ACTs distributed reported by NMCPs is progressively 
nearing the number of malaria patients attending public health 
facilities. The number of ACT treatments distributed, when compared to 
presumed and conﬁ rmed P. falciparum cases at public health facilities, has 
increased over time, reaching 70% in 2013 (IQR 51–88%) among 31 countries 
in the WHO African Region that reported suﬃ  cient information (Figure 6.5).
A similar calculation comparing the number of treatment courses of 
primaquine for radical treatment of P. vivax to the estimated number of 
P. vivax cases attending health facilities shows that, in 2013, more than half 
(18/32) of reporting programmes from all WHO regions distributed suﬃ  cient 
primaquine courses to treat all P. vivax cases.
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ACTs have been progressively replacing other antimalarial treatments 
in both the public and private sectors. Information on ACT treatments 
obtained from household surveys also provides information on malaria 
treatment received by febrile children seeking care in both the public and 
private health sectors, and among those who are not brought for care. The 
proportion of patients receiving ACTs, among all patients who received 
antimalarial medicines, has varied over time for patients receiving care in 
both the public and private sectors (Figure 6.5). In a substantial proportion 
of household surveys, the proportion of treated malaria patients receiving 
ACTs in the public sector falls within the range of that estimated through 
NMCP reports.
Increased malaria diagnostic testing could help direct available 
ACTs to more patients with malaria parasite infection. By considering 
the proportion of malaria patients that could be treated with distributed 
ACTs, the proportion of suspected malaria cases tested and the malaria 
test positivity rate, it is possible to estimate the number of ACT treatments 
received by those patients with or without conﬁ rmed malaria (Figure 6.6). 
For patients attending public health facilities, the estimated proportion of 
conﬁ rmed malaria cases receiving ACTs has increased steadily since 2005. 
At the same time, however, due to the large number of patients treated 
presumptively without a malaria diagnostic test, the proportion of patients 
without malaria receiving an ACT has also risen. If diagnostic testing 
were increased further, and providers adhered to the test results, the ACT 
treatments saved would be suﬃ  cient to treat the conﬁ rmed malaria cases 
that currently do not receive ACTs.
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malaria control programme
Source: NMCP and household survey data
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Figure 6.5 Proportion of children receiving ACT among 
all receiving antimalarials, by public and private sector, in 
household surveys, and proportion of ACT treatment courses 
distributed as a proportion of treated malaria cases in public 
sector, from NMCP reports, sub-Saharan Africa, 2005–2013
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Figure 6.6 Estimated ACT treatments received among malaria 
cases at public health facilities, WHO African Region, 
2005–2013
MALARIA TREATMENTS NEED 
TO BE BETTER DIRECTED TO 
TARGET PATIENTS WITH POSITIVE 
DIAGNOSTIC TEST RESULTS.
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6.2 Antimalarial drug resistance
The number of countries that allow marketing of oral artemisinin-
based monotherapy medicines has declined rapidly. The use of such 
therapies threatens the long-term usefulness of ACTs, because it fosters the 
spread of resistance to artemisinin. WHO recommends that oral artemisinin-
based monotherapies be withdrawn from the market and that marketing 
of these therapies should cease. The number of countries that allow the 
marketing of oral artemisinin-based monotherapies has dropped markedly 
since the World Health Assembly adopted a resolution supporting the ban 
in 2007 (Figure 6.7). As of December 2014, marketing of artemisinin-based 
monotherapies was allowed by only eight countries: Angola, Cabo Verde, 
Colombia, Equatorial Guinea, the Gambia, Sao Tome and Principe, Somalia 
and Swaziland. Also, as of December 2014, 24 pharmaceutical companies, 
half located in India, continued to market oral artemisinin monotherapies.
An increasing number of countries have conducted therapeutic 
effi  cacy studies (TES) for antimalarial medicines. Such studies remain the 
gold standard for guiding antimalarial treatment policy; WHO recommends 
that studies of ﬁ rst- and second-line antimalarial medicines be conducted 
once every 2 years at sentinel sites within each country. For the most recent 
2-year period with available information, studies of ﬁ rst- or second-line 
antimalarial treatments were completed in 48 of 67 (72%) countries where 
P. falciparum eﬃ  cacy studies were feasible (i.e. there were enough cases 
to test), an increase from 41% of countries that conducted studies during 
2008–2009 (Figure 6.8). The proportion of patients who are parasitaemic on 
day 3 of treatment is the indicator used during routine monitoring to identify 
suspected artemisinin resistance in P. falciparum. Recently, a molecular 
marker of artemisinin resistance was identiﬁ ed: speciﬁ c mutations in the 
Kelch 13 (K13)-propeller domain were found to be associated with delayed 
parasite clearance. This may open new possibilities for tracking resistance 
to artemisinin.
EFFECTIVE MANAGEMENT 
OF ANTIMALARIAL DRUG 
RESISTANCE INCLUDES 
BANNING MONOTHERAPIES, 
AND MONITORING 
ANTIMALARIAL EFFECTIVENESS 
REGULARLY.
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Figure 6.7 Number of countries allowing marketing of oral 
artemisinin-based monotherapies by WHO region, 2008–2013
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Figure 6.8 Status of therapeutic eﬃ  cacy monitoring in countries 
with ongoing malaria transmission, 2008–2012
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Resistance of P. falciparum to artemisinin has been detected in fi ve 
countries in the Greater Mekong subregion. Drug eﬃ  cacy studies have 
detected resistance of P. falciparum to artemisinins in Cambodia, the Lao 
People’s Democratic Republic, Myanmar, Thailand and Viet Nam (Figure 6.9). 
Despite changes in parasite sensitivity to artemisinins in these countries, 
ACTs have generally remained clinically and parasitologically eﬃ  cacious, 
provided the partner drug remains eﬃ  cacious. Resistance in P. falciparum to 
most currently available antimalarial medicines has been detected in areas 
at the border of Cambodia and Thailand, complicating the choice of eﬀ ective 
treatment for medical practitioners. P. falciparum resistance to artemisinins 
has not been detected outside of the Greater Mekong subregion. Reports 
of an increased proportion of day-3 positive patients after treatment with 
ACTs in TES conducted in two South American countries are still being 
investigated. Conﬁ rmed chloroquine resistance in P. vivax, which requires 
measurement of drug blood levels, has been detected in 10 countries; ACTs 
are now recommended for the treatment of chloroquine-resistant P. vivax.
The identifi cation of multidrug resistance, including artemisinin 
resistance, in the Greater Mekong subregion makes elimination 
of P. falciparum transmission in this region an important goal. As a 
follow-up to the Global plan for artemisinin resistance containment (GPARC) 
(36), launched in 2011, WHO released the Emergency response to artemisinin 
resistance in the Greater Mekong subregion: A regional framework for 
action 2013–2015 (ERAR) (37) in 2013. The emergency plan provides further 
guidance for ﬁ eld implementation of the containment activities outlined 
in the GPARC. The conﬁ rmation of independent emergence of P. falciparum 
resistance to artemisinins in diﬀ erent locations in the Greater Mekong 
subregion, and the development of resistance to most available antimalarial 
medicines at the border between Cambodia and Thailand, highlight the 
importance of eliminating P. falciparum transmission in the region. Such 
elimination is considered technically and operationally feasible, and was 
endorsed as a goal by the MPAC in September 2014.
RESISTANCE OF P. FALCIPARUM 
TO MULTIPLE ANTIMALARIAL 
MEDICINES HAS BEEN 
DETECTED IN AREAS AT THE 
BORDER OF CAMBODIA AND 
THAILAND.
Figure 6.9 Areas, or tiers, of diﬀ ering risks of artemisinin resistance, 
South-East Asia, December 2014
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Despite impressive increases in malaria intervention coverage, 
millions of people still do not receive the services they need. Based 
on the results presented in Sections 3–6 of this report, it can be estimated 
that, in sub-Saharan Africa in 2013, some 278 million of the 840 million 
people at risk of malaria lived in households without an ITN, 15 million of 
the 35 million pregnant women at risk did not receive IPTp, and between 56 
and 69 million of the 76 million children with malaria did not receive an ACT. 
Gaps in service coverage are evident in all countries that have NMCPs. To 
design programmes that can ﬁ ll these gaps, it is important to have a good 
understanding of the factors responsible for low intervention coverage. 
Some insight can be gained by examining household surveys (which 
document the characteristics of people who do not receive services), and 
by decomposing the explained variance in regression models (which aim 
to identify the factors that are most strongly associated with gaps in service 
coverage) (see Annex 1). 
Poverty and low education are signifi cant predictors of coverage 
gaps for ITNs, IPTp, fever care, diagnostic testing and receipt of ACTs. 
Based on nationally representative household survey data for countries in 
sub-Saharan Africa, in 2011–2013, a median 41% of households did not 
have an ITN (IQR 30–53%, Figure 7.1). Being poor (i.e. in the lowest wealth 
quintile) was the most important predictor of living in a household without 
an ITN (Figure 7.2). Other important factors were the household not having 
a child aged under 5 years or a pregnant woman, being in a rural area, and 
having a head of household with no formal education. 
Poverty was the strongest factor associated with being among the 33% of 
pregnant women that did not receive IPTp (IQR 23–43%) (Figure 7.2). Other 
factors that were signiﬁ cant were having previously given birth, being aged 
under 20 years, having no formal education or living in a rural area. For 
children that did not receive any care for fevers (median 41%, IQR 29–45%), 
strong predictors for not receiving care were being an older child (aged >1 
year of age) or having a household head with no formal education. Predictors 
for not receiving a diagnostic test (75% of children with fever, IQR 70–87%) 
were living in a rural area and poverty, whereas the strongest predictor for 
not receiving an ACT (57% of children with fever, IQR 31–71%), was low 
educational attainment, followed by living in a rural area and being poor. 
7. GAPS IN 
INTERVENTION 
COVERAGE
IN SUBSAHARAN AFRICA 
IN 2013, AN ESTIMATED 
278 MILLION PEOPLE LIVED IN 
HOUSEHOLDS WITHOUT AN ITN, 
15 MILLION PREGNANT WOMEN 
DID NOT RECEIVE IPTp, 
AND 5669 MILLION CHILDREN 
WITH MALARIA DID NOT 
RECEIVE AN ACT.
Figure 7.1 Proportion of households, women or children not covered by interventions, 2011–2013
ACT, artemisinin-based combination therapy; IPTp, intermittent preventive treatment in pregnancy; ITN, insecticide-treated mosquito net
Source: Household surveys 
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Some of those without services live in the most endemic areas. 
The consequences of not having services can vary according to malaria 
endemicity, and it is particularly important to protect populations that have 
higher rates of morbidity and mortality. However, for some interventions 
and countries, those living in areas of high or intermediate malaria risk 
(parasite prevalence of ≥5% among children aged 2–9 years) are less likely 
to have malaria interventions than those living in areas with low or no 
malaria risk (parasite prevalence of <5% among children aged 2–9 years) 
(Figure   7.3). To build upon the impressive progress of the past decade, 
and reach populations not currently beneﬁ ting from interventions, it is 
important to identify and ﬁ ll speciﬁ c gaps in service coverage, particularly in 
areas with the highest malaria transmission intensity. Monitoring of malaria 
interventions should include not only a report of progress to date, but also 
an assessment of where future gains are possible.
FOR SOME INTERVENTIONS 
AND COUNTRIES, THOSE 
LIVING IN AREAS OF HIGH 
OR INTERMEDIATE MALARIA 
RISK ARE LESS LIKELY TO HAVE 
MALARIA INTERVENTIONS THAN 
THOSE LIVING IN AREAS WITH 
LOW OR NO MALARIA RISK.
Figure 7.2 Factors associated with gaps in intervention coverage
a) only in household-level analysis; b) only in child-level analysis; 
c) only in woman-level analysis
ACT, artemisinin-based combination therapy; IPTp, intermittent preventive treatment in 
pregnancy; ITN, insecticide-treated mosquito net
Source: Household surveys 
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Figure 7.3 Diﬀ erence in intervention coverage between areas of 
intermediate to high malaria risk, and low to no malaria, 2011–2013
ACT, artemisinin-based combination therapy; IPTp, intermittent preventive treatment in 
pregnancy; ITN, insecticide-treated mosquito net
*Missing bars indicate that there was no diﬀerence in coverage or that all of the households 
surveyed were from one endemicity level
Source: Household surveys 
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8.1 Reported cases
The reported number of confi rmed malaria cases is a core indicator for 
tracking progress towards the MDGs and the World Health Assembly 
and RBM Partnership targets for 2015. For many high-burden countries 
in the WHO African Region, many patients do not receive a diagnostic 
test; hence, it is not possible to assess trends in conﬁ rmed cases. Instead, 
attempts are made to evaluate such trends using the reported numbers 
of malaria admissions (inpatient cases) and deaths. A description of the 
strategy used to analyse trends is provided in Annex 1. In brief, the strategy 
aims to exclude data-related factors (e.g. incomplete reporting or changes in 
diagnostic practice) as explanations for a change in the reported incidence 
of disease. However, if changes in diagnostic testing or reporting are large, 
then it may not be possible to draw inferences about trends in malaria. 
Of the 106 countries that had ongoing malaria transmission in 2000, 66 
were judged to have submitted data that were suﬃ  ciently complete and 
consistent to reliably assess trends between 2000 and 2013. 
Based on an assessment of trends in reported malaria cases, a total of 
64 out of 106 countries with ongoing transmission of malaria in 2000 
are meeting the MDG target of reversing the incidence of malaria. Of 
these 64 countries, 55 are on track to meet RBM and World Health Assembly 
targets of reducing malaria case incidence rates by 75% by 2015 (Figures 8.1 
and 8.2, and Regional profi les). However, most of those 55 countries had 
low numbers of cases in 2000; in fact, they accounted for only 13 million (6%) 
of the total estimated cases of 227 million in 2000. Only ﬁ ve countries with 
more than 1 million estimated cases in 2000 (Afghanistan, Bangladesh, Brazil, 
Cambodia and Papua New Guinea) are projected to achieve a reduction 
in malaria case incidence of 75% or more. This is partly because progress 
has been faster in countries with lower numbers of cases, but also because 
countries with higher numbers of cases are less likely to submit suﬃ  ciently 
consistent data for assessing trends. In such countries, it is necessary to draw 
inferences about trends using studies of parasite prevalence (Section 8.2) 
or estimated numbers of cases (Section 8.3) rather than surveillance data.
8. TRENDS IN 
INFECTIONS, CASES 
AND DEATHS
FIFTYFIVE COUNTRIES ARE 
ON TRACK TO MEET RBM AND 
WORLD HEALTH ASSEMBLY 
TARGETS OF REDUCING 
MALARIA CASE INCIDENCE 
RATES BY 75% BY 2015.
Figure 8.1 Number of countries with decreases in reported malaria case incidence rates 2000–2013, by WHO region
Source: National malaria control programme data
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An increasing number of countries are moving towards elimination 
of malaria. In 2013, two countries reported zero indigenous cases for the 
ﬁ rst time (Azerbaijan and Sri Lanka), and eleven succeeded in maintaining 
zero cases (Argentina, Armenia, Egypt, Iraq, Georgia, Kyrgyzstan, Morocco, 
Oman, Paraguay, Turkmenistan and Uzbekistan). Another four countries 
reported fewer than 10 local cases in that year (Algeria, Cabo Verde, 
Costa Rica and El Salvador). As of December 2014, 19 countries are in the 
pre-elimination or elimination phase, and seven in the prevention of malaria 
reintroduction phase (Table 8.1, see Annex 1 for deﬁ nitions of elimination 
and pre-elimination stages). Argentina and Kyrgyzstan have asked WHO to 
start the process for certifying their achievement of malaria elimination.
TWELVE COUNTRIES WITH 
TRANSMISSION OF MALARIA 
IN 2000 REPORTED ZERO 
INDIGENOUS CASES IN 2013.
Table 8.1 Classiﬁ cation of countries by stage of malaria elimination, December 2014
Region Pre-elimination Elimination Prevention of reintroduction Malaria free
AFR Cabo Verde Algeria
AMR Belize El Salvador
Costa Rica Mexico
Ecuador Paraguay
Argentina
EMR Iran (Islamic Republic of )
Saudi Arabia
Egypt Oman
Iraq Syrian Arab Republic
Morocco – 2010
United Arab Emirates – 2007
EUR Turkey
Azerbaijan
Tajikistan
Georgia
Kyrgyzstan
Uzbekistan
Turkmenistan – 2010
Armenia – 2011
SEAR Bhutan
Democratic People’s Republic of Korea
Sri Lanka
WPR Malaysia Republic of Korea
AFR, African Region; AMR, Region of the Americas; EMR, Eastern Mediterranean Region; EUR, European Region; SEAR, South-East Asia Region; WPR, Western 
Paciﬁ c Region 
Source: National malaria control programme data
Figure 8.2 Change in reported malaria incidence rates, by country, 2000–2013 
Source: WHO estimates
Change in reported malaria incidence rates,
by country, 2000–2013
Cases reduced to zero since 2000
On track for >75% decrease
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Insuﬃciently consistent data to assess trends
No malaria transmission, 2000
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8.2 Malaria infections in sub-Saharan Africa
Because of the inadequacy of malaria case data from many 
sub-Saharan African countries, population infection prevalence can 
be used to enhance understanding of the level of malaria transmission 
and how it has changed over time. Nationally representative surveys of P. 
falciparum infection prevalence (or parasite rate, PfPR) are increasingly being 
undertaken in sub-Saharan Africa. Large numbers of surveys can be brought 
together in a geospatial model to facilitate mapping of PfPR and analysis 
of trends over time (see Annex 1). This modelling can help to estimate the 
proportion of the population at risk that are infected at any one time, and 
the total number of people infected. 
During 2013, an estimated 128 million people were infected with 
P. falciparum in sub-Saharan Africa at any one time. In total, 18 countries 
account for 90% of infections in sub-Saharan Africa; 37 million infections 
(29%) arose in Nigeria and 14 million (11%) in the Democratic Republic 
of the Congo, the two countries with the highest numbers of infections 
(Figure 8.3a). These ﬁ gures only include patent infections (i.e. those 
detectable using routine microscopy or rapid diagnostic tests). The numbers 
of low-density subpatent infections across Africa are considerably higher. 
Infection prevalence varied greatly across Africa in 2013. Estimated 
rates of infection, standardized to children aged 2–10 years, were highest in 
West Africa, with countries in this region accounting for 7 of the 10 highest 
values of PfPR2–10 (Figure 8.3b). In total, 15 endemic sub-Saharan African 
countries had an infection prevalence in children of above 20%, a further 
16 countries of 5–20%, and 16 countries and areas of below 5%. 
Infection prevalence fell dramatically in sub-Saharan Africa during 
the period 2000–2013. Across the African continent, average infection 
prevalence in children aged 2–10 years fell from 26% in 2000 to 14% in 
2013 (and from  35% in 2000 to 18% in regions of stable transmission), a 
relative decline of 48% (Figure 8.4b). Even with a large growth in underlying 
populations, this resulted in a 26% drop in the number of people infected, 
from an average of 173 million concurrent infections in 2000 to 128 million 
in 2013 (Figure 8.4a). Falls were particularly pronounced in central Africa.
IN SUBSAHARAN AFRICA, 
AVERAGE INFECTION 
PREVALENCE IN CHILDREN AGED 
210 YEARS DECLINED BY 48% 
BETWEEN 2000 AND 2013.
Source: Malaria Atlas Project
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Figure 8.3 a) Countries accounting for 90% of the estimated number of P. falciparum infections in sub-Saharan Africa, 2013, ranked by 
number of infections in all ages, and b) countries ranked by the proportion of children aged 2–10 years infected with P. falciparum 
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Source: Malaria Atlas Project
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Figure 8.4  Change in a) estimated number of P. falciparum infections in sub-Saharan Africa 2000–2013 and b) proportion of children 
aged 2–10 years infected with P. falciparum 2000–2013
Eight sub-Saharan countries are estimated to have achieved declines 
of >75% in PfPR, and 14 countries achieved declines of >50% 
between 2000 and 2013. The biggest absolute reductions in numbers 
of people infected were in high-burden countries with large populations 
and substantial PfPR declines. Despite population growth, Nigeria saw an 
estimated 20% decline in the average number of concurrent infections, 
from 47 million in 2000 to 37 million in 2013.
Figure 8.5  Proportion of children aged 2–10 years infected with P. falciparum, comparison between a) 2000 and b) 2013
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8.3 Estimated cases and deaths, 2013
As outlined in Section 8.1, because surveillance systems do not capture all 
malaria cases and deaths occurring in a country, and the data reported to 
WHO are not reliable for some countries, it is necessary to use estimates 
of cases or deaths occurring in countries to make inferences about 
trends in malaria cases and deaths globally. The methods for producing 
estimates either adjust the number of reported cases to take into account 
the estimated proportion of cases that are not captured by a surveillance 
system, or model the relationship between malaria transmission intensity 
and case incidence or mortality (the latter method is used for countries 
in sub-Saharan Africa with insuﬃ  cient surveillance data). These estimates 
help to make numbers more comparable between countries, and ﬁ ll gaps 
where data are missing. However, the estimates are limited in that they rely 
on relationships between variables that are uncertain, and draw upon data 
that may have been imprecisely measured, or project forward from data 
measured in previous years. Thus, estimates of the number of malaria cases 
or deaths are accompanied by a large degree of uncertainty, and inferences 
concerning trends are less certain than those made directly from high-
quality surveillance data. In 2014, an evidence review group on malaria 
burden estimation advised WHO on what approaches to use to estimate 
the number of malaria cases and deaths. These recommendations are being 
adopted and will be fully implemented in the World malaria report 2015. For 
this report, the methods used are detailed in Annex 1.
In 2013, an estimated 198 million cases of malaria occurred worldwide 
(95% uncertainty interval, 124–283 million). Most of these cases (82%) 
were in the WHO African Region, followed by the WHO South-East Asia 
Region (12%) and the WHO Eastern Mediterranean Region (5%). About 8% 
of estimated cases globally are due to P. vivax, although outside the African 
continent this proportion increases to 47% (Table 8.2a).
Table 8.2 Estimated number of a) malaria cases and b) malaria deaths by WHO region, 2013
(a) Estimated cases (‘000s) Estimated P. vivax cases (‘000s) P. vivax as %
of total casesRegion Estimate Lower Upper Estimate Lower Upper
Africa 163 000 90 000 243 000 1 400 1 000 1 700 1%
Americas  700  600  900  500  400  600 62%
Eastern Mediterranean 9 000 6 000 14 000 3 000 2 300 3 800 33%
Europe 2 2 2 2 2 2 43%
South-East Asia 24 000 17 000 36 000 11 000 7 000 17 000 44%
Western Paciﬁ c 1 000 1 000 2 000  200  100  400 16%
World 198 000 124 000 283 000 15 800 11 900 22 000 8%
Outside sub-Saharan Africa 30 000 22 400 41 500 14 200 10 200 20 300 47%
(b) Estimated deaths Estimated deaths <5 Deaths <5
as % of totalRegion Estimate Lower Upper Estimate Lower Upper
Africa 528 000 315 000 689 000 437 000 324 000 544 000 83%
Americas  800  500 1 200 220  190  290 28%
Eastern Mediterranean 11 000 5 000 23 000 3 900 3 000 4 900 40%
Europe 0 0 0 0 0 0 49%
South-East Asia 41 000 23 000 69 000 11 000 7 000 17 000 29%
Western Paciﬁ c 3 300 1 700 5 600 1 600  700 2 600 49%
World 584 000 367 000 755 000 453 000 341 000 630 000 78%
Outside sub-Saharan Africa 47 000 29 000 75 000 13 000 8 000 21 000 28%
Source: WHO estimates
AN ESTIMATED 198 MILLION 
CASES OF MALARIA AND 
584 000 MALARIA DEATHS 
OCCURRED IN 2013.
TRENDS IN INFECTIONS, CASES AND DEATHS
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The 80% gridline is highlighted to more easily distinguish countries that together account for 80% of the estimated number of malaria cases and deaths in 2013 Source: Malaria Atlas Project
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Figure 8.7 Cumulative proportion of the global estimated cases and deaths accounted for by the countries with the highest number of 
a) total cases, b) P. vivax cases and c) deaths in 2013
In 2013, there were an estimated 584 000 malaria deaths worldwide 
(95% uncertainty interval, 367 000–755 000) (Table 8.2b). It is estimated 
that most (90%) of these deaths were in the WHO African Region, 
followed by the WHO South-East Asia Region (7%) and the WHO Eastern 
Mediterranean Region (2%). About 453 000 malaria deaths (uncertainty 
interval, 341 000–630 000) were estimated to occur in children aged under 
5 years, equivalent to 78% of the global total. An estimated 437 000 of 
deaths occurred in children aged under 5 years in the WHO African Region 
(uncertainty interval, 324 000–544 000). 
About 80% of estimated malaria cases in 2013 occurred in just 
18 countries, and 80% of deaths in 16 countries (Figures 8.3 and 8.4). 
For P. vivax cases, three countries (India, Indonesia and Pakistan) accounted 
for more than 80% of estimated cases. The global burden of mortality 
and morbidity was dominated by countries in sub-Saharan Africa: the 
Democratic Republic of the Congo and Nigeria together accounted for 39% 
of the global total of estimated malaria deaths and 34% of cases in 2013. 
International targets for reducing cases and deaths will not be attained 
unless considerable progress can be made in these two countries.
Figure 8.6 Malaria deaths per 100 000 population, 2013  
Source: WHO estimates
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THE GLOBAL BURDEN OF 
MALARIA MORTALITY IS 
DOMINATED BY COUNTRIES IN 
SUBSAHARAN AFRICA.
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8.4 Changes in estimated cases and deaths, 
2000–2013
The estimated number of malaria cases fell from 227 million in 2000 to 
198 million in 2013 (Table 8.3a). During the same period, the population 
at risk for malaria increased by 25% globally and by 43% in the WHO African 
Region. Consequently, the estimated number of cases per 1000 persons at 
risk of malaria, which takes into account population growth, showed a 30% 
reduction in case incidence globally between 2000 and 2013, and a 34% 
reduction in the WHO African Region. Decreases were greatest in the WHO 
European Region (100%), the WHO Region of the Americas (76%) and the 
WHO Western Paciﬁ c Region (69%). If the rate of decline that has occurred 
over the past 13 years is sustained, then malaria case incidence is projected 
to decrease by 35% globally and 40% in the WHO African Region by 2015. 
The estimated number of deaths fell in all regions between 2000 and 
2013, although there was some fl uctuation year by year (Table 8.3b). 
Malaria mortality rates (which take into account population growth over 
time) are estimated to have declined by 47% globally between 2000 and 
2013 and by 54% in the WHO African Region (Figure 8.8b). In children 
aged under 5 years malaria mortality rates are estimated to have fallen by 
53% globally and by 58% in the WHO African Region. If the annual rate of 
decrease that has occurred over the past 13 years is maintained, then by 
2015, malaria mortality rates across all age groups will fall by 55% globally, 
and by 62% in the WHO African Region. In children aged under 5 years they 
are projected to decrease by 61% globally and by 67% in the WHO African 
Region by 2015.
Table 8.3 Estimated number of a) malaria cases and b) malaria deaths by WHO region, 2000, 2005, and from 2010 to 2013
(a) Number of cases (000’s) 2000 2005 2010 2011 2012 2013
Africa  174 000  192 000  167 000  163 000  163 000  163 000
Americas  2 500  1 700  1 100   800   800   700
Eastern Mediterranean  14 000  10 000  9 000  11 000  10 000  9 000
Europe             
South-East Asia  33 000  34 000  28 000  28 000  27 000  24 000
Western Paciﬁ c  4 000  2 000  2 000  1 000  1 000  1 000
World  227 000  240 000  207 000  203 000  202 000  198 000
Lower bound  150 000  155 000  133 000  129 000  127 000  124 000
Upper bound  304 000  328 000  287 000  282 000  281 000  283 000
(b) Number of deaths 2000 2005 2010 2011 2012 2013
Africa  801 000  761 000  576 000  543 000  530 000  528 000
Americas  2 300  1 800  1 300  1 000   900   800
Eastern Mediterranean  17 000  13 000  12 000  13 000  12 000  11 000
Europe   3           
South-East Asia  53 000  50 000  46 000  44 000  43 000  41 000
Western Paciﬁ c  9 500  4 700  3 900  3 300  3 500  3 300
World  882 000  830 000  639 000  605 000  590 000  584 000
Lower bound  599 000  547 000  405 000  384 000  376 000  367 000
Upper bound 1 104 000 1 029 000  795 000  755 000  742 000  755 000
Source: WHO estimates
MALARIA MORTALITY RATES 
DECREASED BY 53% BETWEEN 
2000 AND 2013 IN CHILDREN 
AGED UNDER 5 YEARS.
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Estimated numbers of cases for 2012 and previous years diﬀ er slightly 
from those reported in the World malaria report 2013, owing to the use of 
an updated ITN model in the calculation of case estimates in Africa, and 
the updating of previous datasets on reported cases. Similarly, estimated 
numbers of deaths diﬀ er slightly from those reported previously, owing to 
revisions to the under-5 mortality envelope by the UN Inter-agency Group 
for Child Mortality Estimation (38) (see Annex 1). 
The pace of decline in estimated malaria incidence and mortality rates 
was initially slow, but accelerated from 2005 (Figure 8.8b). Considerable 
uncertainty is associated with the calculated reductions in incidence and 
mortality rates, since they are based on the estimated numbers of cases and 
deaths, which have wide uncertainty intervals. Nonetheless, it appears that 
the rate of decline in malaria in incidence and mortality rates was initially slow 
but accelerated after 2005, and, for mortality, the rate from 2005 to 2010 was 
suﬃ  ciently fast to achieve a 75% reduction over 15 years (the plotted points 
are parallel to the target line in Figure 8.8). However, the decrease in malaria 
mortality rates was slower between 2011 and 2013. This more recent reduced 
rate of decline is associated with a reduced rate of increase in ITN coverage in 
sub-Saharan Africa in 2012 and 2013 (Section 3.1), a factor that is taken into 
account in estimates of cases and deaths. The number of ITNs distributed in 
sub-Saharan Africa in 2014 exceeded any previous year, and is expected to 
lead to increases in the rate of mortality decline in 2014 and 2015.
Of the 106 countries that had ongoing transmission in 2000, 56 are 
projected to achieve reductions in malaria mortality rates of >75% in 2015, 
or to maintain zero malaria deaths.
M
al
ar
ia
 c
as
es
 p
er
 1
00
0 
pe
rs
on
s a
t r
isk
180
160
140
120
100
80
60
40
20
0
201020052000 2015
75% targetEstimated malaria incidence rate
Source: WHO estimates
(a)
M
al
ar
ia
 d
ea
th
s p
er
 1
00
 0
00
 p
er
so
ns
 a
t r
isk
60
50
40
30
20
10
0
201020052000 2015
75% targetEstimated malaria mortality rate(b)
Figure 8.8 Change in a) Estimated malaria case incidence rate, 2000–2013 and b) Estimated malaria mortality rate, 2000–2013
SIXTY COUNTRIES ARE 
PROJECTED TO ACHIEVE >75% 
REDUCTIONS IN MALARIA 
MORTALITY RATES BY 2015.
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8.5 Estimated cases and deaths averted, 
2001–2013
It is estimated that, globally, 625 million fewer cases and 4.3 million 
fewer malaria deaths occurred between 2001 and 2013 than would 
have occurred had incidence and mortality rates remained unchanged 
since 2000 (Table 8.4). Of the estimated 4.3 million deaths averted between 
2001 and 2013, 3.9 million (92%) were in children aged under 5 years in 
sub-Saharan Africa. These 3.9 million averted deaths accounted for 20% 
of the 20 million fewer deaths that would have occurred in sub-Saharan 
Africa between 2001 and 2013 had under-5 mortality rates for 2000 applied 
for each year between 2001 and 2013. Thus, reductions in malaria deaths 
have contributed substantially to progress towards achieving the target for 
MDG 4 in sub-Saharan Africa, which is to reduce the under-5 mortality rate 
by two thirds between 1990 and 2015.
Figure 8.9 Percentage change in malaria mortality rates, 2000–2013  
Source: WHO estimates
Percentage change in malaria mortality rates, 
2000–2013
Estimated malaria deaths equals zero 
Decrease >75%
Decrease 50–74%
Decrease 25–49%
Decrease <25%
Increases in malaria mortality rates
No malaria transmission, 2000
Not applicable
Table 8.4 Estimated cases and deaths averted by reduction in incidence and mortality rates between 2001 and 2013 
Cases averted Deaths averted Deaths averted <5
Region 2001–2013(million)
Percentage 
of total
2001–2013
(million)
Percentage 
of total
2001–2013
(million)
Percentage 
of total
African  444 66%  3.93 92%  3.92 95%
Region of the Americas  19 3%  0.01 0%  0.00 0%
Eastern Mediterranean  72 11%  0.08 2%  0.04 1%
European  0.3 0%  0.00 0%  0.00 0%
South-East Asia  106 16%  0.17 4%  0.09 2%
Western Paciﬁ c  30 4%  0.08 2%  0.06 1%
World  670 100%  4.28 100%  4.11 100%
Source: WHO estimates
REDUCTIONS IN MALARIA 
DEATHS HAVE CONTRIBUTED 
SUBSTANTIALLY TO PROGRESS 
TOWARDS ACHIEVING 
THE TARGET FOR MDG 4, 
WHICH IS TO REDUCE THE 
UNDER5 MORTALITY RATE BY 
TWO THIRDS.
TRENDS IN INFECTIONS, CASES AND DEATHS
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Most of the malaria cases averted (66%) and lives saved (92%) have 
been in the WHO African Region (Table 8.4). Larger percentage decreases 
in case incidence and mortality rates were seen in countries with the lowest 
estimated malaria burdens in 2000. However, although progress in reducing 
incidence and mortality rates has been faster in countries with smaller 
estimated numbers of malaria cases and deaths, this does not imply a lack 
of impact in higher burden countries. In fact, many cases and deaths were 
averted during 2001–2013 in countries with high malaria burdens. The ten 
countries with the highest estimated malaria burden in 2000 accounted for 
57% of malaria cases and 68% of malaria deaths averted between 2001–2013.
Not all of the cases and deaths averted can be attributed to malaria 
interventions implemented by malaria programmes. Some progress is likely 
to be related to increased urbanization and overall economic development, 
which lead to improvements in housing and nutrition. 
Figure 8.10 Malaria deaths averted, 2001–2013  
Source: WHO estimates
Malaria deaths averted, 2000–2013
>100 000
10 000–99 999
1000–9 999
100–999
1–99
0
No malaria transmission, 2000
Not applicable
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WEST AFRICA A. Conﬁ rmed malaria cases per 1000 population/parasite prevalence, 2013
Population at risk: About 333 million people in the 17 countries 
of this subregion are at some risk for malaria, with 322 million 
at high risk. Cabo Verde is in the pre-elimination programme 
phase, and Algeria in the elimination phase. Malaria cases are 
almost exclusively due to P. falciparum (Figure F). 
Financing: Funding for malaria control rose from US$ 89 million 
in 2005 to US$ 557 million in 2013 (Figure B). During 2011–2013 
it exceeded US$ 4 per capita per year in three countries: Cabo 
Verde, the Gambia and Liberia (Figure C). 
Interventions: In 2013, the proportion of the population at risk 
estimated to have access to an insecticide-treated mosquito net 
(ITN) in their household exceeded 50% in seven countries (Burkina 
Faso, the Gambia, Ghana, Guinea-Bissau, Mali, Senegal and Togo) 
(Figure  D). Cabo Verde and the Gambia protected more than 
40% of their population at risk using indoor residual spraying 
(IRS), whereas Benin, Ghana, Liberia, Mali and Senegal used IRS on 
a more limited scale. Eight countries (Burkina Faso, Cabo Verde, 
the Gambia, Ghana, Liberia, Mali, the Niger and Sierra Leone) 
delivered enough antimalarial medicines to treat >80% of the 
population. Benin and Guinea-Bissau did not report on delivery of 
artemisinin-based combination therapy (ACT) (Figure E). Algeria 
and Cabo Verde implemented active case detection (ACD), case 
investigation and a quality assurance system for malaria diagnostic 
testing (guided by the national reference laboratory), and a radical 
treatment policy with primaquine for P. vivax and gametocytocidal 
treatment for P. falciparum.
Trends in cases and deaths: Both Algeria and Cabo Verde 
achieved a >75% decrease in case incidence between 2000 
and 2013. Algeria is in the elimination phase and reported only 
16 indigenous cases, six introduced cases and one relapsing case 
in 2013; a sharp decrease compared to 2012, when 59 indigenous 
and three introduced cases were reported (the number of 
imported cases also fell from 825 in 2012 to 595 in 2013). Cabo 
Verde has been in the pre-elimination phase since 2010. It reported 
22 indigenous cases in 2013 compared with one case in 2012. In 
the 15 remaining countries, it was not possible to assess trends in 
cases or admissions owing to inconsistent reporting, or changes in 
diagnostic testing or access to health services (Figure G). 
A review of trends in 83 hospitals in Ghana between 2005 and 
2013 showed an increase in conﬁ rmed malaria cases, admissions 
and deaths in all age groups, although malaria deaths in children 
aged under 5 years fell by 29% (WHO, unpublished results). The 
increase appeared to be related to expanded diagnostic testing 
and increased access to health services. The slide positivity rate 
(SPR) remained stable at 34%. A review of trends in 186 hospitals 
in Nigeria between 2005 and 2013 indicated an increase or 
no change in conﬁ rmed malaria cases, admission and deaths 
across all age groups, and a stable SPR (59%) (WHO, unpublished 
results).
Subnational decreases in morbidity and mortality have been 
reported from Burkina Faso (1), Senegal (2,3) and Togo (4,5) 
but these ﬁ ndings are insuﬃ  cient to draw conclusions about 
national trends.
BETWEEN 2000 AND 2013, 
TWO COUNTRIES OUT OF 17 
REPORTED DECREASES IN 
CASE INCIDENCE OF >75%. 
SURVEILLANCE DATA WERE 
INSUFFICIENTLY CONSISTENT 
TO ASSESS TRENDS IN OTHER 
COUNTRIES.
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WEST AFRICA
B.  Financial contribution for malaria control by source, 2005–2013 C. US$ per capita for malaria control, 2011–2013
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CENTRAL AFRICA A. Conﬁ rmed malaria cases per 1000 population/parasite prevalence, 2013
Population at risk: About 144 million people in the 10 countries 
of this subregion are at some risk for malaria, with 127 million 
at high risk (Figure A). Cases are almost exclusively due to 
P. falciparum (Figure F).
Financing: Funding for malaria control in the subregion rose 
from US$ 72 million in 2005 to US$ 263 million in 2013 (Figure B). 
Malaria ﬁ nancing exceeded US$ 4 per capita per year in Equatorial 
Guinea and Sao Tome and Principe during 2011–2013 (Figure C).
Interventions: In 2013, the proportion of the population at 
risk estimated to have access to an ITN in their household 
exceeded 50% in ﬁ ve countries (Burundi, Chad, Congo, the 
Democratic Republic of the Congo, and Sao Tome and Principe) 
(Figure D). Sao Tome and Principe also reported that >60% of 
the population at risk were protected with IRS. Four countries 
(Angola, Burundi, the Democratic Republic of the Congo and 
Sao Tome and Principe) reported distributing suﬃ  cient ACTs to 
treat >50% of estimated malaria cases attending public health 
facilities in 2013. Congo and Gabon did not report on delivery 
of ACT (Figure E). 
Trends in cases and deaths: Between 2000 and 2013, only Sao 
Tome and Principe achieved a >75% decrease in case incidence; 
it also reported >90% decrease in malaria admission and 
death rates. However, the number of cases and admissions in 
2011–2013 was higher than in the previous 4 years, suggesting 
minimal progress in recent years. 
In the nine remaining countries, it was not possible to assess 
trends owing to incomplete reporting or changes in health 
service access or diagnostic testing. In several countries, the 
number of conﬁ rmed malaria cases and admissions increased in 
recent years, possibly reﬂ ecting improved reporting or improved 
access to health services (Figure  G). Subnational decreases in 
malaria morbidity and mortality have been reported in the Island 
of Bioko in Equatorial Guinea (6) (although high transmission 
persists in some foci) (7), Cameroon (8) and Gabon (9). 
OF THE 10 COUNTRIES IN 
THIS SUBREGION, ONLY ONE 
REPORTED DECREASES IN 
CASE INCIDENCE OF >75%. 
SURVEILLANCE DATA WERE 
INSUFFICIENTLY CONSISTENT 
TO ASSESS TRENDS IN OTHER 
COUNTRIES.
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CENTRAL AFRICA
B.  Financial contribution for malaria control by source, 2005–2013 C. US$ per capita for malaria control, 2011–2013
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EAST AND 
SOUTHERN 
AFRICA
(excluding low-transmission 
countries in Southern Africa)
A. Conﬁ rmed malaria cases per 1000 population/parasite prevalence, 2013
Population at risk: About 293 million people in the 12 countries 
in this subregion are at some risk for malaria, with 179 million at 
high risk. About 25% of the population of Ethiopia and Kenya 
live in areas that are free of malaria. P. falciparum is the dominant 
species, except in Eritrea and Ethiopia, where P. vivax accounts 
for about 38% of reported cases (Figure F).
Financing: Funding for malaria control in the subregion 
increased from US$ 217 million in 2005 to US$ 741 million in 
2013. Malaria ﬁ nancing was less than US$ 4 per capita per year 
during 2011–2013 in all countries but exceeded US$ 3 per capita 
in six (Ethiopia, Kenya, Madagascar, Malawi, Rwanda and Zambia) 
(Figure C).
Interventions: In 2013, the proportion of the population at 
risk estimated to have access to an ITN in their household 
exceeded 50% in nine countries (Comoros, Ethiopia, Kenya, 
Madagascar, Malawi, Mozambique, Rwanda, South Sudan and 
Zambia), and in Zanzibar in the United Republic of Tanzania 
(Figure D). IRS was also used in 10 countries, with the proportion 
of the at-risk population protected reaching >37% in Ethiopia 
and Mozambique. In 2013, all countries except Comoros and 
Madagascar reported distribution of suﬃ  cient ACTs to treat all 
patients attending public health facilities (Malawi and Rwanda 
did not report) (Figure E). 
Trends in cases and deaths: Between 2000 and 2013, malaria 
admission rates decreased by >75% in Eritrea, Rwanda and in 
Zanzibar, in the United Republic or Tanzania (consistent with a 
previous study (10)) (Figure G). In Rwanda, conﬁ rmed malaria 
cases and admissions doubled between 2012 and 2013 (483 000 
to 962 000 and 5306 to 9508, respectively), while testing remained 
unchanged. Malaria admission rates are projected to decrease 
by 50–75% by 2015 in Ethiopia (based on a study in 41 hospitals 
(11)) and in Zambia. Decreases in malaria admissions were also 
seen in Mozambique, but no comparable data from earlier than 
2007 are available. Recent increases in admissions and deaths in 
Madagascar reﬂ ect the fragility of the gains achieved if control 
eﬀ orts are not maintained. 
For the seven remaining countries (Comoros, Kenya, Malawi, 
Mozambique, United Republic of Tanzania [Mainland], South 
Sudan and Uganda), it was not possible to assess trends owing 
to inconsistent reporting, changes in health service accessibility 
or diagnostic testing. Evidence of subnational reductions in 
morbidity and mortality have been reported in the United 
Republic of Tanzania (Mainland) (12), Kenya (13), Uganda 
(14,15) and Zambia (16,17) (mixed results) but these results are 
insuﬃ  cient to make inferences about national trends. 
THREE COUNTRIES AND AREAS 
ACHIEVED >75% DECREASE IN 
MALARIA ADMISSION RATES 
BETWEEN 2000 AND 2013. TWO 
COUNTRIES ARE ON TRACK TO 
REDUCE MALARIA ADMISSION 
RATES BY 5075% BY 2015.
Insuﬃcient data
0
0–0.1
0.1–1.0
1.0–10
Conﬁrmed cases 
per 1000 population/
parasite prevalence 
(PP)
PP
>75
0
WORLD MALARIA REPORT 2014 | 51
EAST AND SOUTHERN  AFRICA
B.  Financial contribution for malaria control by source, 2005–2013 C. US$ per capita for malaria control, 2011–2013
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E.  Antimalarial treatment courses distributed as a proportion of 
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LOWTRANSMISSION 
SOUTHERN 
AFRICAN 
COUNTRIES
A. Conﬁ rmed malaria cases per 1000 population/parasite prevalence, 2013
Population at risk: About 15 million people in the ﬁ ve countries 
of this subregion are at some risk for malaria, with 11 million at 
high risk (Figure A). About 80%, or 60 million people, live in areas 
that are free of malaria. Malaria transmission is highly seasonal. 
Most malaria cases are caused by P. falciparum (Figure F).
Financing: Funding for malaria control in this subregion 
increased from US$ 29 million in 2005 to US$ 56 million in 2013 
(Figure B). During 2011–2013, it exceeded US$ 4 per capita per 
year in all countries of the subregion except Botswana (Figure C).
Interventions: In 2013, the population at risk estimated to have 
access to an ITN in their household exceeded 50% in Zimbabwe; 
although IRS was extensively used, countries protected <50% of 
their population at high risk with IRS (Figure D). In South Africa, 
where IRS is the main vector control measure, the proportion 
of the population at risk protected in 2013 was almost half of 
what was reported in 2012. All ﬁ ve countries delivered suﬃ  cient 
antimalarial medicines to treat >80% of malaria cases attending 
public health facilities (Figure E). 
Trends in cases and deaths: Four of the ﬁ ve countries in this 
subregion (Botswana, Namibia, South Africa and Swaziland) 
achieved >75% decrease in case incidence between 2000 
and 2013 (Figure G). Reported malaria mortality rates also fell 
by >75%. However, the number of reported cases in these 
four countries more than doubled between 2012 and 2013. 
The increase in reported cases may be due to higher testing 
rates. In Zimbabwe, the number of diagnostic tests performed 
increased ﬁ vefold between 2004 and 2013, with rapid diagnostic 
tests (RDTs) increasingly replacing microscopy. It is therefore 
not possible to assess trends using nationally reported cases. 
However, a review of data from 45 hospitals indicated a decrease 
in malaria admissions and mortality rates of 64% and 71% 
between 2003 and 2012, suggesting the country is on track to 
achieve a decrease in admission rates of 50–75% and mortality 
rates of >75% by 2015. Another subnational study also showed a 
decrease in malaria case incidence in a district of Zimbabwe (18). 
All ﬁ ve countries in the subregion, together with Angola, 
Mozambique and Zambia, are signatories to the Elimination Eight 
(E8) regional initiative launched in March 2009, a goal of which is 
to achieve the eventual elimination of malaria in the region, and 
to achieve elimination in four countries – Botswana, Namibia, 
South Africa and Swaziland – by 2020. Despite relatively low 
numbers of conﬁ rmed malaria cases in 2013, unconﬁ rmed cases 
were also recorded among the total number of cases reported, 
comprising 10% of the total in Botswana, 2% in South Africa and 
5% in Swaziland. With sustained investments in malaria control, 
and improving diagnostic capacity, it is expected that these 
countries will continue to progress towards elimination.
FOUR OUT OF FIVE COUNTRIES 
ACHIEVED >75% DECREASE IN 
CASE INCIDENCE IN 2013, AND 
ONE COUNTRY IS ON TRACK 
TO REDUCE INCIDENCE BY 
5075% BY 2015.
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B.  Financial contribution for malaria control by source, 2005–2013 C. US$ per capita for malaria control, 2011–2013
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AMERICAS
A. Conﬁ rmed malaria cases per 1000 population, 2013
Population at risk: In the WHO Region of the Americas, about 
120 million people in 21 countries are estimated to be at 
some risk for malaria, with 25 million at high risk. P. falciparum 
is responsible for <30% of malaria cases overall, although the 
proportion is >50% in Guyana and Suriname, and almost 100% 
in the Dominican Republic and Haiti. 
Financing: Funding for malaria control in the region increased 
from US$ 153 million in 2005 to US$ 214 million in 2011, but 
decreased to US$ 140 million in 2013 (Figure B). In ﬁ ve of the 
21 countries, ﬁ nancing for malaria control exceeded US$ 4 
per capita per year during 2011–2013 (Costa Rica, El Salvador, 
Mexico, Paraguay and Suriname) (Figure C). 
Interventions: All the 21 countries or overseas territories of the 
region apply IRS or ITNs (or both) in focal areas with ongoing 
transmission. In 2011−2013, four countries distributed enough 
ITNs to protect more than 60% of the population at high risk, 
of which one (Nicaragua) also protected >60% of its population 
at risk with IRS (Figure D). All the countries distributed 
suﬃ  cient antimalarial medicines to treat all patients attending 
public health facilities (Figure E). All the seven countries in 
pre-elimination and elimination phases (Argentina, Belize, Costa 
Rica, Ecuador, El Salvador, Mexico and Paraguay) undertake 
ACD, case investigation, radical treatment of P. vivax and quality 
assurance of microscopy services.
Trends in cases and deaths: The number of conﬁ rmed 
malaria cases in the region decreased from 1.2 million in 2000 
to 427 000 cases in 2013. Three countries accounted for 72% of 
cases in 2013: Brazil (42%), Bolivarian Republic of Venezuela (18%) 
and Colombia (12%). Reductions of >75% in the incidence of 
microscopically conﬁ rmed malaria cases were reported in 13 out 
of 21 countries and areas with ongoing transmission between 
2000 and 2013 (Argentina, Belize, Plurinational State of Bolivia, 
Costa Rica, Ecuador, El Salvador, Guatemala, Honduras, Mexico, 
Nicaragua, Paraguay, Suriname and French Guiana, France). 
Two countries (Brazil and Colombia) are on track to achieve a 
75% decrease in case incidence by 2015. Three countries (the 
Dominican Republic, Panama and Peru) are on track for a 50–75% 
decrease in case incidence by 2015. Increases in numbers of cases 
between 2000 and 2013 were reported by two countries (Guyana 
and the Bolivarian Republic of Venezuela). In Haiti, the number of 
reported malaria cases increased, but it is unclear whether the 
rise is real, or is simply due to changes in the extent of diagnostic 
testing and reporting (Figure G). The region reported 82 deaths 
due to malaria in 2013, a 79% decline compared with 2000. Brazil 
accounts for half of the deaths due to malaria in the region.
Argentina, which is in the elimination phase, has reported 
zero indigenous cases since 2011, and has initiated the 
process of certiﬁ cation of malaria elimination. Paraguay, in the 
pre-elimination phase, has reported zero indigenous cases and 
11 imported cases since 2012. Costa Rica reported two cases 
of relapse in 2013 (one P. vivax and and one P. malariae) and 
four imported cases; Costa Rica and Paraguay are expected to 
join Argentina in the elimination phase. Four other countries 
in the pre-elimination phase reported fewer than 1000 cases 
in total (Belize – 20 P. vivax cases; Ecuador – 360 P. vivax and 
P. falciparum; El Salvador – ﬁ ve P. vivax; and Mexico – 495 P. vivax). 
Ten countries in Central America and the Caribbean have joined 
a regional initiative that aims to eliminate malaria by 2020, with 
the support of the Global Fund to Fight AIDS, Tuberculosis and 
Malaria (Belize, Costa Rica, the Dominican Republic, El Salvador, 
Guatemala, Haiti, Honduras, Mexico, Nicaragua and Panama).
FIFTEEN OUT OF 
21 COUNTRIES ARE ON TRACK 
TO REDUCE INCIDENCE BY 
75% BY 2015, AND THREE 
COUNTRIES BY 5075%. 
ARGENTINA AND PARAGUAY 
REPORTED ZERO INDIGENOUS 
CASES IN 2013. 
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REGION OF THE AMERICAS
B.  Financial contribution for malaria control by source, 2005–2013 C. US$ per capita for malaria control, 2011–2013
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EASTERN 
MEDITERRANEAN 
REGION
A. Conﬁ rmed malaria cases per 1000 population/parasite prevalence, 2013
Population at risk: In 2013, about 280 million people in eight 
countries in the region were at some risk of malaria, with 
104 million at high risk. Six countries have areas of high malaria 
transmission (Afghanistan, Djibouti, Pakistan, Somalia, the Sudan 
and Yemen); transmission is focal in Iran (Islamic Republic of ) 
and Saudi Arabia. Most cases are due to P. falciparum except 
in Afghanistan, Iran (Islamic Republic of ) and Pakistan, where 
P. vivax predominates (Figure F).
Financing: Funding for malaria control in the region rose from 
US$ 50 million in 2005 to US$ 194 million in 2012 but fell to 
US$ 136 million in 2013 (Figure B). It exceeded US$ 4 per capita 
per year in Iran (Islamic Republic of ) and Saudi Arabia during 
2011–2013. Domestic ﬁ nancing for malaria control in 2013 
accounted for 100% in Saudi Arabia and 59% in Iran (Islamic 
Republic of ).
Interventions: Afghanistan, Iran (Islamic Republic of ) and 
Saudi Arabia distributed suﬃ  cient ITNs in 2011−2013 to protect 
>60% of their population at high risk (Figure D). Vector control 
interventions in Iran (Islamic Republic of ) and Saudi Arabia were 
applied in targeted foci. These two countries reported delivering 
suﬃ  cient antimalarial medicines, including ACTs, to treat all 
cases attending public health facilities (Figure E). 
Trends in cases and deaths: The number of conﬁ rmed malaria 
cases reported in the region decreased from 2 million in 2000 
to 1 million in 2013. Two countries accounted for 84% of cases 
in 2013: the Sudan (57%) and Pakistan (27%). Seven countries 
achieved >75% decrease in the incidence of microscopically 
conﬁ rmed cases between 2000 and 2013 (Afghanistan, Iran 
[Islamic Republic of ], Morocco, Oman, Saudi Arabia and the 
Syrian Arab Republic) (Figure G). Iran (Islamic Republic of ) and 
Saudi Arabia reported only 519 and 34 local cases, respectively, 
in 2013 (50% and 30% decrease, respectively, compared to 
2012). Iraq has not reported any indigenous cases since 2009. 
An assessment of trends was not possible for Djibouti, Pakistan, 
Somalia, the Sudan and Yemen, owing to inconsistent reporting. 
The number of deaths due to malaria in the region fell from 2166 
in 2000 to 1027 in 2013. Two countries accounted for >90% of 
the deaths in 2013: the Sudan (67%) and Pakistan (24%). 
In addition to Iraq, three countries in the region are in the 
prevention of reintroduction phase (Egypt, since 1998; Oman, 
since 2004; and the Syrian Arab Republic, since 2005). Morocco 
was certiﬁ ed as free of malaria in 2010. Egypt reported 22 locally 
acquired cases in a recent outbreak (May–June 2014) in a village 
20 km north of Aswan. The outbreak was successfully controlled 
using preventive measures, prompt treatment, and ACD and 
case investigation of foci covering 16 villages. Oman has been 
battling small outbreaks related to importation of parasites since 
2007; the country reported 1440 imported and 11 introduced 
P. vivax cases in 2013. The Syrian Arab Republic reported 22 
imported cases in 2013 (including 21 P. falciparum). However, 
due to the current situation in the country, the actual numbers 
cannot be veriﬁ ed.
OF 12 COUNTRIES WITH 
ONGOING MALARIA 
TRANSMISSION IN 2000, 
SEVEN ACHIEVED >75% 
DECREASE IN CASE INCIDENCE 
BETWEEN 2000 AND 2013. 
SAUDI ARABIA REPORTED 
ONLY 34 INDIGENOUS CASES 
IN 2013. IRAQ CONTINUES TO 
REPORT ZERO LOCAL CASES.
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EASTERN MEDITERRANEAN REGION
B.  Financial contribution for malaria control by source, 2005–2013 C. US$ per capita for malaria control, 2011–2013
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EUROPEAN 
REGION
A. Conﬁ rmed malaria cases per 1000 population, 2013
Population at risk: In 2000, eight countries in the European 
Region (Armenia, Azerbaijan, Georgia, Kyrgyzstan, Tajikistan, 
Turkey, Turkmenistan and Uzbekistan) had local transmission 
of malaria; however, in 2013, local transmission was conﬁ ned to 
just two countries (Tajikistan and Turkey), in which two million 
people were living in areas with some risk for malaria. All locally 
acquired cases were due to P. vivax (Figure F).
Financing: Funding for malaria control in the region rose from 
about US$ 35 million in 2005 to US$ 54 million in 2009, but 
decreased to US$ 32 million in 2013 (Figure B). Financing per 
capita per year ranged from US$ 1.86 in Tajikistan to US$ 2600 
per capita in Turkey between 2011 and 2013 (Figure C). 
Interventions: In all countries in the region, malaria is a notiﬁ able 
disease. Each case and focus is epidemiologically investigated 
and classiﬁ ed; there are national quality assurance programmes 
for microscopy and radical treatment of P. vivax cases, and 
adequate access to antimalarial medicines (Figures E and F). IRS 
and ITNs are undertaken in targeted malaria focal areas. 
Trends in cases and deaths: All countries in the region achieved 
>75% decrease in case incidence between 2000 and 2013 
(Figure G). Among the eight countries with local transmission 
in 2000, the number of locally acquired conﬁ rmed malaria 
cases decreased from 32 405 in 2000 to only 41 cases in 2013, 
all P. vivax. Of the 41 cases, 34 were from Turkey (all relapsing 
from infections that occurred in 2012) and seven from Tajikistan 
(three indigenous and four introduced). Turkey contained the 
2012 outbreak (219 local cases) through intensive control and 
surveillance eﬀ orts (IRS, ACD, and case-based surveillance).
Azerbaijan reported zero local cases in 2013 for the ﬁ rst time. 
Three other countries have reported zero indigenous cases for the 
past 3 years or more, and are in the prevention of reintroduction 
phase (Georgia, Kyrgyzstan and Uzbekistan). Georgia, which had 
one introduced case in 2011 and one in 2012 (both from migrant 
workers), reported zero cases in 2013. In 2014, Kyrgyzstan 
successfully passed the ﬁ rst WHO evaluation for certiﬁ cation as a 
malaria-free country. Two countries have been certiﬁ ed as free of 
malaria (Turkmenistan in 2010 and Armenia in 2011). 
Greece, which had remained malaria free between 1974 and 
2010, reported three locally acquired P. vivax cases in 2010, 40 in 
2011, 20 in 2012 and three in 2013. These cases originated from 
migrant workers. The resurgence clustered in the Lakonia region 
in the south of mainland Greece was successfully contained 
through intensiﬁ ed control eﬀ orts, with only two locally acquired 
P. vivax cases detected in the Municipality of Alexandroupolis, 
Evros, and one in the Municipality of Sofades, Karditsa, in 2013. 
During 2014, Greece reported zero locally acquired cases. 
The WHO European Region is close to attaining the goal of 
interruption of local malaria transmission by 2015, as set out 
in the 2005 Tashkent Declaration. Nonetheless, the experience 
of Greece and Turkey highlights the persistent threat of 
reintroduction and the need for continued vigilance to ensure 
that any resurgence is rapidly detected and contained.
THE NUMBER OF LOCALLY 
ACQUIRED MALARIA CASES 
FELL FROM 32 405 IN 2000 TO 
ONLY 41 IN 2013. THE REGION 
IS CLOSE TO ATTAINING 
THE GOAL OF ELIMINATING 
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EUROPEAN REGION
B.  Financial contribution for malaria control by source, 2005–2013 C. US$ per capita for malaria control, 2011–2013
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SOUTHEAST 
ASIA REGION
A. Conﬁ rmed malaria cases per 1000 population/parasite prevalence, 2013
Population at risk: About 1.4 billion people are at some risk for 
malaria in the 10 malaria-endemic countries, with 352 million 
at high risk. The proportion of cases due to P. falciparum varies 
greatly within the region, and cases are exclusively due to P. vivax 
in the Democratic People’s Republic of Korea (Figure F). 
Financing: Funding for malaria control in the region increased 
from US$ 104 million in 2005 to US$ 236 million in 2010, but 
then fell to US$ 203 million in 2013 (Figure B). It exceeded US$ 4 
per capita per year in Timor-Leste during 2011–2013 (Figure C). 
Funding is lowest in countries with the largest populations at 
risk, possibly because of the challenge of providing adequate 
ﬁ nancing for large population sizes, but possibly also because 
populations at risk are estimated less precisely and overestimated. 
In other words, populations at risk may be deﬁ ned according 
to comparatively large administrative units in which the entire 
population may be classiﬁ ed as being at high risk, even if malaria 
is conﬁ ned to a limited area.
Interventions: In 2011−2013, ﬁ ve countries (Bangladesh, 
Bhutan, the Democratic People’s Republic of Korea, Nepal and 
Timor-Leste) reported delivering suﬃ  cient ITNs or undertook 
suﬃ  cient IRS to protect >60% of their populations at high risk 
(Figure D). In 2013, Bangladesh, Bhutan, the Democratic People’s 
Republic of Korea and Timor-Leste reported delivering suﬃ  cient 
quantities of antimalarial medicines, including ACTs, to treat all 
reported cases in public health facilities (Figure E). Sri Lanka, 
Bhutan and the Democratic People’s Republic of Korea carried out 
compulsory notiﬁ cation of cases, case and focus investigation, 
radical treatment of P. vivax cases, gametocytocidal treatment of 
P. falciparum cases, and quality assurance of microscopy services. 
Trends in cases and deaths: The number of conﬁ rmed malaria 
cases reported in the region decreased from 2.9 to 1.5 million 
between 2000 and 2013. Three countries accounted for 96% 
of cases in 2013: India (58%), Myanmar (22%) and Indonesia 
(16%). Six countries reported >75% decrease in the incidence 
of microscopically conﬁ rmed cases between 2000 and 2013 
(Bangladesh, Bhutan, the Democratic People’s Republic of Korea, 
Nepal, Timor-Leste and Sri Lanka) (Figure G). Two countries (India 
and Thailand) are on track to achieve a decrease of 50–75% 
in case incidence by 2015. The decrease in Thailand may be 
underestimated, as 2012 and 2013 data include cases reported 
by nongovernmental organizations working on the borders 
of Cambodia and Myanmar. It was not possible to discern the 
direction of trends in Indonesia and Myanmar owing to changes 
in diagnostic testing and reporting over time. Reported malaria 
deaths in the region decreased from 5500 to 776 between 2000 
and 2013 (Annex 6E). Nepal has reported no deaths from malaria 
since 2012. 
Sri Lanka, in the elimination phase, reported zero locally acquired 
cases in 2013 for the ﬁ rst time, a rapid decrease from 124 cases 
in 2011 and 23 in 2012. Bhutan, which is in the pre-elimination 
phase, reported only 15 indigenous and 30 introduced cases 
(compared with 82 indigenous cases in 2012). The Democratic 
People’s Republic of Korea, also in the pre-elimination phase, 
reported 14 407 cases (compared with 21 850 in 2012). 
SIX COUNTRIES OUT OF 10 
ACHIEVED >75% DECREASE 
IN CASE INCIDENCE BETWEEN 
2000 AND 2013. SRI LANKA 
REPORTED ZERO LOCALLY 
ACQUIRED CASES FOR 
THE FIRST TIME. BHUTAN 
REPORTED ONLY 15 CASES.
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SOUTHEAST ASIA REGION
B.  Financial contribution for malaria control by source, 2005–2013 C. US$ per capita for malaria control, 2011–2013
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D.  Percentage of high-risk population potentially protected with 
distributed ITNs and percentage protected with IRS, 2013
E.  Antimalarial treatment courses distributed as a proportion of 
estimated malaria cases in the public sector, 2013
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F.  Percentage of cases due to P. falciparum and P. vivax, 
2009–2013 
G.  Change in case incidence of microscopically conﬁ rmed cases, 
2000–2013
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WESTERN 
PACIFIC REGION
A. Conﬁ rmed malaria cases per 1000 population/parasite prevalence, 2013
Population at risk: About 717 million people in the region 
are at some risk for malaria, with 41 million at high risk. Malaria 
transmission is most intense in Papua New Guinea, Solomon Islands 
and Vanuatu, but is much more focal in other countries in the 
region, disproportionately aﬀ ecting ethnic minorities and migrant 
workers. Both P. falciparum and P. vivax are prevalent, but cases are 
entirely due to P. vivax in the Republic of Korea and in central areas 
of China (Figure F). In recent years, P. knowlesi has accounted for an 
increasing number of cases, especially in Malaysia.
Financing: Funding for malaria control in the region increased 
from US$ 63 million in 2005 to US$ 169 million in 2010, but 
dropped to US$ 123 million in 2013 (Figure B). Malaria funding 
exceeded US$ 4 per capita per year during 2011–2013 in two 
countries (Malaysia and Solomon Islands) (Figure C).
Interventions: In 2011−2013, the number of ITNs delivered was 
suﬃ  cient to protect more than 60% of the population at high 
risk in seven countries, two of which (China and Malaysia) also 
protected >60% of the population with IRS (Figure D). Nationally 
representative surveys in Papua New Guinea showed an increase 
in the proportion of the population with access to a long-lasting 
insecticidal net (LLIN)  in their household from 44% in 2011 to 
68% in 2014, while the proportion of RDT positive cases receiving 
an ACT rose from 0% to 78%. The Republic of Korea reported 
low levels of vector control coverage, possibly due to the focal 
nature of the disease, except around the Korean Demilitarized 
Zone. All countries reported delivering suﬃ  cient antimalarial 
medicines to treat >80% of patients attending public health 
facilities. The Republic of Korea and Malaysia undertake ACD, 
case investigation, radical treatment of P. vivax and quality 
assurance of microscopy services. 
Trends in cases and deaths: Three countries accounted 
for >85% of reported conﬁ rmed cases in 2013: Papua New 
Guinea (70%), the Lao People’s Democratic Republic (9%) and 
Solomon Islands (6%). All countries except Papua New Guinea 
achieved >75% decrease in the incidence of microscopically 
conﬁ rmed cases between 2000 and 2013 (Figure G). The Lao 
People’s Democratic Republic reported a twofold increase 
in cases in 2012 and 2013, but case incidence remains <75% 
of 2000 levels. Papua New Guinea had a twofold increase in 
conﬁ rmed cases in 2013 compared with 2012, resulting from 
an increase in diagnostic testing with RDTs. However, nationally 
representative household surveys indicated a drop in parasite 
prevalence from 12.4% to 1.8% between 2009 and 2014, while 
the incidence of malaria at four sentinel surveillance sites fell 
from 205/1000 to 48/1000.  These data are consistent with a 
reduction in malaria case incidence of >75%. 
Reported malaria deaths in the region decreased by 93% from 
2360 to 406 between 2000 and 2013. In 2013, two countries 
accounted for 83% of all reported deaths: Papua New Guinea 
(76%) and the Lao People’s Democratic Republic (7%) (Annex 6E). 
Vanuatu has reported zero deaths from malaria since 2012. 
Malaysia is in the pre-elimination phase, and it continues to 
progress towards elimination, reporting 2979 locally acquired 
cases in 2013. The number of active foci (3027) and people living 
within them (>1 million) remain high. Malaria transmission occurs 
primarily in the districts of Sabah and Sarawak. In the Republic of 
Korea, which is in the elimination phase, the number of indigenous 
cases dropped to 383 in 2013. China reported just nine indigenous 
cases of P. falciparum malaria in 2013 and 71 of P. vivax and is 
aiming to eliminate malaria nationally by 2020. The Philippines is 
proceeding with a subnational elimination approach, and by 2013 
had declared 28 of its 80 provinces malaria free. The most malaria-
aﬀ ected provinces are Maguindanao, Palawan and Tawi-Tawi.
NINE OUT OF 10 COUNTRIES IN 
THIS REGION ACHIEVED >75% 
DECREASE IN CASE INCIDENCE 
BETWEEN 2000 AND 2013. 
ANOTHER COUNTRY IS ON 
TRACK TO REDUCE INCIDENCE 
BY 2550% BY 2015.
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WESTERN PACIFIC REGION
B.  Financial contribution for malaria control by source, 2005–2013 C. US$ per capita for malaria control, 2011–2013
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D.  Percentage of high-risk population potentially protected with 
distributed ITNs and percentage protected with IRS, 2013
E.  Antimalarial treatment courses distributed as a proportion of 
estimated malaria cases in the public sector, 2013
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F.  Percentage of cases due to P. falciparum and P. vivax, 
2009–2013 
G.  Change in case incidence of microscopically conﬁ rmed cases, 
2000–2013
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Summary of trends in reported malaria incidence, 2000–2013
WHO region
On track for ≥75% decrease 
in incidence 2000–2015
50%–75% 
decrease in 
incidence 
projected 
2000–2015
<50% decrease 
in incidence 
projected 
2000–2015
Increase in 
incidence 
2000–2013
Insuﬃ  ciently consistent data 
to assess trends
African Algeria
Botswana 
Cabo Verde 
Eritrea
Namibia 
Rwanda 
Sao Tome and Principe 
South Africa 
Swaziland 
Ethiopia
Zambia
Zimbabwe
Madagascar Angola 
Benin 
Burkina Faso 
Burundi
Cameroon 
Central African 
Republic 
Chad 
Comoros 
Congo 
Côte d’Ivoire 
Democratic 
Republic of the 
Congo 
Equatorial Guinea
Gabon 
Gambia 
Ghana 
Guinea 
Guinea-Bissau 
Kenya
Liberia
Malawi 
Mali 
Mauritania 
Mayotte, France
Mozambique 
Niger 
Nigeria 
Senegal 
Sierra Leone
Togo
Uganda
United Republic 
of Tanzania
Region of the 
Americas
Argentina*
Belize 
Bolivia 
(Plurinational 
State of) 
Costa Rica 
Ecuador 
El Salvador 
French Guiana, 
France
Guatemala
Honduras 
Mexico 
Nicaragua 
Paraguay*
Suriname
Brazil
Colombia
Peru
Dominican 
Republic
Panama
Guyana
Venezuela
(Bolivarian
Republic of )
Haiti
Eastern 
Mediterranean
Afghanistan
Iran (Islamic 
Republic of)
Iraq*
Morocco*
Oman*
Saudi Arabia
Syrian Arab 
Republic
Djibouti 
Pakistan
Somalia 
Sudan
Yemen
European Armenia*
Azerbaijan*
Georgia*
Kyrgyzstan*
Tajikistan 
Turkey 
Turkmenistan*
Uzbekistan*
South-East Asia Bangladesh
Bhutan 
Democratic 
People’s 
Republic of 
Korea 
Nepal 
Sri Lanka*
Timor-Leste
India
Thailand
Indonesia 
Myanmar
Western Paciﬁ c Cambodia 
China 
Lao People’s 
Democratic 
Republic 
Malaysia
Papua New 
Guinea
Philippines 
Republic of 
Korea
Solomon 
Islands 
Vanuatu 
Viet Nam
Source: National malaria control programme reports
Countries in prevention of reintroduction phase are not included in this table
Countries in bold achieved ≥75% decrease in case incidence by 2013
*Country reported zero indigenous cases in 2013.
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Impact: Achieved >75% decrease in case incidence in 2013
III. Financing Sources of financing Financing by intervention in 2013 
V. Impact  Confirmed malaria cases per 1000 and ABER Malaria admissions and deaths
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Afghanistan Eastern Mediterranean Region
I. Epidemiological profile
Population 2013 %
High transmission (> 1 case per 1000 population) 8 220 000 27
Low transmission (0–1 cases per 1000 population) 14 900 000 49
Malaria-free (0 cases) 7 460 000 24
Total 30 580 000 
Parasites and vectors
Major plasmodium species: P. falciparum (5%), P. vivax (95%)
Major anopheles species: An. stephensi, An. superpictus, An. hyrcanus, An. pulcherrimus, An. culicifacies, An. fluviatilis
Programme phase: Control
Reported confirmed cases: 39 263 
Reported deaths: 24 
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 2010
 ITNs/LLINs distributed to all age groups Yes 2010
IRS IRS is recommended Yes 2012 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended No –
IPT IPT used to prevent malaria during pregnancy N/A –
Diagnosis Patients of all ages should receive diagnostic test Yes 2000
 Malaria diagnosis is free of charge in the public sector Yes 2000
Treatment ACT is free for all ages in public sector Yes 2003
 Artemisinin-based monotherapies withdrawn Yes 2003
 Single dose of primaquine is used as gametocidal medicine for P. falciparum No –
 Primaquine is used for radical treatment of P. vivax Yes 2010
 G6PD test is a requirement before treatment with primaquine Yes 2010
 Directly observed treatment with primaquine is undertaken Yes 2011
 System for monitoring of adverse reactions to antimalarials exists No –
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) Yes 2012
 ACD of febrile cases at community level (pro-active) No –
 Mass screening is undertaken No –
 Uncomplicated P. falciparum cases routinely admitted No –
 Uncomplicated P. vivax cases routinely admitted No –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria CQ –
First-line treatment of P. falciparum AS+SP+PQ 2014
Treatment failure of P. falciparum QN –
Treatment of severe malaria AM; AS; QN –
Treatment of P. vivax CQ+PQ(8w) –
Dosage of primaquine for radical treatment of P. vivax 0.75 mg/kg (8 weeks)
Type of RDT used P.f + P.v, P.o, P.m (Combo)
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
AS+SP 2005–2012 0 0 1 28 days 7 P. falciparum
CQ 2007–2009 0 0 0 28 days 4 P. vivax
       
II. Intervention policies and strategies
Pie chart include 100% 
of total contributions
Funding source(s): Global 
Fund, WHO
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Impact: Achieved >75% decrease in case incidence in 2013
V. Impact Malaria test positivity rate and ABER Number of malaria cases 
IV. Coverage ITN and IRS coverage Cases tested
 Cases treated Cases tracked
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Algeria African Region
I. Epidemiological profile
Parasites and vectors
Major plasmodium species: P. falciparum (88%), P. vivax (13%)
Major anopheles species: An. multicolor, An. labranchiae, An. sergentii, An. hispaniola
Programme phase: Elimination
Total confirmed cases, 2013: 603 Indigenous cases, 2013: 0
Total deaths, 2013: 3 Indigenous deaths, 2013: 0
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge No –
 ITNs/LLINs distributed to all age groups No –
IRS IRS is recommended Yes 1980 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended Yes –
IPT IPT used to prevent malaria during pregnancy – –
Diagnosis Patients of all ages should receive diagnostic test – –
 Malaria diagnosis is free of charge in the public sector Yes 1968
Treatment ACT is free for all ages in public sector – –
 Artemisinin-based monotherapies withdrawn – –
 Single dose of primaquine is used as gametocidal medicine for P. falciparum Yes –
 Primaquine is used for radical treatment of P. vivax Yes –
 G6PD test is a requirement before treatment with primaquine No –
 Directly observed treatment with primaquine is undertaken Yes –
 System for monitoring of adverse reactions to antimalarials exists No –
II. Intervention policies and strategies
Population 2013 %
Number of active foci 0 
Number of people living within active foci – –
Number of people living in malaria-free areas 39 200 000 100
Total 39 200 000 
III. Financing Sources of financing Financing by intervention in 2013 
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) Yes –
 ACD of febrile cases at community level (pro-active) No –
 Mass screening is undertaken No –
 Uncomplicated P. falciparum cases routinely admitted Yes –
 Uncomplicated P. vivax cases routinely admitted Yes –
 Foci and case investigation undertaken Yes 1968
 Case reporting from private sector is mandatory Yes –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria – –
First-line treatment of P. falciparum – –
Treatment failure of P. falciparum – –
Treatment of severe malaria – –
Treatment of P. vivax CQ –
Dosage of primaquine for radical treatment of P. vivax 0.25 mg/kg (14 days)
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
– – – – – – – –
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Impact: Insufficiently consistent data to assess trends
III. Financing Sources of financing Financing by intervention in 2013 
V. Impact  Confirmed malaria cases per 1000 and ABER Malaria admissions and deaths (per 100 000)
IV. Coverage ITN and IRS coverage Cases tested and treated in public sector
 Cases tracked Test positivity
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Angola African Region
I. Epidemiological profile
Population 2013 %
High transmission (> 1 case per 1000 population) 21 500 000 100
Low transmission (0–1 cases per 1000 population) 0 0
Malaria-free (0 cases) 0 0
Total 21 500 000 
Parasites and vectors
Major plasmodium species: P. falciparum (100%), P. vivax (0%)
Major anopheles species: An. gambiae, An. funestus, An. nili
Programme phase: Control
Reported confirmed cases: 1 999 868 
Reported deaths: 7300 
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 2001
 ITNs/LLINs distributed to all age groups No 2010
IRS IRS is recommended Yes 2003 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended Yes 2009
IPT IPT used to prevent malaria during pregnancy Yes 2005
Diagnosis Patients of all ages should receive diagnostic test Yes 2010
 Malaria diagnosis is free of charge in the public sector Yes 2006
Treatment ACT is free for all ages in public sector Yes 2006
 Artemisinin-based monotherapies withdrawn No –
 Single dose of primaquine is used as gametocidal medicine for P. falciparum No –
 Primaquine is used for radical treatment of P. vivax Yes 2006
 G6PD test is a requirement before treatment with primaquine Yes –
 Directly observed treatment with primaquine is undertaken No –
 System for monitoring of adverse reactions to antimalarials exists Yes –
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) No –
 ACD of febrile cases at community level (pro-active) No –
 Mass screening is undertaken No –
 Uncomplicated P. falciparum cases routinely admitted No –
 Uncomplicated P. vivax cases routinely admitted No –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria AL 2006
First-line treatment of P. falciparum AL 2006
Treatment failure of P. falciparum QN 2006
Treatment of severe malaria QN 2006
Treatment of P. vivax – –
Dosage of primaquine for radical treatment of P. vivax 0.25 mg/kg (14 days)
Type of RDT used P.f + P.v specific (Combo)
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
AL 2013–2013 2.7 6.5 10.3 28 days 2 P. falciparum
DHA-PPQ 2013–2013 0 0 0 28 days 2 P. falciparum
       
II. Intervention policies and strategies
Pie chart include 44% 
of total contributions
Funding source(s): Global Fund, 
USAID/PMI, UNICEF
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Impact: Achieved >75% decrease in case incidence in 2013
V. Impact Malaria test positivity rate and ABER Number of malaria cases 
IV. Coverage ITN and IRS coverage Cases tested
 Cases treated Cases tracked
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Argentina Region of the Americas
I. Epidemiological profile
Parasites and vectors
Major plasmodium species: P. falciparum (0%), P. vivax (0%)
Major anopheles species: An. pseudopunctipennis, An. darlingi
Programme phase: Elimination
Total confirmed cases, 2013: 4 Indigenous cases, 2013: 0
Total deaths, 2013: 0 Indigenous deaths, 2013: 0
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge No –
 ITNs/LLINs distributed to all age groups No –
IRS IRS is recommended Yes 2013 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended No –
IPT IPT used to prevent malaria during pregnancy N/A –
Diagnosis Patients of all ages should receive diagnostic test Yes –
 Malaria diagnosis is free of charge in the public sector Yes 1980
Treatment ACT is free for all ages in public sector Yes –
 Artemisinin-based monotherapies withdrawn – –
 Single dose of primaquine is used as gametocidal medicine for P. falciparum Yes –
 Primaquine is used for radical treatment of P. vivax Yes –
 G6PD test is a requirement before treatment with primaquine No –
 Directly observed treatment with primaquine is undertaken Yes –
 System for monitoring of adverse reactions to antimalarials exists Yes –
II. Intervention policies and strategies
Pie chart include 100% 
of total contributions
Funding source(s): Government
Population 2013 %
Number of active foci 0 
Number of people living within active foci 0 0
Number of people living in malaria-free areas 41 400 000 100
Total 41 400 000 
III. Financing Sources of financing Financing by intervention in 2013 
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) Yes –
 ACD of febrile cases at community level (pro-active) No –
 Mass screening is undertaken Yes –
 Uncomplicated P. falciparum cases routinely admitted Yes –
 Uncomplicated P. vivax cases routinely admitted No –
 Foci and case investigation undertaken Yes –
 Case reporting from private sector is mandatory Yes –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria – –
First-line treatment of P. falciparum AL+PQ –
Treatment failure of P. falciparum – –
Treatment of severe malaria – –
Treatment of P. vivax CQ+PQ –
Dosage of primaquine for radical treatment of P. vivax 0.25 mg/kg (14 days)
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
– – – – – – – –
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Impact: Achieved >75% decrease in case incidence in 2013
V. Impact Malaria test positivity rate and ABER Number of malaria cases 
IV. Coverage ITN and IRS coverage Cases tested
 Cases treated Cases tracked
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Azerbaijan European Region
I. Epidemiological profile
Parasites and vectors
Major plasmodium species: P. falciparum (0%), P. vivax (0%)
Major anopheles species: An. sacharovi, An. maculipennis
Programme phase: Elimination
Total confirmed cases, 2013: 4 Indigenous cases, 2013: 0
Total deaths, 2013: 0 Indigenous deaths, 2013: 0
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 2009
 ITNs/LLINs distributed to all age groups No –
IRS IRS is recommended Yes 1930 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended Yes 1930
IPT IPT used to prevent malaria during pregnancy N/A –
Diagnosis Patients of all ages should receive diagnostic test – –
 Malaria diagnosis is free of charge in the public sector Yes 1930
Treatment ACT is free for all ages in public sector Yes 2009
 Artemisinin-based monotherapies withdrawn – –
 Single dose of primaquine is used as gametocidal medicine for P. falciparum No –
 Primaquine is used for radical treatment of P. vivax Yes 1956
 G6PD test is a requirement before treatment with primaquine No –
 Directly observed treatment with primaquine is undertaken Yes 1956
 System for monitoring of adverse reactions to antimalarials exists Yes 1956
II. Intervention policies and strategies
Pie chart include 100% 
of total contributions
Funding source(s): Government, 
Global Fund, USAID/PMI, WHO, 
Other (bilateral)
Population 2013 %
Number of active foci 6 
Number of people living within active foci 12 600 0
Number of people living in malaria-free areas 9 400 000 100
Total 9 412 600 
III. Financing Sources of financing Financing by intervention in 2013 
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) Yes 1930
 ACD of febrile cases at community level (pro-active) Yes 1930
 Mass screening is undertaken No –
 Uncomplicated P. falciparum cases routinely admitted Yes 1998
 Uncomplicated P. vivax cases routinely admitted Yes 1998
 Foci and case investigation undertaken Yes 1930
 Case reporting from private sector is mandatory Yes 2008
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria AS+SP 2008
First-line treatment of P. falciparum AS+SP 2008
Treatment failure of P. falciparum QN+CL 2008
Treatment of severe malaria AS; QN 2008
Treatment of P. vivax CQ+PQ(14d) –
Dosage of primaquine for radical treatment of P. vivax 0.25 mg/kg (14 days)
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
– – – – – – – –
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Impact: Achieved >75% decrease in case incidence in 2013
III. Financing Sources of financing Financing by intervention in 2013 
V. Impact  Confirmed malaria cases per 1000 and ABER Malaria admissions and deaths
IV. Coverage ITN and IRS coverage Cases tested and treated in public sector
 Cases tracked Test positivity
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Bangladesh South-East Asia Region
I. Epidemiological profile
Population 2013 %
High transmission (> 1 case per 1000 population) 4 170 000 3
Low transmission (0–1 cases per 1000 population) 12 100 000 8
Malaria-free (0 cases) 140 400 000 90
Total 156 670 000 
Parasites and vectors
Major plasmodium species: P. falciparum (87%), P. vivax (13%)
Major anopheles species: An. dirus, An. minimus, An. philippinensis, An. sundaicus, An. albimanus, An. annularis
Programme phase: Control
Reported confirmed cases: 3864 
Reported deaths: 15 
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 2008
 ITNs/LLINs distributed to all age groups Yes 2008
IRS IRS is recommended Yes 2008 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended No –
IPT IPT used to prevent malaria during pregnancy N/A –
Diagnosis Patients of all ages should receive diagnostic test Yes 2008
 Malaria diagnosis is free of charge in the public sector Yes 2008
Treatment ACT is free for all ages in public sector Yes 2008
 Artemisinin-based monotherapies withdrawn – –
 Single dose of primaquine is used as gametocidal medicine for P. falciparum Yes –
 Primaquine is used for radical treatment of P. vivax Yes 2008
 G6PD test is a requirement before treatment with primaquine No –
 Directly observed treatment with primaquine is undertaken No –
 System for monitoring of adverse reactions to antimalarials exists Yes 2008
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) Yes 2008
 ACD of febrile cases at community level (pro-active) Yes 2008
 Mass screening is undertaken No –
 Uncomplicated P. falciparum cases routinely admitted No –
 Uncomplicated P. vivax cases routinely admitted No –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria – –
First-line treatment of P. falciparum AL 2004
Treatment failure of P. falciparum QN+D; QN+T 2004
Treatment of severe malaria AM; QN 2004
Treatment of P. vivax CQ+PQ(14d) 2004
Dosage of primaquine for radical treatment of P. vivax 0.25 mg/kg (14 days)
Type of RDT used P.f + P.v specific (Combo)
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
AL 2006–2010 0 0 2 28 days 7 P. falciparum
QN+D 2008–2009 0 0 0 28 days 1 P. falciparum
       
II. Intervention policies and strategies
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Funding source(s): Global 
Fund, WHO
Insucient data
0
0–0.1
0.1–1.0
1.0–10
PP
>75
0
no cases
Insucient data
Very low PP
0–20
20–40
40–60
60–80
80–100
PR
OTHERS
PF-RATIO
Proportion of cases 
due to P. falciparum
Insucient data
0
0–0.1
0.1–1.0
1.0–10
PP
>75
0
no cases
Insucient data
Very low PP
0–20
20–40
40–60
60–80
80–100
PR
OTHERS
PF-RATIO
Confirmed cases  
per 1000 population/
Parasite prevalence 
(PP)
Based on 2012 reported data Based on 2012 reported data
Survey source: DHS 2000, DHS 2004, DHS 2007, DHS 2011
Survey source: DHS 2011
74 | WORLD MALARIA REPORT 2014
Impact: Achieved >75% decrease in case incidence in 2013
V. Impact Malaria test positivity rate and ABER Number of malaria cases 
IV. Coverage ITN and IRS coverage Cases tested
 Cases treated Cases tracked
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Belize Region of the Americas
I. Epidemiological profile
Parasites and vectors
Major plasmodium species: P. falciparum (0%), P. vivax (100%)
Major anopheles species: An. albimanus, An. darlingi
Programme phase: Pre-elimination
Total confirmed cases, 2013: 26 Indigenous cases, 2013: 20
Total deaths, 2013: 0 Indigenous deaths, 2013: 0
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 2009
 ITNs/LLINs distributed to all age groups Yes 2009
IRS IRS is recommended Yes – 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended Yes –
IPT IPT used to prevent malaria during pregnancy N/A –
Diagnosis Patients of all ages should receive diagnostic test Yes –
 Malaria diagnosis is free of charge in the public sector Yes –
Treatment ACT is free for all ages in public sector Yes 2010
 Artemisinin-based monotherapies withdrawn – –
 Single dose of primaquine is used as gametocidal medicine for P. falciparum Yes –
 Primaquine is used for radical treatment of P. vivax Yes –
 G6PD test is a requirement before treatment with primaquine No –
 Directly observed treatment with primaquine is undertaken Yes –
 System for monitoring of adverse reactions to antimalarials exists No –
II. Intervention policies and strategies
Pie chart include 100% 
of total contributions
Funding source(s): Government, 
Other (bilateral), Other (all types)
Population 2013 %
Number of active foci 6 
Number of people living within active foci 4540 1
Number of people living in malaria-free areas 327 000 99
Total 331 540 
III. Financing Sources of financing Financing by intervention in 2013 
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) Yes –
 ACD of febrile cases at community level (pro-active) No –
 Mass screening is undertaken Yes –
 Uncomplicated P. falciparum cases routinely admitted No –
 Uncomplicated P. vivax cases routinely admitted No –
 Foci and case investigation undertaken Yes –
 Case reporting from private sector is mandatory Yes –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria – –
First-line treatment of P. falciparum CQ+PQ (1d) –
Treatment failure of P. falciparum – –
Treatment of severe malaria AL; QN –
Treatment of P. vivax CQ+PQ(14d) –
Dosage of primaquine for radical treatment of P. vivax 0.25 mg/kg (14 days)
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
– – – – – – – –
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Impact: Insufficiently consistent data to assess trends
III. Financing Sources of financing Financing by intervention in 2013 
V. Impact  Confirmed malaria cases per 1000 and ABER Malaria admissions and deaths (per 100 000)
IV. Coverage ITN and IRS coverage Cases tested and treated in public sector
 Cases tracked Test positivity
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Benin African Region
I. Epidemiological profile
Population 2013 %
High transmission (> 1 case per 1000 population) 10 300 000 100
Low transmission (0–1 cases per 1000 population) 0 0
Malaria-free (0 cases) 0 0
Total 10 300 000 
Parasites and vectors
Major plasmodium species: P. falciparum (100%), P. vivax (0%)
Major anopheles species: An. gambiae, An. funestus, An. melas
Programme phase: Control
Reported confirmed cases: 1 078 834 
Reported deaths: 2288 
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 2007
 ITNs/LLINs distributed to all age groups No –
IRS IRS is recommended Yes 2006 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended No –
IPT IPT used to prevent malaria during pregnancy Yes 2005
Diagnosis Patients of all ages should receive diagnostic test Yes 2011
 Malaria diagnosis is free of charge in the public sector Yes 2008
Treatment ACT is free for all ages in public sector No –
 Artemisinin-based monotherapies withdrawn – –
 Single dose of primaquine is used as gametocidal medicine for P. falciparum No –
 Primaquine is used for radical treatment of P. vivax No –
 G6PD test is a requirement before treatment with primaquine – –
 Directly observed treatment with primaquine is undertaken No –
 System for monitoring of adverse reactions to antimalarials exists Yes 2005
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) – –
 ACD of febrile cases at community level (pro-active) Yes –
 Mass screening is undertaken No –
 Uncomplicated P. falciparum cases routinely admitted Yes –
 Uncomplicated P. vivax cases routinely admitted No –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria AL 2004
First-line treatment of P. falciparum AL 2004
Treatment failure of P. falciparum QN 2004
Treatment of severe malaria QN 2004
Treatment of P. vivax – –
Dosage of primaquine for radical treatment of P. vivax –
Type of RDT used –
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
AL 2005–2011 0 0.75 6.5 28 days 6 P. falciparum
       
       
II. Intervention policies and strategies
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Impact: Achieved >75% decrease in case incidence in 2013
V. Impact Malaria test positivity rate and ABER Number of malaria cases 
IV. Coverage ITN and IRS coverage Cases tested
 Cases treated Cases tracked
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Bhutan South-East Asia Region
I. Epidemiological profile
Parasites and vectors
Major plasmodium species: P. falciparum (59%), P. vivax (41%)
Major anopheles species: An. culicifacies, An. maculatus, An. philippiensis, An. annularis
Programme phase: Pre-elimination
Total confirmed cases, 2013: 45 Indigenous cases, 2013: 15
Total deaths, 2013: 0 Indigenous deaths, 2013: 0
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 2006
 ITNs/LLINs distributed to all age groups Yes 2006
IRS IRS is recommended Yes 1964 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended No –
IPT IPT used to prevent malaria during pregnancy N/A –
Diagnosis Patients of all ages should receive diagnostic test Yes 1964
 Malaria diagnosis is free of charge in the public sector Yes 1964
Treatment ACT is free for all ages in public sector Yes 2006
 Artemisinin-based monotherapies withdrawn Yes –
 Single dose of primaquine is used as gametocidal medicine for P. falciparum Yes 2012
 Primaquine is used for radical treatment of P. vivax Yes –
 G6PD test is a requirement before treatment with primaquine No –
 Directly observed treatment with primaquine is undertaken No –
 System for monitoring of adverse reactions to antimalarials exists Yes 2012
II. Intervention policies and strategies
Population 2013 %
Number of active foci – 
Number of people living within active foci 235 000 31
Number of people living in malaria-free areas 519 000 69
Total 754 000 
III. Financing Sources of financing Financing by intervention in 2013 
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) Yes 2013
 ACD of febrile cases at community level (pro-active) No –
 Mass screening is undertaken Yes 2011
 Uncomplicated P. falciparum cases routinely admitted Yes 2012
 Uncomplicated P. vivax cases routinely admitted Yes 2012
 Foci and case investigation undertaken Yes 2012
 Case reporting from private sector is mandatory No –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria – –
First-line treatment of P. falciparum AL 2006
Treatment failure of P. falciparum QN 2006
Treatment of severe malaria AM; QN 2006
Treatment of P. vivax CQ+PQ(14d) 2006
Dosage of primaquine for radical treatment of P. vivax 0.25 mg/kg (14 days)
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
AL 2005–2011 0 0 0 28 days 23 P. falciparum
CQ 2005–2011 0 0 0 28 days 22 P. vivax
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Impact: Achieved >75% decrease in case incidence in 2013
III. Financing Sources of financing Financing by intervention in 2013 
V. Impact  Confirmed malaria cases per 1000 and ABER Malaria admissions and deaths
IV. Coverage ITN and IRS coverage Cases tested and treated in public sector
 Cases tracked Test positivity
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Bolivia (Plurinational State of ) Region of the Americas
I. Epidemiological profile
Population 2013 %
High transmission (> 1 case per 1000 population) 512 000 5
Low transmission (0–1 cases per 1000 population) 3 250 000 31
Malaria-free (0 cases) 6 900 000 65
Total 10 662 000 
Parasites and vectors
Major plasmodium species: P. falciparum (16%), P. vivax (84%)
Major anopheles species: An. darlingi, An. pseudopunctipennis
Programme phase: Control
Reported confirmed cases: 7342 
Reported deaths: 0 
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 2008
 ITNs/LLINs distributed to all age groups Yes 2005
IRS IRS is recommended Yes 1959 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended No –
IPT IPT used to prevent malaria during pregnancy N/A –
Diagnosis Patients of all ages should receive diagnostic test Yes 2000
 Malaria diagnosis is free of charge in the public sector Yes 1996
Treatment ACT is free for all ages in public sector Yes 2003
 Artemisinin-based monotherapies withdrawn Yes –
 Single dose of primaquine is used as gametocidal medicine for P. falciparum Yes –
 Primaquine is used for radical treatment of P. vivax Yes 1998
 G6PD test is a requirement before treatment with primaquine No –
 Directly observed treatment with primaquine is undertaken No –
 System for monitoring of adverse reactions to antimalarials exists No –
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) Yes –
 ACD of febrile cases at community level (pro-active) No –
 Mass screening is undertaken Yes 1998
 Uncomplicated P. falciparum cases routinely admitted No –
 Uncomplicated P. vivax cases routinely admitted No –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria – –
First-line treatment of P. falciparum AS+MQ+PQ 2001
Treatment failure of P. falciparum QN+CL –
Treatment of severe malaria QN 2001
Treatment of P. vivax CQ+PQ(7d) 2001
Dosage of primaquine for radical treatment of P. vivax 0.50 mg/kg (7 days)
Type of RDT used P.f + P.v specific (Combo)
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
CQ 2006–2011 0 7.8 10 28 days 4 P. vivax
       
       
II. Intervention policies and strategies
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Impact: Achieved >75% decrease in case incidence in 2013
III. Financing Sources of financing Financing by intervention in 2013 
V. Impact  Confirmed malaria cases per 1000 and ABER Malaria admissions and deaths (per 100 000)
IV. Coverage ITN and IRS coverage Cases tested and treated in public sector
 Cases tracked Test positivity
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Botswana African Region
I. Epidemiological profile
Population 2013 %
High transmission (> 1 case per 1000 population) 364 000 18
Low transmission (0–1 cases per 1000 population) 950 000 47
Malaria-free (0 cases) 707 000 35
Total 2 021 000 
Parasites and vectors
Major plasmodium species: P. falciparum (100%), P. vivax (0%)
Major anopheles species: An. arabiensis, An. gambiae
Programme phase: Control
Reported confirmed cases: 456 
Reported deaths: 7 
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 2009
 ITNs/LLINs distributed to all age groups Yes 1997
IRS IRS is recommended Yes 1950 
 DDT is authorized for IRS Yes 1950
Larval control Use of larval control recommended Yes –
IPT IPT used to prevent malaria during pregnancy No –
Diagnosis Patients of all ages should receive diagnostic test Yes 2010
 Malaria diagnosis is free of charge in the public sector Yes 1995
Treatment ACT is free for all ages in public sector Yes 2007
 Artemisinin-based monotherapies withdrawn Yes –
 Single dose of primaquine is used as gametocidal medicine for P. falciparum No –
 Primaquine is used for radical treatment of P. vivax No –
 G6PD test is a requirement before treatment with primaquine No –
 Directly observed treatment with primaquine is undertaken No –
 System for monitoring of adverse reactions to antimalarials exists Yes –
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) Yes 2012
 ACD of febrile cases at community level (pro-active) Yes 2012
 Mass screening is undertaken No 2012
 Uncomplicated P. falciparum cases routinely admitted No –
 Uncomplicated P. vivax cases routinely admitted No –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria AL 2007
First-line treatment of P. falciparum AL 2007
Treatment failure of P. falciparum QN 2007
Treatment of severe malaria QN 2007
Treatment of P. vivax – –
Dosage of primaquine for radical treatment of P. vivax –
Type of RDT used P.f only
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
– – – – – – – –
       
       
II. Intervention policies and strategies
Pie chart include 84% 
of total contributions
Funding source(s): Government
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Impact: Increase in case incidence 2000-2015
III. Financing Sources of financing Financing by intervention in 2013 
V. Impact  Confirmed malaria cases per 1000 and ABER Malaria admissions and deaths
IV. Coverage ITN and IRS coverage Cases tested and treated in public sector
 Cases tracked Test positivity
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Brazil Region of the Americas
I. Epidemiological profile
Population 2013 %
High transmission (> 1 case per 1000 population) 4 610 000 2
Low transmission (0–1 cases per 1000 population) 36 100 000 18
Malaria-free (0 cases) 159 700 000 80
Total 200 410 000 
Parasites and vectors
Major plasmodium species: P. falciparum (18%), P. vivax (82%)
Major anopheles species: An. darlingi, An. albitarsis, An. aquasalis
Programme phase: Control
Reported confirmed cases: 177 767 
Reported deaths: 41 
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 2007
 ITNs/LLINs distributed to all age groups Yes 2007
IRS IRS is recommended Yes 1945 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended No –
IPT IPT used to prevent malaria during pregnancy N/A –
Diagnosis Patients of all ages should receive diagnostic test Yes 1972
 Malaria diagnosis is free of charge in the public sector Yes 1972
Treatment ACT is free for all ages in public sector Yes 2006
 Artemisinin-based monotherapies withdrawn Yes 2010
 Single dose of primaquine is used as gametocidal medicine for P. falciparum Yes 2011
 Primaquine is used for radical treatment of P. vivax Yes 1972
 G6PD test is a requirement before treatment with primaquine No –
 Directly observed treatment with primaquine is undertaken No –
 System for monitoring of adverse reactions to antimalarials exists No –
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) Yes –
 ACD of febrile cases at community level (pro-active) Yes –
 Mass screening is undertaken Yes –
 Uncomplicated P. falciparum cases routinely admitted Yes –
 Uncomplicated P. vivax cases routinely admitted Yes –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria – –
First-line treatment of P. falciparum AL+PQ(1d); AS+MQ+PQ(1d) 2012
Treatment failure of P. falciparum QN+D+PQ –
Treatment of severe malaria AM+CL; AS+CL; QN+CL –
Treatment of P. vivax CQ+PQ(7d) 2006
Dosage of primaquine for radical treatment of P. vivax 0.50 mg/kg (7 days)
Type of RDT used P.f + all species (Combo)
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
AL 2005–2007 0 0 0 28 days 2 P. falciparum
AS+MQ 2005–2007 0 0 0 42 days 3 P. falciparum
CQ+PQ 2005–2008 1.3 3.25 5.2 28 days 2 P. vivax
II. Intervention policies and strategies
Pie chart include <1% 
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Funding source(s): USAID/PMI
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Impact: Insufficiently consistent data to assess trends
III. Financing Sources of financing Financing by intervention in 2013 
V. Impact  Confirmed malaria cases per 1000 and ABER Malaria admissions and deaths (per 100 000)
IV. Coverage ITN and IRS coverage Cases tested and treated in public sector
 Cases tracked Test positivity
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Burkina Faso African Region
I. Epidemiological profile
Population 2013 %
High transmission (> 1 case per 1000 population) 16 900 000 100
Low transmission (0–1 cases per 1000 population) 0 0
Malaria-free (0 cases) 0 0
Total 16 900 000 
Parasites and vectors
Major plasmodium species: P. falciparum (100%), P. vivax (0%)
Major anopheles species: An. gambiae, An. funestus, An. arabiensis
Programme phase: Control
Reported confirmed cases: 3 769 051 
Reported deaths: 6294 
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 2007
 ITNs/LLINs distributed to all age groups Yes 1998
IRS IRS is recommended Yes 2006 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended Yes 2012
IPT IPT used to prevent malaria during pregnancy Yes 2005
Diagnosis Patients of all ages should receive diagnostic test Yes 2009
 Malaria diagnosis is free of charge in the public sector Yes 2009
Treatment ACT is free for all ages in public sector No –
 Artemisinin-based monotherapies withdrawn Yes 2009
 Single dose of primaquine is used as gametocidal medicine for P. falciparum No –
 Primaquine is used for radical treatment of P. vivax No –
 G6PD test is a requirement before treatment with primaquine No –
 Directly observed treatment with primaquine is undertaken No –
 System for monitoring of adverse reactions to antimalarials exists Yes 2009
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) No –
 ACD of febrile cases at community level (pro-active) No –
 Mass screening is undertaken No –
 Uncomplicated P. falciparum cases routinely admitted Yes –
 Uncomplicated P. vivax cases routinely admitted No –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria AL; AS+AQ 2005
First-line treatment of P. falciparum AL; AS+AQ 2005
Treatment failure of P. falciparum QN –
Treatment of severe malaria QN –
Treatment of P. vivax – –
Dosage of primaquine for radical treatment of P. vivax –
Type of RDT used P.f only
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
AL 2005–2012 0 6.15 12.5 28 days 9 P. falciparum
AS+AQ 2006–2012 0 5.05 21.5 28 days 6 P. falciparum
       
II. Intervention policies and strategies
Pie chart include 54% 
of total contributions
Funding source(s): Government, 
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Impact: Insufficiently consistent data to assess trends
III. Financing Sources of financing Financing by intervention in 2013 
V. Impact  Confirmed malaria cases per 1000 and ABER Malaria admissions and deaths (per 100 000)
IV. Coverage ITN and IRS coverage Cases tested and treated in public sector
 Cases tracked Test positivity
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Burundi African Region
I. Epidemiological profile
Population 2013 %
High transmission (> 1 case per 1000 population) 2 440 000 24
Low transmission (0–1 cases per 1000 population) 5 490 000 54
Malaria-free (0 cases) 2 240 000 22
Total 10 170 000 
Parasites and vectors
Major plasmodium species: P. falciparum (100%), P. vivax (0%)
Major anopheles species: An. gambiae, An. funestus, An. arabiensis
Programme phase: Control
Reported confirmed cases: 4 141 387 
Reported deaths: 3411 
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 2004
 ITNs/LLINs distributed to all age groups No –
IRS IRS is recommended Yes 2009 
 DDT is authorized for IRS – –
Larval control Use of larval control recommended No –
IPT IPT used to prevent malaria during pregnancy No –
Diagnosis Patients of all ages should receive diagnostic test Yes 2012
 Malaria diagnosis is free of charge in the public sector No –
Treatment ACT is free for all ages in public sector Yes 2009
 Artemisinin-based monotherapies withdrawn No –
 Single dose of primaquine is used as gametocidal medicine for P. falciparum No –
 Primaquine is used for radical treatment of P. vivax No –
 G6PD test is a requirement before treatment with primaquine No –
 Directly observed treatment with primaquine is undertaken No –
 System for monitoring of adverse reactions to antimalarials exists No –
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) – –
 ACD of febrile cases at community level (pro-active) Yes 2010
 Mass screening is undertaken No –
 Uncomplicated P. falciparum cases routinely admitted Yes 2003
 Uncomplicated P. vivax cases routinely admitted No –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria AS+AQ 2003
First-line treatment of P. falciparum AS+AQ 2003
Treatment failure of P. falciparum QN 2003
Treatment of severe malaria QN 2003
Treatment of P. vivax – –
Dosage of primaquine for radical treatment of P. vivax –
Type of RDT used –
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
AS+AQ 2005–2006 2.9 5.2 7.5 28 days 2 P. falciparum
       
       
II. Intervention policies and strategies
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Impact: Achieved >75% decrease in case incidence in 2013
V. Impact Malaria test positivity rate and ABER Number of malaria cases 
IV. Coverage ITN and IRS coverage Cases tested
 Cases treated Cases tracked
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Cabo Verde African Region
I. Epidemiological profile
Parasites and vectors
Major plasmodium species: P. falciparum (100%), P. vivax (0%)
Major anopheles species: An. arabiensis
Programme phase: Pre-elimination
Total confirmed cases, 2013: 46 Indigenous cases, 2013: 22
Total deaths, 2013: 0 Indigenous deaths, 2013: 0
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge No –
 ITNs/LLINs distributed to all age groups No –
IRS IRS is recommended Yes 1998 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended Yes –
IPT IPT used to prevent malaria during pregnancy No –
Diagnosis Patients of all ages should receive diagnostic test Yes 1998
 Malaria diagnosis is free of charge in the public sector Yes 1975
Treatment ACT is free for all ages in public sector Yes 2008
 Artemisinin-based monotherapies withdrawn – –
 Single dose of primaquine is used as gametocidal medicine for P. falciparum Yes –
 Primaquine is used for radical treatment of P. vivax No –
 G6PD test is a requirement before treatment with primaquine – –
 Directly observed treatment with primaquine is undertaken Yes –
 System for monitoring of adverse reactions to antimalarials exists No –
II. Intervention policies and strategies
Pie chart include 100% 
of total contributions
Funding source(s): Government, 
Global Fund, USAID/PMI, WHO
Population 2013 %
Number of active foci 2 
Number of people living within active foci 299 000 60
Number of people living in malaria-free areas 200 000 40
Total 499 000 
III. Financing Sources of financing Financing by intervention in 2013 
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) Yes –
 ACD of febrile cases at community level (pro-active) Yes –
 Mass screening is undertaken No –
 Uncomplicated P. falciparum cases routinely admitted Yes –
 Uncomplicated P. vivax cases routinely admitted – –
 Foci and case investigation undertaken Yes –
 Case reporting from private sector is mandatory Yes –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria AL 2007
First-line treatment of P. falciparum AL 2007
Treatment failure of P. falciparum QN –
Treatment of severe malaria QN –
Treatment of P. vivax – –
Dosage of primaquine for radical treatment of P. vivax –
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
– – – – – – – –
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III. Financing Sources of financing Financing by intervention in 2013 
V. Impact  Confirmed malaria cases per 1000 and ABER Malaria admissions and deaths
IV. Coverage ITN and IRS coverage Cases tested and treated in public sector
 Cases tracked Test positivity
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Cambodia Western Pacific Region
I. Epidemiological profile
Population 2013 %
High transmission (> 1 case per 1000 population) 6 660 000 44
Low transmission (0–1 cases per 1000 population) 1 360 000 9
Malaria-free (0 cases) 7 110 000 47
Total 15 130 000 
Parasites and vectors
Major plasmodium species: P. falciparum (55%), P. vivax (45%)
Major anopheles species: An. dirus, An. minimus, An. maculatus, An. sundaicus
Programme phase: Control
Reported confirmed cases: 21 309 
Reported deaths: 12 
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 2000
 ITNs/LLINs distributed to all age groups Yes 2000
IRS IRS is recommended No – 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended No –
IPT IPT used to prevent malaria during pregnancy N/A –
Diagnosis Patients of all ages should receive diagnostic test Yes 2000
 Malaria diagnosis is free of charge in the public sector Yes 2000
Treatment ACT is free for all ages in public sector Yes 2000
 Artemisinin-based monotherapies withdrawn Yes 2011
 Single dose of primaquine is used as gametocidal medicine for P. falciparum No –
 Primaquine is used for radical treatment of P. vivax Yes 2013
 G6PD test is a requirement before treatment with primaquine Yes 2012
 Directly observed treatment with primaquine is undertaken No –
 System for monitoring of adverse reactions to antimalarials exists Yes 2010
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) Yes 2010
 ACD of febrile cases at community level (pro-active) No –
 Mass screening is undertaken Yes 2010
 Uncomplicated P. falciparum cases routinely admitted No –
 Uncomplicated P. vivax cases routinely admitted No –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria – –
First-line treatment of P. falciparum AS+MQ; DHA-PPQ+PQ 2000
Treatment failure of P. falciparum QN+T 2000
Treatment of severe malaria AM; QN –
Treatment of P. vivax DHA-PPQ 2011
Dosage of primaquine for radical treatment of P. vivax 0.25 mg/kg (14 days)
Type of RDT used P.f + P.v specific (Combo)
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
AS+MQ 2005–2011 0 3.15 19.4 42 days 14 P. falciparum
DHA-PPQ 2008–2014 0 5.9 37.5 42 days 21 P. falciparum
DHA-PPQ 2010–2014 0 0 3.3 28 days 6 P. vivax
II. Intervention policies and strategies
Pie chart include 100% 
of total contributions
Funding source(s): Government, 
Global Fund, USAID/PMI, WHO
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III. Financing Sources of financing Financing by intervention in 2013 
V. Impact  Confirmed malaria cases per 1000 and ABER Malaria admissions and deaths (per 100 000)
IV. Coverage ITN and IRS coverage Cases tested and treated in public sector
 Cases tracked Test positivity
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Cameroon African Region
I. Epidemiological profile
Population 2013 %
High transmission (> 1 case per 1000 population) 15 800 000 71
Low transmission (0–1 cases per 1000 population) 6 450 000 29
Malaria-free (0 cases) 0 0
Total 22 250 000 
Parasites and vectors
Major plasmodium species: P. falciparum (100%), P. vivax (0%)
Major anopheles species: An. gambiae, An. arabiensis, An. funestus, An. moucheti, An. nili
Programme phase: Control
Reported confirmed cases: 26 651 
Reported deaths: 4349 
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 2004
 ITNs/LLINs distributed to all age groups No –
IRS IRS is recommended Yes 2007 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended No –
IPT IPT used to prevent malaria during pregnancy Yes 2004
Diagnosis Patients of all ages should receive diagnostic test Yes 2011
 Malaria diagnosis is free of charge in the public sector No –
Treatment ACT is free for all ages in public sector No –
 Artemisinin-based monotherapies withdrawn – –
 Single dose of primaquine is used as gametocidal medicine for P. falciparum No –
 Primaquine is used for radical treatment of P. vivax No –
 G6PD test is a requirement before treatment with primaquine – –
 Directly observed treatment with primaquine is undertaken – –
 System for monitoring of adverse reactions to antimalarials exists Yes 2004
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) – –
 ACD of febrile cases at community level (pro-active) No –
 Mass screening is undertaken No –
 Uncomplicated P. falciparum cases routinely admitted No –
 Uncomplicated P. vivax cases routinely admitted No –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria AS+AQ 2004
First-line treatment of P. falciparum AS+AQ 2004
Treatment failure of P. falciparum QN 2004
Treatment of severe malaria AM; QN 2004
Treatment of P. vivax – –
Dosage of primaquine for radical treatment of P. vivax –
Type of RDT used –
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
– – – – – – – –
       
       
II. Intervention policies and strategies
Pie chart include 3% 
of total contributions
Funding source(s): WHO
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III. Financing Sources of financing Financing by intervention in 2013 
V. Impact  Confirmed malaria cases per 1000 and ABER Malaria admissions and deaths (per 100 000)
IV. Coverage ITN and IRS coverage Cases tested and treated in public sector
 Cases tracked Test positivity
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Central African Republic African Region
I. Epidemiological profile
Population 2013 %
High transmission (> 1 case per 1000 population) 4 620 000 100
Low transmission (0–1 cases per 1000 population) 0 0
Malaria-free (0 cases) 0 0
Total 4 620 000 
Parasites and vectors
Major plasmodium species: P. falciparum (100%), P. vivax (0%)
Major anopheles species: An. gambiae, An. funestus, An. arabiensis
Programme phase: Control
Reported confirmed cases: 116 300 
Reported deaths: 1026 
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 2006
 ITNs/LLINs distributed to all age groups Yes 2010
IRS IRS is recommended Yes 2012 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended – –
IPT IPT used to prevent malaria during pregnancy Yes 2004
Diagnosis Patients of all ages should receive diagnostic test Yes –
 Malaria diagnosis is free of charge in the public sector No –
Treatment ACT is free for all ages in public sector Yes 2010
 Artemisinin-based monotherapies withdrawn – –
 Single dose of primaquine is used as gametocidal medicine for P. falciparum No –
 Primaquine is used for radical treatment of P. vivax No –
 G6PD test is a requirement before treatment with primaquine No –
 Directly observed treatment with primaquine is undertaken No –
 System for monitoring of adverse reactions to antimalarials exists No –
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) – –
 ACD of febrile cases at community level (pro-active) No –
 Mass screening is undertaken No –
 Uncomplicated P. falciparum cases routinely admitted – –
 Uncomplicated P. vivax cases routinely admitted – –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria AL 2005
First-line treatment of P. falciparum AL –
Treatment failure of P. falciparum QN –
Treatment of severe malaria AM; QN 2005
Treatment of P. vivax – –
Dosage of primaquine for radical treatment of P. vivax –
Type of RDT used –
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
AL 2008–2010 0 3.8 7.6 28 days 2 P. falciparum
AS+AQ 2008–2010 0 3.4 6.8 28 days 2 P. falciparum
       
II. Intervention policies and strategies
Pie chart include 100% 
of total contributions
Funding source(s): Government, 
Global Fund, WHO, UNICEF
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III. Financing Sources of financing Financing by intervention in 2013 
V. Impact  Confirmed malaria cases per 1000 and ABER Malaria admissions and deaths (per 100 000)
IV. Coverage ITN and IRS coverage Cases tested and treated in public sector
 Cases tracked Test positivity
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Chad African Region
I. Epidemiological profile
Population 2013 %
High transmission (> 1 case per 1000 population) 10 300 000 80
Low transmission (0–1 cases per 1000 population) 2 440 000 19
Malaria-free (0 cases) 128 000 1
Total 12 868 000 
Parasites and vectors
Major plasmodium species: P. falciparum (100%), P. vivax (0%)
Major anopheles species: An. arabiensis, An. funestus, An. pharoensis, An. nili
Programme phase: Control
Reported confirmed cases: 754 565 
Reported deaths: 1881 
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 2010
 ITNs/LLINs distributed to all age groups No –
IRS IRS is recommended Yes – 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended No –
IPT IPT used to prevent malaria during pregnancy Yes 2004
Diagnosis Patients of all ages should receive diagnostic test Yes –
 Malaria diagnosis is free of charge in the public sector Yes –
Treatment ACT is free for all ages in public sector Yes –
 Artemisinin-based monotherapies withdrawn No –
 Single dose of primaquine is used as gametocidal medicine for P. falciparum No –
 Primaquine is used for radical treatment of P. vivax No –
 G6PD test is a requirement before treatment with primaquine No –
 Directly observed treatment with primaquine is undertaken No –
 System for monitoring of adverse reactions to antimalarials exists Yes –
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) – –
 ACD of febrile cases at community level (pro-active) No –
 Mass screening is undertaken – –
 Uncomplicated P. falciparum cases routinely admitted Yes –
 Uncomplicated P. vivax cases routinely admitted – –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria AL; AS+AQ –
First-line treatment of P. falciparum AL; AS+AQ –
Treatment failure of P. falciparum QN –
Treatment of severe malaria AM; QN –
Treatment of P. vivax – –
Dosage of primaquine for radical treatment of P. vivax –
Type of RDT used –
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
AS+AQ 2009–2011 0 0 1.8 28 days 3 P. falciparum
       
       
II. Intervention policies and strategies
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Impact: Achieved >75% decrease in case incidence in 2013
III. Financing Sources of financing Financing by intervention in 2013 
V. Impact  Confirmed malaria cases per 1000 and ABER Malaria admissions and deaths
IV. Coverage ITN and IRS coverage Cases tested and treated in public sector
 Cases tracked Test positivity
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China Western Pacific Region
I. Epidemiological profile
Population 2013 %
High transmission (> 1 case per 1000 population) 197 000 0
Low transmission (0–1 cases per 1000 population) 579 300 000 42
Malaria-free (0 cases) 806 100 000 58
Total 1 385 597 000 
Parasites and vectors
Major plasmodium species: P. falciparum (73%), P. vivax (23%)
Major anopheles species: An. sinensis, An. anthropophagus, An. dirus, An. minimus
Programme phase: Control
Reported confirmed cases: 4086 
Reported deaths: 23 
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 2003
 ITNs/LLINs distributed to all age groups Yes 2000
IRS IRS is recommended Yes 2000 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended No –
IPT IPT used to prevent malaria during pregnancy N/A –
Diagnosis Patients of all ages should receive diagnostic test Yes 2000
 Malaria diagnosis is free of charge in the public sector No –
Treatment ACT is free for all ages in public sector Yes 2006
 Artemisinin-based monotherapies withdrawn – –
 Single dose of primaquine is used as gametocidal medicine for P. falciparum No –
 Primaquine is used for radical treatment of P. vivax Yes 1970
 G6PD test is a requirement before treatment with primaquine No –
 Directly observed treatment with primaquine is undertaken Yes 1970
 System for monitoring of adverse reactions to antimalarials exists Yes 1970
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) Yes 2000
 ACD of febrile cases at community level (pro-active) Yes 2000
 Mass screening is undertaken Yes 1970
 Uncomplicated P. falciparum cases routinely admitted No –
 Uncomplicated P. vivax cases routinely admitted No –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria ART+NQ; ART-PPQ; AS+AQ; DHA-PPQ 2009
First-line treatment of P. falciparum – –
Treatment failure of P. falciparum AM; AS; PYR 2009
Treatment of severe malaria CQ+PQ(8d) 2006
Treatment of P. vivax QN –
Dosage of primaquine for radical treatment of P. vivax –
Type of RDT used –
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
DHA-PPQ 2012–2012 0 1.15 2.3 42 days 2 P. falciparum
CQ 2008–2013 0 0 4.3 28 days 11 P. vivax
CQ+PQ 2008–2010 0 0 0 28 days 2 P. vivax
II. Intervention policies and strategies
Pie chart include 100% 
of total contributions
Funding source(s): Government
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Impact: Increase in case incidence 2000-2015
III. Financing Sources of financing Financing by intervention in 2013 
V. Impact  Confirmed malaria cases per 1000 and ABER Malaria admissions and deaths
IV. Coverage ITN and IRS coverage Cases tested and treated in public sector
 Cases tracked Test positivity
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Colombia Region of the Americas
I. Epidemiological profile
Population 2013 %
High transmission (> 1 case per 1000 population) 7 150 000 15
Low transmission (0–1 cases per 1000 population) 3 720 000 8
Malaria-free (0 cases) 37 400 000 78
Total 48 270 000 
Parasites and vectors
Major plasmodium species: P. falciparum (34%), P. vivax (66%)
Major anopheles species: An. darlingi, An. albimanus, An. nunestovari, An. neivai, An. punctimacula, An. pseudopunctipennis
Programme phase: Control
Reported confirmed cases: 51 696 
Reported deaths: 10 
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 2005
 ITNs/LLINs distributed to all age groups Yes 2005
IRS IRS is recommended Yes 1958 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended No –
IPT IPT used to prevent malaria during pregnancy N/A –
Diagnosis Patients of all ages should receive diagnostic test Yes 1984
 Malaria diagnosis is free of charge in the public sector Yes 1958
Treatment ACT is free for all ages in public sector Yes 2008
 Artemisinin-based monotherapies withdrawn No –
 Single dose of primaquine is used as gametocidal medicine for P. falciparum No 2008
 Primaquine is used for radical treatment of P. vivax Yes –
 G6PD test is a requirement before treatment with primaquine No –
 Directly observed treatment with primaquine is undertaken No –
 System for monitoring of adverse reactions to antimalarials exists Yes –
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) Yes 1998
 ACD of febrile cases at community level (pro-active) No –
 Mass screening is undertaken No –
 Uncomplicated P. falciparum cases routinely admitted No –
 Uncomplicated P. vivax cases routinely admitted No –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria – –
First-line treatment of P. falciparum AL 2006
Treatment failure of P. falciparum QN(3d)+CL(5d) 2004
Treatment of severe malaria AS; AL –
Treatment of P. vivax CQ+PQ(14d) 1960s
Dosage of primaquine for radical treatment of P. vivax 0.25 mg/kg (14 days)
Type of RDT used P.f + P.v specific (Combo)
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
AL 2007–2009 0 0.6 1 28 days 3 P. falciparum
CQ+PQ 2006–2011 0 0 0 28 days 2 P. vivax
II. Intervention policies and strategies
Pie chart include 73% 
of total contributions
Funding source(s): Government, 
Global Fund, AMI/RAVREDA
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Impact: Insufficiently consistent data to assess trends
III. Financing Sources of financing Financing by intervention in 2013 
V. Impact  Confirmed malaria cases per 1000 and ABER Malaria admissions and deaths (per 100 000)
IV. Coverage ITN and IRS coverage Cases tested and treated in public sector
 Cases tracked Test positivity
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Comoros African Region
I. Epidemiological profile
Population 2013 %
High transmission (> 1 case per 1000 population) 691 000 94
Low transmission (0–1 cases per 1000 population) 44 100 6
Malaria-free (0 cases) 0 0
Total 735 100 
Parasites and vectors
Major plasmodium species: P. falciparum (99%), P. vivax (0%)
Major anopheles species: An. gambiae, An. funestus
Programme phase: Control
Reported confirmed cases: 53 156 
Reported deaths: 15 
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 2005
 ITNs/LLINs distributed to all age groups Yes 2010
IRS IRS is recommended Yes 2010 
 DDT is authorized for IRS Yes –
Larval control Use of larval control recommended No –
IPT IPT used to prevent malaria during pregnancy Yes 2004
Diagnosis Patients of all ages should receive diagnostic test Yes 1997
 Malaria diagnosis is free of charge in the public sector Yes 2011
Treatment ACT is free for all ages in public sector Yes 2010
 Artemisinin-based monotherapies withdrawn – –
 Single dose of primaquine is used as gametocidal medicine for P. falciparum No –
 Primaquine is used for radical treatment of P. vivax No –
 G6PD test is a requirement before treatment with primaquine – –
 Directly observed treatment with primaquine is undertaken No –
 System for monitoring of adverse reactions to antimalarials exists No –
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) Yes 2013
 ACD of febrile cases at community level (pro-active) No –
 Mass screening is undertaken Yes 2010
 Uncomplicated P. falciparum cases routinely admitted Yes –
 Uncomplicated P. vivax cases routinely admitted No –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria AL 2003
First-line treatment of P. falciparum AL 2003
Treatment failure of P. falciparum QN 2003
Treatment of severe malaria QN 2003
Treatment of P. vivax – –
Dosage of primaquine for radical treatment of P. vivax –
Type of RDT used P.f + P.v, P.o, P.m (Combo)
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
AL 2006–2011 0 0 3.2 28 days 12 P. falciparum
       
       
II. Intervention policies and strategies
Pie chart include 66% 
of total contributions
Funding source(s): Government, 
Global Fund, WHO, UNICEF
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Impact: Insufficiently consistent data to assess trends
III. Financing Sources of financing Financing by intervention in 2013 
V. Impact  Confirmed malaria cases per 1000 and ABER Malaria admissions and deaths (per 100 000)
IV. Coverage ITN and IRS coverage Cases tested and treated in public sector
 Cases tracked Test positivity
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Congo African Region
I. Epidemiological profile
Population 2013 %
High transmission (> 1 case per 1000 population) 4 450 000 100
Low transmission (0–1 cases per 1000 population) 0 0
Malaria-free (0 cases) 0 0
Total 4 450 000 
Parasites and vectors
Major plasmodium species: P. falciparum (100%), P. vivax (0%)
Major anopheles species: An. gambiae, An. funestus, An. nili, An. moucheti
Programme phase: Control
Reported confirmed cases: 43 232 
Reported deaths: 2870 
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 2011
 ITNs/LLINs distributed to all age groups Yes 2011
IRS IRS is recommended Yes 2007 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended No –
IPT IPT used to prevent malaria during pregnancy Yes 2006
Diagnosis Patients of all ages should receive diagnostic test Yes –
 Malaria diagnosis is free of charge in the public sector No –
Treatment ACT is free for all ages in public sector No –
 Artemisinin-based monotherapies withdrawn Yes 2007
 Single dose of primaquine is used as gametocidal medicine for P. falciparum No –
 Primaquine is used for radical treatment of P. vivax No –
 G6PD test is a requirement before treatment with primaquine No –
 Directly observed treatment with primaquine is undertaken No –
 System for monitoring of adverse reactions to antimalarials exists No –
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) No –
 ACD of febrile cases at community level (pro-active) No –
 Mass screening is undertaken No –
 Uncomplicated P. falciparum cases routinely admitted No –
 Uncomplicated P. vivax cases routinely admitted No –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria AS+AQ –
First-line treatment of P. falciparum AS+AQ –
Treatment failure of P. falciparum AL –
Treatment of severe malaria QN –
Treatment of P. vivax – –
Dosage of primaquine for radical treatment of P. vivax –
Type of RDT used –
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
AL 2006–2014 0 2.8 3.6 28 days 3 P. falciparum
AS+AQ 2005–2014 0 2.7 5.6 28 days 3 P. falciparum
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Impact: Achieved >75% decrease in case incidence in 2013
V. Impact Malaria test positivity rate and ABER Number of malaria cases 
IV. Coverage ITN and IRS coverage Cases tested
 Cases treated Cases tracked
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Costa Rica Region of the Americas
I. Epidemiological profile
Parasites and vectors
Major plasmodium species: P. falciparum (0%), P. vivax (100%)
Major anopheles species: An. albimanus
Programme phase: Elimination
Total confirmed cases, 2013: 6 Indigenous cases, 2013: 0
Total deaths, 2013: 0 Indigenous deaths, 2013: 0
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 2009
 ITNs/LLINs distributed to all age groups Yes 2009
IRS IRS is recommended Yes 1957 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended No –
IPT IPT used to prevent malaria during pregnancy N/A –
Diagnosis Patients of all ages should receive diagnostic test Yes –
 Malaria diagnosis is free of charge in the public sector Yes 1957
Treatment ACT is free for all ages in public sector No –
 Artemisinin-based monotherapies withdrawn – –
 Single dose of primaquine is used as gametocidal medicine for P. falciparum Yes –
 Primaquine is used for radical treatment of P. vivax Yes –
 G6PD test is a requirement before treatment with primaquine No –
 Directly observed treatment with primaquine is undertaken Yes –
 System for monitoring of adverse reactions to antimalarials exists Yes –
II. Intervention policies and strategies
Population 2013 %
Number of active foci 1 
Number of people living within active foci 2500 0
Number of people living in malaria-free areas 4 870 000 100
Total 4 872 500 
III. Financing Sources of financing Financing by intervention in 2013 
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) Yes –
 ACD of febrile cases at community level (pro-active) Yes –
 Mass screening is undertaken No –
 Uncomplicated P. falciparum cases routinely admitted Yes –
 Uncomplicated P. vivax cases routinely admitted Yes –
 Foci and case investigation undertaken Yes –
 Case reporting from private sector is mandatory Yes –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria – –
First-line treatment of P. falciparum CQ+PQ(1d) –
Treatment failure of P. falciparum CQ+PQ –
Treatment of severe malaria QN –
Treatment of P. vivax CQ+PQ(7d); CQ+PQ(14d) –
Dosage of primaquine for radical treatment of P. vivax 0.25 mg/kg (14 days); 0.5mg/kg (7 days)
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
– – – – – – – –
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III. Financing Sources of financing Financing by intervention in 2013 
V. Impact  Confirmed malaria cases per 1000 and ABER Malaria admissions and deaths (per 100 000)
IV. Coverage ITN and IRS coverage Cases tested and treated in public sector
 Cases tracked Test positivity
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Côte d’Ivoire African Region
I. Epidemiological profile
Population 2013 %
High transmission (> 1 case per 1000 population) 20 300 000 100
Low transmission (0–1 cases per 1000 population) 0 0
Malaria-free (0 cases) 0 0
Total 20 300 000 
Parasites and vectors
Major plasmodium species: P. falciparum (100%), P. vivax (0%)
Major anopheles species: An. gambiae, An. funestus
Programme phase: Control
Reported confirmed cases: 2 506 953 
Reported deaths: 3261 
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 2008
 ITNs/LLINs distributed to all age groups No –
IRS IRS is recommended Yes – 
 DDT is authorized for IRS Yes –
Larval control Use of larval control recommended – –
IPT IPT used to prevent malaria during pregnancy Yes 2005
Diagnosis Patients of all ages should receive diagnostic test – –
 Malaria diagnosis is free of charge in the public sector Yes 2012
Treatment ACT is free for all ages in public sector Yes –
 Artemisinin-based monotherapies withdrawn Yes 2007
 Single dose of primaquine is used as gametocidal medicine for P. falciparum No –
 Primaquine is used for radical treatment of P. vivax – –
 G6PD test is a requirement before treatment with primaquine – –
 Directly observed treatment with primaquine is undertaken – –
 System for monitoring of adverse reactions to antimalarials exists Yes –
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) No –
 ACD of febrile cases at community level (pro-active) – –
 Mass screening is undertaken – –
 Uncomplicated P. falciparum cases routinely admitted Yes –
 Uncomplicated P. vivax cases routinely admitted No –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria AS+AQ 2003
First-line treatment of P. falciparum AS+AQ 2003
Treatment failure of P. falciparum AL 2003
Treatment of severe malaria QN 2003
Treatment of P. vivax – –
Dosage of primaquine for radical treatment of P. vivax –
Type of RDT used –
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
AL 2005–2009 0 2.6 7.4 28 days 9 P. falciparum
AS+AQ 2007–2009 0 0 1.3 28 days 4 P. falciparum
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Impact: Achieved >75% decrease in case incidence in 2013
V. Impact Malaria test positivity rate and ABER Number of malaria cases 
IV. Coverage ITN and IRS coverage Cases tested
 Cases treated Cases tracked
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Democratic People’s Republic of Korea South-East Asia Region
I. Epidemiological profile
Parasites and vectors
Major plasmodium species: P. falciparum (0%), P. vivax (100%)
Major anopheles species: An. sinensis
Programme phase: Pre-elimination
Total confirmed cases, 2013: 14 407 Indigenous cases, 2013: 14 407
Total deaths, 2013: 0 Indigenous deaths, 2013: 0
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 2002
 ITNs/LLINs distributed to all age groups Yes 2002
IRS IRS is recommended Yes 2007 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended Yes 2002
IPT IPT used to prevent malaria during pregnancy N/A –
Diagnosis Patients of all ages should receive diagnostic test – –
 Malaria diagnosis is free of charge in the public sector Yes 1953
Treatment ACT is free for all ages in public sector – –
 Artemisinin-based monotherapies withdrawn – –
 Single dose of primaquine is used as gametocidal medicine for P. falciparum No –
 Primaquine is used for radical treatment of P. vivax Yes 2000
 G6PD test is a requirement before treatment with primaquine No –
 Directly observed treatment with primaquine is undertaken Yes 2000
 System for monitoring of adverse reactions to antimalarials exists Yes 2002
II. Intervention policies and strategies
Pie chart include 100% 
of total contributions
Funding source(s): Government, 
Global Fund, USAID/PMI, WHO, 
Other (bilateral)
Population 2013 %
Number of active foci 2252 
Number of people living within active foci 13 100 000 53
Number of people living in malaria-free areas 11 800 000 47
Total 24 900 000 
III. Financing Sources of financing Financing by intervention in 2013 
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) No –
 ACD of febrile cases at community level (pro-active) Yes 1999
 Mass screening is undertaken No –
 Uncomplicated P. falciparum cases routinely admitted No –
 Uncomplicated P. vivax cases routinely admitted No –
 Foci and case investigation undertaken No –
 Case reporting from private sector is mandatory No –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria – –
First-line treatment of P. falciparum – –
Treatment failure of P. falciparum – –
Treatment of severe malaria – –
Treatment of P. vivax CQ+PQ(14d) –
Dosage of primaquine for radical treatment of P. vivax 0.25 mg/kg (14 days)
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
– – – – – – – –
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Impact: Insufficiently consistent data to assess trends
III. Financing Sources of financing Financing by intervention in 2013 
V. Impact  Confirmed malaria cases per 1000 and ABER Malaria admissions and deaths (per 100 000)
IV. Coverage ITN and IRS coverage Cases tested and treated in public sector
 Cases tracked Test positivity
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Democratic Republic of the Congo African Region
I. Epidemiological profile
Population 2013 %
High transmission (> 1 case per 1000 population) 65 500 000 97
Low transmission (0–1 cases per 1000 population) 2 030 000 3
Malaria-free (0 cases) 0 0
Total 67 530 000 
Parasites and vectors
Major plasmodium species: P. falciparum (0%), P. vivax (0%)
Major anopheles species: An. gambiae, An. funestus, An. nili, An. moucheti
Programme phase: Control
Reported confirmed cases: 6 715 223 
Reported deaths: 30 918 
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 2008
 ITNs/LLINs distributed to all age groups Yes 2008
IRS IRS is recommended Yes 2007 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended Yes 1998
IPT IPT used to prevent malaria during pregnancy Yes 2004
Diagnosis Patients of all ages should receive diagnostic test Yes 2007
 Malaria diagnosis is free of charge in the public sector Yes 2007
Treatment ACT is free for all ages in public sector Yes 2006
 Artemisinin-based monotherapies withdrawn – –
 Single dose of primaquine is used as gametocidal medicine for P. falciparum No –
 Primaquine is used for radical treatment of P. vivax No –
 G6PD test is a requirement before treatment with primaquine No –
 Directly observed treatment with primaquine is undertaken No –
 System for monitoring of adverse reactions to antimalarials exists Yes 2010
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) – –
 ACD of febrile cases at community level (pro-active) Yes 2010
 Mass screening is undertaken No –
 Uncomplicated P. falciparum cases routinely admitted No –
 Uncomplicated P. vivax cases routinely admitted No –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria AS+AQ 2005
First-line treatment of P. falciparum AS+AQ 2005
Treatment failure of P. falciparum QN 2005
Treatment of severe malaria QN 2005
Treatment of P. vivax – –
Dosage of primaquine for radical treatment of P. vivax –
Type of RDT used P.f + all species (Combo)
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
AL 2005–2013 0 2.4 9.2 28 days 10 P. falciparum
AS+AQ 2005–2012 0 4.2 6.9 28 days 8 P. falciparum
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Impact: Insufficiently consistent data to assess trends
III. Financing Sources of financing Financing by intervention in 2013 
V. Impact  Confirmed malaria cases per 1000 and ABER Malaria admissions and deaths
IV. Coverage ITN and IRS coverage Cases tested and treated in public sector
 Cases tracked Test positivity
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Djibouti Eastern Mediterranean Region
I. Epidemiological profile
Population 2013 %
High transmission (> 1 case per 1000 population) 0 0
Low transmission (0–1 cases per 1000 population) 436 000 50
Malaria-free (0 cases) 436 000 50
Total 872 000 
Parasites and vectors
Major plasmodium species: P. falciparum (100%), P. vivax (0%)
Major anopheles species: An. gambiae, An. arabiensis
Programme phase: Control
Reported confirmed cases: 1684 
Reported deaths: 17 
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 2008
 ITNs/LLINs distributed to all age groups Yes –
IRS IRS is recommended Yes 2006 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended Yes 2008
IPT IPT used to prevent malaria during pregnancy N/A –
Diagnosis Patients of all ages should receive diagnostic test Yes 2007
 Malaria diagnosis is free of charge in the public sector Yes 2007
Treatment ACT is free for all ages in public sector Yes 2007
 Artemisinin-based monotherapies withdrawn – –
 Single dose of primaquine is used as gametocidal medicine for P. falciparum Yes 2014
 Primaquine is used for radical treatment of P. vivax Yes 2014
 G6PD test is a requirement before treatment with primaquine No –
 Directly observed treatment with primaquine is undertaken No –
 System for monitoring of adverse reactions to antimalarials exists No –
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) No –
 ACD of febrile cases at community level (pro-active) No –
 Mass screening is undertaken No –
 Uncomplicated P. falciparum cases routinely admitted No –
 Uncomplicated P. vivax cases routinely admitted No –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria AL 2014
First-line treatment of P. falciparum AL+PQ 2014
Treatment failure of P. falciparum AS+AQ 2014
Treatment of severe malaria QN –
Treatment of P. vivax CQ+PQ (14 days) –
Dosage of primaquine for radical treatment of P. vivax 0.25 mg/kg (14 days)
Type of RDT used –
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
– – – – – – – –
       
       
II. Intervention policies and strategies
Pie chart include 100% 
of total contributions
Funding source(s): WHO, UNICEF, 
Other (all types)
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Impact: On track for 50%-75% decrease in case incidence 2000-2015
III. Financing Sources of financing Financing by intervention in 2013 
V. Impact  Confirmed malaria cases per 1000 and ABER Malaria admissions and deaths
IV. Coverage ITN and IRS coverage Cases tested and treated in public sector
 Cases tracked Test positivity
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Dominican Republic Region of the Americas
I. Epidemiological profile
Population 2013 %
High transmission (> 1 case per 1000 population) 447 000 4
Low transmission (0–1 cases per 1000 population) 8 460 000 81
Malaria-free (0 cases) 1 500 000 14
Total 10 407 000 
Parasites and vectors
Major plasmodium species: P. falciparum (99%), P. vivax (1%)
Major anopheles species: An. albimanus
Programme phase: Control
Reported confirmed cases: 579 
Reported deaths: 5 
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 2008
 ITNs/LLINs distributed to all age groups Yes 2008
IRS IRS is recommended Yes 1946 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended Yes 1964
IPT IPT used to prevent malaria during pregnancy N/A –
Diagnosis Patients of all ages should receive diagnostic test Yes 1964
 Malaria diagnosis is free of charge in the public sector Yes 1964
Treatment ACT is free for all ages in public sector No –
 Artemisinin-based monotherapies withdrawn – –
 Single dose of primaquine is used as gametocidal medicine for P. falciparum Yes 1964
 Primaquine is used for radical treatment of P. vivax Yes 1964
 G6PD test is a requirement before treatment with primaquine No –
 Directly observed treatment with primaquine is undertaken Yes –
 System for monitoring of adverse reactions to antimalarials exists No –
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) Yes –
 ACD of febrile cases at community level (pro-active) Yes 1964
 Mass screening is undertaken Yes 1964
 Uncomplicated P. falciparum cases routinely admitted No –
 Uncomplicated P. vivax cases routinely admitted No –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria – –
First-line treatment of P. falciparum CQ+PQ(1d) –
Treatment failure of P. falciparum CQ; QN –
Treatment of severe malaria CQ; QN –
Treatment of P. vivax CQ+PQ(14d) –
Dosage of primaquine for radical treatment of P. vivax 0.25 mg/kg (14 days)
Type of RDT used P.f only
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
– – – – – – – –
       
       
II. Intervention policies and strategies
Pie chart include 87% 
of total contributions
Funding source(s): Government, 
Global Fund, WHO, Other 
(all types)
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Impact: Achieved >75% decrease in case incidence in 2013
V. Impact Malaria test positivity rate and ABER Number of malaria cases 
IV. Coverage ITN and IRS coverage Cases tested
 Cases treated Cases tracked
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Ecuador Region of the Americas
I. Epidemiological profile
Parasites and vectors
Major plasmodium species: P. falciparum (43%), P. vivax (57%)
Major anopheles species: An. albimanus, An. punctimacula, An. pseudopunctipennis
Programme phase: Pre-elimination
Total confirmed cases, 2013: 378 Indigenous cases, 2013: 368
Total deaths, 2013: 0 Indigenous deaths, 2013: 0
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 2004
 ITNs/LLINs distributed to all age groups Yes –
IRS IRS is recommended Yes 2005 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended Yes –
IPT IPT used to prevent malaria during pregnancy N/A –
Diagnosis Patients of all ages should receive diagnostic test Yes 1956
 Malaria diagnosis is free of charge in the public sector Yes 1956
Treatment ACT is free for all ages in public sector Yes 2005
 Artemisinin-based monotherapies withdrawn Yes –
 Single dose of primaquine is used as gametocidal medicine for P. falciparum Yes –
 Primaquine is used for radical treatment of P. vivax Yes –
 G6PD test is a requirement before treatment with primaquine No –
 Directly observed treatment with primaquine is undertaken Yes –
 System for monitoring of adverse reactions to antimalarials exists No –
II. Intervention policies and strategies
Pie chart include 76% 
of total contributions
Funding source(s): Government, 
Global Fund, Other (bilateral), 
Other (all types)
Population 2013 %
Number of active foci 3 
Number of people living within active foci 265 000 2
Number of people living in malaria-free areas 15 500 000 98
Total 15 765 000 
III. Financing Sources of financing Financing by intervention in 2013 
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) Yes –
 ACD of febrile cases at community level (pro-active) Yes –
 Mass screening is undertaken No –
 Uncomplicated P. falciparum cases routinely admitted No –
 Uncomplicated P. vivax cases routinely admitted No –
 Foci and case investigation undertaken Yes –
 Case reporting from private sector is mandatory No –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria – –
First-line treatment of P. falciparum AL+PQ 2012
Treatment failure of P. falciparum QN+CL 2004
Treatment of severe malaria QN 2004
Treatment of P. vivax CQ+PQ(14d) 2004
Dosage of primaquine for radical treatment of P. vivax 0.50 mg/kg (7 days)
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
AL 2005–2006 0 0 0 28 days 1 P. falciparum
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Impact: Achieved >75% decrease in case incidence in 2013
V. Impact Malaria test positivity rate and ABER Number of malaria cases 
IV. Coverage ITN and IRS coverage Cases tested
 Cases treated Cases tracked
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El Salvador Region of the Americas
I. Epidemiological profile
Parasites and vectors
Major plasmodium species: P. falciparum (0%), P. vivax (100%)
Major anopheles species: An. albimanus, An. pseudopunctipennis
Programme phase: Pre-elimination
Total confirmed cases, 2013: 7 Indigenous cases, 2013: 6
Total deaths, 2013: 0 Indigenous deaths, 2013: 0
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes –
 ITNs/LLINs distributed to all age groups Yes 2013
IRS IRS is recommended Yes – 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended Yes –
IPT IPT used to prevent malaria during pregnancy N/A –
Diagnosis Patients of all ages should receive diagnostic test Yes 2010
 Malaria diagnosis is free of charge in the public sector Yes –
Treatment ACT is free for all ages in public sector No –
 Artemisinin-based monotherapies withdrawn – –
 Single dose of primaquine is used as gametocidal medicine for P. falciparum Yes –
 Primaquine is used for radical treatment of P. vivax Yes –
 G6PD test is a requirement before treatment with primaquine No –
 Directly observed treatment with primaquine is undertaken Yes –
 System for monitoring of adverse reactions to antimalarials exists No –
II. Intervention policies and strategies
Pie chart include 100% 
of total contributions
Funding source(s): Government, 
Global Fund, USAID/PMI, WHO, 
Other (all types)
Population 2013 %
Number of active foci 2 
Number of people living within active foci 54 900 1
Number of people living in malaria-free areas 6 290 000 99
Total 6 344 900 
III. Financing Sources of financing Financing by intervention in 2013 
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) Yes –
 ACD of febrile cases at community level (pro-active) Yes –
 Mass screening is undertaken No –
 Uncomplicated P. falciparum cases routinely admitted No –
 Uncomplicated P. vivax cases routinely admitted No –
 Foci and case investigation undertaken Yes –
 Case reporting from private sector is mandatory No –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria – –
First-line treatment of P. falciparum CQ+PQ(1d) –
Treatment failure of P. falciparum AL –
Treatment of severe malaria QN 2012
Treatment of P. vivax CQ+PQ(14d) –
Dosage of primaquine for radical treatment of P. vivax 0.25 mg/kg (14 days)
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
– – – – – – – –
       
       
Insucient data
API
EURO / PAHO
0
0–0.1
1.0–10
0.1–1.0
10–50
50–100
≥100
Insucient data
no cases
Very low PP
0–20
20–40
40–60
60–80
80–100
PF-RATIO
Confirmed cases  
per 1000 population
Insucient data
0
0–0.1
0.1–1.0
1.0–10
PP
>75
0
no cases
Insucient data
Very low PP
0–20
20–40
40–60
60–80
80–100
PR
OTHERS
PF-RATIO
Proportion of cases 
due to P. falciparum
 Represents foci (active or non-active)
WORLD MALARIA REPORT 2014 | 99
Impact: Insufficiently consistent data to assess trends
III. Financing Sources of financing Financing by intervention in 2013 
V. Impact  Confirmed malaria cases per 1000 and ABER Malaria admissions and deaths
IV. Coverage ITN and IRS coverage Cases tested and treated in public sector
 Cases tracked Test positivity
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Equatorial Guinea African Region
I. Epidemiological profile
Population 2013 %
High transmission (> 1 case per 1000 population) 757 000 100
Low transmission (0–1 cases per 1000 population) 0 0
Malaria-free (0 cases) 0 0
Total 757 000 
Parasites and vectors
Major plasmodium species: P. falciparum (100%), P. vivax (0%)
Major anopheles species: An. gambiae, An. melas
Programme phase: Control
Reported confirmed cases: 13 129 
Reported deaths: 66 
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes –
 ITNs/LLINs distributed to all age groups No –
IRS IRS is recommended Yes – 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended No –
IPT IPT used to prevent malaria during pregnancy – –
Diagnosis Patients of all ages should receive diagnostic test Yes –
 Malaria diagnosis is free of charge in the public sector Yes –
Treatment ACT is free for all ages in public sector Yes –
 Artemisinin-based monotherapies withdrawn – –
 Single dose of primaquine is used as gametocidal medicine for P. falciparum No –
 Primaquine is used for radical treatment of P. vivax No –
 G6PD test is a requirement before treatment with primaquine Yes –
 Directly observed treatment with primaquine is undertaken No –
 System for monitoring of adverse reactions to antimalarials exists No –
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) – –
 ACD of febrile cases at community level (pro-active) No –
 Mass screening is undertaken Yes –
 Uncomplicated P. falciparum cases routinely admitted Yes –
 Uncomplicated P. vivax cases routinely admitted No –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria AS+AQ 2004
First-line treatment of P. falciparum AS+AQ 2004
Treatment failure of P. falciparum QN 2004
Treatment of severe malaria QN 2004
Treatment of P. vivax – –
Dosage of primaquine for radical treatment of P. vivax –
Type of RDT used –
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
AS+AQ 2006–2011 0 2.3 5 28 days 5 P. falciparum
       
       
II. Intervention policies and strategies
Pie chart include 100% 
of total contributions
Funding source(s): Government, 
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Impact: Achieved >75% decrease in case incidence in 2013
III. Financing Sources of financing Financing by intervention in 2013 
V. Impact  Confirmed malaria cases per 1000 and ABER Malaria admissions and deaths (per 100 000)
IV. Coverage ITN and IRS coverage Cases tested and treated in public sector
 Cases tracked Test positivity
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Eritrea African Region
I. Epidemiological profile
Population 2013 %
High transmission (> 1 case per 1000 population) 4 500 000 71
Low transmission (0–1 cases per 1000 population) 1 840 000 29
Malaria-free (0 cases) 0 0
Total 6 340 000 
Parasites and vectors
Major plasmodium species: P. falciparum (60%), P. vivax (39%)
Major anopheles species: An. arabiensis
Programme phase: Control
Reported confirmed cases: 21 317 
Reported deaths: 6 
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 2002
 ITNs/LLINs distributed to all age groups Yes 2002
IRS IRS is recommended Yes 1995 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended Yes 1995
IPT IPT used to prevent malaria during pregnancy No –
Diagnosis Patients of all ages should receive diagnostic test Yes 1997
 Malaria diagnosis is free of charge in the public sector Yes 1997
Treatment ACT is free for all ages in public sector Yes 2007
 Artemisinin-based monotherapies withdrawn Yes –
 Single dose of primaquine is used as gametocidal medicine for P. falciparum No –
 Primaquine is used for radical treatment of P. vivax Yes 2002
 G6PD test is a requirement before treatment with primaquine No –
 Directly observed treatment with primaquine is undertaken No –
 System for monitoring of adverse reactions to antimalarials exists Yes 2013
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) Yes –
 ACD of febrile cases at community level (pro-active) No –
 Mass screening is undertaken No –
 Uncomplicated P. falciparum cases routinely admitted No –
 Uncomplicated P. vivax cases routinely admitted No –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria AS+AQ 2007
First-line treatment of P. falciparum AS+AQ 2007
Treatment failure of P. falciparum QN 2002
Treatment of severe malaria QN 2002
Treatment of P. vivax AS+AQ+PQ 2007
Dosage of primaquine for radical treatment of P. vivax 0.25 mg/kg (14 days)
Type of RDT used P.f + P.v specific (Combo)
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
AS+AQ 2006–2012 0 2.25 9.3 28 days 16 P. falciparum
       
       
II. Intervention policies and strategies
Pie chart include 100% 
of total contributions
Funding source(s): Global Fund, 
Other (all types)
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Impact: On track for 50%-75% decrease in case incidence 2000-2015
III. Financing Sources of financing Financing by intervention in 2013 
V. Impact  Confirmed malaria cases per 1000 and ABER Malaria admissions and deaths (per 100 000)
IV. Coverage ITN and IRS coverage Cases tested and treated in public sector
 Cases tracked Test positivity
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Ethiopia African Region
I. Epidemiological profile
Population 2013 %
High transmission (> 1 case per 1000 population) 941 000 1
Low transmission (0–1 cases per 1000 population) 62 100 000 66
Malaria-free (0 cases) 31 100 000 33
Total 94 141 000 
Parasites and vectors
Major plasmodium species: P. falciparum (64%), P. vivax (36%)
Major anopheles species: An. arabiensis, An. pharoensis, An. funestus, An. nili
Programme phase: Control
Reported confirmed cases: 2 645 454 
Reported deaths: 358 
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 2004
 ITNs/LLINs distributed to all age groups Yes 2004
IRS IRS is recommended Yes 1960 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended Yes 1960
IPT IPT used to prevent malaria during pregnancy No –
Diagnosis Patients of all ages should receive diagnostic test Yes 1960
 Malaria diagnosis is free of charge in the public sector Yes 1960
Treatment ACT is free for all ages in public sector Yes 2004
 Artemisinin-based monotherapies withdrawn – –
 Single dose of primaquine is used as gametocidal medicine for P. falciparum No –
 Primaquine is used for radical treatment of P. vivax No –
 G6PD test is a requirement before treatment with primaquine No –
 Directly observed treatment with primaquine is undertaken No –
 System for monitoring of adverse reactions to antimalarials exists No –
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) No –
 ACD of febrile cases at community level (pro-active) No –
 Mass screening is undertaken No –
 Uncomplicated P. falciparum cases routinely admitted No –
 Uncomplicated P. vivax cases routinely admitted No –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria AL 2004
First-line treatment of P. falciparum AL 2004
Treatment failure of P. falciparum QN 2004
Treatment of severe malaria QN 2004
Treatment of P. vivax CQ 2004
Dosage of primaquine for radical treatment of P. vivax –
Type of RDT used –
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
AL 2006–2012 0 1 7.5 28 days 15 P. falciparum
QN 2006–2006 10 10 10 28 days 1 P. falciparum
CQ 2006–2010 3.8 7.05 13.7 28 days 4 P. vivax
II. Intervention policies and strategies
Pie chart include 77% 
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Funding source(s): Global Fund, 
USAID/PMI
Insucient data
0
0–0.1
0.1–1.0
1.0–10
PP
>75
0
no cases
Insucient data
Very low PP
0–20
20–40
40–60
60–80
80–100
PR
OTHERS
PF-RATIO
Proportion of cases 
due to P. falciparum
Insucient data
0
0–0.1
0.1–1.0
1.0–10
PP
>75
0
no cases
Insucient data
Very low PP
0–20
20–40
40–60
60–80
80–100
PR
OTHERS
PF-RATIO
Confirmed cases  
per 1000 population/
Parasite prevalence 
(PP)
Based on 2012 reported data Based on 2012 reported data
Survey source: DHS 2005
Survey source: DHS 2000, DHS 2005, DHS 2011
Survey source: DHS 2011
102 | WORLD MALARIA REPORT 2014
Impact: Achieved >75% decrease in case incidence in 2013
III. Financing Sources of financing Financing by intervention in 2013 
V. Impact  Confirmed malaria cases per 1000 and ABER Malaria admissions and deaths
IV. Coverage ITN and IRS coverage Cases tested and treated in public sector
 Cases tracked Test positivity
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French Guiana, France Region of the Americas
I. Epidemiological profile
Population 2013 %
High transmission (> 1 case per 1000 population) 213 000 86
Low transmission (0–1 cases per 1000 population) 36 100 14
Malaria-free (0 cases) 0 0
Total 249 100 
Parasites and vectors
Major plasmodium species: P. falciparum (31%), P. vivax (68%)
Major anopheles species: An. darlingi
Programme phase: Control
Reported confirmed cases: 875 
Reported deaths: 3 
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 2012
 ITNs/LLINs distributed to all age groups Yes 2012
IRS IRS is recommended Yes – 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended Yes –
IPT IPT used to prevent malaria during pregnancy N/A –
Diagnosis Patients of all ages should receive diagnostic test Yes –
 Malaria diagnosis is free of charge in the public sector Yes –
Treatment ACT is free for all ages in public sector – –
 Artemisinin-based monotherapies withdrawn – –
 Single dose of primaquine is used as gametocidal medicine for P. falciparum Yes –
 Primaquine is used for radical treatment of P. vivax Yes –
 G6PD test is a requirement before treatment with primaquine – –
 Directly observed treatment with primaquine is undertaken – –
 System for monitoring of adverse reactions to antimalarials exists – –
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) – –
 ACD of febrile cases at community level (pro-active) – –
 Mass screening is undertaken – –
 Uncomplicated P. falciparum cases routinely admitted – –
 Uncomplicated P. vivax cases routinely admitted – –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria – –
First-line treatment of P. falciparum AL; AT+PG –
Treatment failure of P. falciparum – –
Treatment of severe malaria AS; QN+D –
Treatment of P. vivax CQ+PQ –
Dosage of primaquine for radical treatment of P. vivax –
Type of RDT used P.f + P.v, P.o, P.m (Combo)
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
– – – – – – – –
       
       
II. Intervention policies and strategies
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Impact: Insufficiently consistent data to assess trends
III. Financing Sources of financing Financing by intervention in 2013 
V. Impact  Confirmed malaria cases per 1000 and ABER Malaria admissions and deaths (per 100 000)
IV. Coverage ITN and IRS coverage Cases tested and treated in public sector
 Cases tracked Test positivity
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Gabon African Region
I. Epidemiological profile
Population 2013 %
High transmission (> 1 case per 1000 population) 1 670 000 100
Low transmission (0–1 cases per 1000 population) 0 0
Malaria-free (0 cases) 0 0
Total 1 670 000 
Parasites and vectors
Major plasmodium species: P. falciparum (100%), P. vivax (0%)
Major anopheles species: An. funestus, An. gambiae, An. funestus
Programme phase: Control
Reported confirmed cases: 28 982 
Reported deaths: 273 
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge No –
 ITNs/LLINs distributed to all age groups Yes 2007
IRS IRS is recommended Yes 2013 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended No –
IPT IPT used to prevent malaria during pregnancy Yes 2003
Diagnosis Patients of all ages should receive diagnostic test Yes 2009
 Malaria diagnosis is free of charge in the public sector No –
Treatment ACT is free for all ages in public sector Yes 2003
 Artemisinin-based monotherapies withdrawn – –
 Single dose of primaquine is used as gametocidal medicine for P. falciparum No –
 Primaquine is used for radical treatment of P. vivax No –
 G6PD test is a requirement before treatment with primaquine No –
 Directly observed treatment with primaquine is undertaken No –
 System for monitoring of adverse reactions to antimalarials exists No –
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) – –
 ACD of febrile cases at community level (pro-active) No –
 Mass screening is undertaken No –
 Uncomplicated P. falciparum cases routinely admitted No –
 Uncomplicated P. vivax cases routinely admitted No –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria AS+AQ 2003
First-line treatment of P. falciparum AS+AQ 2003
Treatment failure of P. falciparum AL 2003
Treatment of severe malaria QN 2003
Treatment of P. vivax – –
Dosage of primaquine for radical treatment of P. vivax –
Type of RDT used P.f + P.v, P.o, P.m (Combo)
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
– – – – – – – –
       
       
II. Intervention policies and strategies
Pie chart include 100% 
of total contributions
Funding source(s): Government, 
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Impact: Insufficiently consistent data to assess trends
III. Financing Sources of financing Financing by intervention in 2013 
V. Impact  Confirmed malaria cases per 1000 and ABER Malaria admissions and deaths (per 100 000)
IV. Coverage ITN and IRS coverage Cases tested and treated in public sector
 Cases tracked Test positivity
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Gambia African Region
I. Epidemiological profile
Population 2013 %
High transmission (> 1 case per 1000 population) 1 850 000 100
Low transmission (0–1 cases per 1000 population) 0 0
Malaria-free (0 cases) 0 0
Total 1 850 000 
Parasites and vectors
Major plasmodium species: P. falciparum (100%), P. vivax (0%)
Major anopheles species: An. gambiae, An. arabiensis, An. melas, An. pharoensis, An. funestus, An. nili
Programme phase: Control
Reported confirmed cases: 240 792 
Reported deaths: 262 
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 2000
 ITNs/LLINs distributed to all age groups Yes 1998
IRS IRS is recommended Yes 2008 
 DDT is authorized for IRS Yes 2007
Larval control Use of larval control recommended – –
IPT IPT used to prevent malaria during pregnancy Yes 2002
Diagnosis Patients of all ages should receive diagnostic test Yes 2009
 Malaria diagnosis is free of charge in the public sector Yes 1998
Treatment ACT is free for all ages in public sector Yes 2008
 Artemisinin-based monotherapies withdrawn – –
 Single dose of primaquine is used as gametocidal medicine for P. falciparum – –
 Primaquine is used for radical treatment of P. vivax – –
 G6PD test is a requirement before treatment with primaquine – –
 Directly observed treatment with primaquine is undertaken – –
 System for monitoring of adverse reactions to antimalarials exists – –
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) – –
 ACD of febrile cases at community level (pro-active) – –
 Mass screening is undertaken – –
 Uncomplicated P. falciparum cases routinely admitted – –
 Uncomplicated P. vivax cases routinely admitted – –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria AL 2005
First-line treatment of P. falciparum AL 2005
Treatment failure of P. falciparum QN 2005
Treatment of severe malaria QN 2005
Treatment of P. vivax – –
Dosage of primaquine for radical treatment of P. vivax –
Type of RDT used P.f only
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
AL 2007–2013 0 1.6 11.9 28 days 7 P. falciparum
       
       
II. Intervention policies and strategies
Pie chart include 100% 
of total contributions
Funding source(s): Global Fund
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Impact: Insufficiently consistent data to assess trends
III. Financing Sources of financing Financing by intervention in 2013 
V. Impact  Confirmed malaria cases per 1000 and ABER Malaria admissions and deaths (per 100 000)
IV. Coverage ITN and IRS coverage Cases tested and treated in public sector
 Cases tracked Test positivity
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Ghana African Region
I. Epidemiological profile
Population 2013 %
High transmission (> 1 case per 1000 population) 25 900 000 100
Low transmission (0–1 cases per 1000 population) 0 0
Malaria-free (0 cases) 0 0
Total 25 900 000 
Parasites and vectors
Major plasmodium species: P. falciparum (100%), P. vivax (0%)
Major anopheles species: An. gambiae, An. funestus, An. arabiensis
Programme phase: Control
Reported confirmed cases: 1 639 451 
Reported deaths: 2506 
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 2004
 ITNs/LLINs distributed to all age groups Yes 2010
IRS IRS is recommended Yes 2005 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended Yes 1999
IPT IPT used to prevent malaria during pregnancy Yes 2003
Diagnosis Patients of all ages should receive diagnostic test Yes 2008
 Malaria diagnosis is free of charge in the public sector No –
Treatment ACT is free for all ages in public sector No –
 Artemisinin-based monotherapies withdrawn – –
 Single dose of primaquine is used as gametocidal medicine for P. falciparum No –
 Primaquine is used for radical treatment of P. vivax No –
 G6PD test is a requirement before treatment with primaquine No –
 Directly observed treatment with primaquine is undertaken No –
 System for monitoring of adverse reactions to antimalarials exists Yes 2001
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) No –
 ACD of febrile cases at community level (pro-active) No –
 Mass screening is undertaken No –
 Uncomplicated P. falciparum cases routinely admitted No –
 Uncomplicated P. vivax cases routinely admitted No –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria AS+AQ 2004
First-line treatment of P. falciparum AL; AS+AQ 2004
Treatment failure of P. falciparum QN 2004
Treatment of severe malaria QN 2004
Treatment of P. vivax – –
Dosage of primaquine for radical treatment of P. vivax –
Type of RDT used P.f only
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
AL 2005–2011 0 0 13.8 28 days 11 P. falciparum
AS+AQ 2005–2011 0 3.15 14 28 days 12 P. falciparum
II. Intervention policies and strategies
Pie chart include 100% 
of total contributions
Funding source(s): Government, 
Global Fund, USAID/PMI, WHO, 
Other (bilateral), Other (all types)
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Impact: Achieved >75% decrease in case incidence in 2013
III. Financing Sources of financing Financing by intervention in 2013 
V. Impact  Confirmed malaria cases per 1000 and ABER Malaria admissions and deaths
IV. Coverage ITN and IRS coverage Cases tested and treated in public sector
 Cases tracked Test positivity
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Guatemala Region of the Americas
I. Epidemiological profile
Population 2013 %
High transmission (> 1 case per 1000 population) 2 320 000 15
Low transmission (0–1 cases per 1000 population) 4 720 000 31
Malaria-free (0 cases) 8 430 000 54
Total 15 470 000 
Parasites and vectors
Major plasmodium species: P. falciparum (2%), P. vivax (98%)
Major anopheles species: An. albimanus, An. pseudopunctipennis, An. darlingi
Programme phase: Control
Reported confirmed cases: 6214 
Reported deaths: 0 
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 2006
 ITNs/LLINs distributed to all age groups Yes 2006
IRS IRS is recommended Yes – 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended Yes –
IPT IPT used to prevent malaria during pregnancy N/A –
Diagnosis Patients of all ages should receive diagnostic test Yes –
 Malaria diagnosis is free of charge in the public sector Yes –
Treatment ACT is free for all ages in public sector Yes –
 Artemisinin-based monotherapies withdrawn No –
 Single dose of primaquine is used as gametocidal medicine for P. falciparum Yes –
 Primaquine is used for radical treatment of P. vivax Yes –
 G6PD test is a requirement before treatment with primaquine No –
 Directly observed treatment with primaquine is undertaken No –
 System for monitoring of adverse reactions to antimalarials exists Yes –
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) Yes –
 ACD of febrile cases at community level (pro-active) No –
 Mass screening is undertaken No –
 Uncomplicated P. falciparum cases routinely admitted No –
 Uncomplicated P. vivax cases routinely admitted No –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria – –
First-line treatment of P. falciparum CQ+PQ(3d) –
Treatment failure of P. falciparum – –
Treatment of severe malaria QN –
Treatment of P. vivax CQ+PQ(14d) –
Dosage of primaquine for radical treatment of P. vivax 0.25 mg/kg (14 days)
Type of RDT used –
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
– – – – – – – –
       
       
II. Intervention policies and strategies
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Impact: Insufficiently consistent data to assess trends
III. Financing Sources of financing Financing by intervention in 2013 
V. Impact  Confirmed malaria cases per 1000 and ABER Malaria admissions and deaths (per 100 000)
IV. Coverage ITN and IRS coverage Cases tested and treated in public sector
 Cases tracked Test positivity
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Guinea African Region
I. Epidemiological profile
Population 2013 %
High transmission (> 1 case per 1000 population) 11 700 000 100
Low transmission (0–1 cases per 1000 population) 0 0
Malaria-free (0 cases) 0 0
Total 11 700 000 
Parasites and vectors
Major plasmodium species: P. falciparum (100%), P. vivax (0%)
Major anopheles species: An. gambiae, An. funestus, An. melas, An. arabiensis
Programme phase: Control
Reported confirmed cases: 211 257 
Reported deaths: 108 
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 2009
 ITNs/LLINs distributed to all age groups Yes 2009
IRS IRS is recommended Yes 2013 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended No –
IPT IPT used to prevent malaria during pregnancy Yes 2005
Diagnosis Patients of all ages should receive diagnostic test Yes 2012
 Malaria diagnosis is free of charge in the public sector Yes 2012
Treatment ACT is free for all ages in public sector Yes 2010
 Artemisinin-based monotherapies withdrawn – –
 Single dose of primaquine is used as gametocidal medicine for P. falciparum No –
 Primaquine is used for radical treatment of P. vivax No –
 G6PD test is a requirement before treatment with primaquine No –
 Directly observed treatment with primaquine is undertaken No –
 System for monitoring of adverse reactions to antimalarials exists Yes 2009
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) – –
 ACD of febrile cases at community level (pro-active) No –
 Mass screening is undertaken No –
 Uncomplicated P. falciparum cases routinely admitted Yes 2009
 Uncomplicated P. vivax cases routinely admitted No –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria AS+AQ –
First-line treatment of P. falciparum AS+AQ –
Treatment failure of P. falciparum QN –
Treatment of severe malaria QN –
Treatment of P. vivax – –
Dosage of primaquine for radical treatment of P. vivax –
Type of RDT used –
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
– – – – – – – –
       
       
II. Intervention policies and strategies
Pie chart include 100% 
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Funding source(s): Government, 
USAID/PMI, WHO, UNICEF, Other 
(all types)
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Impact: Insufficiently consistent data to assess trends
III. Financing Sources of financing Financing by intervention in 2013 
V. Impact  Confirmed malaria cases per 1000 and ABER Malaria admissions and deaths (per 100 000)
IV. Coverage ITN and IRS coverage Cases tested and treated in public sector
 Cases tracked Test positivity
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Guinea-Bissau African Region
I. Epidemiological profile
Population 2013 %
High transmission (> 1 case per 1000 population) 1 700 000 100
Low transmission (0–1 cases per 1000 population) 0 0
Malaria-free (0 cases) 0 0
Total 1 700 000 
Parasites and vectors
Major plasmodium species: P. falciparum (100%), P. vivax (0%)
Major anopheles species: An. gambiae, An. funestus
Programme phase: Control
Reported confirmed cases: 54 584 
Reported deaths: 418 
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 2005
 ITNs/LLINs distributed to all age groups No –
IRS IRS is recommended No – 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended No –
IPT IPT used to prevent malaria during pregnancy Yes 2005
Diagnosis Patients of all ages should receive diagnostic test Yes 2008
 Malaria diagnosis is free of charge in the public sector Yes 2008
Treatment ACT is free for all ages in public sector No –
 Artemisinin-based monotherapies withdrawn – –
 Single dose of primaquine is used as gametocidal medicine for P. falciparum No –
 Primaquine is used for radical treatment of P. vivax No –
 G6PD test is a requirement before treatment with primaquine No –
 Directly observed treatment with primaquine is undertaken No –
 System for monitoring of adverse reactions to antimalarials exists Yes –
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) – –
 ACD of febrile cases at community level (pro-active) No –
 Mass screening is undertaken No –
 Uncomplicated P. falciparum cases routinely admitted – –
 Uncomplicated P. vivax cases routinely admitted – –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria AL –
First-line treatment of P. falciparum AL –
Treatment failure of P. falciparum QN –
Treatment of severe malaria QN –
Treatment of P. vivax – –
Dosage of primaquine for radical treatment of P. vivax –
Type of RDT used –
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
AL 2006–2008 3.6 3.6 3.6 28 days 1 P. falciparum
       
       
II. Intervention policies and strategies
Pie chart include 100% 
of total contributions
Funding source(s): Government, 
Global Fund, WHO, UNICEF
Insucient data
0
0–0.1
0.1–1.0
1.0–10
PP
>75
0
no cases
Insucient data
Very low PP
0–20
20–40
40–60
60–80
80–100
PR
OTHERS
PF-RATIO
Proportion of cases 
due to P. falciparum
Insucient data
0
0–0.1
0.1–1.0
1.0–10
PP
>75
0
no cases
Insucient data
Very low PP
0–20
20–40
40–60
60–80
80–100
PR
OTHERS
PF-RATIO
Confirmed cases  
per 1000 population/
Parasite prevalence 
(PP)
Survey source: MICS 2006
Survey source: MICS 2006
WORLD MALARIA REPORT 2014 | 109
Impact: Increase in case incidence 2000-2015
III. Financing Sources of financing Financing by intervention in 2013 
V. Impact  Confirmed malaria cases per 1000 and ABER Malaria admissions and deaths
IV. Coverage ITN and IRS coverage Cases tested and treated in public sector
 Cases tracked Test positivity
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Guyana Region of the Americas
I. Epidemiological profile
Population 2013 %
High transmission (> 1 case per 1000 population) 280 000 35
Low transmission (0–1 cases per 1000 population) 464 000 58
Malaria-free (0 cases) 56 000 7
Total 800 000 
Parasites and vectors
Major plasmodium species: P. falciparum (55%), P. vivax (44%)
Major anopheles species: An. darlingi, An. aquasalis
Programme phase: Control
Reported confirmed cases: 31 479 
Reported deaths: 3 
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 2005
 ITNs/LLINs distributed to all age groups Yes 2005
IRS IRS is recommended Yes – 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended No –
IPT IPT used to prevent malaria during pregnancy N/A –
Diagnosis Patients of all ages should receive diagnostic test Yes 1946
 Malaria diagnosis is free of charge in the public sector Yes 1946
Treatment ACT is free for all ages in public sector Yes 2005
 Artemisinin-based monotherapies withdrawn Yes –
 Single dose of primaquine is used as gametocidal medicine for P. falciparum Yes –
 Primaquine is used for radical treatment of P. vivax Yes –
 G6PD test is a requirement before treatment with primaquine No –
 Directly observed treatment with primaquine is undertaken No –
 System for monitoring of adverse reactions to antimalarials exists No –
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) Yes –
 ACD of febrile cases at community level (pro-active) Yes –
 Mass screening is undertaken Yes –
 Uncomplicated P. falciparum cases routinely admitted No –
 Uncomplicated P. vivax cases routinely admitted No –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria – –
First-line treatment of P. falciparum AL+PQ(1d) 2004
Treatment failure of P. falciparum QN+T 2004
Treatment of severe malaria AM –
Treatment of P. vivax CQ+PQ(14d) 2004
Dosage of primaquine for radical treatment of P. vivax 0.25 mg/kg (14 days)
Type of RDT used –
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
CQ 2006–2006 32.4 32.4 32.4 28 days 1 P. vivax
       
       
II. Intervention policies and strategies
Pie chart include 51% 
of total contributions
Funding source(s): Global Fund, 
USAID/PMI, WHO
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Impact: Increase in case incidence 2000-2015
III. Financing Sources of financing Financing by intervention in 2013 
V. Impact  Confirmed malaria cases per 1000 and ABER Malaria admissions and deaths
IV. Coverage ITN and IRS coverage Cases tested and treated in public sector
 Cases tracked Test positivity
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Haiti Region of the Americas
I. Epidemiological profile
Population 2013 %
High transmission (> 1 case per 1000 population) 5 470 000 53
Low transmission (0–1 cases per 1000 population) 4 850 000 47
Malaria-free (0 cases) 0 0
Total 10 320 000 
Parasites and vectors
Major plasmodium species: P. falciparum (100%), P. vivax (0%)
Major anopheles species: An. albimanus
Programme phase: Control
Reported confirmed cases: 20 586 
Reported deaths: 10 
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 2012
 ITNs/LLINs distributed to all age groups Yes 2012
IRS IRS is recommended No – 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended Yes 2011
IPT IPT used to prevent malaria during pregnancy N/A –
Diagnosis Patients of all ages should receive diagnostic test Yes 1988
 Malaria diagnosis is free of charge in the public sector Yes 2011
Treatment ACT is free for all ages in public sector Yes –
 Artemisinin-based monotherapies withdrawn – –
 Single dose of primaquine is used as gametocidal medicine for P. falciparum Yes –
 Primaquine is used for radical treatment of P. vivax Yes –
 G6PD test is a requirement before treatment with primaquine No –
 Directly observed treatment with primaquine is undertaken No –
 System for monitoring of adverse reactions to antimalarials exists Yes –
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) Yes –
 ACD of febrile cases at community level (pro-active) No –
 Mass screening is undertaken No –
 Uncomplicated P. falciparum cases routinely admitted No –
 Uncomplicated P. vivax cases routinely admitted No –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria – –
First-line treatment of P. falciparum CQ+PQ(1d) –
Treatment failure of P. falciparum MQ; SP –
Treatment of severe malaria QN –
Treatment of P. vivax CQ+PQ(14d) –
Dosage of primaquine for radical treatment of P. vivax 0.25 mg/kg (14 days)
Type of RDT used P.f + all species (Combo)
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
– – – – – – – –
       
       
II. Intervention policies and strategies
Pie chart include 93% 
of total contributions
Funding source(s): Government, 
Global Fund, Other (all types)
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Impact: Achieved >75% decrease in case incidence in 2013
III. Financing Sources of financing Financing by intervention in 2013 
V. Impact  Confirmed malaria cases per 1000 and ABER Malaria admissions and deaths
IV. Coverage ITN and IRS coverage Cases tested and treated in public sector
 Cases tracked Test positivity
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Honduras Region of the Americas
I. Epidemiological profile
Population 2013 %
High transmission (> 1 case per 1000 population) 1 130 000 14
Low transmission (0–1 cases per 1000 population) 4 760 000 59
Malaria-free (0 cases) 2 200 000 27
Total 8 090 000 
Parasites and vectors
Major plasmodium species: P. falciparum (21%), P. vivax (79%)
Major anopheles species: An. albimanus, An. pseudopunctipennis, An. darlingi, An. cruzii, An. argyritarsis
Programme phase: Control
Reported confirmed cases: 5428 
Reported deaths: 1 
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 2009
 ITNs/LLINs distributed to all age groups Yes 2009
IRS IRS is recommended Yes – 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended Yes –
IPT IPT used to prevent malaria during pregnancy N/A –
Diagnosis Patients of all ages should receive diagnostic test Yes –
 Malaria diagnosis is free of charge in the public sector Yes –
Treatment ACT is free for all ages in public sector Yes –
 Artemisinin-based monotherapies withdrawn – –
 Single dose of primaquine is used as gametocidal medicine for P. falciparum Yes –
 Primaquine is used for radical treatment of P. vivax Yes –
 G6PD test is a requirement before treatment with primaquine No –
 Directly observed treatment with primaquine is undertaken No –
 System for monitoring of adverse reactions to antimalarials exists No –
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) Yes –
 ACD of febrile cases at community level (pro-active) Yes –
 Mass screening is undertaken Yes –
 Uncomplicated P. falciparum cases routinely admitted No –
 Uncomplicated P. vivax cases routinely admitted No –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria – –
First-line treatment of P. falciparum CQ+PQ(1d) –
Treatment failure of P. falciparum SP 2011
Treatment of severe malaria QN –
Treatment of P. vivax CQ+PQ(14d) –
Dosage of primaquine for radical treatment of P. vivax 0.25 mg/kg (14 days)
Type of RDT used P.f + P.v specific (Combo)
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
– – – – – – – –
       
       
II. Intervention policies and strategies
Pie chart include 100% 
of total contributions
Funding source(s): Government, 
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Impact: On track for 50%-75% decrease in case incidence 2000-2015
III. Financing Sources of financing Financing by intervention in 2013 
V. Impact  Confirmed malaria cases per 1000 and ABER Malaria admissions and deaths
IV. Coverage ITN and IRS coverage Cases tested and treated in public sector
 Cases tracked Test positivity
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India South-East Asia Region
I. Epidemiological profile
Population 2013 %
High transmission (> 1 case per 1000 population) 275 500 000 22
Low transmission (0–1 cases per 1000 population) 838 900 000 67
Malaria-free (0 cases) 137 700 000 11
Total 1 252 100 000 
Parasites and vectors
Major plasmodium species: P. falciparum (53%), P. vivax (47%)
Major anopheles species: An. culicifacies, An. fluviatilis, An. stephensi, An. minimus, An. dirus, An. annularis
Programme phase: Control
Reported confirmed cases: 881 730 
Reported deaths: 440 
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 2001
 ITNs/LLINs distributed to all age groups Yes 2001
IRS IRS is recommended Yes 1953 
 DDT is authorized for IRS Yes 1953
Larval control Use of larval control recommended Yes –
IPT IPT used to prevent malaria during pregnancy N/A –
Diagnosis Patients of all ages should receive diagnostic test Yes 1958
 Malaria diagnosis is free of charge in the public sector Yes 1953
Treatment ACT is free for all ages in public sector Yes 2006
 Artemisinin-based monotherapies withdrawn Yes –
 Single dose of primaquine is used as gametocidal medicine for P. falciparum Yes –
 Primaquine is used for radical treatment of P. vivax Yes –
 G6PD test is a requirement before treatment with primaquine Yes –
 Directly observed treatment with primaquine is undertaken No –
 System for monitoring of adverse reactions to antimalarials exists Yes –
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) Yes –
 ACD of febrile cases at community level (pro-active) No –
 Mass screening is undertaken Yes –
 Uncomplicated P. falciparum cases routinely admitted No –
 Uncomplicated P. vivax cases routinely admitted No –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria CQ 2007
First-line treatment of P. falciparum AS+SP+PQ 2007
Treatment failure of P. falciparum QN+D; QN+T –
Treatment of severe malaria AM; AS; QN 2007
Treatment of P. vivax CQ+PQ(14d) 2007
Dosage of primaquine for radical treatment of P. vivax 0.25 mg/kg (14 days)
Type of RDT used P.f + P.v specific (Combo)
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
– – – – – – – –
       
       
II. Intervention policies and strategies
Pie chart include 100% 
of total contributions
Funding source(s): Government, 
Global Fund, World Bank
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Impact: Insufficiently consistent data to assess trends
III. Financing Sources of financing Financing by intervention in 2013 
V. Impact  Confirmed malaria cases per 1000 and ABER Malaria admissions and deaths
IV. Coverage ITN and IRS coverage Cases tested and treated in public sector
 Cases tracked Test positivity
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Indonesia South-East Asia Region
I. Epidemiological profile
Population 2013 %
High transmission (> 1 case per 1000 population) 42 500 000 17
Low transmission (0–1 cases per 1000 population) 109 900 000 44
Malaria-free (0 cases) 97 400 000 39
Total 249 800 000 
Parasites and vectors
Major plasmodium species: P. falciparum (56%), P. vivax (44%)
Major anopheles species: An. sundaicus, An. balabacensis, An. maculatus, An. farauti, An. subpictus, An. subpictus
Programme phase: Control
Reported confirmed cases: 343 527 
Reported deaths: 45 
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 2006
 ITNs/LLINs distributed to all age groups Yes 2004
IRS IRS is recommended Yes 1959 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended Yes 1990
IPT IPT used to prevent malaria during pregnancy N/A –
Diagnosis Patients of all ages should receive diagnostic test Yes 2007
 Malaria diagnosis is free of charge in the public sector Yes 1959
Treatment ACT is free for all ages in public sector Yes 2004
 Artemisinin-based monotherapies withdrawn – –
 Single dose of primaquine is used as gametocidal medicine for P. falciparum Yes –
 Primaquine is used for radical treatment of P. vivax Yes –
 G6PD test is a requirement before treatment with primaquine No –
 Directly observed treatment with primaquine is undertaken No –
 System for monitoring of adverse reactions to antimalarials exists Yes –
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) Yes –
 ACD of febrile cases at community level (pro-active) Yes –
 Mass screening is undertaken Yes –
 Uncomplicated P. falciparum cases routinely admitted Yes –
 Uncomplicated P. vivax cases routinely admitted Yes –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria – –
First-line treatment of P. falciparum AS+AQ; DHA-PP+PQ 2008
Treatment failure of P. falciparum QN+D+PQ 2004
Treatment of severe malaria AM; AS; QN 2004
Treatment of P. vivax AS+AQ; DHA-PP+PQ(14d) 2008
Dosage of primaquine for radical treatment of P. vivax 0.25 mg/kg (14 days)
Type of RDT used P.f + P.v specific (Combo)
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
– – – – – – – –
       
       
II. Intervention policies and strategies
Pie chart include 100% 
of total contributions
Funding source(s): Global Fund, 
WHO, UNICEF
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Impact: Achieved >75% decrease in case incidence in 2013
V. Impact Malaria test positivity rate and ABER Number of malaria cases 
IV. Coverage ITN and IRS coverage Cases tested
 Cases treated Cases tracked
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Iran (Islamic Republic of ) Eastern Mediterranean Region
I. Epidemiological profile
Parasites and vectors
Major plasmodium species: P. falciparum (18%), P. vivax (82%)
Major anopheles species: An. stephensi, An. culicifacies, An. fluviatilis, An. superpictus
Programme phase: Elimination
Total confirmed cases, 2013: 1373 Indigenous cases, 2013: 479
Total deaths, 2013: 2 Indigenous deaths, 2013: 0
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 2005
 ITNs/LLINs distributed to all age groups Yes 2005
IRS IRS is recommended Yes – 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended Yes 1949
IPT IPT used to prevent malaria during pregnancy N/A –
Diagnosis Patients of all ages should receive diagnostic test Yes –
 Malaria diagnosis is free of charge in the public sector Yes 1949
Treatment ACT is free for all ages in public sector – –
 Artemisinin-based monotherapies withdrawn – –
 Single dose of primaquine is used as gametocidal medicine for P. falciparum Yes 1949
 Primaquine is used for radical treatment of P. vivax Yes 1949
 G6PD test is a requirement before treatment with primaquine No –
 Directly observed treatment with primaquine is undertaken Yes 1949
 System for monitoring of adverse reactions to antimalarials exists Yes 1949
II. Intervention policies and strategies
Pie chart include 100% 
of total contributions
Funding source(s): Government, 
Global Fund, USAID/PMI, WHO, 
Other (bilateral)
Population 2013 %
Number of active foci 282 
Number of people living within active foci 746 000 1
Number of people living in malaria-free areas 76 700 000 99
Total 77 446 000 
III. Financing Sources of financing Financing by intervention in 2013 
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) Yes 1949
 ACD of febrile cases at community level (pro-active) Yes 1949
 Mass screening is undertaken No –
 Uncomplicated P. falciparum cases routinely admitted No –
 Uncomplicated P. vivax cases routinely admitted No –
 Foci and case investigation undertaken Yes 2010
 Case reporting from private sector is mandatory Yes 1949
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria – –
First-line treatment of P. falciparum AS+SP; AS+SP+PQ 2010
Treatment failure of P. falciparum AL; AL+PQ 2010
Treatment of severe malaria AS; QN+D –
Treatment of P. vivax CQ+PQ(14d &amp; 8w) –
Dosage of primaquine for radical treatment of P. vivax 0.75 mg/kg (8 weeks)
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
AS+SP 2005–2012 0 0 1 28 days 15 P. falciparum
CQ+PQ 2008–2011 0 0 0 28 days 4 P. vivax
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Impact: Insufficiently consistent data to assess trends
III. Financing Sources of financing Financing by intervention in 2013 
V. Impact  Confirmed malaria cases per 1000 and ABER Malaria admissions and deaths (per 100 000)
IV. Coverage ITN and IRS coverage Cases tested and treated in public sector
 Cases tracked Test positivity
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Kenya African Region
I. Epidemiological profile
Population 2013 %
High transmission (> 1 case per 1000 population) 16 000 000 36
Low transmission (0–1 cases per 1000 population) 17 700 000 40
Malaria-free (0 cases) 10 600 000 24
Total 44 300 000 
Parasites and vectors
Major plasmodium species: P. falciparum (100%), P. vivax (0%)
Major anopheles species: An. gambiae, An. arabiensis, An. funestus, An. merus
Programme phase: Control
Reported confirmed cases: 2 335 286 
Reported deaths: 360 
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 2006
 ITNs/LLINs distributed to all age groups Yes 2010
IRS IRS is recommended Yes 2003 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended No –
IPT IPT used to prevent malaria during pregnancy Yes 2001
Diagnosis Patients of all ages should receive diagnostic test Yes 2009
 Malaria diagnosis is free of charge in the public sector Yes –
Treatment ACT is free for all ages in public sector Yes 2006
 Artemisinin-based monotherapies withdrawn Yes –
 Single dose of primaquine is used as gametocidal medicine for P. falciparum No –
 Primaquine is used for radical treatment of P. vivax – –
 G6PD test is a requirement before treatment with primaquine – –
 Directly observed treatment with primaquine is undertaken – –
 System for monitoring of adverse reactions to antimalarials exists Yes –
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) No –
 ACD of febrile cases at community level (pro-active) No –
 Mass screening is undertaken No –
 Uncomplicated P. falciparum cases routinely admitted No –
 Uncomplicated P. vivax cases routinely admitted – –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria AL 2004
First-line treatment of P. falciparum AL 2004
Treatment failure of P. falciparum QN 2004
Treatment of severe malaria QN 2004
Treatment of P. vivax – –
Dosage of primaquine for radical treatment of P. vivax –
Type of RDT used –
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
– – – – – – – –
       
       
II. Intervention policies and strategies
Pie chart include 54% 
of total contributions
Funding source(s): Government, 
Global Fund, USAID/PMI
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Impact: Increase in case incidence 2000-2015
III. Financing Sources of financing Financing by intervention in 2013 
V. Impact  Confirmed malaria cases per 1000 and ABER Malaria admissions and deaths
IV. Coverage ITN and IRS coverage Cases tested and treated in public sector
 Cases tracked Test positivity
Government Global Fund World Bank USAID/PMI WHO/UNICEF Others
Co
nt
rib
ut
ion
 (U
S$
m
)
0
2
4
6
8
10
Others
WHO_UNICEF
USAID/PMI
Worldbank (USD)
Global Fund (USD)
Malaria budget (USD)
20132012201120102009200820072006200520042003200220012000
Po
pu
lat
ion
 (%
)
At high risk protected with ITNs
Households with at least one ITN
All ages who slept under an ITN (survey)
At high risk protected with IRS
0
20
40
60
80
100
At high risk protected with ITNs
All ages who slept under an ITN (survey)
Households with at least one ITN
At high risk protected with IRS Points
At high risk protected with IRS
20132012201120102009200820072006200520042003200220012000
(%
)
0
20
40
60
80
100
Estimated cases detected - top
Estimated cases detected - bottom
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
20132012201120102009200820072006200520042003200220012000
% fever cases <5 seeking treatment at public HF (survey) Reporting completeness
Ca
se
s p
er 
10
00
ABER (microscopy & RDT) Cases (P. vivax)Cases (all species)
AB
ER
 (%
)
0
2
4
6
8
10
Aber (microscopy & RDT)
0
2
4
6
8
10
Cases (p.vivax) points
Cases (p.vivax)
Cases (all species) points
Cases (all species)
20132012201120102009200820072006200520042003200220012000
Te
sts
 (%
)
Parasite prevalence (survey) RDT positivity rateSlide positivity rate
0
20
40
60
80
100
Parasite prevalence
Slide positivity rate points
Slide positivity rate
RDT positivity rate points
RDT positivity rate
20132012201120102009200820072006200520042003200220012000
Ad
m
iss
ion
s
Admissions (P. vivax)
De
ath
s
0
70
140
210
280
350
Deaths (P.vivax) points
Deaths (P.vivax)
Deaths (all species) points
Deaths (all species)
0
5000
10000
15000
20000
25000
Admissions (P.vivax) points
Admissions (P.vivax)
Admissions (all species) points
Admissions (all species)
20132012201120102009200820072006200520042003200220012000
Admissions (all species)
Deaths (all species) Deaths (P. vivax)
Ca
se
s (
%
)
0
20
40
60
80
100
Suspected cases tested
<5 with fever with nger/heel stick (survey)
ACTs as % of all antimalarials received by <5
Primaquine distributed vs reported P.v cases points
Primaquine distributed vs reported P.v cases
ACTs distributed vs reported P.f cases points
ACTs distributed vs reported P.f cases
Antimalarials distributed vs reported cases points
Antimalarials distributed vs reported cases
20132012201120102009200820072006200520042003200220012000
Suspected cases tested
<5 with fever with nger/heel stick (survey)
ACTs as % of all antimalarials received by <5 (survey) Primaquine distributed vs reported  P. v. cases
Antimalarials distributed vs reported cases
ACTs distributed vs reported  P. f. cases
Insecticides & spray materials
ITNs
Diagnostic testing
Antimalarial medicines
Monitoring and evaluation
Human resources & technical assistance
Management and other costs
Management and other costs
Human Resources & technical Assistance
Monitoring and evaluation
Antimalarial medicines
Diagnostics
ITNs
Insecticide & spraying materials
Lao People’s Democratic Republic Western Pacific Region
I. Epidemiological profile
Population 2013 %
High transmission (> 1 case per 1000 population) 2 440 000 36
Low transmission (0–1 cases per 1000 population) 1 560 000 23
Malaria-free (0 cases) 2 780 000 41
Total 6 780 000 
Parasites and vectors
Major plasmodium species: P. falciparum (73%), P. vivax (27%)
Major anopheles species: An. dirus, An. minimus, An. maculatus, An. jeyporiensis
Programme phase: Control
Reported confirmed cases: 38 131 
Reported deaths: 28 
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 2003
 ITNs/LLINs distributed to all age groups Yes 2000
IRS IRS is recommended Yes 2010 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended No –
IPT IPT used to prevent malaria during pregnancy N/A –
Diagnosis Patients of all ages should receive diagnostic test Yes 2003
 Malaria diagnosis is free of charge in the public sector Yes 2005
Treatment ACT is free for all ages in public sector Yes 2005
 Artemisinin-based monotherapies withdrawn Yes 2007
 Single dose of primaquine is used as gametocidal medicine for P. falciparum No –
 Primaquine is used for radical treatment of P. vivax No –
 G6PD test is a requirement before treatment with primaquine Yes 2010
 Directly observed treatment with primaquine is undertaken No –
 System for monitoring of adverse reactions to antimalarials exists No –
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) Yes 2012
 ACD of febrile cases at community level (pro-active) Yes 2012
 Mass screening is undertaken No –
 Uncomplicated P. falciparum cases routinely admitted No –
 Uncomplicated P. vivax cases routinely admitted No –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria AL 2001
First-line treatment of P. falciparum QN+D 2001
Treatment failure of P. falciparum CQ+PQ(14d) 2001
Treatment of severe malaria CQ+PQ(14d) 2001
Treatment of P. vivax AL –
Dosage of primaquine for radical treatment of P. vivax –
Type of RDT used P.f + P.v specific (Combo)
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
AL 2005–2013 0 1.2 18.1 28 days 12 P. falciparum
       
       
II. Intervention policies and strategies
Pie chart include 100% 
of total contributions
Funding source(s): Government, 
Global Fund, USAID/PMI, WHO
Insucient data
0
0–0.1
0.1–1.0
1.0–10
PP
>75
0
no cases
Insucient data
Very low PP
0–20
20–40
40–60
60–80
80–100
PR
OTHERS
PF-RATIO
Proportion of cases 
due to P. falciparum
Insucient data
0
0–0.1
0.1–1.0
1.0–10
PP
>75
0
no cases
Insucient data
Very low PP
0–20
20–40
40–60
60–80
80–100
PR
OTHERS
PF-RATIO
Confirmed cases  
per 1000 population/
Parasite prevalence 
(PP)
WORLD MALARIA REPORT 2014 | 117
Impact: Insufficiently consistent data to assess trends
III. Financing Sources of financing Financing by intervention in 2013 
V. Impact  Confirmed malaria cases per 1000 and ABER Malaria admissions and deaths (per 100 000)
IV. Coverage ITN and IRS coverage Cases tested and treated in public sector
 Cases tracked Test positivity
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Liberia African Region
I. Epidemiological profile
Population 2013 %
High transmission (> 1 case per 1000 population) 4 290 000 100
Low transmission (0–1 cases per 1000 population) 0 0
Malaria-free (0 cases) 0 0
Total 4 290 000 
Parasites and vectors
Major plasmodium species: P. falciparum (100%), P. vivax (0%)
Major anopheles species: An. gambiae
Programme phase: Control
Reported confirmed cases: 1 244 220 
Reported deaths: 1191 
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 2005
 ITNs/LLINs distributed to all age groups Yes 2008
IRS IRS is recommended Yes 2009 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended No –
IPT IPT used to prevent malaria during pregnancy Yes 2005
Diagnosis Patients of all ages should receive diagnostic test Yes 2005
 Malaria diagnosis is free of charge in the public sector Yes 2005
Treatment ACT is free for all ages in public sector Yes 2005
 Artemisinin-based monotherapies withdrawn – –
 Single dose of primaquine is used as gametocidal medicine for P. falciparum No –
 Primaquine is used for radical treatment of P. vivax No –
 G6PD test is a requirement before treatment with primaquine No –
 Directly observed treatment with primaquine is undertaken No –
 System for monitoring of adverse reactions to antimalarials exists Yes –
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) No –
 ACD of febrile cases at community level (pro-active) No –
 Mass screening is undertaken No –
 Uncomplicated P. falciparum cases routinely admitted No –
 Uncomplicated P. vivax cases routinely admitted No –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria AS+AQ 2004
First-line treatment of P. falciparum AS+AQ 2004
Treatment failure of P. falciparum QN 2004
Treatment of severe malaria QN 2004
Treatment of P. vivax – –
Dosage of primaquine for radical treatment of P. vivax –
Type of RDT used P.f only
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
AS+AQ 2007–2009 0 0 1 28 days 3 P. falciparum
       
       
II. Intervention policies and strategies
Pie chart include 100% 
of total contributions
Funding source(s): Government, 
Global Fund, USAID/PMI, WHO, 
UNICEF
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Impact: Insufficiently consistent data to assess trends
III. Financing Sources of financing Financing by intervention in 2013 
V. Impact  Confirmed malaria cases per 1000 and ABER Malaria admissions and deaths (per 100 000)
IV. Coverage ITN and IRS coverage Cases tested and treated in public sector
 Cases tracked Test positivity
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Madagascar African Region
I. Epidemiological profile
Population 2013 %
High transmission (> 1 case per 1000 population) 6 880 000 30
Low transmission (0–1 cases per 1000 population) 16 000 000 70
Malaria-free (0 cases) 0 0
Total 22 880 000 
Parasites and vectors
Major plasmodium species: P. falciparum (100%), P. vivax (0%)
Major anopheles species: An. funestus, An. gambiae, An. arabiensis
Programme phase: Control
Reported confirmed cases: 387 045 
Reported deaths: 641 
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 2004
 ITNs/LLINs distributed to all age groups Yes 2009
IRS IRS is recommended Yes 1993 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended No –
IPT IPT used to prevent malaria during pregnancy Yes 2006
Diagnosis Patients of all ages should receive diagnostic test Yes 2006
 Malaria diagnosis is free of charge in the public sector Yes 2006
Treatment ACT is free for all ages in public sector Yes 2006
 Artemisinin-based monotherapies withdrawn Yes 2006
 Single dose of primaquine is used as gametocidal medicine for P. falciparum No –
 Primaquine is used for radical treatment of P. vivax No –
 G6PD test is a requirement before treatment with primaquine No –
 Directly observed treatment with primaquine is undertaken No –
 System for monitoring of adverse reactions to antimalarials exists Yes 2008
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) Yes 2003
 ACD of febrile cases at community level (pro-active) Yes 1993
 Mass screening is undertaken Yes 2003
 Uncomplicated P. falciparum cases routinely admitted Yes 2006
 Uncomplicated P. vivax cases routinely admitted No –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria AS+AQ 2006
First-line treatment of P. falciparum AS+AQ 2006
Treatment failure of P. falciparum QN 2006
Treatment of severe malaria QN 2006
Treatment of P. vivax – –
Dosage of primaquine for radical treatment of P. vivax –
Type of RDT used P.f + P.v specific (Combo)
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
– – – – – – – –
       
       
II. Intervention policies and strategies
Pie chart include 76% 
of total contributions
Funding source(s): Government, 
Global Fund, USAID/PMI, WHO, 
UNICEF, Other (bilateral)
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Impact: Insufficiently consistent data to assess trends
III. Financing Sources of financing Financing by intervention in 2013 
V. Impact  Confirmed malaria cases per 1000 and ABER Malaria admissions and deaths (per 100 000)
IV. Coverage ITN and IRS coverage Cases tested and treated in public sector
 Cases tracked Test positivity
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Malawi African Region
I. Epidemiological profile
Population 2013 %
High transmission (> 1 case per 1000 population) 16 400 000 100
Low transmission (0–1 cases per 1000 population) 0 0
Malaria-free (0 cases) 0 0
Total 16 400 000 
Parasites and vectors
Major plasmodium species: P. falciparum (100%), P. vivax (0%)
Major anopheles species: An. funestus, An. gambiae, An. arabiensis
Programme phase: Control
Reported confirmed cases: 1 280 892 
Reported deaths: 3723 
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 2006
 ITNs/LLINs distributed to all age groups Yes 2010
IRS IRS is recommended Yes 2007 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended No –
IPT IPT used to prevent malaria during pregnancy Yes 1993
Diagnosis Patients of all ages should receive diagnostic test Yes 2011
 Malaria diagnosis is free of charge in the public sector No –
Treatment ACT is free for all ages in public sector Yes 2007
 Artemisinin-based monotherapies withdrawn – –
 Single dose of primaquine is used as gametocidal medicine for P. falciparum No –
 Primaquine is used for radical treatment of P. vivax No –
 G6PD test is a requirement before treatment with primaquine No –
 Directly observed treatment with primaquine is undertaken No –
 System for monitoring of adverse reactions to antimalarials exists Yes 2007
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) No –
 ACD of febrile cases at community level (pro-active) No –
 Mass screening is undertaken No –
 Uncomplicated P. falciparum cases routinely admitted No –
 Uncomplicated P. vivax cases routinely admitted No –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria AL 2007
First-line treatment of P. falciparum AL 2007
Treatment failure of P. falciparum AS+AQ 2007
Treatment of severe malaria QN 2007
Treatment of P. vivax – –
Dosage of primaquine for radical treatment of P. vivax –
Type of RDT used P.f only
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
AL 2005–2012 0 4.45 19.5 28 days 8 P. falciparum
AS+AQ 2005–2012 0 1.7 3.6 28 days 3 P. falciparum
       
II. Intervention policies and strategies
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Impact: Achieved >75% decrease in case incidence in 2013
V. Impact Malaria test positivity rate and ABER Number of malaria cases 
IV. Coverage ITN and IRS coverage Cases tested
 Cases treated Cases tracked
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Malaysia Western Pacific Region
I. Epidemiological profile
Parasites and vectors
Major plasmodium species: P. falciparum (9%), P. vivax (8%)
Major anopheles species: An. balabacensis, An. donaldi, An. maculatus, An. sundaicus, An. flavirostris
Programme phase: Pre-elimination
Total confirmed cases, 2013: 3850 Indigenous cases, 2013: 2921
Total deaths, 2013: 14 Indigenous deaths, 2013: 10
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 1995
 ITNs/LLINs distributed to all age groups Yes 1995
IRS IRS is recommended – – 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended Yes –
IPT IPT used to prevent malaria during pregnancy N/A –
Diagnosis Patients of all ages should receive diagnostic test – –
 Malaria diagnosis is free of charge in the public sector Yes 1967
Treatment ACT is free for all ages in public sector – –
 Artemisinin-based monotherapies withdrawn – –
 Single dose of primaquine is used as gametocidal medicine for P. falciparum Yes –
 Primaquine is used for radical treatment of P. vivax Yes –
 G6PD test is a requirement before treatment with primaquine Yes –
 Directly observed treatment with primaquine is undertaken Yes –
 System for monitoring of adverse reactions to antimalarials exists Yes –
II. Intervention policies and strategies
Pie chart include 100% 
of total contributions
Funding source(s): Government
Population 2013 %
Number of active foci 3027 
Number of people living within active foci 1 050 000 4
Number of people living in malaria-free areas 28 700 000 96
Total 29 750 000 
III. Financing Sources of financing Financing by intervention in 2013 
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) Yes –
 ACD of febrile cases at community level (pro-active) Yes –
 Mass screening is undertaken Yes –
 Uncomplicated P. falciparum cases routinely admitted Yes –
 Uncomplicated P. vivax cases routinely admitted Yes –
 Foci and case investigation undertaken Yes 1995
 Case reporting from private sector is mandatory Yes 1988
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria – –
First-line treatment of P. falciparum AS+MQ –
Treatment failure of P. falciparum QN+T –
Treatment of severe malaria QN+T –
Treatment of P. vivax CQ+PQ(14d) –
Dosage of primaquine for radical treatment of P. vivax 0.50 mg/kg (14 days)
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
– – – – – – – –
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Impact: Insufficiently consistent data to assess trends
III. Financing Sources of financing Financing by intervention in 2013 
V. Impact  Confirmed malaria cases per 1000 and ABER Malaria admissions and deaths (per 100 000)
IV. Coverage ITN and IRS coverage Cases tested and treated in public sector
 Cases tracked Test positivity
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Mali African Region
I. Epidemiological profile
Population 2013 %
High transmission (> 1 case per 1000 population) 13 800 000 90
Low transmission (0–1 cases per 1000 population) 1 530 000 10
Malaria-free (0 cases) 0 0
Total 15 330 000 
Parasites and vectors
Major plasmodium species: P. falciparum (100%), P. vivax (0%)
Major anopheles species: An. gambiae, An. funestus, An. funestus, An. funestus
Programme phase: Control
Reported confirmed cases: 1 367 218 
Reported deaths: 1680 
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 2005
 ITNs/LLINs distributed to all age groups No –
IRS IRS is recommended Yes 2007 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended No –
IPT IPT used to prevent malaria during pregnancy Yes 2003
Diagnosis Patients of all ages should receive diagnostic test Yes 2008
 Malaria diagnosis is free of charge in the public sector Yes 2008
Treatment ACT is free for all ages in public sector No –
 Artemisinin-based monotherapies withdrawn – –
 Single dose of primaquine is used as gametocidal medicine for P. falciparum No –
 Primaquine is used for radical treatment of P. vivax No –
 G6PD test is a requirement before treatment with primaquine – –
 Directly observed treatment with primaquine is undertaken No –
 System for monitoring of adverse reactions to antimalarials exists Yes 2010
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) – –
 ACD of febrile cases at community level (pro-active) Yes 2008
 Mass screening is undertaken No –
 Uncomplicated P. falciparum cases routinely admitted Yes 1993
 Uncomplicated P. vivax cases routinely admitted – –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria AS+AQ 2007
First-line treatment of P. falciparum AL; AS+AQ 2007
Treatment failure of P. falciparum AL 2007
Treatment of severe malaria QN –
Treatment of P. vivax – –
Dosage of primaquine for radical treatment of P. vivax –
Type of RDT used –
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
– – – – – – – –
       
       
II. Intervention policies and strategies
Pie chart include 96% 
of total contributions
Funding source(s): Global Fund, 
USAID/PMI, WHO, UNICEF
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Impact: Insufficiently consistent data to assess trends
III. Financing Sources of financing Financing by intervention in 2013 
V. Impact  Confirmed malaria cases per 1000 and ABER Malaria admissions and deaths (per 100 000)
IV. Coverage ITN and IRS coverage Cases tested and treated in public sector
 Cases tracked Test positivity
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Mauritania African Region
I. Epidemiological profile
Population 2013 %
High transmission (> 1 case per 1000 population) 2 300 000 59
Low transmission (0–1 cases per 1000 population) 1 210 000 31
Malaria-free (0 cases) 389 000 10
Total 3 899 000 
Parasites and vectors
Major plasmodium species: P. falciparum (100%), P. vivax (0%)
Major anopheles species: An. gambiae, An. arabiensis, An. pharoensis
Programme phase: Control
Reported confirmed cases: 1587 
Reported deaths: 25 
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 1998
 ITNs/LLINs distributed to all age groups No –
IRS IRS is recommended No – 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended No –
IPT IPT used to prevent malaria during pregnancy Yes 2008
Diagnosis Patients of all ages should receive diagnostic test Yes 2011
 Malaria diagnosis is free of charge in the public sector Yes 2009
Treatment ACT is free for all ages in public sector Yes 2009
 Artemisinin-based monotherapies withdrawn Yes –
 Single dose of primaquine is used as gametocidal medicine for P. falciparum No –
 Primaquine is used for radical treatment of P. vivax Yes –
 G6PD test is a requirement before treatment with primaquine Yes –
 Directly observed treatment with primaquine is undertaken No –
 System for monitoring of adverse reactions to antimalarials exists Yes –
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) – –
 ACD of febrile cases at community level (pro-active) – –
 Mass screening is undertaken Yes –
 Uncomplicated P. falciparum cases routinely admitted Yes –
 Uncomplicated P. vivax cases routinely admitted Yes –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria AS+AQ –
First-line treatment of P. falciparum AL; AS+AQ –
Treatment failure of P. falciparum – –
Treatment of severe malaria QN –
Treatment of P. vivax – –
Dosage of primaquine for radical treatment of P. vivax –
Type of RDT used –
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
AS+AQ 2012–2012 1.8 1.8 1.8 28 days 2 P. falciparum
       
       
II. Intervention policies and strategies
Pie chart include 100% 
of total contributions
Funding source(s): Government, 
WHO, UNICEF
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Impact: On track for >75% decrease in incidence 2000–2015
V. Impact Malaria test positivity rate and ABER Number of malaria cases 
IV. Coverage ITN and IRS coverage Cases tested
 Cases treated Cases tracked
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Mayotte, France African Region
I. Epidemiological profile
Parasites and vectors
Major plasmodium species: P. falciparum (100%), P. vivax (0%)
Major anopheles species: An. funestus, An. gambiae
Programme phase: Elimination
Total confirmed cases, 2013: 82 Indigenous cases, 2013: 1
Total deaths, 2013: 0 Indigenous deaths, 2013: 0
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 2010
 ITNs/LLINs distributed to all age groups Yes 2010
IRS IRS is recommended – – 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended Yes –
IPT IPT used to prevent malaria during pregnancy – –
Diagnosis Patients of all ages should receive diagnostic test – –
 Malaria diagnosis is free of charge in the public sector Yes –
Treatment ACT is free for all ages in public sector – –
 Artemisinin-based monotherapies withdrawn – –
 Single dose of primaquine is used as gametocidal medicine for P. falciparum No –
 Primaquine is used for radical treatment of P. vivax Yes –
 G6PD test is a requirement before treatment with primaquine Yes –
 Directly observed treatment with primaquine is undertaken Yes –
 System for monitoring of adverse reactions to antimalarials exists Yes –
II. Intervention policies and strategies
Population 2013 %
Number of active foci 0 
Number of people living within active foci 0 0
Number of people living in malaria-free areas 222 000 100
Total 222 000 
III. Financing Sources of financing Financing by intervention in 2013 
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) Yes –
 ACD of febrile cases at community level (pro-active) No –
 Mass screening is undertaken No –
 Uncomplicated P. falciparum cases routinely admitted Yes –
 Uncomplicated P. vivax cases routinely admitted Yes –
 Foci and case investigation undertaken Yes –
 Case reporting from private sector is mandatory Yes –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria – –
First-line treatment of P. falciparum AL –
Treatment failure of P. falciparum QN –
Treatment of severe malaria – –
Treatment of P. vivax CQ+PQ –
Dosage of primaquine for radical treatment of P. vivax –
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
– – – – – – – –
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Impact: Achieved >75% decrease in case incidence in 2013
V. Impact Malaria test positivity rate and ABER Number of malaria cases 
IV. Coverage ITN and IRS coverage Cases tested
 Cases treated Cases tracked
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Mexico Region of the Americas
I. Epidemiological profile
Parasites and vectors
Major plasmodium species: P. falciparum (1%), P. vivax (99%)
Major anopheles species: An. pseudopunctipennis, An. albimanus, An. darlingi, An. punctimacula, An. punctimacula
Programme phase: Pre-elimination
Total confirmed cases, 2013: 499 Indigenous cases, 2013: 495
Total deaths, 2013: 0 Indigenous deaths, 2013: 0
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 2012
 ITNs/LLINs distributed to all age groups Yes 2012
IRS IRS is recommended No – 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended Yes –
IPT IPT used to prevent malaria during pregnancy N/A –
Diagnosis Patients of all ages should receive diagnostic test Yes –
 Malaria diagnosis is free of charge in the public sector Yes –
Treatment ACT is free for all ages in public sector No –
 Artemisinin-based monotherapies withdrawn – –
 Single dose of primaquine is used as gametocidal medicine for P. falciparum Yes –
 Primaquine is used for radical treatment of P. vivax Yes –
 G6PD test is a requirement before treatment with primaquine No –
 Directly observed treatment with primaquine is undertaken Yes –
 System for monitoring of adverse reactions to antimalarials exists Yes –
II. Intervention policies and strategies
Population 2013 %
Number of active foci 61 
Number of people living within active foci 4 060 000 3
Number of people living in malaria-free areas 118 300 000 97
Total 122 360 000 
III. Financing Sources of financing Financing by intervention in 2013 
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) Yes –
 ACD of febrile cases at community level (pro-active) Yes –
 Mass screening is undertaken Yes –
 Uncomplicated P. falciparum cases routinely admitted Yes –
 Uncomplicated P. vivax cases routinely admitted Yes –
 Foci and case investigation undertaken Yes –
 Case reporting from private sector is mandatory Yes –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria – –
First-line treatment of P. falciparum CQ+PQ –
Treatment failure of P. falciparum AL+QN –
Treatment of severe malaria AL –
Treatment of P. vivax CQ+PQ –
Dosage of primaquine for radical treatment of P. vivax 0.25 mg/kg (14 days)
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
– – – – – – – –
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Impact: Insufficiently consistent data to assess trends
III. Financing Sources of financing Financing by intervention in 2013 
V. Impact  Confirmed malaria cases per 1000 and ABER Malaria admissions and deaths (per 100 000)
IV. Coverage ITN and IRS coverage Cases tested and treated in public sector
 Cases tracked Test positivity
Government Global Fund World Bank USAID/PMI WHO/UNICEF Others
Co
nt
rib
ut
ion
 (U
S$
m
)
0
24
48
72
96
120
Others
WHO_UNICEF
USAID/PMI
Worldbank (USD)
Global Fund (USD)
Malaria expenditure (USD)
20132012201120102009200820072006200520042003200220012000
Po
pu
lat
ion
 (%
)
With access to an ITN (model) All ages who slept under an ITN (survey)
With access to an ITN (survey) At risk protected with IRS
0
20
40
60
80
100
With access to an ITN (model)
All ages who slept under an ITN (survey)
With access to an ITN (survey)
At risk protected with IRS points
At risk protected with IRS
20132012201120102009200820072006200520042003200220012000
(%
)
0
20
40
60
80
100
Estimated cases detected - top
Estimated cases detected - bottom
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
20132012201120102009200820072006200520042003200220012000
% fever cases <5 seeking treatment at public HF (survey) Reporting completeness
Ca
se
s p
er 
10
00
ABER (microscopy & RDT) Cases (P. vivax)Cases (all species)
AB
ER
 (%
)
0
6
12
18
24
30
Aber (microscopy & RDT)
0
24
48
72
96
120
Cases (p.vivax) points
Cases (p.vivax)
Cases (all species) points
Cases (all species)
20132012201120102009200820072006200520042003200220012000
Te
sts
 (%
)
Parasite prevalence (survey) RDT positivity rateSlide positivity rate
0
20
40
60
80
100
Parasite prevalence
Slide positivity rate points
Slide positivity rate
RDT positivity rate points
RDT positivity rate
20132012201120102009200820072006200520042003200220012000
Ad
m
iss
ion
s
Admissions (P. vivax)
De
ath
s
0
6
12
18
24
30
Deaths (P.vivax) points
Deaths (P.vivax)
Deaths (all species) points
Deaths (all species)
0
160
320
480
640
800
Admissions (P.vivax) points
Admissions (P.vivax)
Admissions (all species) points
Admissions (all species)
20132012201120102009200820072006200520042003200220012000
Admissions (all species)
Deaths (all species) Deaths (P. vivax)
Ca
se
s (
%
)
0
20
40
60
80
100
Suspected cases tested
<5 with fever with finger/heel stick (survey)
ACTs as % of all antimalarials received by <5
Primaquine distributed vs reported P.v cases points
Primaquine distributed vs reported P.v cases
ACTs distributed vs reported P.f cases points
ACTs distributed vs reported P.f cases
Antimalarials distributed vs reported cases points
Antimalarials distributed vs reported cases
20132012201120102009200820072006200520042003200220012000
Suspected cases tested
<5 with fever with finger/heel stick (survey)
ACTs as % of all antimalarials received by <5 (survey) Primaquine distributed vs reported  P. v. cases
Antimalarials distributed vs reported cases
ACTs distributed vs reported  P. f. cases
Insecticides & spray materials
ITNs
Diagnostic testing
Antimalarial medicines
Monitoring and evaluation
Human resources & technical assistance
Management and other costs
Management and other costs
Human Resources & technical Assistance
Monitoring and evaluation
Antimalarial medicines
Diagnostics
ITNs
Insecticide & spraying materials
Mozambique African Region
I. Epidemiological profile
Population 2013 %
High transmission (> 1 case per 1000 population) 25 800 000 100
Low transmission (0–1 cases per 1000 population) 0 0
Malaria-free (0 cases) 0 0
Total 25 800 000 
Parasites and vectors
Major plasmodium species: P. falciparum (100%), P. vivax (0%)
Major anopheles species: An. funestus, An. gambiae, An. arabiensis
Programme phase: Control
Reported confirmed cases: 2 998 874 
Reported deaths: 2941 
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes –
 ITNs/LLINs distributed to all age groups Yes –
IRS IRS is recommended Yes – 
 DDT is authorized for IRS Yes –
Larval control Use of larval control recommended – –
IPT IPT used to prevent malaria during pregnancy Yes –
Diagnosis Patients of all ages should receive diagnostic test Yes –
 Malaria diagnosis is free of charge in the public sector Yes –
Treatment ACT is free for all ages in public sector Yes –
 Artemisinin-based monotherapies withdrawn – –
 Single dose of primaquine is used as gametocidal medicine for P. falciparum – –
 Primaquine is used for radical treatment of P. vivax – –
 G6PD test is a requirement before treatment with primaquine – –
 Directly observed treatment with primaquine is undertaken – –
 System for monitoring of adverse reactions to antimalarials exists – –
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) – –
 ACD of febrile cases at community level (pro-active) – –
 Mass screening is undertaken – –
 Uncomplicated P. falciparum cases routinely admitted – –
 Uncomplicated P. vivax cases routinely admitted – –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria AL 2004
First-line treatment of P. falciparum AL 2004
Treatment failure of P. falciparum – –
Treatment of severe malaria QN 2004
Treatment of P. vivax – –
Dosage of primaquine for radical treatment of P. vivax –
Type of RDT used –
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
AL 2005–2012 0 3.1 5.8 28 days 9 P. falciparum
       
       
II. Intervention policies and strategies
Pie chart include 32% 
of total contributions
Funding source(s): USAID/PMI, 
WHO, UNICEF
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Impact: Increase in case incidence 2000-2015
III. Financing Sources of financing Financing by intervention in 2013 
V. Impact  Confirmed malaria cases per 1000 and ABER Malaria admissions and deaths
IV. Coverage ITN and IRS coverage Cases tested and treated in public sector
 Cases tracked Test positivity
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Myanmar South-East Asia Region
I. Epidemiological profile
Population 2013 %
High transmission (> 1 case per 1000 population) 19 700 000 37
Low transmission (0–1 cases per 1000 population) 12 200 000 23
Malaria-free (0 cases) 21 300 000 40
Total 53 200 000 
Parasites and vectors
Major plasmodium species: P. falciparum (74%), P. vivax (26%)
Major anopheles species: An. minimus, An. dirus
Programme phase: Control
Reported confirmed cases: 333 871 
Reported deaths: 236 
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 2003
 ITNs/LLINs distributed to all age groups Yes 2003
IRS IRS is recommended Yes – 
 DDT is authorized for IRS Yes –
Larval control Use of larval control recommended No –
IPT IPT used to prevent malaria during pregnancy N/A –
Diagnosis Patients of all ages should receive diagnostic test Yes –
 Malaria diagnosis is free of charge in the public sector Yes –
Treatment ACT is free for all ages in public sector Yes –
 Artemisinin-based monotherapies withdrawn Yes 2012
 Single dose of primaquine is used as gametocidal medicine for P. falciparum Yes 2010
 Primaquine is used for radical treatment of P. vivax Yes –
 G6PD test is a requirement before treatment with primaquine No –
 Directly observed treatment with primaquine is undertaken No –
 System for monitoring of adverse reactions to antimalarials exists Yes –
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) No –
 ACD of febrile cases at community level (pro-active) No –
 Mass screening is undertaken No –
 Uncomplicated P. falciparum cases routinely admitted No –
 Uncomplicated P. vivax cases routinely admitted No –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria – –
First-line treatment of P. falciparum AL; AM; AS+MQ; DHA-PPQ; PQ 2008
Treatment failure of P. falciparum AS+D; AS+T 2008
Treatment of severe malaria AM; AS; QN 2008
Treatment of P. vivax CQ+PQ(14d) 2008
Dosage of primaquine for radical treatment of P. vivax 0.25 mg/kg (14 days)
Type of RDT used –
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
AL 2007–2013 0 1 6 28 days 20 P. falciparum
AS+MQ 2011–2013 0 0 2.2 42 days 5 P. falciparum
DHA-PPQ 2011–2013 2.5 3.4 4.8 42 days 3 P. falciparum
II. Intervention policies and strategies
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Impact: Achieved >75% decrease in case incidence in 2013
III. Financing Sources of financing Financing by intervention in 2013 
V. Impact  Confirmed malaria cases per 1000 and ABER Malaria admissions and deaths (per 100 000)
IV. Coverage ITN and IRS coverage Cases tested and treated in public sector
 Cases tracked Test positivity
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Namibia African Region
I. Epidemiological profile
Population 2013 %
High transmission (> 1 case per 1000 population) 1 540 000 67
Low transmission (0–1 cases per 1000 population) 115 000 5
Malaria-free (0 cases) 645 000 28
Total 2 300 000 
Parasites and vectors
Major plasmodium species: P. falciparum (100%), P. vivax (0%)
Major anopheles species: An. arabiensis, An. gambiae, An. funestus
Programme phase: Control
Reported confirmed cases: 4911 
Reported deaths: 21 
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 1998
 ITNs/LLINs distributed to all age groups Yes –
IRS IRS is recommended Yes 1965 
 DDT is authorized for IRS Yes 1965
Larval control Use of larval control recommended Yes –
IPT IPT used to prevent malaria during pregnancy Yes 2005
Diagnosis Patients of all ages should receive diagnostic test Yes 2005
 Malaria diagnosis is free of charge in the public sector Yes 1990
Treatment ACT is free for all ages in public sector Yes 2005
 Artemisinin-based monotherapies withdrawn Yes 2005
 Single dose of primaquine is used as gametocidal medicine for P. falciparum No –
 Primaquine is used for radical treatment of P. vivax Yes –
 G6PD test is a requirement before treatment with primaquine No –
 Directly observed treatment with primaquine is undertaken No –
 System for monitoring of adverse reactions to antimalarials exists Yes –
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) Yes 2012
 ACD of febrile cases at community level (pro-active) No –
 Mass screening is undertaken Yes –
 Uncomplicated P. falciparum cases routinely admitted No –
 Uncomplicated P. vivax cases routinely admitted No –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria AL 2006
First-line treatment of P. falciparum AL 2006
Treatment failure of P. falciparum QN 2006
Treatment of severe malaria QN 2006
Treatment of P. vivax AL 2006
Dosage of primaquine for radical treatment of P. vivax –
Type of RDT used P.f + P.v, P.o, P.m (Combo)
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
– – – – – – – –
       
       
II. Intervention policies and strategies
Pie chart include 99% 
of total contributions
Funding source(s): Government, 
Global Fund, WHO
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Impact: Increase in case incidence 2000-2015
III. Financing Sources of financing Financing by intervention in 2013
V. Impact Confirmed malaria cases per 1000 and ABER Malaria admissions and deaths
IV. Coverage ITN and IRS coverage Cases tested and treated in public sector
Cases tracked Test positivity
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Nepal South-East Asia Region
I. Epidemiological profile
Population 2013 %
High transmission (> 1 case per 1000 population) 1 010 000 4
Low transmission (0–1 cases per 1000 population) 12 300 000 44
Malaria-free (0 cases) 14 500 000 52
Total 27 810 000 
Parasites and vectors
Major plasmodium species: P. falciparum (12%), P. vivax (88%)
Major anopheles species: An. fluviatilis, An. annularis, An. maculatus
Programme phase: Control
Reported confirmed cases: 1974 
Reported deaths: 0 
Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 2007
ITNs/LLINs distributed to all age groups Yes 2007
IRS IRS is recommended Yes 1962 
DDT is authorized for IRS No –
Larval control Use of larval control recommended No –
IPT IPT used to prevent malaria during pregnancy N/A –
Diagnosis Patients of all ages should receive diagnostic test Yes –
Malaria diagnosis is free of charge in the public sector Yes 1962
Treatment ACT is free for all ages in public sector Yes 2005
Artemisinin-based monotherapies withdrawn – –
Single dose of primaquine is used as gametocidal medicine for P. falciparum – –
Primaquine is used for radical treatment of P. vivax Yes –
G6PD test is a requirement before treatment with primaquine No –
Directly observed treatment with primaquine is undertaken – –
System for monitoring of adverse reactions to antimalarials exists Yes –
Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) Yes –
ACD of febrile cases at community level (pro-active) No –
Mass screening is undertaken No –
Uncomplicated P. falciparum cases routinely admitted No –
Uncomplicated P. vivax cases routinely admitted No –
 Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria CQ –
First-line treatment of P. falciparum AL+PQ 2004
Treatment failure of P. falciparum AS; QN –
Treatment of severe malaria AS; QN –
Treatment of P. vivax CQ+PQ(14d) 2004
Dosage of primaquine for radical treatment of P. vivax 3.75 mg -15 mg/day (2 weeks)
Type of RDT used P.f + P.v specific (Combo)
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
AL 2005–2011 0 0 0 28 days 8 P. falciparum
CQ 2008–2011 0 0 0 28 days 8 P. vivax
II. Intervention policies and strategies
Pie chart include 89% 
of total contributions
Funding source(s): Government, 
Global Fund, WHO
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Impact: Achieved >75% decrease in case incidence in 2013
III. Financing Sources of financing Financing by intervention in 2013 
V. Impact  Confirmed malaria cases per 1000 and ABER Malaria admissions and deaths
IV. Coverage ITN and IRS coverage Cases tested and treated in public sector
 Cases tracked Test positivity
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Nicaragua Region of the Americas
I. Epidemiological profile
Population 2013 %
High transmission (> 1 case per 1000 population) 79 000 1
Low transmission (0–1 cases per 1000 population) 2 970 000 49
Malaria-free (0 cases) 3 030 000 50
Total 6 079 000 
Parasites and vectors
Major plasmodium species: P. falciparum (18%), P. vivax (82%)
Major anopheles species: An. albimanus, An. pseudopunctipennis
Programme phase: Control
Reported confirmed cases: 1194 
Reported deaths: 0 
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 2004
 ITNs/LLINs distributed to all age groups Yes 2004
IRS IRS is recommended Yes 1959 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended Yes –
IPT IPT used to prevent malaria during pregnancy N/A –
Diagnosis Patients of all ages should receive diagnostic test Yes –
 Malaria diagnosis is free of charge in the public sector Yes –
Treatment ACT is free for all ages in public sector Yes –
 Artemisinin-based monotherapies withdrawn No –
 Single dose of primaquine is used as gametocidal medicine for P. falciparum Yes 2013
 Primaquine is used for radical treatment of P. vivax Yes –
 G6PD test is a requirement before treatment with primaquine No –
 Directly observed treatment with primaquine is undertaken Yes –
 System for monitoring of adverse reactions to antimalarials exists No –
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) Yes –
 ACD of febrile cases at community level (pro-active) Yes –
 Mass screening is undertaken Yes –
 Uncomplicated P. falciparum cases routinely admitted Yes –
 Uncomplicated P. vivax cases routinely admitted No –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria – –
First-line treatment of P. falciparum CQ+PQ(1d) –
Treatment failure of P. falciparum AS+MQ; AS+SP –
Treatment of severe malaria QN –
Treatment of P. vivax CQ+PQ(7d) –
Dosage of primaquine for radical treatment of P. vivax 0.50 mg/kg (7 days)
Type of RDT used P.f + P.v specific (Combo)
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
– – – – – – – –
       
       
II. Intervention policies and strategies
Pie chart include 100% 
of total contributions
Funding source(s): Government, 
Global Fund, USAID/PMI
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Impact: Insufficiently consistent data to assess trends
III. Financing Sources of financing Financing by intervention in 2013 
V. Impact  Confirmed malaria cases per 1000 and ABER Malaria admissions and deaths (per 100 000)
IV. Coverage ITN and IRS coverage Cases tested and treated in public sector
 Cases tracked Test positivity
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Niger African Region
I. Epidemiological profile
Population 2013 %
High transmission (> 1 case per 1000 population) 12 300 000 69
Low transmission (0–1 cases per 1000 population) 5 530 000 31
Malaria-free (0 cases) 0 0
Total 17 830 000 
Parasites and vectors
Major plasmodium species: P. falciparum (98%), P. vivax (0%)
Major anopheles species: An. gambiae, An. funestus, An. arabiensis
Programme phase: Control
Reported confirmed cases: 1 431 798 
Reported deaths: 2209 
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 2005
 ITNs/LLINs distributed to all age groups No –
IRS IRS is recommended Yes 2003 
 DDT is authorized for IRS Yes –
Larval control Use of larval control recommended Yes 2010
IPT IPT used to prevent malaria during pregnancy Yes 2005
Diagnosis Patients of all ages should receive diagnostic test Yes 2010
 Malaria diagnosis is free of charge in the public sector Yes –
Treatment ACT is free for all ages in public sector No –
 Artemisinin-based monotherapies withdrawn Yes –
 Single dose of primaquine is used as gametocidal medicine for P. falciparum No –
 Primaquine is used for radical treatment of P. vivax No –
 G6PD test is a requirement before treatment with primaquine – –
 Directly observed treatment with primaquine is undertaken No –
 System for monitoring of adverse reactions to antimalarials exists Yes –
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) No –
 ACD of febrile cases at community level (pro-active) No –
 Mass screening is undertaken No –
 Uncomplicated P. falciparum cases routinely admitted Yes –
 Uncomplicated P. vivax cases routinely admitted No –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria AL 2005
First-line treatment of P. falciparum AL 2005
Treatment failure of P. falciparum QN 2005
Treatment of severe malaria QN 2005
Treatment of P. vivax – –
Dosage of primaquine for radical treatment of P. vivax –
Type of RDT used P.f only
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
AL 2005–2011 3.7 5.55 10.4 28 days 6 P. falciparum
       
       
II. Intervention policies and strategies
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Impact: Insufficiently consistent data to assess trends
III. Financing Sources of financing Financing by intervention in 2013 
V. Impact  Confirmed malaria cases per 1000 and ABER Malaria admissions and deaths (per 100 000)
IV. Coverage ITN and IRS coverage Cases tested and treated in public sector
 Cases tracked Test positivity
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Nigeria African Region
I. Epidemiological profile
Population 2013 %
High transmission (> 1 case per 1000 population) 173 600 000 100
Low transmission (0–1 cases per 1000 population) 0 0
Malaria-free (0 cases) 0 0
Total 173 600 000 
Parasites and vectors
Major plasmodium species: P. falciparum (100%), P. vivax (0%)
Major anopheles species: An. gambiae, An. funestus, An. arabiensis, An. moucheti, An. melas, An. nili
Programme phase: Control
Reported confirmed cases:  
Reported deaths: 7878 
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 2001
 ITNs/LLINs distributed to all age groups Yes 2009
IRS IRS is recommended Yes 2007 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended Yes 2010
IPT IPT used to prevent malaria during pregnancy Yes 2004
Diagnosis Patients of all ages should receive diagnostic test Yes 2010
 Malaria diagnosis is free of charge in the public sector Yes –
Treatment ACT is free for all ages in public sector Yes 2009
 Artemisinin-based monotherapies withdrawn Yes –
 Single dose of primaquine is used as gametocidal medicine for P. falciparum No –
 Primaquine is used for radical treatment of P. vivax No –
 G6PD test is a requirement before treatment with primaquine No –
 Directly observed treatment with primaquine is undertaken No –
 System for monitoring of adverse reactions to antimalarials exists Yes –
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) No –
 ACD of febrile cases at community level (pro-active) No –
 Mass screening is undertaken No –
 Uncomplicated P. falciparum cases routinely admitted No –
 Uncomplicated P. vivax cases routinely admitted No –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria AL; AS+AQ 2004
First-line treatment of P. falciparum AL; AS+AQ 2004
Treatment failure of P. falciparum QN 2004
Treatment of severe malaria AM; AS; QN 2004
Treatment of P. vivax – –
Dosage of primaquine for radical treatment of P. vivax –
Type of RDT used P.f + all species (Combo)
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
– – – – – – – –
       
       
II. Intervention policies and strategies
Pie chart include 16% 
of total contributions
Funding source(s): Global Fund
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Impact: Insufficiently consistent data to assess trends
III. Financing Sources of financing Financing by intervention in 2013 
V. Impact  Confirmed malaria cases per 1000 and ABER Malaria admissions and deaths
IV. Coverage ITN and IRS coverage Cases tested and treated in public sector
 Cases tracked Test positivity
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Pakistan Eastern Mediterranean Region
I. Epidemiological profile
Population 2013 %
High transmission (> 1 case per 1000 population) 52 700 000 29
Low transmission (0–1 cases per 1000 population) 126 400 000 69
Malaria-free (0 cases) 3 080 000 2
Total 182 180 000 
Parasites and vectors
Major plasmodium species: P. falciparum (17%), P. vivax (83%)
Major anopheles species: An. culicifacies, An. stephensi
Programme phase: Control
Reported confirmed cases: 281 755 
Reported deaths: 244 
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 2008
 ITNs/LLINs distributed to all age groups No 2008
IRS IRS is recommended Yes 1961 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended Yes 1961
IPT IPT used to prevent malaria during pregnancy N/A –
Diagnosis Patients of all ages should receive diagnostic test Yes 2011
 Malaria diagnosis is free of charge in the public sector Yes 1961
Treatment ACT is free for all ages in public sector Yes 2009
 Artemisinin-based monotherapies withdrawn Yes 2009
 Single dose of primaquine is used as gametocidal medicine for P. falciparum Yes 2012
 Primaquine is used for radical treatment of P. vivax Yes 2009
 G6PD test is a requirement before treatment with primaquine Yes 2009
 Directly observed treatment with primaquine is undertaken No –
 System for monitoring of adverse reactions to antimalarials exists No –
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) No –
 ACD of febrile cases at community level (pro-active) No –
 Mass screening is undertaken No –
 Uncomplicated P. falciparum cases routinely admitted No –
 Uncomplicated P. vivax cases routinely admitted No –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria CQ –
First-line treatment of P. falciparum AS+SP+PQ 2013
Treatment failure of P. falciparum AL; QN 2013
Treatment of severe malaria AS; QN 2007
Treatment of P. vivax CQ+PQ(14d) 2007
Dosage of primaquine for radical treatment of P. vivax 0.25 mg/kg (14 days)
Type of RDT used P.f + P.v specific (Combo)
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
AL 2012–2013 0 0.6 1.2 28 days 2 P. falciparum
AS+SP 2007–2012 0 0 1.5 28 days 9 P. falciparum
       
II. Intervention policies and strategies
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Impact: On track for 50%-75% decrease in case incidence 2000-2015
III. Financing Sources of financing Financing by intervention in 2013 
V. Impact  Confirmed malaria cases per 1000 and ABER Malaria admissions and deaths
IV. Coverage ITN and IRS coverage Cases tested and treated in public sector
 Cases tracked Test positivity
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Panama Region of the Americas
I. Epidemiological profile
Population 2013 %
High transmission (> 1 case per 1000 population) 170 000 4
Low transmission (0–1 cases per 1000 population) 2 750 000 71
Malaria-free (0 cases) 943 000 24
Total 3 863 000 
Parasites and vectors
Major plasmodium species: P. falciparum (1%), P. vivax (99%)
Major anopheles species: An. albimanus, An. pseudopunctipennis, An. punctimacula, An. aquasalis, An. darlingi
Programme phase: Control
Reported confirmed cases: 705 
Reported deaths: 0 
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes –
 ITNs/LLINs distributed to all age groups No –
IRS IRS is recommended Yes 1957 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended Yes 1957
IPT IPT used to prevent malaria during pregnancy N/A –
Diagnosis Patients of all ages should receive diagnostic test Yes 1957
 Malaria diagnosis is free of charge in the public sector Yes 1957
Treatment ACT is free for all ages in public sector Yes –
 Artemisinin-based monotherapies withdrawn No –
 Single dose of primaquine is used as gametocidal medicine for P. falciparum Yes –
 Primaquine is used for radical treatment of P. vivax Yes –
 G6PD test is a requirement before treatment with primaquine No –
 Directly observed treatment with primaquine is undertaken Yes –
 System for monitoring of adverse reactions to antimalarials exists No –
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) Yes –
 ACD of febrile cases at community level (pro-active) Yes –
 Mass screening is undertaken Yes –
 Uncomplicated P. falciparum cases routinely admitted No –
 Uncomplicated P. vivax cases routinely admitted No –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria – –
First-line treatment of P. falciparum AL+PQ(1d) 2012
Treatment failure of P. falciparum – –
Treatment of severe malaria QN –
Treatment of P. vivax CQ+PQ(7d); CQ+PQ(14d) –
Dosage of primaquine for radical treatment of P. vivax 0.25 mg/kg (14 days)
Type of RDT used –
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
– – – – – – – –
       
       
II. Intervention policies and strategies
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Impact: Increase in case incidence 2000-2015
III. Financing Sources of financing Financing by intervention in 2013 
V. Impact  Confirmed malaria cases per 1000 and ABER Malaria admissions and deaths
IV. Coverage ITN and IRS coverage Cases tested and treated in public sector
 Cases tracked Test positivity
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Papua New Guinea Western Pacific Region
I. Epidemiological profile
Population 2013 %
High transmission (> 1 case per 1000 population) 6 880 000 94
Low transmission (0–1 cases per 1000 population) 439 000 6
Malaria-free (0 cases) 0 0
Total 7 319 000 
Parasites and vectors
Major plasmodium species: P. falciparum (87%), P. vivax (11%)
Major anopheles species: An. punctulatus, An. farauti, An. koliensis
Programme phase: Control
Reported confirmed cases: 279 994 
Reported deaths: 307 
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 2004
 ITNs/LLINs distributed to all age groups Yes 2005
IRS IRS is recommended Yes 2000 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended No –
IPT IPT used to prevent malaria during pregnancy N/A 2010
Diagnosis Patients of all ages should receive diagnostic test Yes 2010
 Malaria diagnosis is free of charge in the public sector Yes 2004
Treatment ACT is free for all ages in public sector Yes 2010
 Artemisinin-based monotherapies withdrawn Yes 2012
 Single dose of primaquine is used as gametocidal medicine for P. falciparum No –
 Primaquine is used for radical treatment of P. vivax Yes 2009
 G6PD test is a requirement before treatment with primaquine No –
 Directly observed treatment with primaquine is undertaken No –
 System for monitoring of adverse reactions to antimalarials exists Yes 2000
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) No –
 ACD of febrile cases at community level (pro-active) No –
 Mass screening is undertaken No –
 Uncomplicated P. falciparum cases routinely admitted No –
 Uncomplicated P. vivax cases routinely admitted No –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria AL 2008
First-line treatment of P. falciparum DHA-PPQ 2008
Treatment failure of P. falciparum AM; AS 2008
Treatment of severe malaria AL+PQ 2009
Treatment of P. vivax AL; QN –
Dosage of primaquine for radical treatment of P. vivax 7.5 mg - adult (14 days)
Type of RDT used P.f + P.v, P.o, P.m (Combo)
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
AL 2005–2007 2.7 2.7 2.7 28 days 1 P. falciparum
DHA-PPQ 2005–2007 12 12 12 42 days 1 P. falciparum
       
II. Intervention policies and strategies
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Impact: Achieved >75% decrease in case incidence in 2013
V. Impact Malaria test positivity rate and ABER Number of malaria cases 
IV. Coverage ITN and IRS coverage Cases tested
 Cases treated Cases tracked
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Paraguay Region of the Americas
I. Epidemiological profile
Parasites and vectors
Major plasmodium species: P. falciparum (0%), P. vivax (0%)
Major anopheles species: An. darlingi, An. albitarsis
Programme phase: Elimination
Total confirmed cases, 2013: 11 Indigenous cases, 2013: 0
Total deaths, 2013: 0 Indigenous deaths, 2013: 0
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge No –
 ITNs/LLINs distributed to all age groups No –
IRS IRS is recommended Yes 1957 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended No –
IPT IPT used to prevent malaria during pregnancy N/A –
Diagnosis Patients of all ages should receive diagnostic test Yes 1957
 Malaria diagnosis is free of charge in the public sector Yes 1957
Treatment ACT is free for all ages in public sector Yes 2005
 Artemisinin-based monotherapies withdrawn – –
 Single dose of primaquine is used as gametocidal medicine for P. falciparum Yes –
 Primaquine is used for radical treatment of P. vivax Yes 1957
 G6PD test is a requirement before treatment with primaquine No –
 Directly observed treatment with primaquine is undertaken – –
 System for monitoring of adverse reactions to antimalarials exists No –
II. Intervention policies and strategies
Pie chart include 100% 
of total contributions
Funding source(s): Government
Population 2013 %
Number of active foci 0 
Number of people living within active foci 1 060 000 16
Number of people living in malaria-free areas 5 740 000 84
Total 6 800 000 
III. Financing Sources of financing Financing by intervention in 2013 
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) Yes 1957
 ACD of febrile cases at community level (pro-active) Yes 1957
 Mass screening is undertaken No –
 Uncomplicated P. falciparum cases routinely admitted Yes 1957
 Uncomplicated P. vivax cases routinely admitted Yes 1957
 Foci and case investigation undertaken Yes 1957
 Case reporting from private sector is mandatory No –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria – –
First-line treatment of P. falciparum AL+PQ –
Treatment failure of P. falciparum – –
Treatment of severe malaria AS –
Treatment of P. vivax CQ+PQ –
Dosage of primaquine for radical treatment of P. vivax 0.25mk/kg (14days)
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
– – – – – – – –
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Impact: On track for 50%-75% decrease in case incidence 2000-2015
III. Financing Sources of financing Financing by intervention in 2013 
V. Impact  Confirmed malaria cases per 1000 and ABER Malaria admissions and deaths
IV. Coverage ITN and IRS coverage Cases tested and treated in public sector
 Cases tracked Test positivity
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Peru Region of the Americas
I. Epidemiological profile
Population 2013 %
High transmission (> 1 case per 1000 population) 1 370 000 5
Low transmission (0–1 cases per 1000 population) 3 490 000 12
Malaria-free (0 cases) 25 500 000 84
Total 30 360 000 
Parasites and vectors
Major plasmodium species: P. falciparum (16%), P. vivax (84%)
Major anopheles species: An. pseudopunctipennis, An. albimanus, An. darlingi
Programme phase: Control
Reported confirmed cases: 43 468 
Reported deaths: 4 
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes –
 ITNs/LLINs distributed to all age groups Yes –
IRS IRS is recommended Yes – 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended No –
IPT IPT used to prevent malaria during pregnancy N/A –
Diagnosis Patients of all ages should receive diagnostic test Yes –
 Malaria diagnosis is free of charge in the public sector Yes –
Treatment ACT is free for all ages in public sector Yes –
 Artemisinin-based monotherapies withdrawn Yes –
 Single dose of primaquine is used as gametocidal medicine for P. falciparum No –
 Primaquine is used for radical treatment of P. vivax Yes –
 G6PD test is a requirement before treatment with primaquine No –
 Directly observed treatment with primaquine is undertaken Yes –
 System for monitoring of adverse reactions to antimalarials exists Yes –
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) Yes –
 ACD of febrile cases at community level (pro-active) Yes –
 Mass screening is undertaken Yes –
 Uncomplicated P. falciparum cases routinely admitted Yes –
 Uncomplicated P. vivax cases routinely admitted Yes –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria – –
First-line treatment of P. falciparum AS+MQ 2001
Treatment failure of P. falciparum – –
Treatment of severe malaria AS+MQ –
Treatment of P. vivax CQ+PQ(7d) –
Dosage of primaquine for radical treatment of P. vivax 0.50 mg/kg (7 days)
Type of RDT used –
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
AS+MQ 2005–2006 1.1 1.1 1.1 28 days 1 P. falciparum
CQ+PQ 2006–2008 0.5 0.6 1.1 28 days 3 P. vivax
       
II. Intervention policies and strategies
Pie chart include 12% 
of total contributions
Funding source(s): USAID/PMI
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Impact: Achieved >75% decrease in case incidence in 2013
III. Financing Sources of financing Financing by intervention in 2013 
V. Impact  Confirmed malaria cases per 1000 and ABER Malaria admissions and deaths
IV. Coverage ITN and IRS coverage Cases tested and treated in public sector
 Cases tracked Test positivity
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Philippines Western Pacific Region
I. Epidemiological profile
Population 2013 %
High transmission (> 1 case per 1000 population) 7 060 000 7
Low transmission (0–1 cases per 1000 population) 71 400 000 73
Malaria-free (0 cases) 19 900 000 20
Total 98 360 000 
Parasites and vectors
Major plasmodium species: P. falciparum (79%), P. vivax (20%)
Major anopheles species: An. flavirostris, An. maculatus, An. balabacensis, An. litoralis
Programme phase: Control
Reported confirmed cases: 6514 
Reported deaths: 12 
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 2006
 ITNs/LLINs distributed to all age groups Yes 2000
IRS IRS is recommended Yes 2002 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended Yes –
IPT IPT used to prevent malaria during pregnancy N/A –
Diagnosis Patients of all ages should receive diagnostic test Yes 2004
 Malaria diagnosis is free of charge in the public sector Yes 2003
Treatment ACT is free for all ages in public sector Yes 2003
 Artemisinin-based monotherapies withdrawn Yes 2003
 Single dose of primaquine is used as gametocidal medicine for P. falciparum Yes 2006
 Primaquine is used for radical treatment of P. vivax Yes 2007
 G6PD test is a requirement before treatment with primaquine Yes 2011
 Directly observed treatment with primaquine is undertaken Yes 2010
 System for monitoring of adverse reactions to antimalarials exists Yes 2009
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) Yes 2009
 ACD of febrile cases at community level (pro-active) No –
 Mass screening is undertaken Yes 2009
 Uncomplicated P. falciparum cases routinely admitted No –
 Uncomplicated P. vivax cases routinely admitted No –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria AL 2009
First-line treatment of P. falciparum AL+PQ 2009
Treatment failure of P. falciparum QN+CL; QN+D; QN+T 2002
Treatment of severe malaria QN+T 2002
Treatment of P. vivax CQ+PQ(14d) 2002
Dosage of primaquine for radical treatment of P. vivax 0.50 mg/kg (14 days)
Type of RDT used P.f + P.v specific (Combo)
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
CQ 2005–2010 0 0 0 28 days 2 P. vivax
       
       
II. Intervention policies and strategies
Pie chart include 86% 
of total contributions
Funding source(s): Government, 
Global Fund, WHO
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Impact: Achieved >75% decrease in case incidence in 2013
V. Impact Malaria test positivity rate and ABER Number of malaria cases 
IV. Coverage ITN and IRS coverage Cases tested
 Cases treated Cases tracked
Government Global Fund World Bank USAID/PMI WHO/UNICEF Others
Co
nt
rib
ut
ion
 (U
S$
m
)
0
1
2
3
4
5
Others
WHO_UNICEF
USAID/PMI
Worldbank (USD)
Global Fund (USD)
Malaria expenditure (USD)
20132012201120102009200820072006200520042003200220012000
Po
pu
lat
ion
 (%
)
At high risk protected with ITNs
Households with at least one ITN
All ages who slept under an ITN (survey)
At high risk protected with IRS
0
20
40
60
80
100
At high risk protected with ITNs
All ages who slept under an ITN (survey)
Households with at least one ITN
At high risk protected with IRS Points
At high risk protected with IRS
20132012201120102009200820072006200520042003200220012000
Ca
se
s (
%
)
0
20
40
60
80
100
ACTs as % of all antimalarials received by <5 (survey)
Antimalarials distributed vs reported cases
Primaquine distributed vs reported P.vivax cases
ACTs distributed vs reported P.falciparum cases points
ACTs distributed vs reported P.falciparum cases
20132012201120102009200820072006200520042003200220012000
Antimalarials distributed vs reported cases ACTs distributed vs reported P. falciparum cases
Primaquine distributed vs reported P. v cases ACTs as % of all antimalarials received by <5 (survey)
 (%
)
Reporting completeness Foci investigatedCases investigated
0
20
40
60
80
100
Reporting completeness
Foci investigated
Cases investigated points
Cases investigated
20132012201120102009200820072006200520042003200220012000
Ca
se
s 
0
1000
2000
3000
4000
5000
Imported cases points
Imported cases
Indigenous (P.vivax) points
Indigenous (P.vivax)
Total cases points
Total cases
Indigenous (P.falciparum) points
Indigenous (P.falciparum)
20132012201120102009200820072006200520042003200220012000
Total cases
Indigenous cases  (P.  falciparum)
Imported cases
Indigenous cases (P. vivax)
Insecticides & spray materials
ITNs
Diagnostic testing
Antimalarial medicines
Monitoring and evaluation
Human resources & technical assistance
Management and other costs
Management and other costs
Human Resources & technical Assistance
Monitoring and evaluation
Antimalarial medicines
Diagnostics
ITNs
Insecticide & spraying materials
Republic of Korea Western Pacific Region
I. Epidemiological profile
Parasites and vectors
Major plasmodium species: P. falciparum (0%), P. vivax (100%)
Major anopheles species: An. sinensis
Programme phase: Elimination
Total confirmed cases, 2013: 443 Indigenous cases, 2013: 383
Total deaths, 2013: 2 Indigenous deaths, 2013: 0
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 2001
 ITNs/LLINs distributed to all age groups No –
IRS IRS is recommended – – 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended Yes 2001
IPT IPT used to prevent malaria during pregnancy N/A –
Diagnosis Patients of all ages should receive diagnostic test – –
 Malaria diagnosis is free of charge in the public sector Yes 2001
Treatment ACT is free for all ages in public sector – –
 Artemisinin-based monotherapies withdrawn – –
 Single dose of primaquine is used as gametocidal medicine for P. falciparum No –
 Primaquine is used for radical treatment of P. vivax Yes 2001
 G6PD test is a requirement before treatment with primaquine No –
 Directly observed treatment with primaquine is undertaken No –
 System for monitoring of adverse reactions to antimalarials exists Yes 2011
II. Intervention policies and strategies
Pie chart include 97% 
of total contributions
Funding source(s): Government
Population 2013 %
Number of active foci 25 
Number of people living within active foci 5 630 000 11
Number of people living in malaria-free areas 43 600 000 89
Total 49 230 000 
III. Financing Sources of financing Financing by intervention in 2013 
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) No –
 ACD of febrile cases at community level (pro-active) No –
 Mass screening is undertaken No –
 Uncomplicated P. falciparum cases routinely admitted No –
 Uncomplicated P. vivax cases routinely admitted Yes 2001
 Foci and case investigation undertaken Yes 2001
 Case reporting from private sector is mandatory Yes 2001
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria CQ –
First-line treatment of P. falciparum – –
Treatment failure of P. falciparum – –
Treatment of severe malaria – –
Treatment of P. vivax CQ+PQ(14d) –
Dosage of primaquine for radical treatment of P. vivax 0.25 mg/kg (14 days)
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
– – – – – – – –
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Impact: Achieved >75% decrease in case incidence in 2013
III. Financing Sources of financing Financing by intervention in 2013 
V. Impact  Confirmed malaria cases per 1000 and ABER Malaria admissions and deaths (per 100 000)
IV. Coverage ITN and IRS coverage Cases tested and treated in public sector
 Cases tracked Test positivity
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Rwanda African Region
I. Epidemiological profile
Population 2013 %
High transmission (> 1 case per 1000 population) 11 800 000 100
Low transmission (0–1 cases per 1000 population) 0 0
Malaria-free (0 cases) 0 0
Total 11 800 000 
Parasites and vectors
Major plasmodium species: P. falciparum (100%), P. vivax (0%)
Major anopheles species: An. gambiae, An. funestus, An. arabiensis
Programme phase: Control
Reported confirmed cases: 962 618 
Reported deaths: 409 
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 2004
 ITNs/LLINs distributed to all age groups No –
IRS IRS is recommended Yes 2009 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended No –
IPT IPT used to prevent malaria during pregnancy No –
Diagnosis Patients of all ages should receive diagnostic test Yes 2009
 Malaria diagnosis is free of charge in the public sector No –
Treatment ACT is free for all ages in public sector No –
 Artemisinin-based monotherapies withdrawn – –
 Single dose of primaquine is used as gametocidal medicine for P. falciparum No –
 Primaquine is used for radical treatment of P. vivax No –
 G6PD test is a requirement before treatment with primaquine No –
 Directly observed treatment with primaquine is undertaken No –
 System for monitoring of adverse reactions to antimalarials exists No –
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) No –
 ACD of febrile cases at community level (pro-active) No –
 Mass screening is undertaken No –
 Uncomplicated P. falciparum cases routinely admitted No –
 Uncomplicated P. vivax cases routinely admitted No –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria AL 2005
First-line treatment of P. falciparum AL 2005
Treatment failure of P. falciparum QN 2005
Treatment of severe malaria AS 2012
Treatment of P. vivax – –
Dosage of primaquine for radical treatment of P. vivax –
Type of RDT used P.f + all species (Combo)
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
AL 2006–2009 0 1.3 4.5 28 days 3 P. falciparum
       
       
II. Intervention policies and strategies
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Impact: Achieved >75% decrease in case incidence in 2013
III. Financing Sources of financing Financing by intervention in 2013 
V. Impact  Confirmed malaria cases per 1000 and ABER Malaria admissions and deaths (per 100 000)
IV. Coverage ITN and IRS coverage Cases tested and treated in public sector
 Cases tracked Test positivity
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Sao Tome and Principe African Region
I. Epidemiological profile
Population 2013 %
High transmission (> 1 case per 1000 population) 193 000 100
Low transmission (0–1 cases per 1000 population) 0 0
Malaria-free (0 cases) 0 0
Total 193 000 
Parasites and vectors
Major plasmodium species: P. falciparum (100%), P. vivax (0%)
Major anopheles species: An. gambiae
Programme phase: Control
Reported confirmed cases: 9243 
Reported deaths: 11 
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 2005
 ITNs/LLINs distributed to all age groups Yes 2008
IRS IRS is recommended Yes 2003 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended Yes 2004
IPT IPT used to prevent malaria during pregnancy Yes 2004
Diagnosis Patients of all ages should receive diagnostic test Yes 2001
 Malaria diagnosis is free of charge in the public sector Yes 2008
Treatment ACT is free for all ages in public sector Yes 2008
 Artemisinin-based monotherapies withdrawn No –
 Single dose of primaquine is used as gametocidal medicine for P. falciparum Yes 2013
 Primaquine is used for radical treatment of P. vivax Yes 2013
 G6PD test is a requirement before treatment with primaquine No –
 Directly observed treatment with primaquine is undertaken Yes 2013
 System for monitoring of adverse reactions to antimalarials exists No –
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) Yes 2008
 ACD of febrile cases at community level (pro-active) Yes 2013
 Mass screening is undertaken No –
 Uncomplicated P. falciparum cases routinely admitted No –
 Uncomplicated P. vivax cases routinely admitted No –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria AS+AQ 2004
First-line treatment of P. falciparum AS+AQ 2004
Treatment failure of P. falciparum AL 2004
Treatment of severe malaria QN 2004
Treatment of P. vivax – –
Dosage of primaquine for radical treatment of P. vivax 0.25 mg/kg (14 days)
Type of RDT used –
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
– – – – – – – –
       
       
II. Intervention policies and strategies
Pie chart include 100% 
of total contributions
Funding source(s): Government, 
Global Fund, USAID/PMI, World 
Bank, WHO, UNICEF, Other 
(bilateral), Other (all types)
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Impact: Achieved >75% decrease in case incidence in 2013
V. Impact Malaria test positivity rate and ABER Number of malaria cases 
IV. Coverage ITN and IRS coverage Cases tested
 Cases treated Cases tracked
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Saudi Arabia Eastern Mediterranean Region
I. Epidemiological profile
Parasites and vectors
Major plasmodium species: P. falciparum (100%), P. vivax (0%)
Major anopheles species: An. arabiensis, An. sergentii, An. stephensi, An. fluviatilis, An. multicolor
Programme phase: Elimination
Total confirmed cases, 2013: 2513 Indigenous cases, 2013: 34
Total deaths, 2013:  Indigenous deaths, 2013: 0
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 1980
 ITNs/LLINs distributed to all age groups Yes 1980
IRS IRS is recommended Yes – 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended Yes –
IPT IPT used to prevent malaria during pregnancy N/A –
Diagnosis Patients of all ages should receive diagnostic test Yes –
 Malaria diagnosis is free of charge in the public sector Yes 1963
Treatment ACT is free for all ages in public sector – –
 Artemisinin-based monotherapies withdrawn – –
 Single dose of primaquine is used as gametocidal medicine for P. falciparum Yes 1985
 Primaquine is used for radical treatment of P. vivax Yes –
 G6PD test is a requirement before treatment with primaquine Yes 1985
 Directly observed treatment with primaquine is undertaken No –
 System for monitoring of adverse reactions to antimalarials exists Yes 1990
II. Intervention policies and strategies
Population 2013 %
Number of active foci 29 
Number of people living within active foci 40 400 0
Number of people living in malaria-free areas 28 800 000 100
Total 28 840 400 
III. Financing Sources of financing Financing by intervention in 2013 
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) Yes 1980
 ACD of febrile cases at community level (pro-active) Yes 1980
 Mass screening is undertaken No –
 Uncomplicated P. falciparum cases routinely admitted No –
 Uncomplicated P. vivax cases routinely admitted No –
 Foci and case investigation undertaken Yes 1990
 Case reporting from private sector is mandatory No –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria – –
First-line treatment of P. falciparum AS+SP+PQ 2012
Treatment failure of P. falciparum AL 2007
Treatment of severe malaria AM; AS; QN 2007
Treatment of P. vivax CQ+PQ(14d) –
Dosage of primaquine for radical treatment of P. vivax 0.25 mg/kg (14 days)
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
– – – – – – – –
       
       
Insucient data
0
0–0.1
0.1–1.0
1.0–10
PP
>75
0
no cases
Insucient data
Very low PP
0–20
20–40
40–60
60–80
80–100
PR
OTHERS
PF-RATIO
Proportion of cases 
due to P. falciparum
Insucient data
0
0–0.1
0.1–1.0
1.0–10
PP
>75
0
no cases
Insucient data
Very low PP
0–20
20–40
40–60
60–80
80–100
PR
OTHERS
PF-RATIO
Confirmed cases  
per 1000 population/
Parasite prevalence 
(PP)
No data reported for 2013
142 | WORLD MALARIA REPORT 2014
Impact: Insufficiently consistent data to assess trends
III. Financing Sources of financing Financing by intervention in 2013 
V. Impact  Confirmed malaria cases per 1000 and ABER Malaria admissions and deaths (per 100 000)
IV. Coverage ITN and IRS coverage Cases tested and treated in public sector
 Cases tracked Test positivity
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Senegal African Region
I. Epidemiological profile
Population 2013 %
High transmission (> 1 case per 1000 population) 13 600 000 96
Low transmission (0–1 cases per 1000 population) 565 000 4
Malaria-free (0 cases) 0 0
Total 14 165 000 
Parasites and vectors
Major plasmodium species: P. falciparum (100%), P. vivax (0%)
Major anopheles species: An. gambiae, An. arabiensis, An. funestus, An. pharoensis, An. melas
Programme phase: Control
Reported confirmed cases: 345 889 
Reported deaths: 815 
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 1998
 ITNs/LLINs distributed to all age groups Yes 1998
IRS IRS is recommended Yes 2005 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended Yes 2010
IPT IPT used to prevent malaria during pregnancy Yes 2003
Diagnosis Patients of all ages should receive diagnostic test Yes 2007
 Malaria diagnosis is free of charge in the public sector Yes 2007
Treatment ACT is free for all ages in public sector Yes 2010
 Artemisinin-based monotherapies withdrawn Yes 2010
 Single dose of primaquine is used as gametocidal medicine for P. falciparum No –
 Primaquine is used for radical treatment of P. vivax No –
 G6PD test is a requirement before treatment with primaquine No –
 Directly observed treatment with primaquine is undertaken No –
 System for monitoring of adverse reactions to antimalarials exists Yes 2007
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) Yes 2012
 ACD of febrile cases at community level (pro-active) Yes 2012
 Mass screening is undertaken No –
 Uncomplicated P. falciparum cases routinely admitted No –
 Uncomplicated P. vivax cases routinely admitted No –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria AS+AQ 2005
First-line treatment of P. falciparum AL; AS+AQ 2005
Treatment failure of P. falciparum – –
Treatment of severe malaria QN 2005
Treatment of P. vivax – –
Dosage of primaquine for radical treatment of P. vivax –
Type of RDT used P.f only
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
– – – – – – – –
       
       
II. Intervention policies and strategies
Pie chart include 99% 
of total contributions
Funding source(s): Global Fund, 
USAID/PMI, WHO, UNICEF
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Impact: Insufficiently consistent data to assess trends
III. Financing Sources of financing Financing by intervention in 2013 
V. Impact  Confirmed malaria cases per 1000 and ABER Malaria admissions and deaths (per 100 000)
IV. Coverage ITN and IRS coverage Cases tested and treated in public sector
 Cases tracked Test positivity
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Sierra Leone African Region
I. Epidemiological profile
Population 2013 %
High transmission (> 1 case per 1000 population) 6 090 000 100
Low transmission (0–1 cases per 1000 population) 0 0
Malaria-free (0 cases) 0 0
Total 6 090 000 
Parasites and vectors
Major plasmodium species: P. falciparum (100%), P. vivax (0%)
Major anopheles species: An. gambiae, An. funestus, An. melas
Programme phase: Control
Reported confirmed cases: 1 701 958 
Reported deaths: 4326 
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 2002
 ITNs/LLINs distributed to all age groups Yes 2010
IRS IRS is recommended Yes 2010 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended No –
IPT IPT used to prevent malaria during pregnancy Yes 2005
Diagnosis Patients of all ages should receive diagnostic test Yes 2010
 Malaria diagnosis is free of charge in the public sector Yes 2008
Treatment ACT is free for all ages in public sector Yes 2010
 Artemisinin-based monotherapies withdrawn Yes 2005
 Single dose of primaquine is used as gametocidal medicine for P. falciparum No –
 Primaquine is used for radical treatment of P. vivax No –
 G6PD test is a requirement before treatment with primaquine No –
 Directly observed treatment with primaquine is undertaken No –
 System for monitoring of adverse reactions to antimalarials exists Yes 2005
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) No –
 ACD of febrile cases at community level (pro-active) No –
 Mass screening is undertaken No –
 Uncomplicated P. falciparum cases routinely admitted No –
 Uncomplicated P. vivax cases routinely admitted No –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria AS+AQ 2004
First-line treatment of P. falciparum AL; AS+AQ 2004
Treatment failure of P. falciparum QN 2004
Treatment of severe malaria AM; QN 2004
Treatment of P. vivax – –
Dosage of primaquine for radical treatment of P. vivax –
Type of RDT used P.f only
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
AL 2011–2011 0 0 0 28 days 2 P. falciparum
AS+AQ 2011–2011 0 0 0 28 days 2 P. falciparum
       
II. Intervention policies and strategies
Pie chart include 100% 
of total contributions
Funding source(s): Government, 
Global Fund, World Bank, UNICEF, 
Other (bilateral), Other (all types)
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Impact: Increase in case incidence 2000-2015
III. Financing Sources of financing Financing by intervention in 2013
V. Impact Confirmed malaria cases per 1000 and ABER Malaria admissions and deaths
IV. Coverage ITN and IRS coverage Cases tested and treated in public sector
Cases tracked Test positivity
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Solomon Islands Western Pacific Region
I. Epidemiological profile
Population 2013 %
High transmission (> 1 case per 1000 population) 556 000 99
Low transmission (0–1 cases per 1000 population) 0 0
Malaria-free (0 cases) 5610 1
Total 561 610 
Parasites and vectors
Major plasmodium species: P. falciparum (53%), P. vivax (47%)
Major anopheles species: An. farauti, An. punctulatus, An. koliensis
Programme phase: Control
Reported confirmed cases: 25 609 
Reported deaths: 18 
Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 2009
ITNs/LLINs distributed to all age groups Yes 1996
IRS IRS is recommended Yes – 
DDT is authorized for IRS No 1969
Larval control Use of larval control recommended No –
IPT IPT used to prevent malaria during pregnancy N/A –
Diagnosis Patients of all ages should receive diagnostic test Yes 1968
Malaria diagnosis is free of charge in the public sector Yes 2007
Treatment ACT is free for all ages in public sector Yes 2008
Artemisinin-based monotherapies withdrawn – –
Single dose of primaquine is used as gametocidal medicine for P. falciparum No –
Primaquine is used for radical treatment of P. vivax Yes 2009
G6PD test is a requirement before treatment with primaquine Yes 2009
Directly observed treatment with primaquine is undertaken No –
System for monitoring of adverse reactions to antimalarials exists No –
Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) Yes 1990
ACD of febrile cases at community level (pro-active) Yes 2013
Mass screening is undertaken Yes –
Uncomplicated P. falciparum cases routinely admitted No –
Uncomplicated P. vivax cases routinely admitted No –
 Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria AL 2009
First-line treatment of P. falciparum AL 2009
Treatment failure of P. falciparum QN 2009
Treatment of severe malaria AL; AS 2009
Treatment of P. vivax AL+PQ(14d) 2009
Dosage of primaquine for radical treatment of P. vivax 0.25 mg/kg (14 days)
Type of RDT used P.f + P.v specific (Combo)
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
AL 2008–2013 0 0 6.3 28 days 3 P. falciparum
AL 2008–2013 4 5.1 31.6 28 days 3 P. vivax
II. Intervention policies and strategies
Pie chart include 100% 
of total contributions
Funding source(s): Government, 
Global Fund, USAID/PMI, World 
Bank, WHO, UNICEF, Other 
(bilateral), Other (all types)
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Impact: Insufficiently consistent data to assess trends
III. Financing Sources of financing Financing by intervention in 2013 
V. Impact  Confirmed malaria cases per 1000 and ABER Malaria admissions and deaths
IV. Coverage ITN and IRS coverage Cases tested and treated in public sector
 Cases tracked Test positivity
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Somalia Eastern Mediterranean Region
I. Epidemiological profile
Population 2013 %
High transmission (> 1 case per 1000 population) 7 310 000 70
Low transmission (0–1 cases per 1000 population) 3 180 000 30
Malaria-free (0 cases) 0 0
Total 10 490 000 
Parasites and vectors
Major plasmodium species: P. falciparum (100%), P. vivax (0%)
Major anopheles species: An. arabiensis, An. funestus
Programme phase: Control
Reported confirmed cases: 10 470 
Reported deaths:  
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 2005
 ITNs/LLINs distributed to all age groups Yes 2005
IRS IRS is recommended Yes 2004 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended No –
IPT IPT used to prevent malaria during pregnancy N/A –
Diagnosis Patients of all ages should receive diagnostic test Yes 2006
 Malaria diagnosis is free of charge in the public sector Yes 2006
Treatment ACT is free for all ages in public sector Yes 2006
 Artemisinin-based monotherapies withdrawn – –
 Single dose of primaquine is used as gametocidal medicine for P. falciparum No –
 Primaquine is used for radical treatment of P. vivax No –
 G6PD test is a requirement before treatment with primaquine No –
 Directly observed treatment with primaquine is undertaken No –
 System for monitoring of adverse reactions to antimalarials exists No –
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) Yes 2006
 ACD of febrile cases at community level (pro-active) No –
 Mass screening is undertaken No –
 Uncomplicated P. falciparum cases routinely admitted No –
 Uncomplicated P. vivax cases routinely admitted No –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria AS+SP 2011
First-line treatment of P. falciparum AS+SP 2011
Treatment failure of P. falciparum AL 2011
Treatment of severe malaria AS; QN 2006
Treatment of P. vivax CQ+PQ 2006
Dosage of primaquine for radical treatment of P. vivax –
Type of RDT used P.f + all species (Combo)
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
AL 2013–2013 0 0.5 1 28 days 2 P. falciparum
AS+SP 2005–2011 0 1 22.2 28 days 5 P. falciparum
       
II. Intervention policies and strategies
Pie chart include 76% 
of total contributions
Funding source(s): Global 
Fund, WHO
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Impact: Achieved >75% decrease in case incidence in 2013
III. Financing Sources of financing Financing by intervention in 2013 
V. Impact  Confirmed malaria cases per 1000 and ABER Malaria admissions and deaths (per 100 000)
IV. Coverage ITN and IRS coverage Cases tested and treated in public sector
 Cases tracked Test positivity
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South Africa African Region
I. Epidemiological profile
Population 2013 %
High transmission (> 1 case per 1000 population) 2 110 000 4
Low transmission (0–1 cases per 1000 population) 3 170 000 6
Malaria-free (0 cases) 47 500 000 90
Total 52 780 000 
Parasites and vectors
Major plasmodium species: P. falciparum (100%), P. vivax (0%)
Major anopheles species: An. arabiensis, An. funestus
Programme phase: Control
Reported confirmed cases: 8645 
Reported deaths: 105 
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge No –
 ITNs/LLINs distributed to all age groups No –
IRS IRS is recommended Yes 1930 
 DDT is authorized for IRS Yes –
Larval control Use of larval control recommended Yes –
IPT IPT used to prevent malaria during pregnancy No –
Diagnosis Patients of all ages should receive diagnostic test Yes –
 Malaria diagnosis is free of charge in the public sector Yes 1997
Treatment ACT is free for all ages in public sector Yes 2001
 Artemisinin-based monotherapies withdrawn Yes –
 Single dose of primaquine is used as gametocidal medicine for P. falciparum No –
 Primaquine is used for radical treatment of P. vivax No –
 G6PD test is a requirement before treatment with primaquine Yes –
 Directly observed treatment with primaquine is undertaken No –
 System for monitoring of adverse reactions to antimalarials exists Yes –
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) Yes –
 ACD of febrile cases at community level (pro-active) Yes –
 Mass screening is undertaken No –
 Uncomplicated P. falciparum cases routinely admitted No –
 Uncomplicated P. vivax cases routinely admitted No –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria – –
First-line treatment of P. falciparum AL; QN+CL; QN+D 2001
Treatment failure of P. falciparum AS; QN 2001
Treatment of severe malaria QN 2001
Treatment of P. vivax AL+PQ; CQ+PQ –
Dosage of primaquine for radical treatment of P. vivax –
Type of RDT used –
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
– – – – – – – –
       
       
II. Intervention policies and strategies
Pie chart include 100% 
of total contributions
Funding source(s): Government, 
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Impact: Insufficiently consistent data to assess trends
III. Financing Sources of financing Financing by intervention in 2013 
V. Impact  Confirmed malaria cases per 1000 and ABER Malaria admissions and deaths (per 100 000)
IV. Coverage ITN and IRS coverage Cases tested and treated in public sector
 Cases tracked Test positivity
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South Sudan African Region
I. Epidemiological profile
Population 2013 %
High transmission (> 1 case per 1000 population) 11 300 000 100
Low transmission (0–1 cases per 1000 population) 0 0
Malaria-free (0 cases) 0 0
Total 11 300 000 
Parasites and vectors
Major plasmodium species: P. falciparum (100%), P. vivax (0%)
Major anopheles species: An. gambiae, An. arabiensis, An. funestus, An. nili
Programme phase: Control
Reported confirmed cases: 262 520 
Reported deaths: 1311 
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 2008
 ITNs/LLINs distributed to all age groups Yes 2008
IRS IRS is recommended Yes 2006 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended Yes –
IPT IPT used to prevent malaria during pregnancy Yes 2006
Diagnosis Patients of all ages should receive diagnostic test Yes –
 Malaria diagnosis is free of charge in the public sector Yes 2005
Treatment ACT is free for all ages in public sector Yes 2006
 Artemisinin-based monotherapies withdrawn – –
 Single dose of primaquine is used as gametocidal medicine for P. falciparum No –
 Primaquine is used for radical treatment of P. vivax No –
 G6PD test is a requirement before treatment with primaquine No –
 Directly observed treatment with primaquine is undertaken No –
 System for monitoring of adverse reactions to antimalarials exists No –
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) No –
 ACD of febrile cases at community level (pro-active) No –
 Mass screening is undertaken No –
 Uncomplicated P. falciparum cases routinely admitted No –
 Uncomplicated P. vivax cases routinely admitted No –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria AS+AQ 2006
First-line treatment of P. falciparum AS+AQ 2006
Treatment failure of P. falciparum AL 2006
Treatment of severe malaria AM; AS; QN 2004
Treatment of P. vivax AS+AQ+PQ –
Dosage of primaquine for radical treatment of P. vivax –
Type of RDT used P.f + all species (Combo)
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
– – – – – – – –
       
       
II. Intervention policies and strategies
Pie chart include 100% 
of total contributions
Funding source(s): Government, 
Global Fund, USAID/PMI, WHO, 
Other (bilateral), Other (all types)
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Impact: Achieved >75% decrease in case incidence in 2013
V. Impact Malaria test positivity rate and ABER Number of malaria cases 
IV. Coverage ITN and IRS coverage Cases tested
 Cases treated Cases tracked
Government Global Fund World Bank USAID/PMI WHO/UNICEF Others
Co
nt
rib
ut
ion
 (U
S$
m
)
0
3
6
9
12
15
Others
WHO_UNICEF
USAID/PMI
Worldbank (USD)
Global Fund (USD)
Malaria expenditure (USD)
20132012201120102009200820072006200520042003200220012000
Po
pu
lat
ion
 (%
)
At high risk protected with ITNs
Households with at least one ITN
All ages who slept under an ITN (survey)
At high risk protected with IRS
0
20
40
60
80
100
At high risk protected with ITNs
All ages who slept under an ITN (survey)
Households with at least one ITN
At high risk protected with IRS Points
At high risk protected with IRS
20132012201120102009200820072006200520042003200220012000
Ca
se
s (
%
)
0
20
40
60
80
100
ACTs as % of all antimalarials received by <5 (survey)
Antimalarials distributed vs reported cases
Primaquine distributed vs reported P.vivax cases
ACTs distributed vs reported P.falciparum cases points
ACTs distributed vs reported P.falciparum cases
20132012201120102009200820072006200520042003200220012000
Antimalarials distributed vs reported cases ACTs distributed vs reported P. falciparum cases
Primaquine distributed vs reported P. v cases ACTs as % of all antimalarials received by <5 (survey)
Po
sit
ivi
ty 
rat
e (
%
)
ABER (microscopy & RDT) RDT positivity rateSlide positivity rate
AB
ER
 (%
)
0
10
20
30
40
50
Aber (microscopy & RDT)
20132012201120102009200820072006200520042003200220012000
0
3
6
9
12
15
RDT positivity rate points
RDT positivity rate
Slide positivity points
Slide positivity rate
 (%
)
Reporting completeness Foci investigatedCases investigated
0
20
40
60
80
100
Reporting completeness
Foci investigated
Cases investigated points
Cases investigated
20132012201120102009200820072006200520042003200220012000
Ca
se
s 
0
50000
100000
150000
200000
250000
Imported cases points
Imported cases
Indigenous (P.vivax) points
Indigenous (P.vivax)
Total cases points
Total cases
Indigenous (P.falciparum) points
Indigenous (P.falciparum)
20132012201120102009200820072006200520042003200220012000
Total cases
Indigenous cases  (P.  falciparum)
Imported cases
Indigenous cases (P. vivax)
Ca
se
s (
%
)
Suspected cases tested
0
20
40
60
80
100
Suspected cases tested points
Suspected cases tested
20132012201120102009200820072006200520042003200220012000
Insecticides & spray materials
ITNs
Diagnostic testing
Antimalarial medicines
Monitoring and evaluation
Human resources & technical assistance
Management and other costs
Management and other costs
Human Resources & technical Assistance
Monitoring and evaluation
Antimalarial medicines
Diagnostics
ITNs
Insecticide & spraying materials
Sri Lanka South-East Asia Region
I. Epidemiological profile
Parasites and vectors
Major plasmodium species: P. falciparum (0%), P. vivax (0%)
Major anopheles species: An. culicifacies, An. subpictus, An. annularis, An. varuna
Programme phase: Elimination
Total confirmed cases, 2013: 95 Indigenous cases, 2013: 0
Total deaths, 2013: 0 Indigenous deaths, 2013: 0
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 1992
 ITNs/LLINs distributed to all age groups Yes 2004
IRS IRS is recommended Yes 1945 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended Yes –
IPT IPT used to prevent malaria during pregnancy N/A –
Diagnosis Patients of all ages should receive diagnostic test – –
 Malaria diagnosis is free of charge in the public sector Yes 1911
Treatment ACT is free for all ages in public sector – –
 Artemisinin-based monotherapies withdrawn – –
 Single dose of primaquine is used as gametocidal medicine for P. falciparum Yes –
 Primaquine is used for radical treatment of P. vivax Yes –
 G6PD test is a requirement before treatment with primaquine Yes –
 Directly observed treatment with primaquine is undertaken Yes –
 System for monitoring of adverse reactions to antimalarials exists Yes –
II. Intervention policies and strategies
Pie chart include 99% 
of total contributions
Funding source(s): Government, 
Global Fund
Population 2013 %
Number of active foci 0 
Number of people living within active foci 0 0
Number of people living in malaria-free areas 21 300 000 100
Total 21 300 000 
III. Financing Sources of financing Financing by intervention in 2013 
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) Yes –
 ACD of febrile cases at community level (pro-active) Yes –
 Mass screening is undertaken Yes –
 Uncomplicated P. falciparum cases routinely admitted Yes 2008
 Uncomplicated P. vivax cases routinely admitted No –
 Foci and case investigation undertaken Yes 1958
 Case reporting from private sector is mandatory Yes 2008
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria – –
First-line treatment of P. falciparum AL+PQ 2008
Treatment failure of P. falciparum QN 1936
Treatment of severe malaria CQ+PQ(14d) 2008
Treatment of P. vivax AL (2nd &amp; 3rd trimester); QN –
Dosage of primaquine for radical treatment of P. vivax 0.25 mg/kg (14 days)
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
– – – – – – – –
       
       
Insucient data
0
0–0.1
0.1–1.0
1.0–10
PP
>75
0
no cases
Insucient data
Very low PP
0–20
20–40
40–60
60–80
80–100
PR
OTHERS
PF-RATIO
Proportion of cases 
due to P. falciparum
Insucient data
0
0–0.1
0.1–1.0
1.0–10
PP
>75
0
no cases
Insucient data
Very low PP
0–20
20–40
40–60
60–80
80–100
PR
OTHERS
PF-RATIO
Confirmed cases  
per 1000 population/
Parasite prevalence 
(PP)
WORLD MALARIA REPORT 2014 | 149
Impact: Insufficiently consistent data to assess trends
III. Financing Sources of financing Financing by intervention in 2013 
V. Impact  Confirmed malaria cases per 1000 and ABER Malaria admissions and deaths
IV. Coverage ITN and IRS coverage Cases tested and treated in public sector
 Cases tracked Test positivity
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Sudan Eastern Mediterranean Region
I. Epidemiological profile
Population 2013 %
High transmission (> 1 case per 1000 population) 33 000 000 87
Low transmission (0–1 cases per 1000 population) 4 970 000 13
Malaria-free (0 cases) 0 0
Total 37 970 000 
Parasites and vectors
Major plasmodium species: P. falciparum (95%), P. vivax (5%)
Major anopheles species: An. arabiensis, An. funestus, An. gambiae, An. nili, An. pharoensis
Programme phase: Control
Reported confirmed cases: 592 383 
Reported deaths: 685 
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 2005
 ITNs/LLINs distributed to all age groups Yes 2010
IRS IRS is recommended Yes 1956 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended Yes –
IPT IPT used to prevent malaria during pregnancy N/A –
Diagnosis Patients of all ages should receive diagnostic test Yes 2009
 Malaria diagnosis is free of charge in the public sector No –
Treatment ACT is free for all ages in public sector Yes 2005
 Artemisinin-based monotherapies withdrawn Yes 2004
 Single dose of primaquine is used as gametocidal medicine for P. falciparum No –
 Primaquine is used for radical treatment of P. vivax Yes 2005
 G6PD test is a requirement before treatment with primaquine No –
 Directly observed treatment with primaquine is undertaken No –
 System for monitoring of adverse reactions to antimalarials exists No –
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) No –
 ACD of febrile cases at community level (pro-active) No –
 Mass screening is undertaken No –
 Uncomplicated P. falciparum cases routinely admitted No –
 Uncomplicated P. vivax cases routinely admitted No –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria AS+SP 2011
First-line treatment of P. falciparum AS+SP 2011
Treatment failure of P. falciparum AL 2011
Treatment of severe malaria AM; QN 2011
Treatment of P. vivax AL+PQ(14d) 2011
Dosage of primaquine for radical treatment of P. vivax 0.25 mg/kg (14 days)
Type of RDT used P.f + P.v specific (Combo)
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
– – – – – – – –
       
       
II. Intervention policies and strategies
Pie chart include  
of total contributions
Funding source(s): Government, 
Global Fund, USAID/PMI, World 
Bank, WHO, UNICEF, Other 
(bilateral), Other (all types)
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Impact: Achieved >75% decrease in case incidence in 2013
III. Financing Sources of financing Financing by intervention in 2013 
V. Impact  Confirmed malaria cases per 1000 and ABER Malaria admissions and deaths
IV. Coverage ITN and IRS coverage Cases tested and treated in public sector
 Cases tracked Test positivity
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Suriname Region of the Americas
I. Epidemiological profile
Population 2013 %
High transmission (> 1 case per 1000 population) 84 700 16
Low transmission (0–1 cases per 1000 population) 0 0
Malaria-free (0 cases) 455 000 84
Total 539 700 
Parasites and vectors
Major plasmodium species: P. falciparum (46%), P. vivax (54%)
Major anopheles species: An. darlingi, An. nuneztovari
Programme phase: Control
Reported confirmed cases: 729 
Reported deaths: 1 
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 2006
 ITNs/LLINs distributed to all age groups Yes 2006
IRS IRS is recommended No 2006 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended No –
IPT IPT used to prevent malaria during pregnancy N/A –
Diagnosis Patients of all ages should receive diagnostic test Yes 1955
 Malaria diagnosis is free of charge in the public sector Yes 1955
Treatment ACT is free for all ages in public sector Yes 2004
 Artemisinin-based monotherapies withdrawn Yes –
 Single dose of primaquine is used as gametocidal medicine for P. falciparum Yes 2004
 Primaquine is used for radical treatment of P. vivax Yes 2004
 G6PD test is a requirement before treatment with primaquine No –
 Directly observed treatment with primaquine is undertaken No –
 System for monitoring of adverse reactions to antimalarials exists No –
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) Yes 2000
 ACD of febrile cases at community level (pro-active) No 2000
 Mass screening is undertaken Yes 2000
 Uncomplicated P. falciparum cases routinely admitted No –
 Uncomplicated P. vivax cases routinely admitted No –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria – –
First-line treatment of P. falciparum AL+PQ 2004
Treatment failure of P. falciparum AS+MQ 2004
Treatment of severe malaria AS –
Treatment of P. vivax CQ+PQ(14d) 2004
Dosage of primaquine for radical treatment of P. vivax –
Type of RDT used –
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
AL 2005–2011 0 2.35 4.7 28 days 2 P. falciparum
       
       
II. Intervention policies and strategies
Pie chart include 9% 
of total contributions
Funding source(s): USAID/PMI, 
World Bank, WHO, UNICEF, Other 
(all types)
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Impact: Achieved >75% decrease in case incidence in 2013
III. Financing Sources of financing Financing by intervention in 2013 
V. Impact  Confirmed malaria cases per 1000 and ABER Malaria admissions and deaths (per 100 000)
IV. Coverage ITN and IRS coverage Cases tested and treated in public sector
 Cases tracked Test positivity
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Swaziland African Region
I. Epidemiological profile
Population 2013 %
High transmission (> 1 case per 1000 population) 0 0
Low transmission (0–1 cases per 1000 population) 350 000 28
Malaria-free (0 cases) 900 000 72
Total 1 250 000 
Parasites and vectors
Major plasmodium species: P. falciparum (100%), P. vivax (0%)
Major anopheles species: An. arabiensis, An. gambiae, An. funestus
Programme phase: Control
Reported confirmed cases: 131 
Reported deaths: 4 
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 2002
 ITNs/LLINs distributed to all age groups Yes 2010
IRS IRS is recommended Yes 1946 
 DDT is authorized for IRS Yes –
Larval control Use of larval control recommended No –
IPT IPT used to prevent malaria during pregnancy No –
Diagnosis Patients of all ages should receive diagnostic test Yes 2010
 Malaria diagnosis is free of charge in the public sector Yes 2010
Treatment ACT is free for all ages in public sector Yes 2010
 Artemisinin-based monotherapies withdrawn – –
 Single dose of primaquine is used as gametocidal medicine for P. falciparum No –
 Primaquine is used for radical treatment of P. vivax No –
 G6PD test is a requirement before treatment with primaquine No –
 Directly observed treatment with primaquine is undertaken No –
 System for monitoring of adverse reactions to antimalarials exists Yes 2010
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) Yes 2012
 ACD of febrile cases at community level (pro-active) Yes 2010
 Mass screening is undertaken Yes 2010
 Uncomplicated P. falciparum cases routinely admitted No –
 Uncomplicated P. vivax cases routinely admitted No –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria AL 2009
First-line treatment of P. falciparum QN 2009
Treatment failure of P. falciparum QN –
Treatment of severe malaria – –
Treatment of P. vivax QN –
Dosage of primaquine for radical treatment of P. vivax –
Type of RDT used –
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
– – – – – – – –
       
       
II. Intervention policies and strategies
Pie chart include 100% 
of total contributions
Funding source(s): Government, 
Global Fund, WHO, Other 
(all types)
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Impact: Achieved >75% decrease in case incidence in 2013
V. Impact Malaria test positivity rate and ABER Number of malaria cases 
IV. Coverage ITN and IRS coverage Cases tested
 Cases treated Cases tracked
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Tajikistan European Region
I. Epidemiological profile
Parasites and vectors
Major plasmodium species: P. falciparum (0%), P. vivax (100%)
Major anopheles species: An. superpictus, An. pulcherrimus
Programme phase: Elimination
Total confirmed cases, 2013: 14 Indigenous cases, 2013: 3
Total deaths, 2013: 0 Indigenous deaths, 2013: 0
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 2006
 ITNs/LLINs distributed to all age groups Yes 2006
IRS IRS is recommended Yes 1997 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended Yes 1998
IPT IPT used to prevent malaria during pregnancy N/A –
Diagnosis Patients of all ages should receive diagnostic test – –
 Malaria diagnosis is free of charge in the public sector Yes 1997
Treatment ACT is free for all ages in public sector Yes –
 Artemisinin-based monotherapies withdrawn – –
 Single dose of primaquine is used as gametocidal medicine for P. falciparum Yes 2004
 Primaquine is used for radical treatment of P. vivax Yes 1997
 G6PD test is a requirement before treatment with primaquine No 2014
 Directly observed treatment with primaquine is undertaken Yes 2004
 System for monitoring of adverse reactions to antimalarials exists Yes 1997
II. Intervention policies and strategies
Pie chart include 100% 
of total contributions
Funding source(s): Government, 
Global Fund, USAID/PMI, WHO, 
Other (all types)
Population 2013 %
Number of active foci 14 
Number of people living within active foci 1 950 000 24
Number of people living in malaria-free areas 6 260 000 76
Total 8 210 000 
III. Financing Sources of financing Financing by intervention in 2013 
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) Yes 2004
 ACD of febrile cases at community level (pro-active) No –
 Mass screening is undertaken No –
 Uncomplicated P. falciparum cases routinely admitted Yes 1997
 Uncomplicated P. vivax cases routinely admitted No –
 Foci and case investigation undertaken Yes 2009
 Case reporting from private sector is mandatory Yes 2000
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria – –
First-line treatment of P. falciparum AL 2008
Treatment failure of P. falciparum QN 2004
Treatment of severe malaria QN 2004
Treatment of P. vivax CQ+PQ(14d) 2004
Dosage of primaquine for radical treatment of P. vivax 0.25 mg/kg (14 days)
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
– – – – – – – –
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Impact: On track for 50%-75% decrease in case incidence 2000-2015
III. Financing Sources of financing Financing by intervention in 2013 
V. Impact  Confirmed malaria cases per 1000 and ABER Malaria admissions and deaths
IV. Coverage ITN and IRS coverage Cases tested and treated in public sector
 Cases tracked Test positivity
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Thailand South-East Asia Region
I. Epidemiological profile
Population 2013 %
High transmission (> 1 case per 1000 population) 5 360 000 8
Low transmission (0–1 cases per 1000 population) 28 100 000 42
Malaria-free (0 cases) 33 500 000 50
Total 66 960 000 
Parasites and vectors
Major plasmodium species: P. falciparum (44%), P. vivax (47%)
Major anopheles species: An. dirus, An. minimus, An. maculatus, An. sundaicus
Programme phase: Control
Reported confirmed cases: 33 302 
Reported deaths: 37 
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 1992
 ITNs/LLINs distributed to all age groups Yes 1992
IRS IRS is recommended Yes 1953 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended Yes 1953
IPT IPT used to prevent malaria during pregnancy N/A –
Diagnosis Patients of all ages should receive diagnostic test Yes 1991
 Malaria diagnosis is free of charge in the public sector Yes 1953
Treatment ACT is free for all ages in public sector Yes 1995
 Artemisinin-based monotherapies withdrawn Yes 1995
 Single dose of primaquine is used as gametocidal medicine for P. falciparum Yes 1995
 Primaquine is used for radical treatment of P. vivax Yes 1965
 G6PD test is a requirement before treatment with primaquine No –
 Directly observed treatment with primaquine is undertaken Yes 2008
 System for monitoring of adverse reactions to antimalarials exists No –
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) Yes 1958
 ACD of febrile cases at community level (pro-active) Yes 1958
 Mass screening is undertaken Yes 1958
 Uncomplicated P. falciparum cases routinely admitted Yes 1995
 Uncomplicated P. vivax cases routinely admitted Yes 1995
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria – –
First-line treatment of P. falciparum AS+MQ 2007
Treatment failure of P. falciparum QN+D 2007
Treatment of severe malaria QN+D 2007
Treatment of P. vivax CQ+PQ(14d) 2007
Dosage of primaquine for radical treatment of P. vivax 0.25 mg/kg (14 days)
Type of RDT used –
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
– – – – – – – –
       
       
II. Intervention policies and strategies
Pie chart include 100% 
of total contributions
Funding source(s): Government, 
Global Fund, USAID/PMI, WHO
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Impact: Achieved >75% decrease in case incidence in 2013
III. Financing Sources of financing Financing by intervention in 2013 
V. Impact  Confirmed malaria cases per 1000 and ABER Malaria admissions and deaths
IV. Coverage ITN and IRS coverage Cases tested and treated in public sector
 Cases tracked Test positivity
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Timor-Leste South-East Asia Region
I. Epidemiological profile
Population 2013 %
High transmission (> 1 case per 1000 population) 872 000 77
Low transmission (0–1 cases per 1000 population) 261 000 23
Malaria-free (0 cases) 0 0
Total 1 133 000 
Parasites and vectors
Major plasmodium species: P. falciparum (50%), P. vivax (50%)
Major anopheles species: An. subpictus, An. barbirostris
Programme phase: Control
Reported confirmed cases: 1025 
Reported deaths: 3 
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 2005
 ITNs/LLINs distributed to all age groups Yes 2009
IRS IRS is recommended Yes 2006 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended Yes 2007
IPT IPT used to prevent malaria during pregnancy N/A –
Diagnosis Patients of all ages should receive diagnostic test Yes 2007
 Malaria diagnosis is free of charge in the public sector Yes 2000
Treatment ACT is free for all ages in public sector Yes 2007
 Artemisinin-based monotherapies withdrawn – –
 Single dose of primaquine is used as gametocidal medicine for P. falciparum No –
 Primaquine is used for radical treatment of P. vivax Yes 2006
 G6PD test is a requirement before treatment with primaquine No –
 Directly observed treatment with primaquine is undertaken No –
 System for monitoring of adverse reactions to antimalarials exists No –
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) Yes 2002
 ACD of febrile cases at community level (pro-active) Yes 2009
 Mass screening is undertaken No –
 Uncomplicated P. falciparum cases routinely admitted No –
 Uncomplicated P. vivax cases routinely admitted No –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria – –
First-line treatment of P. falciparum AL –
Treatment failure of P. falciparum QN+D –
Treatment of severe malaria AM; AS; QN –
Treatment of P. vivax CQ+PQ(14d) –
Dosage of primaquine for radical treatment of P. vivax –
Type of RDT used –
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
– – – – – – – –
       
       
II. Intervention policies and strategies
Pie chart include 80% 
of total contributions
Funding source(s): Government, 
Global Fund
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Impact: Insufficiently consistent data to assess trends
III. Financing Sources of financing Financing by intervention in 2013 
V. Impact  Confirmed malaria cases per 1000 and ABER Malaria admissions and deaths (per 100 000)
IV. Coverage ITN and IRS coverage Cases tested and treated in public sector
 Cases tracked Test positivity
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Togo African Region
I. Epidemiological profile
Population 2013 %
High transmission (> 1 case per 1000 population) 6 820 000 100
Low transmission (0–1 cases per 1000 population) 0 0
Malaria-free (0 cases) 0 0
Total 6 820 000 
Parasites and vectors
Major plasmodium species: P. falciparum (100%), P. vivax (0%)
Major anopheles species: An. gambiae, An. funestus, An. melas, An. arabiensis
Programme phase: Control
Reported confirmed cases: 882 430 
Reported deaths: 1361 
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 2004
 ITNs/LLINs distributed to all age groups Yes 2011
IRS IRS is recommended Yes 2011 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended No –
IPT IPT used to prevent malaria during pregnancy Yes 2003
Diagnosis Patients of all ages should receive diagnostic test Yes 2010
 Malaria diagnosis is free of charge in the public sector Yes 2012
Treatment ACT is free for all ages in public sector No –
 Artemisinin-based monotherapies withdrawn Yes –
 Single dose of primaquine is used as gametocidal medicine for P. falciparum No –
 Primaquine is used for radical treatment of P. vivax No –
 G6PD test is a requirement before treatment with primaquine – –
 Directly observed treatment with primaquine is undertaken – –
 System for monitoring of adverse reactions to antimalarials exists Yes 2009
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) – –
 ACD of febrile cases at community level (pro-active) No –
 Mass screening is undertaken No –
 Uncomplicated P. falciparum cases routinely admitted Yes –
 Uncomplicated P. vivax cases routinely admitted No –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria AL; AS+AQ –
First-line treatment of P. falciparum AL; AS+AQ –
Treatment failure of P. falciparum – –
Treatment of severe malaria QN –
Treatment of P. vivax – –
Dosage of primaquine for radical treatment of P. vivax –
Type of RDT used P.f only
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
AL 2005–2013 0 1.4 4.4 28 days 11 P. falciparum
AS+AQ 2005–2013 0 0 6 28 days 11 P. falciparum
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Impact: Achieved >75% decrease in case incidence in 2013
V. Impact Malaria test positivity rate and ABER Number of malaria cases 
IV. Coverage ITN and IRS coverage Cases tested
 Cases treated Cases tracked
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Turkey European Region
I. Epidemiological profile
Parasites and vectors
Major plasmodium species: P. falciparum (0%), P. vivax (100%)
Major anopheles species: An. sacharovi, An. superpictus, An. maculipennis
Programme phase: Elimination
Total confirmed cases, 2013: 285 Indigenous cases, 2013: 0
Total deaths, 2013: 3 Indigenous deaths, 2013: 0
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge No –
 ITNs/LLINs distributed to all age groups No –
IRS IRS is recommended Yes 1926 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended Yes 1926
IPT IPT used to prevent malaria during pregnancy N/A –
Diagnosis Patients of all ages should receive diagnostic test – –
 Malaria diagnosis is free of charge in the public sector Yes 1926
Treatment ACT is free for all ages in public sector – –
 Artemisinin-based monotherapies withdrawn – –
 Single dose of primaquine is used as gametocidal medicine for P. falciparum No –
 Primaquine is used for radical treatment of P. vivax Yes 1926
 G6PD test is a requirement before treatment with primaquine No –
 Directly observed treatment with primaquine is undertaken Yes 2007
 System for monitoring of adverse reactions to antimalarials exists No –
II. Intervention policies and strategies
Population 2013 %
Number of active foci 0 
Number of people living within active foci 0 0
Number of people living in malaria-free areas 74 900 000 100
Total 74 900 000 
III. Financing Sources of financing Financing by intervention in 2013 
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) Yes 2010
 ACD of febrile cases at community level (pro-active) No –
 Mass screening is undertaken No –
 Uncomplicated P. falciparum cases routinely admitted No –
 Uncomplicated P. vivax cases routinely admitted No –
 Foci and case investigation undertaken Yes 1926
 Case reporting from private sector is mandatory Yes 1930
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria – –
First-line treatment of P. falciparum – –
Treatment failure of P. falciparum – –
Treatment of severe malaria – –
Treatment of P. vivax CQ+PQ(14d) –
Dosage of primaquine for radical treatment of P. vivax 0.25 mg/kg (14 days)
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
– – – – – – – –
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Impact: Insufficiently consistent data to assess trends
III. Financing Sources of financing Financing by intervention in 2013 
V. Impact  Confirmed malaria cases per 1000 and ABER Malaria admissions and deaths (per 100 000)
IV. Coverage ITN and IRS coverage Cases tested and treated in public sector
 Cases tracked Test positivity
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Uganda African Region
I. Epidemiological profile
Population 2013 %
High transmission (> 1 case per 1000 population) 33 800 000 90
Low transmission (0–1 cases per 1000 population) 3 760 000 10
Malaria-free (0 cases) 0 0
Total 37 560 000 
Parasites and vectors
Major plasmodium species: P. falciparum (100%), P. vivax (0%)
Major anopheles species: An. gambiae, An. funestus, An. funestus
Programme phase: Control
Reported confirmed cases: 1 502 362 
Reported deaths: 7277 
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 2006
 ITNs/LLINs distributed to all age groups Yes 2013
IRS IRS is recommended Yes 2005 
 DDT is authorized for IRS Yes 2008
Larval control Use of larval control recommended Yes 2011
IPT IPT used to prevent malaria during pregnancy Yes 1998
Diagnosis Patients of all ages should receive diagnostic test Yes 2012
 Malaria diagnosis is free of charge in the public sector Yes 2001
Treatment ACT is free for all ages in public sector Yes 2005
 Artemisinin-based monotherapies withdrawn – –
 Single dose of primaquine is used as gametocidal medicine for P. falciparum No –
 Primaquine is used for radical treatment of P. vivax No –
 G6PD test is a requirement before treatment with primaquine No –
 Directly observed treatment with primaquine is undertaken No –
 System for monitoring of adverse reactions to antimalarials exists Yes –
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) No –
 ACD of febrile cases at community level (pro-active) No –
 Mass screening is undertaken No –
 Uncomplicated P. falciparum cases routinely admitted No –
 Uncomplicated P. vivax cases routinely admitted No –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria AL 2004
First-line treatment of P. falciparum AL 2004
Treatment failure of P. falciparum QN 2004
Treatment of severe malaria QN 2004
Treatment of P. vivax – –
Dosage of primaquine for radical treatment of P. vivax –
Type of RDT used –
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
– – – – – – – –
       
       
II. Intervention policies and strategies
Pie chart include 100% 
of total contributions
Funding source(s): Government, 
Global Fund, USAID/PMI, UNICEF, 
Other (bilateral), Other (all types)
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Impact: Insufficiently consistent data to assess trends
III. Financing Sources of financing Financing by intervention in 2013 
V. Impact  Confirmed malaria cases per 1000 and ABER Malaria admissions and deaths (per 100 000)
IV. Coverage ITN and IRS coverage Cases tested and treated in public sector
 Cases tracked Test positivity
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United Republic of Tanzania (Mainland) African Region
I. Epidemiological profile
Population 2013 %
High transmission (> 1 case per 1000 population) 34 900 000 73
Low transmission (0–1 cases per 1000 population) 12 900 000 27
Malaria-free (0 cases) 0 0
Total 47 800 000 
Parasites and vectors
Major plasmodium species: P. falciparum (100%), P. vivax (0%)
Major anopheles species: An. gambiae, An. arabiensis, An. funestus
Programme phase: Control
Reported confirmed cases: 1 550 250 
Reported deaths: 8526 
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes –
 ITNs/LLINs distributed to all age groups No –
IRS IRS is recommended Yes 2006 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended Yes –
IPT IPT used to prevent malaria during pregnancy Yes 2001
Diagnosis Patients of all ages should receive diagnostic test Yes 2009
 Malaria diagnosis is free of charge in the public sector Yes –
Treatment ACT is free for all ages in public sector Yes –
 Artemisinin-based monotherapies withdrawn – –
 Single dose of primaquine is used as gametocidal medicine for P. falciparum No –
 Primaquine is used for radical treatment of P. vivax No –
 G6PD test is a requirement before treatment with primaquine No –
 Directly observed treatment with primaquine is undertaken No –
 System for monitoring of adverse reactions to antimalarials exists Yes –
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) No –
 ACD of febrile cases at community level (pro-active) No –
 Mass screening is undertaken No –
 Uncomplicated P. falciparum cases routinely admitted No –
 Uncomplicated P. vivax cases routinely admitted No –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria AL 2004
First-line treatment of P. falciparum AL 2004
Treatment failure of P. falciparum QN 2004
Treatment of severe malaria QN 2004
Treatment of P. vivax – –
Dosage of primaquine for radical treatment of P. vivax –
Type of RDT used P.f + P.v specific (Combo)
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
– – – – – – – –
       
       
II. Intervention policies and strategies
Pie chart include 100% 
of total contributions
Funding source(s): Government, 
Global Fund, USAID/PMI, World 
Bank, WHO, UNICEF, Other 
(bilateral), Other (all types)
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Impact: Insufficiently consistent data to assess trends
III. Financing Sources of financing Financing by intervention in 2013 
V. Impact  Confirmed malaria cases per 1000 and ABER Malaria admissions and deaths (per 100 000)
IV. Coverage ITN and IRS coverage Cases tested and treated in public sector
 Cases tracked Test positivity
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United Republic of Tanzania (Zanzibar) African Region
I. Epidemiological profile
Population 2013 %
High transmission (> 1 case per 1000 population) 1 390 000 100
Low transmission (0–1 cases per 1000 population) 0 0
Malaria-free (0 cases) 0 0
Total 1 390 000 
Parasites and vectors
Major plasmodium species: P. falciparum (100%), P. vivax (0%)
Major anopheles species: An. gambiae
Programme phase: Control
Reported confirmed cases: 2194 
Reported deaths: 2 
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 2005
 ITNs/LLINs distributed to all age groups Yes 2008
IRS IRS is recommended Yes 2006 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended Yes 2012
IPT IPT used to prevent malaria during pregnancy Yes 2004
Diagnosis Patients of all ages should receive diagnostic test Yes 2007
 Malaria diagnosis is free of charge in the public sector Yes 2004
Treatment ACT is free for all ages in public sector Yes 2003
 Artemisinin-based monotherapies withdrawn – –
 Single dose of primaquine is used as gametocidal medicine for P. falciparum No –
 Primaquine is used for radical treatment of P. vivax No –
 G6PD test is a requirement before treatment with primaquine No –
 Directly observed treatment with primaquine is undertaken No –
 System for monitoring of adverse reactions to antimalarials exists Yes 2003
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) Yes 2008
 ACD of febrile cases at community level (pro-active) Yes 2011
 Mass screening is undertaken Yes 2011
 Uncomplicated P. falciparum cases routinely admitted No –
 Uncomplicated P. vivax cases routinely admitted No –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria AS+AQ 2004
First-line treatment of P. falciparum AS+AQ 2004
Treatment failure of P. falciparum QN 2004
Treatment of severe malaria QN 2004
Treatment of P. vivax – –
Dosage of primaquine for radical treatment of P. vivax –
Type of RDT used P.f + all species (Combo)
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
AL 2006–2007 0 0 0 28 days 2 P. falciparum
       
       
II. Intervention policies and strategies
Pie chart include 100% 
of total contributions
Funding source(s): Government, 
Global Fund, USAID/PMI
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Impact: Increase in case incidence 2000-2015
III. Financing Sources of financing Financing by intervention in 2013 
V. Impact  Confirmed malaria cases per 1000 and ABER Malaria admissions and deaths
IV. Coverage ITN and IRS coverage Cases tested and treated in public sector
 Cases tracked Test positivity
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Vanuatu Western Pacific Region
I. Epidemiological profile
Population 2013 %
High transmission (> 1 case per 1000 population) 250 000 99
Low transmission (0–1 cases per 1000 population) 0 0
Malaria-free (0 cases) 2530 1
Total 252 530 
Parasites and vectors
Major plasmodium species: P. falciparum (31%), P. vivax (69%)
Major anopheles species: An. farauti
Programme phase: Control
Reported confirmed cases: 2381 
Reported deaths: 0 
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 2008
 ITNs/LLINs distributed to all age groups Yes 1990
IRS IRS is recommended Yes 2008 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended Yes 2010
IPT IPT used to prevent malaria during pregnancy N/A –
Diagnosis Patients of all ages should receive diagnostic test Yes 2009
 Malaria diagnosis is free of charge in the public sector No –
Treatment ACT is free for all ages in public sector Yes 2009
 Artemisinin-based monotherapies withdrawn Yes 2012
 Single dose of primaquine is used as gametocidal medicine for P. falciparum No –
 Primaquine is used for radical treatment of P. vivax Yes 2009
 G6PD test is a requirement before treatment with primaquine Yes 2009
 Directly observed treatment with primaquine is undertaken Yes 2009
 System for monitoring of adverse reactions to antimalarials exists No –
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) Yes 2013
 ACD of febrile cases at community level (pro-active) Yes 2013
 Mass screening is undertaken Yes 2013
 Uncomplicated P. falciparum cases routinely admitted No –
 Uncomplicated P. vivax cases routinely admitted No –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria – –
First-line treatment of P. falciparum AL 2007
Treatment failure of P. falciparum QN 2007
Treatment of severe malaria QN 2007
Treatment of P. vivax AL+PQ(14d) 2007
Dosage of primaquine for radical treatment of P. vivax –
Type of RDT used P.f + P.v specific (Combo)
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
AL 2011–2012 2.8 2.8 2.8 28 days 1 P. vivax
       
       
II. Intervention policies and strategies
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Impact: Increase in case incidence 2000-2015
III. Financing Sources of financing Financing by intervention in 2013 
V. Impact  Confirmed malaria cases per 1000 and ABER Malaria admissions and deaths
IV. Coverage ITN and IRS coverage Cases tested and treated in public sector
 Cases tracked Test positivity
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Venezuela (Bolivarian Republic of ) Region of the Americas
I. Epidemiological profile
Population 2013 %
High transmission (> 1 case per 1000 population) 791 000 3
Low transmission (0–1 cases per 1000 population) 4 930 000 16
Malaria-free (0 cases) 24 700 000 81
Total 30 421 000 
Parasites and vectors
Major plasmodium species: P. falciparum (35%), P. vivax (65%)
Major anopheles species: An. darlingi, An. aquasalis, An. nuneztovari, An. braziliensis, An. albitarsis
Programme phase: Control
Reported confirmed cases: 78 643 
Reported deaths: 6 
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 2005
 ITNs/LLINs distributed to all age groups Yes 2005
IRS IRS is recommended Yes – 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended Yes –
IPT IPT used to prevent malaria during pregnancy N/A –
Diagnosis Patients of all ages should receive diagnostic test Yes 1936
 Malaria diagnosis is free of charge in the public sector Yes 1936
Treatment ACT is free for all ages in public sector Yes 2004
 Artemisinin-based monotherapies withdrawn Yes –
 Single dose of primaquine is used as gametocidal medicine for P. falciparum Yes –
 Primaquine is used for radical treatment of P. vivax Yes –
 G6PD test is a requirement before treatment with primaquine No –
 Directly observed treatment with primaquine is undertaken Yes –
 System for monitoring of adverse reactions to antimalarials exists No –
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) – –
 ACD of febrile cases at community level (pro-active) Yes –
 Mass screening is undertaken Yes –
 Uncomplicated P. falciparum cases routinely admitted No –
 Uncomplicated P. vivax cases routinely admitted No –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria – –
First-line treatment of P. falciparum AS+MQ+PQ 2004
Treatment failure of P. falciparum QN+CL; QN+D; QN+T 2004
Treatment of severe malaria AM; QN 2004
Treatment of P. vivax CQ+PQ(14d) 2004
Dosage of primaquine for radical treatment of P. vivax 0.25 mg/kg (14 days)
Type of RDT used –
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
AS+MQ 2005–2006 0 0 0 28 days 2 P. falciparum
       
       
II. Intervention policies and strategies
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Impact: Achieved >75% decrease in case incidence in 2013
III. Financing Sources of financing Financing by intervention in 2013 
V. Impact  Confirmed malaria cases per 1000 and ABER Malaria admissions and deaths
IV. Coverage ITN and IRS coverage Cases tested and treated in public sector
 Cases tracked Test positivity
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Viet Nam Western Pacific Region
I. Epidemiological profile
Population 2013 %
High transmission (> 1 case per 1000 population) 16 100 000 18
Low transmission (0–1 cases per 1000 population) 18 300 000 20
Malaria-free (0 cases) 57 300 000 63
Total 91 700 000 
Parasites and vectors
Major plasmodium species: P. falciparum (60%), P. vivax (40%)
Major anopheles species: An. minimus, An. dirus, An. sundaicus
Programme phase: Control
Reported confirmed cases: 17 128 
Reported deaths: 6 
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 1992
 ITNs/LLINs distributed to all age groups Yes 1992
IRS IRS is recommended Yes 1958 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended No –
IPT IPT used to prevent malaria during pregnancy N/A –
Diagnosis Patients of all ages should receive diagnostic test Yes 1958
 Malaria diagnosis is free of charge in the public sector Yes 1958
Treatment ACT is free for all ages in public sector Yes 2003
 Artemisinin-based monotherapies withdrawn Yes 2013
 Single dose of primaquine is used as gametocidal medicine for P. falciparum Yes 2003
 Primaquine is used for radical treatment of P. vivax Yes 1960
 G6PD test is a requirement before treatment with primaquine No –
 Directly observed treatment with primaquine is undertaken No –
 System for monitoring of adverse reactions to antimalarials exists Yes 1980
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) Yes 1958
 ACD of febrile cases at community level (pro-active) Yes 1958
 Mass screening is undertaken No –
 Uncomplicated P. falciparum cases routinely admitted No –
 Uncomplicated P. vivax cases routinely admitted No –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria DHA-PPQ –
First-line treatment of P. falciparum QN+CL; QN+D 2013
Treatment failure of P. falciparum AS; QN 2013
Treatment of severe malaria CQ+PQ(14d) 2013
Treatment of P. vivax AS - 2nd &amp; 3rd trimesters; QN –
Dosage of primaquine for radical treatment of P. vivax –
Type of RDT used P.f + P.v specific (Combo)
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
– – – – – – – –
       
       
II. Intervention policies and strategies
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Impact: Insufficiently consistent data to assess trends
III. Financing Sources of financing Financing by intervention in 2013 
V. Impact  Confirmed malaria cases per 1000 and ABER Malaria admissions and deaths
IV. Coverage ITN and IRS coverage Cases tested and treated in public sector
 Cases tracked Test positivity
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Yemen Eastern Mediterranean Region
I. Epidemiological profile
Population 2013 %
High transmission (> 1 case per 1000 population) 10 400 000 43
Low transmission (0–1 cases per 1000 population) 6 290 000 26
Malaria-free (0 cases) 7 670 000 31
Total 24 360 000 
Parasites and vectors
Major plasmodium species: P. falciparum (99%), P. vivax (1%)
Major anopheles species: An. arabiensis, An. culicifacies, An. sergentii
Programme phase: Control
Reported confirmed cases: 102 778 
Reported deaths: 55 
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 2002
 ITNs/LLINs distributed to all age groups Yes 2009
IRS IRS is recommended Yes 2001 
 DDT is authorized for IRS No –
Larval control Use of larval control recommended Yes 2002
IPT IPT used to prevent malaria during pregnancy N/A –
Diagnosis Patients of all ages should receive diagnostic test Yes 2001
 Malaria diagnosis is free of charge in the public sector Yes 2002
Treatment ACT is free for all ages in public sector Yes 2009
 Artemisinin-based monotherapies withdrawn Yes 2009
 Single dose of primaquine is used as gametocidal medicine for P. falciparum No –
 Primaquine is used for radical treatment of P. vivax Yes 2001
 G6PD test is a requirement before treatment with primaquine Yes 2009
 Directly observed treatment with primaquine is undertaken No –
 System for monitoring of adverse reactions to antimalarials exists No –
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) Yes 2006
 ACD of febrile cases at community level (pro-active) No –
 Mass screening is undertaken Yes 2001
 Uncomplicated P. falciparum cases routinely admitted No –
 Uncomplicated P. vivax cases routinely admitted No –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria AS+SP 2009
First-line treatment of P. falciparum AS+SP 2009
Treatment failure of P. falciparum AL 2009
Treatment of severe malaria AM; QN 2009
Treatment of P. vivax CQ+PQ(14d) –
Dosage of primaquine for radical treatment of P. vivax 0.25 mg/kg (14 days)
Type of RDT used P.f only
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
AL 2007–2010 0 0 1.1 28 days 3 P. falciparum
AS+SP 2007–2011 0 0 1.5 28 days 6 P. falciparum
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Impact: On track for 50%-75% decrease in case incidence 2000-2015
III. Financing Sources of financing Financing by intervention in 2013 
V. Impact  Confirmed malaria cases per 1000 and ABER Malaria admissions and deaths (per 100 000)
IV. Coverage ITN and IRS coverage Cases tested and treated in public sector
 Cases tracked Test positivity
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Zambia African Region
I. Epidemiological profile
Population 2013 %
High transmission (> 1 case per 1000 population) 14 300 000 100
Low transmission (0–1 cases per 1000 population) 0 0
Malaria-free (0 cases) 0 0
Total 14 300 000 
Parasites and vectors
Major plasmodium species: P. falciparum (100%), P. vivax (0%)
Major anopheles species: An. gambiae, An. funestus, An. arabiensis
Programme phase: Control
Reported confirmed cases:  
Reported deaths: 3548 
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 2005
 ITNs/LLINs distributed to all age groups Yes 1998
IRS IRS is recommended Yes – 
 DDT is authorized for IRS Yes –
Larval control Use of larval control recommended No –
IPT IPT used to prevent malaria during pregnancy Yes –
Diagnosis Patients of all ages should receive diagnostic test Yes –
 Malaria diagnosis is free of charge in the public sector Yes –
Treatment ACT is free for all ages in public sector Yes 2003
 Artemisinin-based monotherapies withdrawn Yes –
 Single dose of primaquine is used as gametocidal medicine for P. falciparum No –
 Primaquine is used for radical treatment of P. vivax No –
 G6PD test is a requirement before treatment with primaquine No –
 Directly observed treatment with primaquine is undertaken No –
 System for monitoring of adverse reactions to antimalarials exists No –
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) Yes –
 ACD of febrile cases at community level (pro-active) No –
 Mass screening is undertaken No –
 Uncomplicated P. falciparum cases routinely admitted No –
 Uncomplicated P. vivax cases routinely admitted No –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria AL 2002
First-line treatment of P. falciparum AL 2002
Treatment failure of P. falciparum QN 2002
Treatment of severe malaria QN 2002
Treatment of P. vivax – –
Dosage of primaquine for radical treatment of P. vivax –
Type of RDT used –
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
AL 2005–2012 0 0 6.7 28 days 12 P. falciparum
       
       
II. Intervention policies and strategies
Pie chart include 100% 
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Funding source(s): Government, 
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UNICEF, Other bilateral, Other 
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III. Financing Sources of financing Financing by intervention in 2013 
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I. Epidemiological profile
Population 2013 %
High transmission (> 1 case per 1000 population) 6 660 000 50
Low transmission (0–1 cases per 1000 population) 0 0
Malaria-free (0 cases) 6 660 000 50
Total 13 320 000 
Parasites and vectors
Major plasmodium species: P. falciparum (100%), P. vivax (0%)
Major anopheles species: An. arabiensis, An. gambiae, An. funestus
Programme phase: Control
Reported confirmed cases: 422 633 
Reported deaths: 352 
  Yes/ Year
Intervention Policies/strategies No adopted
ITN ITNs/LLINs distributed free of charge Yes 2009
 ITNs/LLINs distributed to all age groups Yes 2009
IRS IRS is recommended Yes 1947 
 DDT is authorized for IRS Yes 2004
Larval control Use of larval control recommended Yes –
IPT IPT used to prevent malaria during pregnancy Yes 2004
Diagnosis Patients of all ages should receive diagnostic test Yes 2009
 Malaria diagnosis is free of charge in the public sector Yes 2009
Treatment ACT is free for all ages in public sector Yes 2009
 Artemisinin-based monotherapies withdrawn Yes –
 Single dose of primaquine is used as gametocidal medicine for P. falciparum No –
 Primaquine is used for radical treatment of P. vivax No –
 G6PD test is a requirement before treatment with primaquine No –
 Directly observed treatment with primaquine is undertaken No –
 System for monitoring of adverse reactions to antimalarials exists Yes –
  Yes/ Year
Intervention Policies/strategies No adopted
Surveillance ACD for case investigation (reactive) Yes 2012
 ACD of febrile cases at community level (pro-active) No –
 Mass screening is undertaken No –
 Uncomplicated P. falciparum cases routinely admitted No –
 Uncomplicated P. vivax cases routinely admitted No –
   Year
Antimalaria treatment policy Medicine adopted
First-line treatment of unconfirmed malaria AL 2004
First-line treatment of P. falciparum AL 2004
Treatment failure of P. falciparum QN 2004
Treatment of severe malaria QN 2004
Treatment of P. vivax – –
Dosage of primaquine for radical treatment of P. vivax –
Type of RDT used P.f only
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine Year Min Median Max Follow-up No. of studies Species
AL 2006–2010 0 2.4 14.3 28 days 28 P. falciparum
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Annex 1 – Data sources and methods
Sections 1–8
Section 1: Introduction
Figure 1.1 The map shows the estimated incidence of malaria 
cases per 1000 population in 2013. See notes for Figures 8.3–8.5 
for estimation of malaria cases per 1000 population.
Figure 1.2 The map shows the proportion of a country’s 
population that lives on less than US$ 2 per day, as estimated 
by the World Bank.1
Section 2: Financing for malaria programmes
Figures 2.1 and 2.2 International financing data were obtained 
from three sources. The Global Fund supplied information 
on disbursements for malaria control to WHO up to 2013. 
Information on funding from the United States Agency for 
International Development (USAID) was obtained from 
ForeignAssistance.gov.2 Malaria funding for the United States 
Centers for Disease Control was obtained from Congressional 
Justifications and Operating Plans (1).3 For other development 
agencies, information on disbursements was available up to 
and including 2012, through the Organisation for Economic 
Co-operation and Development (OECD) Development 
Co-operation Directorate database on official development 
assistance (ODA).4 Contributions from the Department for 
International Development (DFID), United Kingdom of Great 
Britain and Northern Ireland (UK) were assumed to have 
increased in 2013 in line with 2010–2012 disbursements. 
For other agencies, funding for 2013 was assumed to have 
remained at 2012 levels. 
Domestic financing data were obtained from national malaria 
control programmes (NMCPs). Data included government total 
malaria budget and expenditures, broken down by programme 
components including malaria commodities, programme 
supervision and management, training, and behavioural 
change interventions. Where domestic financing data were 
not available, data from previous years were used. Domestic 
financing data do not include the cost of the time that health 
workers spend testing, treating and tracking malaria patients; 
capital costs (e.g. infrastructure or vehicles); and household 
spending on malaria prevention and treatment.
Figures 2.3 and 2.4 The potential for increasing global (domestic 
and international) malaria investments between 2014 and 2020 
was explored through two financing scenarios:
  Global investments from endemic and donor countries 
increase at the projected rate of total government 
expenditures estimated by the International Monetary Fund 
1  http://data.worldbank.org/products/wdi
2  http://www.foreignassistance.gov/web/default.aspx
3  http://www.cdc.gov/fmo/topic/Budget%20Information/
4  http://stats.oecd.org/Index.aspx?datasetcode=CRS1#
(IMF) for 2014–2020.5 In the case of multilateral donors such 
as the Global Fund to Fight AIDS, Tuberculosis and Malaria 
(Global Fund), the average growth rate of government 
expenditures for all the countries contributing to the 
Global Fund over the 2014–2020 period was used.6 For the 
European Union (EU), which is a Global Fund contributor, 
the average government expenditure growth rate of EU 
countries contributing to the Global Fund’s budget in 
2011–2013 was used.
  Data on net ODA from countries that participated in funding 
malaria control and elimination activities between 2010 
and 2013 were used to calculate a donor investment effort 
for 2012,7 as the percentage of the donor country’s gross 
national income (GNI) allocated to ODA. The 2012 global 
average donor investment effort was then compared 
to the 0.7% target of GNI for ODA by 2015 (2, 3), and the 
necessary rate of increase was calculated for the 2012 global 
investment effort to reach the 2015 target of 0.7%. The rate 
of increase was then applied to international investments 
in malaria control until 2015. It was assumed that, after 
2015, investments in malaria control and elimination would 
match the rate of increase of total government expenditures 
estimated by the IMF for 2016–2020. This second scenario 
also assumed that governments of endemic countries 
increase the priority they give to malaria funding. Levels 
of investment priority for malaria were estimated using 
the domestic investment priority index (DIPI), calculated as 
(government spending on malaria/government revenue) × 
(total population/population at risk). Countries were then 
classified into quartiles depending on their DIPI. Countries 
in the lowest quartile, Q1 (i.e. with DIPI ≤25th percentile), 
were assumed to increase their investment in malaria 
to reach the level of priority of countries in Q2. Similarly, 
countries in Q2 were assumed to increase their investments 
to the level of the next quartile (Q3). Countries in Q3 or 
Q4 were assumed to increase their investments in malaria 
control and elimination at the same rate of growth as their 
total government expenditures (as under scenario 2). For 
countries with insufficient data available for calculating the 
DIPI, it was assumed that spending increased at the same 
rate as government expenditures; for countries for which 
there were no IMF data, it was assumed that domestic 
funding remained constant.
Section 3: Vector control for malaria
Tables 3.1 and 3.2 Policies regarding vector control interventions 
were reported to WHO by NMCPs.
5  http://www.imf.org/external/pubs/ft/weo/2014/02/weodata/weoselgr.
aspx
6  http://www.theglobalfund.org/en/partners/governments/
7  http://www.oecd.org/dac/stats/documentupload/ODA%202013%20
Tables%20and%20Charts%20En.pdf
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Figures 3.1 and 3.2 Estimates of insecticide-treated mosquito 
net (ITN) coverage were derived from a model developed by the 
Malaria Atlas Project (MAP), University of Oxford. The model built 
on two earlier studies that sought to model aspects of ITN delivery, 
distribution and coverage – a study by Flaxman et al. (4) and the 
work of Killian, which culminated in the NetCALC tool (5) – and a 
series of related publications (6). A two-stage process was followed. 
First, a mechanism was defined for estimating net crop – that is, the 
total number of ITNs in households in a country at a given point in 
time – taking into account inputs to the system (e.g. deliveries of 
ITNs to a country) and outputs (e.g. the discard of worn ITNs from 
households). Second, empirical modelling was used to translate 
estimated net crops into resulting levels of coverage (e.g. access 
within households).
Sources of data for the models
  Long-lasting insecticidal nets (LLINs) delivered to countries: Milliner 
Global Associates provided data to WHO by on the number of 
LLINs delivered by approved manufacturers to each country 
each year (7). The data were complete for each country from 
2000 to 2013 inclusive.
  ITNs distributed within countries: NMCPs provided data to WHO 
on the number of conventional ITNs and LLINs distributed 
annually within each country. Data were available for 400 of 
the 616 country-years addressed in the study.
  Nationally representative household surveys: a total of 93 national 
surveys from 39 sub-Saharan African countries from 2001 to 
2013 were assembled, covering 15% of all possible country-
years since 2000. For 89 of the 93 surveys, it was possible to 
access the underlying data; for the remaining four surveys, 
data from the survey reports were used.
Countries and populations at risk
The main analysis covered 40 of the 47 (8) malaria endemic 
countries or areas of sub-Saharan Africa. The islands of Mayotte 
(for which no ITN delivery or distribution data were available) 
and Cabo Verde (which does not distribute ITNs) were excluded, 
as were the low-transmission countries of Namibia, Sao Tome 
and Principe, South Africa and Swaziland, for which ITNs make 
up a small proportion of vector control. Analyses were limited to 
populations categorized by NMCPs as being at risk.
Estimating national net crops through time
As outlined in Flaxman et al. (4), national ITN systems were 
represented using a discrete time stock-and-flow model. Nets 
delivered to a country by manufacturers were modelled as first 
entering a “country stock” compartment (i.e. stored in-country 
but not yet distributed to households). Nets were then available 
from this stock for distribution to households by the NMCP or 
other distribution channels. To accommodate uncertainty in 
net distribution, we specified the number of nets distributed in 
a given year as a range, with all available country stock (i.e. the 
maximum nets that could be delivered) as one extreme and the 
NMCP-reported value (i.e. the assumed minimum distribution 
level) as the other. New nets reaching households joined older 
nets remaining from earlier time-steps to constitute the total 
household net crop, with the duration of net retention by households 
governed by a loss function. Rather than fitting the loss function 
to a small external dataset, as was done by Flaxman et al., the loss 
function was fitted directly to the distribution and net crop data 
within the stock-and-flow model itself. Loss functions were fitted 
on a country-by-country basis, allowed to vary through time, and 
defined separately for conventional ITNs and LLINs. The fitted loss 
functions were compared to existing assumptions about rates of 
net loss from households. The stock-and-flow model was fitted 
using Bayesian inference and Markov chain Monte Carlo (MCMC) 
methods, providing time-series estimates of national household 
net crop for conventional ITNs and LLINs in each country, together 
with evaluation of under-distribution, all with posterior credible 
intervals.
Estimating national ITN access and use indicators from net crop
Rates of ITN access within households depend not only on the 
total number of ITNs in a country (i.e. net crop), but also on how 
those nets are distributed between households. One aspect that 
is known to strongly influence the relationship between net crop 
and the distribution of household ownership of nets is the size of 
households found in different countries (6), which varies greatly 
across sub-Saharan Africa.
Many recent national surveys report the number of ITNs observed 
in each surveyed household. These data make it possible not 
only to estimate net crop, but also to generate a histogram that 
summarizes the net ownership pattern (i.e. the proportion of 
households with zero nets, one net, two nets and so on). In this 
way, the size of the net crop can be linked to distribution patterns 
among households, taking into account household size, making it 
possible to generate ownership distributions for each household 
size stratum. The bivariate histogram of net crop to distribution of 
nets among households by household size allowed for calculation 
of the proportion of households with at least one ITN. Also, because 
the number of both ITNs and people in every household can be 
triangulated, this histogram allowed for the direct calculation of 
two additional indicators: the proportion of households with at 
least one ITN for every two people, and the proportion of the 
population with access to an ITN within their household.
For the final ITN indicator – the proportion of the population who 
slept under an ITN the previous night – the relationship between 
ITN use and each of the three access indicators was explored 
in 74 of the 93 national surveys for which sufficient data were 
available. The proportion of the population with access to an ITN 
within their household displayed the largest correlation (adjusted 
R2 = 0.96). This relationship was fitted using a simple Bayesian 
regression model, which was used to predict a time series of ITN 
use for every country.
WORLD MALARIA REPORT 2014 | 169
A
nn
ex
 1
 –
 D
at
a 
so
ur
ce
s 
an
d 
m
et
ho
ds
 (c
on
tin
ue
d)
Estimating ITN requirements to achieve universal access
The two-stage modelling framework represented the pathway 
from ITN delivery from manufacturers through to resulting 
levels of net access and use in households. It also accounted 
for two potential factors that may reduce access levels (i.e. the 
efficiency of allocation of nets to households during distribution, 
and the loss of nets from households over time), and allowed 
these to be quantified through time for each country. Using 
this architecture, it was possible to simulate delivery of any 
volume of ITNs to a given country over a given future time 
period, to predict the levels of access and use that would result, 
and to examine the impact of different amounts of allocation 
efficiency and net loss. The model was used to estimate the 
levels of access likely to be achieved by 2016 under a broad 
spectrum of LLIN delivery levels across the 4-year period. These 
simulations were run under two scenarios: the first being 
“business-as-usual”, where current levels were maintained for 
allocation efficiency and net loss (~a 2-year median retention 
time), and the second using maximized allocation efficiency 
and a 3-year median retention time.
Figure 3.3 The number of ITNs available in households was 
derived from the ITN coverage model described above. The 
number of ITNs (LLINs and conventional ITNs) distributed within 
countries were reported by NMCPs to WHO. The number of 
LLINs delivered to malaria endemic countries was reported 
by the seven World Health Organization Pesticide Evaluation 
Scheme (WHOPES)-approved manufacturers.
Figure 3.4 Estimates of the number of ITNs needed for different 
levels of access to nets in the population were derived from 
the ITN coverage model described above.
Figure 3.5 A total of 50 household surveys from 31 countries, 
conducted between 2000 and 2013, were analysed to establish a 
relationship between the proportion of different subpopulations 
sleeping under ITNs (children aged under 5 years, children aged 
5–19 years and pregnant women) and the total population 
sleeping under an ITN. The results of the linear regression 
were then applied to estimates of the proportion of the total 
population sleeping under an ITN, produced by the model 
described above.
Figure 3.6 The proportion of households using ITNs below, at 
or above the standard capacity of two persons per net was 
calculated by comparing the number of persons with access to 
an ITN in each household to the number of persons who slept 
under an ITN as recorded in household surveys. Households 
in which the number of persons sleeping under an ITN was 
the same or greater than the number of persons who could 
have slept under an available ITN were categorized as using 
ITNs at or above capacity. Households in which the number 
of persons sleeping under an ITN was less than the number of 
persons who could have slept under an ITN were categorized 
as using ITNs below standard capacity.
Figure 3.7 The number of persons protected by indoor residual 
spraying (IRS) and the population at risk of malaria was reported 
by NMCPs to WHO.
Figure 3.8 See notes for Figures 3.1, 3.2 and 3.7 for derivation of 
the population at risk with access to an ITN in their household, 
and the proportion benefitting from IRS. Analysis of household-
survey data indicates that about half of the people in IRS-sprayed 
households are also protected by ITNs (9). Therefore, the 
proportion of the population protected by either ITNs or IRS 
was estimated by adding half the proportion of the population 
protected by IRS to the proportion with access to an ITN. The 
coverage estimate is for June 30, 2013.
Figures 3.9 and 3.10 Insecticide resistance monitoring results 
were collected from NMCP reports to WHO, the African Network 
for Vector Resistance, the MAP, the PMI and the published 
literature. In these studies, confirmed resistance was defined 
as mosquito mortality of <90% on bioassay test.
Section 4: Preventive therapies for malaria
Table 4.1 Policies regarding preventive therapies were reported 
by NMCPs to WHO. The number of countries where seasonal 
malaria chemoprevention, intermittent preventive treatment 
in pregnancy (IPTp) and intermittent preventive treatment in 
infants (IPTi) are appropriate was based on criteria described 
in published WHO guidance for these interventions (10).
Figure 4.1 The number of pregnant women who attended 
an antenatal care clinic at least once and who received one, 
two or three doses of IPTp was derived from NMCP reports to 
WHO. The number of pregnant women receiving IPTp beyond 
their first trimester was calculated using the population at risk 
of malaria and the crude birth rate adjusted for still births and 
spontaneous abortions after the first trimester, published by 
the United Nations (UN) Development Programme (8):
2013 population at risk (country-specific) × crude birth rate 
(country-specific) × (1.023 [to account for all still births] × 
1.004 [to account for spontaneous abortions after the first 
trimester])
For countries that reported on at least one of the IPTp data 
elements for 2013, having no visible bar for a data element 
denotes missing data. The Central African Republic, Gabon, 
Namibia, Nigeria and Somalia did not report on any IPTp data 
elements for 2013.
Figure 4.2 The proportion of pregnant women in the population 
receiving IPTp was derived from both NMCP-reported data 
and household survey data.
  Using NMCP reports and expected number of pregnancies 
in the population, as described above, the median value 
of the proportion of pregnant women who were receiving 
one dose of IPTp was calculated for each year, among 
reporting countries, from 2000 to 2013.
  For the estimates based on household survey data, the 
proportion of pregnant women receiving one, two or 
three or more doses of IPTp was calculated by approximate 
year of pregnancy, as determined by child-birth date in 
the household member roster. Most household surveys 
collected information on pregnancies during the 3–5 years 
before the survey date. IPTp indicators recommended by 
WHO and the Roll Back Malaria (RBM) Partnership Monitoring 
and Evaluation Reference Group (MERG) were reported by 
household survey year; the indicators include births within 
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2 years of the survey date, in an attempt to reduce recall bias 
regarding pregnancies that occurred more than 2 years before 
the survey. Calculating receipt of IPTp by year of pregnancy 
for all years covered by the survey increases the amount of 
information available to assess trends across countries. The 
observations for all surveys with data for a given year were 
combined and reweighted, based on type of survey, survey 
sampling design and country-year population estimates. The 
country-year point estimates were recalculated using the 
new weights. The median and interquartile range were then 
calculated among countries that had point estimates each 
year from 2000 to 2013.
  Since few surveys with 2013 data were available, the estimates 
from 2013 household survey data for the first, second and third 
dose of IPTp shown in Figure 4.2 are projections from 6-year 
linear trend analyses. The NMCP data-derived estimates for 
first-dose IPTp (also shown in Figure 4.2) were not a projection; 
they provide the most recent and comprehensive estimates 
of IPTp coverage across countries implementing IPTp in Africa.
Section 5: Malaria diagnostic testing
Table 5.1 Policies regarding diagnostic testing were reported by 
NMCPs to WHO.
Figure 5.1 The proportion of suspected malaria cases receiving 
a malaria diagnostic test in public facilities was calculated from 
NMCP reports to WHO. The number of malaria diagnostic tests 
performed included the number of rapid diagnostic tests (RDTs) 
and microscopic slide examinations. Few countries reported the 
number of suspected malaria cases as an independent value. For 
countries reporting the total number of malaria cases as presumed 
malaria cases (i.e. cases classified as malaria without undergoing 
malaria parasitological testing) and confirmed malaria cases, the 
number of suspected cases was calculated by adding the number 
of negative diagnostic tests to the number of presumed and 
confirmed cases. Using this method for countries that reported 
only confirmed malaria cases for the total number of malaria 
cases, the number of suspected cases was equal to the number 
of cases tested. Such data are not informative when determining 
the proportion of suspected cases tested; therefore, countries 
were excluded from the regional calculation for those years in 
which they reported only confirmed cases for total malaria cases.
Figure 5.2 The proportion of children aged under 5 years with fever 
who received a finger or heel stick, and where they were brought 
for care, were calculated from available household survey data for 
2000–2014 (the most recent surveys from 29 countries). Places of 
care that were included in the public sector health management 
information system were categorized as public facilities, and 
included public clinics and hospitals. Private facilities included 
private clinics, pharmacies and shops.
Figures 5.3, 5.4 and 5.5 Manufacturers reporting the number 
of RDT sales included 41 manufacturers that participate in RDT 
product testing by WHO, the Foundation for Innovative New 
Diagnostics (FIND), the United States Centers for Disease Control 
and Prevention (CDC) and the Special Programme for Research and 
Training in Tropical Diseases (TDR). The number of RDTs reported 
by manufacturers represents total sales to the public and private 
sector worldwide. The number of RDTs and artemisinin-based 
combination therapies (ACTs) distributed within countries by 
national programmes are reported by NMCPs to WHO, as are the 
number of microscopic examinations of blood slides performed 
for malaria parasites and number of RDTs performed.
Figure 5.6 Results of RDT product testing conducting by WHO, 
FIND, CDC and TDR were taken from Malaria rapid diagnostic test 
performance: Results of WHO product testing of malaria RDTs: Round 5 (11). 
The panel detection score used to quantify RDT performance is an 
index that measures test positivity as well as inter-test and inter-lot 
consistency. The score is the frequency with which all RDTs tested 
on a sample in the evaluation panel are positive (two RDTs from 
each of two lots positive against 200 parasite/µl sample, and one 
RDT from each lot positive for 2000–5000 parasite/µl sample). 
Therefore, for a sample at 200 parasites/µl, four of four tests have 
to be positive for that sample to be considered detected by RDT; 
for a sample at 2000–5000 parasites/µl two of two tests have to 
be positive for that sample to be considered detected by RDT.
Section 6: Malaria treatment
Table 6.1 Policies regarding malaria treatment were reported by 
NMCPs to WHO.
Figure 6.1 The proportion of children with uncomplicated malaria 
(defined as fever in the 2 weeks preceding the survey and parasite 
infection measured by an RDT at the time of the survey) receiving 
an ACT was estimated for all countries in sub-Saharan Africa in 
2003–2012, using a three-step modelling approach:
1. Fitting a model to predict whether a child with fever has a 
malaria infection: For 37 countries with a demographic and 
health survey (DHS) or malaria indicator survey (MIS), the malaria 
parasite infection status of a child was assessed from an RDT 
given at the time of the survey. It was assumed that a positive 
RDT provides a reasonable measure of a 2-week prevalence 
of infection (12-14). A logistic regression model was created to 
predict malaria parasite infection amongst febrile children in 
surveys in which RDT testing was not performed. Covariates 
in the model included the child’s age and sex, household 
wealth quintile, ITN ownership, facility type where treatment 
was sought (public or other), urban or rural status, and malaria 
transmission intensity, as measured by the Plasmodium falciparum 
parasite rate (PfPR) of children aged 2–10 years (PfPR2–10).
2. Predicting the infection status of children in surveys in which 
RDTs were not used: Coefficients estimated from the logistic 
regression model in Step 1 were used to obtain predictions of 
infection status among all children with a fever from DHS and 
multiple indicator cluster surveys (MICS) in which RDT testing 
had not been performed (66 surveys). The national survey-
weighted proportion of febrile children with a malaria parasite 
infection (RDT measured or imputed) aged under 5 years who 
received an ACT was then calculated for all surveys.
3. Estimating the proportion of children with malaria that received 
an ACT: ACT distribution data reported by NMCPs were used 
to calculate a predicted ACT “availability” per person at risk for 
P. falciparum malaria in each country. A linear model was then 
created to predict the proportion of children with malaria 
receiving an ACT, using ACT availability per capita in the 
current and previous year as a covariate. Additional covariates, 
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obtained from the World Bank dataset,8 included national 
ITN coverage (by year), measles vaccination coverage, GNI 
and the proportion of births with a skilled birth attendant. 
The model was run in a Bayesian framework using MCMC 
methods, and included uncorrelated random effects for each 
country and correlated (autoregressive) random effects for 
each year. For non-survey years, the proportion of children 
who received ACT for each country and year (2003–2012) 
was imputed based on the relationship between ACT 
coverage and ACT availability across countries.
Publicly available sources of population-based survey data 
were considered if they included a module assessing fever 
treatment for children aged under 5 years, categorized by type of 
antimalarial received. For the period 2003–2012, 16 MIS, 55 DHS 
and 20 MICS were included. Estimates of mean PfPR2–10, as 
well as the total population at risk of malaria, were ascertained 
from the MAP for 2010. Population growth rates were derived 
from the UN Population Prospects database.9
Figure 6.2 The proportion of children aged under 5 years brought 
for care, and where they were brought for care, were calculated 
from the most recent household survey undertaken for each 
country in sub-Saharan Africa (a total of 29 surveys). Public 
sector places of care included hospitals, health centres and 
health posts. The formal private sector included private clinics 
and doctors. The informal private sector included pharmacies, 
drug stores, shops and traditional healers. Community included 
care provided by community health workers.
Figures 6.3 and 6.4 Data on ACT sales were provided by eight 
manufacturers eligible for procurement by WHO/United Nations 
Children’s Fund (UNICEF). ACT sales were categorized as either 
to the public sector or to the private sector, and products were 
grouped according to type of ACT and product presentation 
(i.e. co-formulated and co-blistered). Data on ACTs distributed 
within countries through the public sector were taken from 
NMCP reports to WHO.
Figure 6.5 The availability of ACTs in public sector health facilities 
was measured as the ratio of distributed ACTs reported by 
NMCPs to the estimated number of presumed and confirmed 
malaria cases attending public sector health facilities. For 
countries outside Africa and countries in Africa with consistent 
reporting, the estimated number of presumed and confirmed 
cases in the public sector was derived from NMCP reports, 
corrected for reporting completeness. For countries in Africa 
with inconsistent reporting, the estimated number of presumed 
and confirmed cases in the public sector was derived from the 
estimated number of confirmed malaria cases (see Section 
8.3); the proportion of suspected cases tested; and the slide 
positivity rate (SPR), where:
estimated presumed case = 1 − (% suspected cases 
tested × estimated confirmed cases / SPR)
The proportion of children aged under 5 years with fever who 
received ACT among those who received any antimalarial 
treatment was calculated from available household survey data 
8  http://data.worldbank.org/products/wdi
9  http://esa.un.org/unpd/wpp/unpp/panel_population.htm
for countries in sub-Saharan Africa for 2005–2013. Definitions 
of public sector and private places of care were as described in 
the diagnostic testing section. Places of care that were included 
in the public sector health management information system 
were categorized as public facilities, and they included public 
clinics and hospitals. Private facilities included private clinics, 
pharmacies and shops. For recent surveys for which the dataset 
was not available but a written report had been released, the 
proportion of ACTs among any antimalarial treatment given 
was imputed based on the relationship between the indicator 
for all febrile children and for those children in the public and 
private sector in other household surveys.
Figure 6.6 The proportions of children aged under 5 years, 
attending public facilities and with confirmed malaria, who 
received ACT or did not receive ACT were derived from the ACT 
treatment model described above. Similarly, the proportion 
of children without malaria receiving ACT and the proportion 
not receiving ACT were also derived from the model, as was 
the proportion of febrile patients attending public facilities 
with confirmed malaria, defined as a positive RDT at the time 
of the household survey.
Section 7: Gaps in intervention coverage
Figure 7.1 Data on intervention coverage were derived from 
nationally representative household survey data from MICS, 
MIS and DHS conducted in 2011–2013. In total, 21 surveys 
included data about households without nets; 20 surveys 
included data on pregnant women who did not receive IPTp; 
and 23 surveys included data on febrile children aged under 
5 years who did not seek treatment and did not receive an ACT, 
20 of which also included data on febrile children who did not 
receive a diagnostic test. For each survey, the proportions of 
households or children aged under 5 years not covered by a 
given intervention were calculated over the entire population 
and within various subpopulations, taking into account the 
sampling design. The median de facto household population 
size within each survey was calculated for inclusion in the final 
analysis. The quartile estimates and interquartile ranges were 
calculated across all of the country-level proportions.
Figure 7.2 The proportions of the subpopulations not covered 
by a given intervention within each survey were assembled and 
used to fit linear regression models for each service, to predict 
the overall lack of coverage. The choices of subpopulations 
were based on published literature reviews that identified 
the factors most likely to influence coverage estimates. For 
the household-level analysis, the subpopulations included 
levels of wealth, presence (or lack) of at least one pregnant 
woman or child aged under 5 years, education level of the 
household head, type of residence and relative household 
size. For the child-level analyses, the subpopulations included 
levels of household wealth, type of residence, education level 
of the mother, age of the child, gender of the child and relative 
household size. Model selection was based on the optimal 
R2, Akaike information criterion and Bayesian information 
criterion scores for all possible predictor combinations. The 
decomposition of the R2 goodness-of-fit estimator for linear 
models has been suggested as a method to describe the 
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relative contribution of predictors across the entire distribution of 
a continuous outcome (15). In this analysis, the decompositions of 
the goodness-of-fit estimators for each linear model, presented 
as Owen decomposition values, describe the degree to which 
different factors contributed to the observed lack of coverage across 
the surveys. This does not necessarily imply a causal relationship, 
and the contributions of the individual factors do not necessarily 
reflect their level of statistical significance in any given country.
Figure 7.3 The country-specific differences in coverage between 
levels of endemicity were examined by calculating the absolute 
difference between the intermediate-to-high malaria risk coverage 
estimates and the no-to-low malaria risk coverage estimates. The 
malaria endemicity level was determined by extracting the raster 
values from the data layers of MAP’s forthcoming 2000–2013 time 
series of PfPR at all available survey cluster locations, and classifying 
those within each cluster as having no-to-low risk or intermediate-
to-high risk of malaria. The cluster-level extraction data from PfPR 
raster values were provided by the MAP. The household-level 
analysis used cluster-level classifications based on PfPRs for the 
year 2000 to take into account the impact of ITNs on the parasite 
rate. In the other analyses, endemicity classifications were based 
on the PfPRs for the survey year.
Section 8: Trends in infections, cases and deaths
Figures 8.1 and 8.2 The main source of information on reported 
numbers of malaria cases and deaths are the disease surveillance 
systems operated by ministries of health. Data from such systems 
have three strengths: (i) case reports are recorded continuously 
over time and can thus reflect changes in the implementation of 
interventions or other factors; (ii) routine case and death reports 
are often available for all geographical units of a country; and 
(iii) the data reflect the burden that malaria places on the health 
system. Changes in the numbers of cases and deaths reported 
by countries do not, however, necessarily reflect changes in the 
incidence of disease in the general population, for several reasons. 
First, not all health facilities report each month; hence, variations 
in case numbers may reflect fluctuations in the number of health 
facilities reporting rather than a change in underlying disease 
incidence. Second, routine reporting systems often do not include 
patients attending private clinics or morbidity treated at home, so 
disease trends in health facilities may not reflect trends in the entire 
community. Finally, not all malaria cases reported are confirmed by 
microscopy or RDT; hence, some of the cases reported as malaria 
may actually be other febrile illnesses (16, 17).
When reviewing data supplied by ministries of health in malaria 
endemic countries, the following strategy was used to minimize 
the influence of these sources of error and bias:
  Focusing on confirmed cases (by microscopy or RDT) to ensure 
that malaria (not other febrile illnesses) was tracked. For high-
burden countries in the WHO African Region, where there is 
little confirmation of cases, the numbers of malaria admissions 
(in-patient cases) and deaths were reviewed, because the 
predictive value of malaria diagnosis for an admitted patient is 
considered to be higher than that of an outpatient diagnosis. 
In such countries, the analysis may be heavily influenced by 
trends in cases of severe malaria rather than trends in all cases.
  Monitoring the number of laboratory tests undertaken. It is 
useful to measure the annual blood examination rate (ABER), 
to ensure that potential differences in diagnostic effort or 
completeness of reporting are taken into account. To discern 
decreases in malaria incidence, the ABER should ideally remain 
constant or be increased. In addition, it is useful to monitor 
the percentage of suspected malaria cases that are examined 
with a parasite-based test. Some authorities recommend that 
the ABER should be >10%, to ensure that all febrile cases are 
examined; however, the observed rate depends partly on how 
the population at risk is estimated, and trends may still be valid 
if the rate is <10%. A value of 10% may not be sufficient to 
detect all febrile cases. In Solomon Islands, a highly endemic 
country, the ABER exceeds 60%, with an SPR of 25%, achieved 
solely through passive case detection.
  Monitoring trends in the SPR or RDT positivity rate. This rate 
should be less severely distorted by variations in the ABER than 
trends in the number of confirmed cases.
  Monitoring malaria admissions and deaths. For high-burden 
African countries, when reviewing the number of malaria 
admissions or deaths, it is also informative to examine the 
number of admissions from all causes, which should remain 
constant or be increased. If the total number of admissions 
fluctuates, then it may be preferable to examine the percentage 
of admissions or deaths due to malaria, because this proportion 
is less sensitive to variation in reporting rates than the number 
of malaria admissions or deaths.
  Monitoring the number of cases detected in the surveillance 
system in relation to the total number of cases estimated to 
occur in a country. Trends derived from countries with high 
case detection rates are more likely to reflect trends in the 
broader community. When examining trends in the number 
of deaths, it is useful to compare the total number of deaths 
occurring in health facilities with the total number of deaths 
estimated to occur in the country.
  Examining the consistency of trends. Unusual variation in the 
number of cases or deaths that cannot be explained by climate 
or other factors, or inconsistency between trends in cases and 
in deaths, can suggest deficiencies in reporting systems.
  Monitoring changes in the proportion of cases due to 
P. falciparum or the proportion of cases occurring in children 
aged under 5 years. Decreases in the incidence of P. falciparum 
malaria may precede decreases in P. vivax malaria, and there 
may be a gradual shift in the proportion of cases occurring in 
children aged under 5 years; however, unusual fluctuations 
in these proportions may point to changes in health-facility 
reporting or to errors in recording.
These procedures help to rule out data-related factors (e.g. 
incomplete reporting or changes in diagnostic practice) as 
explanations for a change in the incidence of disease. The aim 
is to ensure that trends in health-facility data reflect changes in 
the wider community, which is more likely in situations where 
changes in disease incidence are large; coverage with public health 
services is high; and interventions promoting change, such as use 
of ITNs, are delivered throughout the community rather than being 
restricted to health facilities.
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Where data reported by NMCPs were sufficiently complete 
and consistent to reliably assess trends between 2000 and 
2013, a country was classified as being on track to achieve, 
by 2015, a decrease in case incidence of >75%, 50–75% or 
<50%, or to experience an increase in case incidence by 2015, 
using 2000 as the baseline. A 75% reduction in malaria case 
incidence is equivalent to a 5% reduction per year between 
2000 and 2015. Thus, to achieve a reduction of 75% by 2015, 
countries need to have reduced the incidence of malaria by 
at least 65% between 2000 and 2013. Countries that reduced 
malaria incidence rates by 43–65% between 2000 and 2013 
are projected to achieve reductions in malaria case incidence 
of 50–75% in 2015.
Table 8.1 The criteria used to classify countries according to 
programme phase were updated in 2012 to facilitate tracking 
of progress over time (18). The updated criteria are based 
on an evaluation of three main components: the malaria 
epidemiological situation, case-management practices and 
the state of the surveillance system (as shown in Table A.1). The 
evaluation concentrates on the situation in those districts of 
the country reporting the highest annual parasite index (API). 
Other components – for example, the stated programme goal, 
vector control and malaria prevention practices, and health 
systems and financing – are also important for tracking progress 
towards elimination; however, they are less specific and are 
therefore not included as classification criteria.
Table A.1  Criteria for classifying countries according to malaria programme phase
Pre-elimination Elimination Prevention of reintroduction
Malaria situation in areas with most intense 
transmission
(1)  Recently endemic country with zero local 
transmission for at least 3 years; or 
(2)  country on the register or supplementary 
list that has ongoing local transmissiona
Test positivity rate <5% among suspected malaria patients (PCD) throughout the year
API in the district with the highest number of 
cases/1000 population/ year (ACD and PCD),b averaged 
over the past 2 years
<5 (i.e. fewer than 
5 cases/1000 population)
<1 (i.e. fewer than 1 case/1000 
population)
Total number of reported malaria cases nationwide A manageable number (e.g. <1000 cases, local and imported) nationwide 
Case management Imported malaria. Maintain capacity to 
detect malaria infection and manage clinical 
disease
All cases detected in the private sector are 
microscopically confirmed National policy being rolled out Yes Yes
All cases detected in the public sector are 
microscopically confirmed National policy being rolled out Yes Yes
Nationwide microscopy quality assurance system 
covers public and private sector Initiated Yes Yes
Radical treatment with primaquine for P. vivax National policy being updated National policy fully implemented Yes
Treatment with ACT plus single-dose primaquine for 
P. falciparum National policy being updated National policy fully implemented Yes
Surveillance Vigilance by the general health services 
Malaria is a notifiable disease nationwide 
(<24–48 hours) Laws and systems being put in place Yes Yes
Centralized register on cases, foci and vectors Initiated Yes Yes
Malaria elimination database Initiated Yes Certification process (optional)
Active case detection in groups at high risk or with poor 
access to services (proactive case detection) Initiated Yes
In residual and cleared-up foci, among 
high-risk population groups 
Case and foci investigation and classification 
(including reactive case detection and entomological 
investigation)
Initiated Yes Yes
ABER: annual blood examination rate; ACD: active case detection; API: annual parasite index; PCD: passive case detection.
a Ongoing local transmission = 2 consecutive years of local P. falciparum malaria transmission, or 3 consecutive years of local P. vivax malaria transmission, in the same locality or otherwise 
epidemiologically linked.
b The API has to be evaluated against the diagnostic activity in the risk area (measured as the ABER). Low values of ABER in a district raise the possibility that more cases would be found with 
improved diagnostic efforts.
Figures 8.3–8.5
Maps of P. falciparum infection prevalence (PfPR
2-10
) and associated 
national-level estimates of average PfPR
2-10
 for countries in 
sub-Saharan Africa were derived from a geostatistical modelling 
framework developed by the MAP. The model drew on three 
categories of data:
  Geopositioned community-based survey measurements 
of PfPR were identified through periodic literature searches 
for published data sources, direct communication with 
malaria specialists for unpublished data sources, and national 
household surveys. Surveys were primarily conducted in 
children aged under 5 years, although those based on 
any defined age range of individuals were included. Most 
surveys were conducted using microscopy or RDTs to 
identify infected individuals. After checks for consistency, 
completeness and duplication, a final assembly was defined 
for subsequent modelling consisting of 28 361 spatio-
temporally unique observations at time points between 
1995 and 2014.
  Input data layers were also assembled, to represent levels 
of intervention coverage. For ITNs, national-level trends in 
ITN use were taken from the coverage model described 
earlier (see Section 3). This was used in conjunction with a 
geostatistical model to generate a continuous space-time 
“cube” predicting the proportion of individuals sleeping 
under an ITN the previous night for every 5 × 5 km pixel, 
and expressed as an annual mean. For IRS, annual reports 
from NMCPs were assembled, detailing the proportion of 
the population at risk targeted for coverage each year (note: 
this does not necessarily represent the proportion ultimately 
receiving and protected by the intervention). For ACTs, 
national household survey data were assembled from 93 
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surveys on the proportion of children with fever accessing an 
ACT; this was used as a proxy for access to effective antimalarial 
drugs in clinical malaria cases across the population as a whole. 
To estimate this coverage in country-years for which no was 
survey available, an empirical model was built that related 
coverage levels to the number of ACT courses distributed 
per capita in each country each year. The latter variable was 
available from NMCP reported data, and was largely complete 
for the period 2000–2013.
  A suite of 20 environmental and sociodemographic geospatial 
input layers were also developed and used as covariates in the 
PfPR model. Existing approaches to constructing and selecting 
covariates for this purpose are crucial, but have often been 
subjective and ad hoc (e.g. a huge variety of covariates are used 
in modelling with little quantitative justification). To address this, 
we undertook an exhaustive covariate construction and selection 
process. First, a literature review was conducted to establish a 
comprehensive list of variables that have been used as covariates 
in malaria mapping. Second, a large library of covariate data 
was assembled to reflect this list, including the construction 
of dynamic versions where possible. Third, the resulting set of 
33 base covariates was leveraged to create more than 50 million 
possible covariate terms via factorial combinations of different 
spatial and temporal aggregations, transformations and pair-
wise interactions. Fourth, the expanded set of covariates was 
tested via successive selection criteria to yield an optimum 
covariate subset that maximized out-of-sample predictive 
accuracy. The final subset included predominately dynamic 
covariates; it substantially out-performed earlier sets used in 
global malaria risk maps from the MAP.
These data sources were then used in a space–time Bayesian 
geostatistical model that was a more sophisticated version of an 
earlier approach constructed by the MAP (19). The new model 
included mechanisms to adjust the PfPR survey data by the age 
range of individuals observed, the season of each survey and the 
type of diagnostic used. The impact of interventions was modelled 
by fitting flexible functional forms to capture the separate effects 
of ITNs, IRS and ACTs on declining PfPR as a function of coverage 
reached, and the starting (pre-intervention) PfPR in the year 2000. The 
model was used to predict a spatio-temporal cube of age-specific 
PfPR at 5 × 5 km resolution across Africa for each year from 2000 
to 2013. Detailed maps of year-specific human population density 
from the WorldPop project10 were used, in conjunction with the 
PfPR cube, to calculate population-weighted mean PfPR
2-10
 for each 
country and each year. The average number of contemporaneous 
infections in each country and year was calculated by multiplying 
the annual mean all-age PfPR by the population in each pixel, then 
summing across all pixels in each country.
Tables 8.2 and 8.3, and Figures 8.6–8.8 The methods for producing 
estimates of malaria cases and deaths in 2000–2013 either adjusted 
the number of reported cases to take into account the proportion 
of cases that were not captured by a surveillance system or, for 
countries with insufficient surveillance data, produced estimates 
using a modelled relationship between malaria transmission, case 
incidence or mortality, and intervention vector control coverage, 
as outlined below.
10  http://www.worldpop.org.uk/
Cases The number of malaria cases was estimated by one of two 
methods:
  For countries outside the WHO African Region and 
low-transmission countries in Africa: estimates of the number of 
cases were made by adjusting the number of reported malaria 
cases for completeness of reporting, the likelihood that cases 
are parasite-positive and the extent of health-service use. The 
procedure, which is described in the World malaria report 2008 
(16, 20), combines data reported by NMCPs (reported cases, 
reporting completeness, likelihood that cases are parasite-
positive) with those obtained from nationally representative 
household surveys on health-service use. If data from more than 
one household survey were available for a country, estimates of 
health-service use for intervening years were imputed by linear 
regression. If only one household survey was available, then 
health-service use was assumed to remain constant over time; 
analyses summarized in the World malaria report 2008 indicated 
that the percentage of fever cases seeking treatment in public 
sector facilities varies little over time in countries with multiple 
surveys. Such a procedure results in an estimate with wide 
uncertainty intervals around the point estimate.
  For countries in the WHO African Region: for some African 
countries, the quality of surveillance data did not permit a 
convincing estimate to be made from the number of reported 
cases. For these countries, an estimate of the number of malaria 
cases was derived from an estimate of the number of people 
living at high, low or no risk of malaria. Malaria incidence rates 
for these populations were inferred from longitudinal studies 
of malaria incidence recorded in the published literature. 
Incidence rates were adjusted downwards for populations 
living in urban settings, and for the expected impact of ITN 
and IRS programmes. The procedure was initially developed 
by the RBM MERG in 2004 (21) and also described in the World 
malaria report 2008.
Deaths The number of malaria deaths was estimated by one of 
two methods:
  For countries outside the WHO African Region and for 
low-transmission countries in Africa:11 the number of deaths was 
estimated by multiplying the estimated number of P. falciparum 
malaria cases by a fixed case fatality rate for each country, as 
described in the World malaria report 2008. This method was 
used for all countries outside the WHO African Region and for 
countries within the WHO African Region where estimates of 
case incidence were derived from routine reporting systems 
and where malaria causes less than 5% of all deaths in children 
aged under 5 years, as described in the Global Burden of Disease 
2004 update (22). A case fatality rate of 0.45% was applied to the 
estimated number of P. falciparum cases for countries in the WHO 
African Region, and a case fatality rate of 0.3% for P. falciparum 
cases in other regions. In situations where the fraction of all 
deaths due to malaria is small, the use of a case fatality rate in 
conjunction with estimates of case incidence was considered 
to provide a better guide to the levels of malaria mortality than 
attempts to estimate the fraction of deaths due to malaria.
11  Botswana, Cabo Verde, Eritrea, Madagascar, Namibia, South Africa, Swaziland 
and Zimbabwe
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  For countries in the WHO African Region: child malaria 
deaths were estimated using a verbal autopsy multi-cause 
model developed by the WHO Child Health Epidemiology 
Reference Group to estimate causes of death for children 
aged 1–59 months in countries with less than 80% of vital 
registration coverage (23-25). A total of 128 data points 
from 95 verbal autopsy studies and 37 countries that met 
the inclusion criteria were included. Among them, 47 data 
points were either new or updated from the previous 
estimates of malaria deaths published in the World malaria 
report 2012. Mortality estimates were derived for seven 
causes of post-neonatal death (pneumonia, diarrhoea, 
malaria, meningitis, injuries, pertussis and other disorders), 
causes arising in the neonatal period (prematurity, birth 
asphyxia and trauma, sepsis, and other conditions of the 
neonate) and other causes (e.g. malnutrition). Deaths due 
to measles, unknown causes and HIV/AIDS were estimated 
separately. The resulting cause-specific estimates were 
adjusted country by country to fit the estimated 1–59 month 
mortality envelopes (excluding HIV and measles deaths) 
for corresponding years. Estimates were then further 
adjusted for intervention coverage; that is, pneumonia 
and meningitis estimates were adjusted for the use of 
Haemophilus influenzae type b vaccine, and malaria estimates 
were adjusted for the use of ITNs.
The bootstrap method was employed to estimate uncertainty 
intervals by re-sampling from the study-level data to in turn 
estimate the distribution of the predicted percentage of deaths 
due to each cause. Deaths in those above the age of 5 years 
were inferred from a relationship between levels of malaria 
mortality in different age groups and the intensity of malaria 
transmission (26); thus, the estimated malaria mortality rate in 
children aged under 5 years was used to infer malaria-specific 
mortality in older age groups.
Malaria incidence and mortality rates were estimated using “total 
population at risk for malaria” as a denominator. Projections 
to 2015 were based on a linear extrapolation of the trend in 
incidence and mortality rates from 2000 to 2013. 
Table 8.4, Figures 8.9 and 8.10 The number of cases averted 
and lives saved between 2001 and 2012 was estimated by 
calculating the number of cases and deaths that would have 
occurred if incidence and mortality rates had remained at 
2000 levels until 2013 (i.e. had there been no progress). The 
calculated number of cases and deaths was compared with 
the estimated number of cases and deaths presented above. 
The lower numbers of cases and deaths in 2013 compared to 
2000 may be due in part to factors other than the expansion 
of malaria programmes. Some progress is likely to be related 
to increased urbanization and overall economic development, 
which lead to improvements in housing and nutrition.
Regional profiles
Figure A. Incidence rates are derived from reports of confirmed 
malaria cases in 2013 (by microscopy or RDT) from ministries 
of health to WHO, and from the number of people living at risk 
for malaria in each geographical unit as reported by NMCPs. 
Incidence rates are corrected for reporting completeness by 
dividing by the proportion of health-facility reports received 
in 2013 by the number expected. If subnational data on 
population or malaria cases were lacking, an administrative 
unit was labelled “no data” on the map. In some cases, the 
subnational data provided by the NMCP did not correspond to 
a mapping area known to WHO, either because of modifications 
to administrative boundaries, or the use of names not verifiable 
by WHO. The maps for countries in sub-Saharan Africa display a 
combination of: cases per 1000 per year, and parasite prevalence 
in areas with >10 cases per 1000 population per year. To 
obtain a measure of combined parasite prevalence for both 
P. falciparum and P. vivax, the sum of the two independent parasite 
rates (19, 27) was calculated at each point (~5 km2). Data on 
environmental suitability for malaria transmission were used 
to identify areas that would be free of malaria.
Figure B. Sources of data for the financial contributions are as 
described for Figure 3.1.
Figure C. Sources of data for international and domestic 
contributions are as described in the notes for Figure 3.1. 
Funding per capita at risk was calculated by giving populations 
at low risk for malaria (i.e. those living in areas with fewer 
than one case reported per 1000 per year) half the weight of 
populations at high risk (i.e. those living in areas with one or 
more cases reported per 1000 per year). This procedure was 
followed to ensure that countries with populations at low risk 
for malaria could be included in the analysis, and also to take 
into account the greater need for malaria programmes and 
funds in countries with larger proportions of their population 
at high risk for malaria.
Figure D. For the WHO African Region and for Djibouti, Somalia 
and the Sudan in the WHO Eastern Mediterranean Region, the 
proportion of the population with access to an ITN is derived 
from a model that takes into account household survey data, 
ITNs distributed by NMCPs, and ITNs delivered by manufacturers 
(see methods for Figures 3.1 and 3.2). For other countries, the 
proportion of the population protected with ITNs is estimated 
from the number of ITNs delivered by NMCPs in the past 3 
years divided by the population at high risk. It is assumed 
that each net delivered can cover on average 1.8 people, that 
conventional nets are re-treated regularly, and that nets have a 
lifespan of 3 years. The denominator is the population living at 
high risk for malaria, since it is assumed that, in countries with 
lower levels of transmission, ITNs will be preferentially targeted 
to populations at higher risk. IRS coverage is calculated as the 
total number of people protected with IRS, divided by the 
population at high risk. There are limited data on the extent 
to which these interventions overlap, so the two bars simply 
represent the percentage of populations protected by the 
respective interventions individually.
Figure E. Few countries have information systems that record 
treatments given to individual patients. It is therefore necessary 
to use aggregate information on numbers of treatment courses 
delivered to public health facilities, and relate this information 
to the number of malaria cases among patients attending such 
facilities. For countries in the WHO African Region, the number 
of treatment courses available is calculated as the total number 
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of ACT courses distributed by a ministry of health, divided by the 
estimated number of presumed cases recorded as malaria (without a 
diagnostic test having been performed) plus confirmed P. falciparum 
malaria cases at public health facilities. In other WHO regions, the 
number of treatment courses available is shown as a percentage of 
confirmed malaria cases plus presumed malaria cases reported in 
the public sector, correcting for reporting completeness. The bars 
for any antimalarial treatment show the number of all treatment 
courses supplied in relation to all malaria cases of any plasmodium 
species, including the ACT to treat P. falciparum.
Figure F. The percentage of confirmed cases in which P. falciparum or 
a mixed infection was detected was calculated as the total number 
of P. falciparum and mixed infections between 2009 and 2013, divided 
by the number of confirmed cases over that period. For countries 
in the elimination phase, only locally acquired P. falciparum cases 
and mixed infections were considered.
Figure G. Analysis of changes in malaria incidence rates focuses 
on confirmed cases (by microscopy or RDT) reported by ministries 
of health, to ensure that malaria (not other febrile illnesses) is 
tracked. For countries in the WHO African Region, the figure shows 
percentage reductions in the rate of hospital admissions and 
deaths (except for Algeria, Botswana, Cabo Verde, Namibia, Sao 
Tome and Principe, South Africa, Swaziland and Zimbabwe) and 
in the rate of reported malaria deaths. Although the diagnosis of 
admitted patients is not always confirmed with a diagnostic test, 
the predictive value of diagnosis undertaken for an admitted patient 
is considered to be higher than for outpatient diagnosis. See notes 
for Figures 8.1 and 8.2 for more details of analysis undertaken.
Country profiles
I. Epidemiological profile
Maps: The procedures used for the map of confirmed cases per 1000 
population divided by parasite prevalence were the same as those 
used for Figure A of the regional profiles. For the map showing the 
proportion of cases due to P. falciparum, the total number of cases due 
to P. falciparum was divided by the total number of confirmed malaria 
cases. If no data were available for a subnational geographical area, 
or there were too few cases to calculate a reliable proportion, the 
area was highlighted as such. For areas where parasite prevalence 
was used, the total number of infections due to P. falciparum was 
divided by the total of P. falciparum and P. vivax infections. Data on 
environmental suitability for malaria transmission were used to 
identify areas that would be free of malaria.
Population: The total population of each country was taken from 
the 2012 revision of the World population prospects.12 The country 
population was subdivided into three levels of malaria endemicity, 
as reported by the NMCP: (i) areas of high transmission, where 
the reported incidence of confirmed malaria due to all species 
was >1 per 1000 population per year in 2013; (ii) areas of low 
transmission, where the reported malaria case incidence from 
all species was ≤1 per 1000 population per year in 2013, but >0 
(transmission in these areas is generally highly seasonal, with or 
12  http://esa.un.org/unpd/wpp/unpp/panel_population.htm
without epidemic peaks); and (iii) malaria free areas, where there is 
no continuing local mosquito-borne malaria transmission, and all 
reported malaria cases are imported. An area is designated “malaria 
free” when no cases have occurred for several years. Areas may be 
naturally malaria free because of factors that are unfavourable for 
malaria transmission (e.g. altitude or other environmental factors), 
or they may become malaria free as a result of effective control 
efforts. In practice, malaria free areas can be accurately designated 
by NMCPs only after the local epidemiological situation and the 
results of entomological and biomarker investigations have been 
taken into account. 
In cases where an NMCP did not provide the number of people 
living in high- and low-risk areas, the numbers were inferred from 
subnational case incidence data provided by the programme. 
The population at risk is the total population living in areas where 
malaria is endemic (low and high transmission), excluding the 
population living in malaria free areas. The population at risk is 
used as the denominator in calculating the coverage of malaria 
interventions, and is therefore used in assessing current and future 
needs for malaria control interventions, taking into account the 
population already covered. For countries in the pre-elimination 
and elimination stages, “population at risk” is defined by the 
countries, based on the resident populations in foci where active 
malaria transmission occurs.
Parasites and vectors: The species of mosquito responsible for 
malaria transmission in a country, and the species of Plasmodium 
involved, are listed according to information provided by WHO 
regional offices. The proportion of malaria cases due to P. falciparum 
was estimated from the number of P. falciparum and mixed infections 
detected by microscopy, divided by the total number of malaria 
cases confirmed by microscopy in 2013.
II. Intervention policies and strategies
Intervention policy: The policies and strategies adopted by each 
country were reported by NMCPs to WHO. They vary according 
to the epidemiological setting, socioeconomic factors and the 
capacity of the NMCP or the country’s health system. Adoption 
of policies does not necessarily imply immediate implementation, 
nor does it indicate full, continuous implementation nationwide.
Antimalarial treatment policy: Antimalarial treatment policies 
were reported by NMCPs to WHO. 
Therapeutic efficacy tests: Data on therapeutic efficacy were 
extracted from the WHO global database on antimalarial drug 
efficacy. The data originated from three main sources: published data, 
unpublished data and regular monitoring data from surveillance 
studies conducted according to the WHO standard protocol. The 
percentage of treatment failures is the total number of failures 
(early treatment failures + late clinical failures + late parasitological 
failures), divided by the total number of patients who completed the 
study follow-up. The number of studies included in the analysis and 
the years during which the studies were conducted are shown for 
each antimalarial medicine. The minimum, median and maximum 
describe the range of treatment failures observed in the studies 
for each antimalarial medicine.
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III. Financing
Sources of financing: The data shown are those reported 
by NMCPs. The government contribution is usually the 
declared government expenditure for the year. In cases where 
government expenditure was not reported by the programme, 
the government budget was used. External contributions 
are those allocated to the programme by external agencies; 
however, such contributions may or may not be disbursed. 
Additional information about contributions from specific donor 
agencies, as reported by these agencies, is given in Annex 2. 
All countries were asked to convert their local currencies to 
US$ for reporting on sources of financing.
Expenditure by intervention in 2013: The pie chart shows the 
proportion of malaria funding from all sources that was spent 
on ITNs, insecticides and spraying materials, IRS, diagnosis, 
antimalarial medicines, monitoring and evaluation, human 
resources, technical assistance and management. There are 
differences in the completeness of data between countries, 
and the activities for which expenditures are reported do 
not necessarily include all items of expenditure. For example, 
government expenditures usually only include expenditures 
specific to malaria control, and do not take into account costs 
related to health facility staff, infrastructure and so on.
IV. Coverage
ITN and IRS coverage: Indicators are shown according to data 
availability: 
  With access to an ITN (survey) – the proportion of all individuals 
that could be covered by available ITNs in each household, 
assuming each ITN can be shared by two people. The 
indicator is calculated from nationally representative 
household surveys such as DHS, MICS and MIS.
  All ages who slept under an ITN (survey) – the proportion of 
all individuals who spent the previous night in surveyed 
households who slept under an ITN, as measured in a 
nationally representative household survey such as DHS, 
MICS or MIS.
  With access to an ITN (model) – For high-transmission countries 
in the WHO African Region, a model was used to estimate 
the proportion of the population with access to an ITN 
within their household for years in which household 
survey results were not available. The methods used to 
estimate the indicator were the same as those described 
for Figures 3.1 and 3.2.
  At high risk protected by ITNs – For countries in WHO regions 
other than the African Region, nationally representative 
household surveys are not undertaken sufficiently frequently 
to allow an assessment of levels and trends in ITN coverage. 
Therefore, the number of ITNs distributed by NMCPs is used. 
The proportion of the population potentially protected 
with ITNs is calculated as:
1.8 × (number of LLINs distributed in the past 3 years + 
number of conventional ITNs distributed or retreated in the 
past year) / the population at high risk for malaria
LLINs are considered to have an average useful lifespan of 3 
years and conventional ITNs 1 year; also, each net is assumed 
to protect two people. The ratio of 1.8 is used in the formula 
to allow for only one person sleeping under some ITNs in 
households with an odd number of inhabitants. The population 
at high risk is used as the denominator since it is assumed 
that populations at high risk will be preferentially targeted to 
receive an ITN. For countries in the elimination phase, those 
residing in foci are considered to be the population at risk.
  At high risk protected by IRS – calculated as the number of 
people living in a household where IRS has been applied 
during the preceding 12 months, divided by the population 
at risk (the sum of populations living in low- and high-
transmission areas). For areas outside Africa, the population 
at high risk is used as the denominator. The percentage 
of people protected by IRS is a measure of the extent to 
which IRS is implemented and the extent to which the 
population at risk benefits from IRS nationwide. The data 
show neither the quality of spraying nor the geographical 
distribution of IRS coverage in a country.
Cases tested and cases treated in the public sector
Suspected cases tested – the number of suspected cases 
examined by microscopy or by RDT, divided by the total number 
of suspected malaria cases. For countries that do not report 
the number of suspected cases independently, the number 
of suspected malaria cases is derived from the number of 
presumed and confirmed cases, the number tested and the 
number of positive tests. This indicator reflects the extent to 
which a programme can provide diagnostic services to patients 
attending public health facilities. It does not consider patients 
attending privately run health facilities, and therefore does not 
reflect the experience of all patients seeking treatment. In many 
situations, health facilities in the private sector are less likely 
to provide a diagnostic test than those in the public sector. 
The indicator may also be biased if those health facilities that 
provide a diagnostic test (e.g. hospitals) are more likely than 
other facilities to submit monthly reports.
Under 5 with fever with finger/heel stick (survey) – the proportion 
of children aged under 5 years with fever in the past weeks 
who had a finger or heel stick, as measured in a nationally 
representative household survey such as DHS, MICS or MIS.
Antimalarial medicines distributed versus cases – Few countries 
have information systems that are able to record the treatments 
given to individual patients. Instead, data on the numbers of 
antimalarial medicines distributed by the country’s ministry 
of health are used to calculate proxy indicators of access to 
treatment. Three indicators are shown:
  Antimalarials distributed versus all malaria cases – the number 
of first-line treatment courses distributed, divided by the 
estimated number of malaria cases attending public sector 
health facilities.
  ACTs distributed versus P. falciparum malaria cases – the number 
of ACT treatment courses distributed, divided by the 
estimated number of P. falciparum malaria cases attending 
public sector health facilities.
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  Primaquine distributed versus P. vivax malaria cases – the number 
of primaquine treatment courses distributed, divided by the 
estimated number of P. vivax malaria cases attending public 
sector health facilities.
For high-transmission countries in the WHO African Region, 
the estimated number of malaria cases attending public sector 
health facilities is used as a denominator. For other countries, the 
denominator is the number of confirmed cases plus the number 
of presumed cases, adjusted for reporting completeness. These 
indicators can provide information on whether the NMCP delivers 
sufficient antimalarial medicines to treat all malaria patients who 
seek treatment in the public sector. It is not a direct measure of 
the proportion of patients with malaria cases that have received 
treatment.
ACTs as percentage of all antimalarials received (survey) – children 
aged under 5 years with fever in the past 2 weeks who received 
ACTs as a proportion of children aged under 5 years with fever 
who received any antimalarial. 
Cases tracked
Reporting completeness – calculated as the total number of health 
facility reports received by a ministry of health during a year, divided 
by the total number of facility reports that were expected in that 
year. The expected number of facility reports is the number of 
health facilities multiplied by the frequency of reporting; that is, 
if 100 facilities are expected to report each month, 1200 reports 
would be expected during a year.
Percentage fever cases <5 seeking treatment at public health facility 
(survey) – the proportion of children aged under 5 years with fever 
in the past 2 weeks who sought treatment at a public health facility, 
derived from a nationally representative household survey such 
as DHS, MICS or MIS (for programmes in the control phase only).
Cases investigated – the proportion of reported confirmed malaria 
cases that are investigated for additional information on the 
characteristics of the case; most importantly, whether the case was 
imported or locally acquired (for programmes in the pre-elimination 
and elimination phase only).
Foci investigated – the proportion of foci of malaria transmission that 
are investigated for additional information on the characteristics 
of transmission of malaria, including evidence of local malaria 
transmission and entomological information such as vector 
breeding sites within the transmission focus (for programmes in 
the pre-elimination and elimination phase only). 
V. Impact
Test positivity
SPR – the number of microscopically positive cases divided by the 
total number of slides examined.
RDT positivity rate – the number of positive RDT tests divided by 
the total number of RDT tests carried out. The RDT positivity rate 
and SPR are derived from the number of parasitologically positive 
cases per 100 cases examined by RDT or microscopy. They measure 
the prevalence of malaria parasites among people who seek care 
and are examined in health facilities. Trends in these indicators 
may be less distorted by variations in the ABER than trends in the 
number of confirmed cases.
Parasite prevalence (survey) – the proportion of people tested for 
malaria parasites in a survey (most often children aged under 5 years) 
who have malaria parasites (programmes in control phase only).
Confirmed malaria cases per 1000 and ABER
ABER (microscopy and RDT) – the number of parasitological tests 
(by microscopy or RDT) undertaken per 100 population at risk 
per year. The numbers of parasitological tests were derived from 
reports by NMCPs to WHO. The ABER provides information on the 
extent of diagnostic testing in a population. It can be useful to 
take into account when interpreting trends in confirmed cases. 
To discern changes in malaria incidence, the ABER should ideally 
remain constant (see notes for Figures 8.1 and 8.2). There is no set 
threshold or target for ABER; rather, it is the trend in ABER in relation 
to reported case incidence that is most informative. 
Cases (all species) – the total number of confirmed malaria cases 
(by microscopy or RDT) divided by the population at risk. The 
numbers of confirmed cases were derived from reports by NMCPs 
to WHO. The indicator is useful in assessing changes in the incidence 
of malaria over time, provided that there has been consistency 
in patient attendance at facilities, diagnostic testing and case 
reporting over time.
Cases (P. vivax) – the total number of confirmed P. vivax malaria 
cases (by microscopy or RDT) divided by the population at risk. The 
numbers of confirmed P. vivax cases were derived from reports by 
NMCPs to WHO (the numbers exclude mixed infections).
For countries in the pre-elimination or elimination phases, the 
total number of indigenous cases (acquired within the country) 
and imported cases were also plotted.
Malaria admissions and deaths (for countries in the control phase)
Numbers for malaria admissions and deaths for countries in the 
control phase were derived from reports by NMCPs to WHO.
Admissions (all species) – the number of patients admitted for 
malaria with malaria as the primary discharge diagnosis, divided 
by the population at risk. 
Admissions (P. vivax) – the number of patients admitted for malaria 
with P. vivax malaria as the primary discharge diagnosis, divided by 
the population at risk. 
Deaths (all species) – the number of patients dying in health 
facilities with malaria as the primary cause of death, divided by 
the population at risk. 
Deaths (P. vivax) – the number of patients dying in health facilities 
with P. vivax malaria as the primary cause of death, divided by the 
population at risk. 
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